BROAD SPECTRUM INFLUENZA VIRUS VACCINE

Abstract

The disclosure relates to influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Description

BACKGROUND

Influenza viruses are members of the orthomyxoviridae family, and are classified into three distinct types (A, B, and C), based on antigenic differences between their nucleoprotein (NP) and matrix (M) protein. The orthomyxoviruses are enveloped animal viruses of approximately 100 nm in diameter. The influenza virions consist of an internal ribonucleoprotein core (a helical nucleocapsid) containing a single-stranded RNA genome, and an outer lipoprotein envelope lined inside by a matrix protein (M1). The segmented genome of influenza A virus consists of eight molecules (seven for influenza C virus) of linear, negative polarity, single-stranded RNAs, which encode several polypeptides including: the RNA-directed RNA polymerase proteins (PB2, PB1 and PA) and nucleoprotein (NP), which form the nucleocapsid; the matrix proteins (M1, M2, which is also a surface-exposed protein embedded in the virus membrane); two surface glycoproteins, which project from the lipoprotein envelope: hemagglutinin (HA) and neuraminidase (NA); and nonstructural proteins (NS1 and NS2). Transcription and replication of the genome takes place in the nucleus and assembly takes place at the plasma membrane.

Hemagglutinin is the major envelope glycoprotein of influenza A and B viruses, and hemagglutinin-esterase (HE) of influenza C viruses is a protein homologous to HA. The rapid evolution of the HA protein of the influenza virus results in the constant emergence of new strains, rendering the adaptive immune response of the host only partially protective to new infections. The biggest challenge for therapy and prophylaxis against influenza and other infections using traditional vaccines is the limitation of vaccines in breadth, providing protection only against closely related subtypes. In addition, the length of time required to complete current standard influenza virus vaccine production processes inhibits the rapid development and production of an adapted vaccine in a pandemic situation.

Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responses to foreign antigens, such as influenza antigens. The direct injection of genetically engineered DNA (e.g., naked plasmid DNA) into a living host results in a small number of its cells directly producing an antigen, resulting in a protective immunological response. With this technique, however, come potential problems, including the possibility of insertional mutagenesis, which could lead to the activation of oncogenes or the inhibition of tumor suppressor genes.

SUMMARY

Provided herein is a ribonucleic acid (RNA) vaccine (or a composition or an immunogenic composition) that builds on the knowledge that RNA (e.g., messenger RNA (mRNA)) can safely direct the body's cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells. The RNA vaccines of the present disclosure may be used to induce a balanced immune response against influenza virus, comprising both cellular and humoral immunity, without risking the possibility of insertional mutagenesis, for example.

The RNA (e.g., mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. The RNA vaccines may be utilized to treat and/or prevent an influenza virus of various genotypes, strains, and isolates. The RNA vaccines typically have superior properties in that they produce much larger antibody titers and produce responses earlier than commercially available anti-viral therapeutic treatments. While not wishing to be bound by theory, it is believed that the RNA vaccines, as mRNA polynucleotides, are better designed to produce the appropriate protein conformation upon translation as the RNA vaccines co-opt natural cellular machinery. Unlike traditional vaccines, which are manufactured ex vivo and may trigger unwanted cellular responses, RNA (e.g., mRNA) vaccines are presented to the cellular system in a more native fashion.

There may be situations where persons are at risk for infection with more than one strain of influenza virus. RNA (e.g., mRNA) therapeutic vaccines are particularly amenable to combination vaccination approaches due to a number of factors including, but not limited to, speed of manufacture, ability to rapidly tailor vaccines to accommodate perceived geographical threat, and the like. Moreover, because the vaccines utilize the human body to produce the antigenic protein, the vaccines are amenable to the production of larger, more complex antigenic proteins, allowing for proper folding, surface expression, antigen presentation, etc. in the human subject. To protect against more than one strain of influenza, a combination vaccine can be administered that includes RNA (e.g., mRNA) encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a first influenza virus or organism and further includes RNA encoding at least one antigenic polypeptide protein (or antigenic portion thereof) of a second influenza virus or organism. RNA (e.g., mRNA) can be co-formulated, for example, in a single lipid nanoparticle (LNP) or can be formulated in separate LNPs for co-administration.

Some embodiments of the present disclosure provide influenza virus (influenza) vaccines (or compositions or immunogenic compositions) that include at least one RNA polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide or an immunogenic fragment thereof (e.g., an immunogenic fragment capable of inducing an immune response to influenza).

In some embodiments, the at least one antigenic polypeptide is one of the defined antigenic subdomains of HA, termed HA1, HA2, or a combination of HA1 and HA2, and at least one antigenic polypeptide selected from neuraminidase (NA), nucleoprotein (NP), matrix protein 1 (M1), matrix protein 2 (M2), non-structural protein 1 (NS1) and non-structural protein 2 (NS2).

In some embodiments, the at least one antigenic polypeptide is HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2, and at least one antigenic polypeptide selected from NA, NP, M1, M2, NS1 and NS2.

In some embodiments, the at least one antigenic polypeptide is HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2 and at least two antigenic polypeptides selected from NA, NP, M1, M2, NS1 and NS2.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza virus protein, or an immunogenic fragment thereof.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding multiple influenza virus proteins, or immunogenic fragments thereof.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one HA1, HA2, or a combination of both).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one HA1, HA2, or a combination of both, of any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least one other RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a protein selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least two other RNAs (e.g., mRNAs) polynucleotides having two open reading frames encoding two proteins selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one of any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least three other RNAs (e.g., mRNAs) polynucleotides having three open reading frames encoding three proteins selected from a NP protein, a NA protein, a M protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one of any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least four other RNAs (e.g., mRNAs) polynucleotides having four open reading frames encoding four proteins selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or an immunogenic fragment thereof (e.g., at least one of any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18) and at least five other RNAs (e.g., mRNAs) polynucleotides having five open reading frames encoding five proteins selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein or an immunogenic fragment thereof (e.g., at least one of any one of or a combination of any or all of H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, and/or H18), a NP protein or an immunogenic fragment thereof, a NA protein or an immunogenic fragment thereof, a M1 protein or an immunogenic fragment thereof, a M2 protein or an immunogenic fragment thereof, a NS1 protein or an immunogenic fragment thereof and a NS2 protein or an immunogenic fragment thereof obtained from influenza virus.

Some embodiments of the present disclosure provide the following novel influenza virus polypeptide sequences: H1HA10-Foldon_ΔNgly1; H1HA10TM-PR8 (H1 A/Puerto Rico/8/34 HA); H1HA10-PR8-DS (H1 A/Puerto Rico/8/34 HA; pH1HA10-Cal04-DS (H1 A/California/04/2009 HA); Pandemic H1HA10 from California 04; pH1HA10-ferritin; HA10; Pandemic H1HA10 from California 04; Pandemic H1HA10 from California 04 strain/without foldon and with K68C/R76C mutation for trimerization; H1HA10 from A/Puerto Rico/8/34 strain, without foldon and with Y94D/N95L mutation for trimerization; H1HA10 from A/Puerto Rico/8/34 strain, without foldon and with K68C/R76C mutation for trimerization; H1N1 A/Viet Nam/850/2009; H3N2 A/Wisconsin/67/2005; H7N9 (A/Anhui/1/2013); H9N2 A/Hong Kong/1073/99; H10N8 A/JX346/2013.

Some embodiments of the present disclosure provide influenza virus (influenza) vaccines that include at least one RNA polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide or an immunogenic fragment of the novel influenza virus polypeptide sequences described above (e.g., an immunogenic fragment capable of inducing an immune response to influenza). In some embodiments, an influenza vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide comprising a modified sequence that is at least 75% (e.g., any number between 75% and 100%, inclusive, e.g., 70%, 80%, 85%, 90%, 95%, 99%, and 100%) identity to an amino acid sequence of the novel influenza virus sequences described above. The modified sequence can be at least 75% (e.g., any number between 75% and 100%, inclusive, e.g., 70%, 80%, 85%, 90%, 95%, 99%, and 100%) identical to an amino acid sequence of the novel influenza virus sequences described above.

Some embodiments of the present disclosure provide an isolated nucleic acid comprising a sequence encoding the novel influenza virus polypeptide sequences described above; an expression vector comprising the nucleic acid; and a host cell comprising the nucleic acid. The present disclosure also provides a method of producing a polypeptide of any of the novel influenza virus sequences described above. A method may include culturing the host cell in a medium under conditions permitting nucleic acid expression of the novel influenza virus sequences described above, and purifying from the cultured cell or the medium of the cell a novel influenza virus polypeptide. The present disclosure also provides antibody molecules, including full length antibodies and antibody derivatives, directed against the novel influenza virus sequences.

In some embodiments, an open reading frame of a RNA (e.g., mRNA) vaccine is codon-optimized. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and is codon optimized mRNA.

In some embodiments, a RNA (e.g., mRNA) vaccine further comprising an adjuvant.

Tables 7-13 provide National Center for Biotechnology Information (NCBI) accession numbers of interest. It should be understood that the phrase “an amino acid sequence of Tables 7-13” refers to an amino acid sequence identified by one or more NCBI accession numbers listed in 7-13. Each of the amino acid sequences, and variants having greater than 95% identity or greater than 98% identity to each of the amino acid sequences encompassed by the accession numbers of Tables 7-13 are included within the constructs (polynucleotides/polypeptides) of the present disclosure.

In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 447-457, 459, 461 and having less than 80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one SEQ ID NO: 447-457, 459, 461 and having less than 75%, 85% or 95% identity to a wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by nucleic acid comprising a sequence identified by any one of SEQ ID NO: 447-457, 459, 461 and having less than 50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80% or 78-80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 447-457, 459, 461 and having less than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%, 75-85% or 80-85% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 447-457, 459, 461 and having less than 40-90%, 50-90%, 60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90% identity to wild-type mRNA sequence.

In some embodiments, at least one mRNA polynucleotide comprises a sequence identified by any one of SEQ ID NO: 491-503 and has less than 80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one SEQ ID NO: 491-503 and has less than 75%, 85% or 95% identity to a wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by nucleic acid comprising a sequence identified by any one of SEQ ID NO: 491-503 and has less than 50-80%, 60-80%, 40-80%, 30-80%, 70-80%, 75-80% or 78-80% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 491-503 and has less than 40-85%, 50-85%, 60-85%, 30-85%, 70-85%, 75-85% or 80-85% identity to wild-type mRNA sequence. In some embodiments, at least one mRNA polynucleotide is encoded by a nucleic acid comprising a sequence identified by any one of SEQ ID NO: 491-503 and has less than 40-90%, 50-90%, 60-90%, 30-90%, 70-90%, 75-90%, 80-90%, or 85-90% identity to wild-type mRNA sequence.

In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and having at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) identity to wild-type mRNA sequence, but does not include wild-type mRNA sequence.

In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and has less than 95%, 90%, 85%, 80% or 75% identity to wild-type mRNA sequence. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide comprising an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and has 30-80%, 40-80%, 50-80%, 60-80%, 70-80%, 75-80% or 78-80%, 30-85%, 40-85%, 50-805%, 60-85%, 70-85%, 75-85% or 78-85%, 30-90%, 40-90%, 50-90%, 60-90%, 70-90%, 75-90%, 80-90% or 85-90% identity to wild-type mRNA sequence.

In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13). In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to an amino acid sequence identified by any one of 1-444, 458, 460, 462-479 (see also Tables 7-13).

In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and having membrane fusion activity. In some embodiments, at least one RNA polynucleotide encodes at least one antigenic polypeptide having 95%-99% identity to amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) and having membrane fusion activity.

In some embodiments, at least one RNA polynucleotide encodes at least one influenza antigenic polypeptide that attaches to cell receptors.

In some embodiments, at least one RNA polynucleotide encodes at least one influenza antigenic polypeptide that causes fusion of viral and cellular membranes.

In some embodiments, at least one RNA polynucleotide encodes at least one influenza antigenic polypeptide that is responsible for binding of the virus to a cell being infected.

Some embodiments of the present disclosure provide a vaccine that includes at least one ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide, at least one 5′ terminal cap and at least one chemical modification, formulated within a lipid nanoparticle.

In some embodiments, a 5′ terminal cap is 7mG(5′)ppp(5′)NlmpNp.

In some embodiments, at least one chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In some embodiments, the chemical modification is in the 5-position of the uracil. In some embodiments, the chemical modification is a N1-methylpseudouridine. In some embodiments, the chemical modification is a N1-ethylpseudouridine.

In some embodiments, a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, a cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, a cationic lipid is selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), (12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (L608), and N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]heptadecan-8-amine (L530).

In some embodiments, the lipid is

In some embodiments, the lipid is

Some embodiments of the present disclosure provide a vaccine that includes at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide, wherein at least 80% (e.g., 85%, 90%, 95%, 98%, 99%) of the uracil in the open reading frame have a chemical modification, optionally wherein the vaccine is formulated in a lipid nanoparticle (e.g., a lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid).

In some embodiments, 100% of the uracil in the open reading frame have a chemical modification. In some embodiments, a chemical modification is in the 5-position of the uracil. In some embodiments, a chemical modification is a N1-methyl pseudouridine. In some embodiments, 100% of the uracil in the open reading frame have a N1-methyl pseudouridine in the 5-position of the uracil.

In some embodiments, an open reading frame of a RNA (e.g., mRNA) polynucleotide encodes at least two influenza antigenic polypeptides. In some embodiments, the open reading frame encodes at least five or at least ten antigenic polypeptides. In some embodiments, the open reading frame encodes at least 100 antigenic polypeptides. In some embodiments, the open reading frame encodes 2-100 antigenic polypeptides.

In some embodiments, a vaccine comprises at least two RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one influenza antigenic polypeptide. In some embodiments, the vaccine comprises at least five or at least ten RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide or an immunogenic fragment thereof. In some embodiments, the vaccine comprises at least 100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide. In some embodiments, the vaccine comprises 2-100 RNA (e.g., mRNA) polynucleotides, each having an open reading frame encoding at least one antigenic polypeptide.

In some embodiments, at least one influenza antigenic polypeptide is fused to a signal peptide. In some embodiments, the signal peptide is selected from: a HuIgGk signal peptide (METPAQLLFLLLLWLPDTTG; SEQ ID NO: 480); IgE heavy chain epsilon-1 signal peptide (MDWTWILFLVAAATRVHS; SEQ ID NO: 481); Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 482), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 483) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 484).

In some embodiments, the signal peptide is fused to the N-terminus of at least one antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of at least one antigenic polypeptide.

In some embodiments, at least one influenza antigenic polypeptide comprises a mutated N-linked glycosylation site.

Also provided herein is an influenza RNA (e.g., mRNA) vaccine of any one of the foregoing paragraphs formulated in a nanoparticle (e.g., a lipid nanoparticle).

In some embodiments, the nanoparticle has a mean diameter of 50-200 nm. In some embodiments, the nanoparticle is a lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid. In some embodiments, the lipid nanoparticle comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid. In some embodiments, the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol. In some embodiments, the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

In some embodiments, the nanoparticle has a polydispersity value of less than 0.4 (e.g., less than 0.3, 0.2 or 0.1).

In some embodiments, the nanoparticle has a net neutral charge at a neutral pH value.

In some embodiments, the RNA (e.g., mRNA) vaccine is multivalent.

Some embodiments of the present disclosure provide methods of inducing an antigen specific immune response in a subject, comprising administering to the subject any of the RNA (e.g., mRNA) vaccine as provided herein in an amount effective to produce an antigen-specific immune response. In some embodiments, the RNA (e.g., mRNA) vaccine is an influenza vaccine. In some embodiments, the RNA (e.g., mRNA) vaccine is a combination vaccine comprising a combination of influenza vaccines (a broad spectrum influenza vaccine).

In some embodiments, an antigen-specific immune response comprises a T cell response or a B cell response.

In some embodiments, a method of producing an antigen-specific immune response comprises administering to a subject a single dose (no booster dose) of an influenza RNA (e.g., mRNA) vaccine of the present disclosure.

In some embodiments, a method further comprises administering to the subject a second (booster) dose of an influenza RNA (e.g., mRNA) vaccine. Additional doses of an influenza RNA (e.g., mRNA) vaccine may be administered.

In some embodiments, the subjects exhibit a seroconversion rate of at least 80% (e.g., at least 85%, at least 90%, or at least 95%) following the first dose or the second (booster) dose of the vaccine. Seroconversion is the time period during which a specific antibody develops and becomes detectable in the blood. After seroconversion has occurred, a virus can be detected in blood tests for the antibody. During an infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but antibodies are considered absent. During seroconversion, antibodies are present but not yet detectable. Any time after seroconversion, the antibodies can be detected in the blood, indicating a prior or current infection.

In some embodiments, an influenza RNA (e.g., mRNA) vaccine is administered to a subject by intradermal injection, intramuscular injection, or by intranasal administration. In some embodiments, an influenza RNA (e.g., mRNA) vaccine is administered to a subject by intramuscular injection.

Some embodiments, of the present disclosure provide methods of inducing an antigen specific immune response in a subject, including administering to a subject an influenza RNA (e.g., mRNA) vaccine in an effective amount to produce an antigen specific immune response in a subject. Antigen-specific immune responses in a subject may be determined, in some embodiments, by assaying for antibody titer (for titer of an antibody that binds to an influenza antigenic polypeptide) following administration to the subject of any of the influenza RNA (e.g., mRNA) vaccines of the present disclosure. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.

In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased at least 2 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 5 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.

In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated or inactivated influenza, or wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant or purified influenza protein vaccine. In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered an influenza virus-like particle (VLP) vaccine (see, e.g., Cox R G et al., J Virol. 2014 June; 88(11): 6368-6379).

A RNA (e.g., mRNA) vaccine of the present disclosure is administered to a subject in an effective amount (an amount effective to induce an immune response). In some embodiments, the effective amount is a dose equivalent to an at least 2-fold, at least 4-fold, at least 10-fold, at least 100-fold, at least 1000-fold reduction in the standard of care dose of a recombinant influenza protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant influenza protein vaccine, a purified influenza protein vaccine, a live attenuated influenza vaccine, an inactivated influenza vaccine, or an influenza VLP vaccine. In some embodiments, the effective amount is a dose equivalent to 2-1000-fold reduction in the standard of care dose of a recombinant influenza protein vaccine, wherein the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant influenza protein vaccine, a purified influenza protein vaccine, a live attenuated influenza vaccine, an inactivated influenza vaccine, or an influenza VLP vaccine.

In some embodiments, the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a virus-like particle (VLP) vaccine comprising structural proteins of influenza.

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject.

In some embodiments, the effective amount is a total dose of 25 μg to 1000 μg, or 50 μg to 1000 μg. In some embodiments, the effective amount is a total dose of 100 μg. In some embodiments, the effective amount is a dose of 25 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 100 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 400 μg administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 500 μg administered to the subject a total of two times.

In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is greater than 60%. In some embodiments, the RNA (e.g., mRNA) polynucleotide of the vaccine at least one Influenza antigenic polypeptide.

Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:

Efficacy=(ARU−ARV)/ARU×100; and

Efficacy=(1−RR)×100.

Likewise, vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun. 1; 201(11):1607-10). Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial. Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the ‘real-world’ outcomes of hospitalizations, ambulatory visits, or costs. For example, a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared. Vaccine effectiveness may be expressed as a rate difference, with use of the odds ratio (OR) for developing infection despite vaccination:

Effectiveness=(1−OR)×100.

In some embodiments, the efficacy (or effectiveness) of a RNA (e.g., mRNA) vaccine is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%.

In some embodiments, the vaccine immunizes the subject against Influenza for up to 2 years. In some embodiments, the vaccine immunizes the subject against Influenza for more than 2 years, more than 3 years, more than 4 years, or for 5-10 years.

In some embodiments, the subject is about 5 years old or younger. For example, the subject may be between the ages of about 1 year and about 5 years (e.g., about 1, 2, 3, 5 or 5 years), or between the ages of about 6 months and about 1 year (e.g., about 6, 7, 8, 9, 10, 11 or 12 months). In some embodiments, the subject is about 12 months or younger (e.g., 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 months or 1 month). In some embodiments, the subject is about 6 months or younger.

In some embodiments, the subject was born full term (e.g., about 37-42 weeks). In some embodiments, the subject was born prematurely, for example, at about 36 weeks of gestation or earlier (e.g., about 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26 or 25 weeks). For example, the subject may have been born at about 32 weeks of gestation or earlier. In some embodiments, the subject was born prematurely between about 32 weeks and about 36 weeks of gestation. In such subjects, a RNA (e.g., mRNA) vaccine may be administered later in life, for example, at the age of about 6 months to about 5 years, or older.

In some embodiments, the subject is a young adult between the ages of about 20 years and about 50 years (e.g., about 20, 25, 30, 35, 40, 45 or 50 years old).

In some embodiments, the subject is an elderly subject about 60 years old, about 70 years old, or older (e.g., about 60, 65, 70, 75, 80, 85 or 90 years old).

In some embodiments, the subject has been exposed to influenza (e.g., C. trachomatis); the subject is infected with influenza (e.g., C. trachomatis); or subject is at risk of infection by influenza (e.g., C. trachomatis).

In some embodiments, the subject is immunocompromised (has an impaired immune system, e.g., has an immune disorder or autoimmune disorder).

In some embodiments the nucleic acid vaccines described herein are chemically modified. In other embodiments the nucleic acid vaccines are unmodified.

Yet other aspects provide compositions for and methods of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first virus antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and wherein an adjuvant is not coformulated or co-administered with the vaccine.

In other aspects the invention is a composition for or method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide wherein a dosage of between 10 μg/kg and 400 μg/kg of the nucleic acid vaccine is administered to the subject. In some embodiments the dosage of the RNA polynucleotide is 1-5 μg, 5-10 μg, 10-15 μg, 15-20 μg, 10-25 μg, 20-25 μg, 20-50 μg, 30-50 μg, 40-50 μg, 40-60 μg, 60-80 μg, 60-100 μg, 50-100 μg, 80-120 μg, 40-120 μg, 40-150 μg, 50-150 μg, 50-200 μg, 80-200 μg, 100-200 μg, 120-250 μg, 150-250 μg, 180-280 μg, 200-300 μg, 50-300 μg, 80-300 μg, 100-300 μg, 40-300 μg, 50-350 μg, 100-350 μg, 200-350 μg, 300-350 μg, 320-400 μg, 40-380 μg, 40-100 μg, 100-400 μg, 200-400 μg, or 300-400 μg per dose. In some embodiments, the nucleic acid vaccine is administered to the subject by intradermal or intramuscular injection. In some embodiments, the nucleic acid vaccine is administered to the subject on day zero. In some embodiments, a second dose of the nucleic acid vaccine is administered to the subject on day twenty one.

In some embodiments, a dosage of 25 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 100 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 50 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 75 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 150 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 400 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, a dosage of 200 micrograms of the RNA polynucleotide is included in the nucleic acid vaccine administered to the subject. In some embodiments, the RNA polynucleotide accumulates at a 100 fold higher level in the local lymph node in comparison with the distal lymph node. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not chemically modified.

Aspects of the invention provide a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide does not include a stabilization element, and a pharmaceutically acceptable carrier or excipient, wherein an adjuvant is not included in the vaccine. In some embodiments, the stabilization element is a histone stem-loop. In some embodiments, the stabilization element is a nucleic acid sequence having increased GC content relative to wild type sequence.

Aspects of the invention provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host, which confers an antibody titer superior to the criterion for seroprotection for the first antigen for an acceptable percentage of human subjects. In some embodiments, the antibody titer produced by the mRNA vaccines of the invention is a neutralizing antibody titer. In some embodiments the neutralizing antibody titer is greater than a protein vaccine. In other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is greater than an adjuvanted protein vaccine. In yet other embodiments the neutralizing antibody titer produced by the mRNA vaccines of the invention is 1,000-10,000, 1,200-10,000, 1,400-10,000, 1,500-10,000, 1,000-5,000, 1,000-4,000, 1,800-10,000, 2000-10,000, 2,000-5,000, 2,000-3,000, 2,000-4,000, 3,000-5,000, 3,000-4,000, or 2,000-2,500. A neutralization titer is typically expressed as the highest serum dilution required to achieve a 50% reduction in the number of plaques.

Also provided are nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in a formulation for in vivo administration to a host for eliciting a longer lasting high antibody titer than an antibody titer elicited by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide. In some embodiments, the RNA polynucleotide is formulated to produce a neutralizing antibodies within one week of a single administration. In some embodiments, the adjuvant is selected from a cationic peptide and an immunostimulatory nucleic acid. In some embodiments, the cationic peptide is protamine.

Aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no modified nucleotides, the open reading frame encoding a first antigenic polypeptide, wherein the RNA polynucleotide is present in the formulation for in vivo administration to a host such that the level of antigen expression in the host significantly exceeds a level of antigen expression produced by an mRNA vaccine having a stabilizing element or formulated with an adjuvant and encoding the first antigenic polypeptide.

Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no modified nucleotides, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

Aspects of the invention also provide a unit of use vaccine, comprising between 10 ug and 400 ug of one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification or optionally no modified nucleotides, the open reading frame encoding a first antigenic polypeptide, and a pharmaceutically acceptable carrier or excipient, formulated for delivery to a human subject. In some embodiments, the vaccine further comprises a cationic lipid nanoparticle.

Aspects of the invention provide methods of creating, maintaining or restoring antigenic memory to a virus strain in an individual or population of individuals comprising administering to said individual or population an antigenic memory booster nucleic acid vaccine comprising (a) at least one RNA polynucleotide, said polynucleotide comprising at least one chemical modification or optionally no modified nucleotides and two or more codon-optimized open reading frames, said open reading frames encoding a set of reference antigenic polypeptides, and (b) optionally a pharmaceutically acceptable carrier or excipient. In some embodiments, the vaccine is administered to the individual via a route selected from the group consisting of intramuscular administration, intradermal administration and subcutaneous administration. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition. In some embodiments, the administering step comprises contacting a muscle tissue of the subject with a device suitable for injection of the composition in combination with electroporation.

Aspects of the invention provide methods of vaccinating a subject comprising administering to the subject a single dosage of between 25 ug/kg and 400 ug/kg of a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding a first antigenic polypeptide in an effective amount to vaccinate the subject.

Other aspects provide nucleic acid vaccines comprising one or more RNA polynucleotides having an open reading frame comprising at least one chemical modification, the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

Other aspects provide nucleic acid vaccines comprising an LNP formulated RNA polynucleotide having an open reading frame comprising no nucleotide modifications (unmodified), the open reading frame encoding a first antigenic polypeptide, wherein the vaccine has at least 10 fold less RNA polynucleotide than is required for an unmodified mRNA vaccine not formulated in a LNP to produce an equivalent antibody titer. In some embodiments, the RNA polynucleotide is present in a dosage of 25-100 micrograms.

The data presented in the Examples demonstrate significant enhanced immune responses using the formulations of the invention. Both chemically modified and unmodified RNA vaccines are useful according to the invention. Surprisingly, in contrast to prior art reports that it was preferable to use chemically unmodified mRNA formulated in a carrier for the production of vaccines, it is described herein that chemically modified mRNA-LNP vaccines required a much lower effective mRNA dose than unmodified mRNA, i.e., tenfold less than unmodified mRNA when formulated in carriers other than LNP. Both the chemically modified and unmodified RNA vaccines of the invention produce better immune responses than mRNA vaccines formulated in a different lipid carrier.

In other aspects the invention encompasses a method of treating an elderly subject age 60 years or older comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding an virus antigenic polypeptide in an effective amount to vaccinate the subject.

In other aspects the invention encompasses a method of treating a young subject age 17 years or younger comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding an virus antigenic polypeptide in an effective amount to vaccinate the subject.

In other aspects the invention encompasses a method of treating an adult subject comprising administering to the subject a nucleic acid vaccine comprising one or more RNA polynucleotides having an open reading frame encoding an virus antigenic polypeptide in an effective amount to vaccinate the subject.

In some aspects the invention is a method of vaccinating a subject with a combination vaccine including at least two nucleic acid sequences encoding antigens wherein the dosage for the vaccine is a combined therapeutic dosage wherein the dosage of each individual nucleic acid encoding an antigen is a sub therapeutic dosage. In some embodiments, the combined dosage is 25 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 100 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments the combined dosage is 50 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 75 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 150 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the combined dosage is 400 micrograms of the RNA polynucleotide in the nucleic acid vaccine administered to the subject. In some embodiments, the sub therapeutic dosage of each individual nucleic acid encoding an antigen is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 micrograms. In other embodiments the nucleic acid vaccine is chemically modified and in other embodiments the nucleic acid vaccine is not nucleotide modified.

The RNA polynucleotide is one of SEQ ID NO: 447-457, 459, 461 and 491-503 and includes at least one chemical modification. In other embodiments the RNA polynucleotide is one of SEQ ID NO: 447-457, 459, 461 and 491-503 and does not include any nucleotide modifications, or is unmodified. In yet other embodiments the at least one RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 1-444, 458, 460, and 462-479 and includes at least one chemical modification. In other embodiments the RNA polynucleotide encodes an antigenic protein of any of SEQ ID NO: 1-444, 458, 460, and 462-479 and does not include any nucleotide modifications, or is unmodified.

In preferred aspects, vaccines of the invention (e.g., LNP-encapsulated mRNA vaccines) produce prophylactically- and/or therapeutically-efficacious levels, concentrations and/or titers of antigen-specific antibodies in the blood or serum of a vaccinated subject. As defined herein, the term antibody titer refers to the amount of antigen-specific antibody produces in s subject, e.g., a human subject. In exemplary embodiments, antibody titer is expressed as the inverse of the greatest dilution (in a serial dilution) that still gives a positive result. In exemplary embodiments, antibody titer is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody titer is determined or measured by neutralization assay, e.g., by microneutralization assay. In certain aspects, antibody titer measurement is expressed as a ratio, such as 1:40, 1:100, etc.

In exemplary embodiments of the invention, an efficacious vaccine produces an antibody titer of greater than 1:40, greater that 1:100, greater than 1:400, greater than 1:1000, greater than 1:2000, greater than 1:3000, greater than 1:4000, greater than 1:500, greater than 1:6000, greater than 1:7500, greater than 1:10000. In exemplary embodiments, the antibody titer is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the titer is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the titer is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.) In exemplary aspects of the invention, antigen-specific antibodies are measured in units of μg/ml or are measured in units of IU/L (International Units per liter) or mIU/ml (milli International Units per ml). In exemplary embodiments of the invention, an efficacious vaccine produces >0.5 μg/ml, >0.1 μg/ml, >0.2 μg/ml, >0.35 μg/ml, >0.5 μg/ml, >1 μg/ml, >2 μg/ml, >5 μg/ml or >10 μg/ml. In exemplary embodiments of the invention, an efficacious vaccine produces >10 mIU/ml, >20 mIU/ml, >50 mIU/ml, >100 mIU/ml, >200 mIU/ml, >500 mIU/ml or >1000 mIU/ml. In exemplary embodiments, the antibody level or concentration is produced or reached by 10 days following vaccination, by 20 days following vaccination, by 30 days following vaccination, by 40 days following vaccination, or by 50 or more days following vaccination. In exemplary embodiments, the level or concentration is produced or reached following a single dose of vaccine administered to the subject. In other embodiments, the level or concentration is produced or reached following multiple doses, e.g., following a first and a second dose (e.g., a booster dose.) In exemplary embodiments, antibody level or concentration is determined or measured by enzyme-linked immunosorbent assay (ELISA). In exemplary embodiments, antibody level or concentration is determined or measured by neutralization assay, e.g., by microneutralization assay.

The details of various embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the invention.

FIG. 1 shows data obtained from an ELISA, demonstrating that vaccination with RNA encoding HA stem protein sequences from different strains induces serum antibodies that bind to diverse panel of recombinant HA (rHA) proteins.

FIG. 2 shows data demonstrating that serum antibody titers obtained from mice vaccinated with a second set of mRNA vaccine antigens induces serum antibodies that bind to a diverse panel of recombinant HA (rHA) proteins.

FIG. 3 shows combining mRNAs encoding HA stem protein from an H1 strain with mRNA encoding HA stem protein from an H3 strain did not result in interference in the immune response to either HA.

FIGS. 4A-4B depict endpoint titers of the pooled serum from animals vaccinated with the test vaccines. In FIG. 4A, the vaccines tested are shown on the x-axis and the binding to HA from each of the different strains of influenza is plotted as an endpoint titer. In FIG. 4B, the vaccines tested are shown on the x-axis, and the endpoint titer to NP protein is plotted.

FIG. 5 shows an examination of functional antibody response through an assessment of the ability of serum to neutralize a panel of HA-pseudotyped viruses.

FIG. 6 shows data plotted as fold induction (sample luminescence/background luminescence) versus serum concentration.

FIG. 7 is a representation of cell-mediated immune responses following mRNA vaccination. Splenocytes were harvested from vaccinated mice and stimulated with a pool of overlapping NP peptides. The % of CD4 or CD8 T cells secreting one of the three cytokines (IFN-γ, IL-2, or TNF-α) is plotted.

FIG. 8 is a representation of cell-mediated immune responses following mRNA vaccination. Splenocytes were harvested from vaccinated mice and stimulated with a pool of overlapping HA peptides. The % of CD4 or CD8 T cells secreting one of the three cytokines (IFN-γ, IL-2, or TNF-α) is plotted.

FIG. 9 shows murine weight loss following challenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934. The percentage of weight lost as compared to baseline was calculated for each animal and was averaged across the group. The group average was plotted over time in days. Error bars represent standard error of the mean. Efficacy of the NIHGen6HASS-foldon+NP combination vaccine was better than that of either the NIHGen6HASS-foldon or NP mRNA vaccine alone.

FIG. 10 shows vaccine efficacy was similar at all vaccine doses, as well as with all co-formulation and co-delivery methods assessed. Following challenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934, the percentage of weight lost as compared to baseline was calculated for each animal and was averaged across the group. The group average was plotted over time in days. Error bars represent standard error of the mean.

FIG. 11A depicts the endpoint titers of the pooled serum from animals vaccinated with the test vaccines. FIG. 11B shows efficacy of the test vaccines (NIHGen6HASS-foldon and NIHGen6HASS-TM2) is similar. Following challenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934, the percentage of group weight lost as compared to baseline was calculated and plotted over time in days.

FIG. 12A shows that serum from mice immunized with mRNA encoding consensus HA antigens from the H1 subtype was able to detectably neutralize the PR8 luciferase virus. FIG. 12B shows that serum from mice immunized with mRNA encoding H1 subtype consensus HA antigens with a ferritin fusion sequence was able to detectably neutralize the PR8 luciferase virus, except for the Merck_pH1_Con_ferritin mRNA, while serum from mice vaccinated with an mRNA encoding the consensus H3 antigen with a ferritin fusion sequence was not able to neutralize the PR8 luciferase virus.

FIGS. 13A-13B show murine weight loss following challenge with a lethal dose of mouse-adapted H1N1 A/Puerto Rico/8/1934. The percentage of group weight lost as compared to baseline was calculated and plotted over time in days.

FIG. 14 shows the results of neutralization assays performed on a panel of pseudoviruses to assess the breadth of the serum-neutralizing activity elicited by the consensus HA antigens.

FIG. 15A depicts the ELISA endpoint anti-HA antibody titers of the pooled serum from animals vaccinated with the test vaccines. FIG. 15B shows murine weight loss following challenge with a lethal dose of mouse-adapted B/Ann Arbor/1954. The percentage of group weight lost as compared to baseline was calculated and plotted over time in days. FIGS. 16A-16C show data depicting the NIHGen6HASS-foldon vaccine's robust antibody response as measured by ELISA assay (plates coated with recombinantly-expressed NIHGen6HASS-foldon [HA stem] or NP proteins). FIG. 16A shows titers to HA stem, over time, for four rhesus macaques previously vaccinated with FLUZONE® and boosted a single time with NIHGen6HASS-foldon mRNA vaccine. FIG. 16B depicts titers to HA stem, over time, from four rhesus macaques vaccinated at days 0, 28 and 56 with the same NIHGen6HASS-foldon RNA vaccine. FIG. 16C illustrates antibody titers to NP, over time, for four rhesus macaques vaccinated at days 0, 28 and 56 with the NP mRNA vaccine and shows that the vaccine elicited a robust antibody response to NP.

FIGS. 17A-17B show the results of ELISAs examining the presence of antibody capable of binding to recombinant hemagglutinin (rHA) from a wide variety of influenza strains. FIG. 17A shows the results of rhesus macaques previously vaccinated with FLUZONE® and boosted a single time with NIHGen6HASS-foldon mRNA vaccine, and FIG. 17B shows the results of niave rhesus macaques vaccinated at days 0, 28 and 56 with the same NIHGen6HASS-foldon RNA vaccine.

FIG. 18 is a representation of cell-mediated immune responses following mRNA vaccination. Peripheral blood mononuclear cells were harvested from vaccinated macaques and stimulated with a pool of overlapping NP peptides. The % of CD4 or CD8 T cells secreting one of the three cytokines (IFN-γ, IL-2, or TNF-α) is plotted.

FIG. 19 shows the results of hemagglutination inhibition (HAI) tests. Placebo subjects (targeted to be 25% of each cohort) are included. The data is shown per protocol, and excludes those that did not receive the day 22 injection.

FIG. 20 shows the HAI test kinetics per subject, including the placebo subjects (targeted to be 25% of each cohort).

FIG. 21 shows the results of microneutralization (MN) tests, including placebo subjects (targeted to be 25% of each cohort). The data shown is per protocol, and excludes those that did not receive a day 22 injection.

FIG. 22 shows the MN test kinetics per subject, including the placebo subjects (targeted to be 25% of each cohort).

FIG. 23 is a graph depicting the very strong correlation between HAI and MN. The data includes placebo subjects (targeted to be 25% of each cohort).

DETAILED DESCRIPTION

Embodiments of the present disclosure provide RNA (e.g., mRNA) vaccines that include polynucleotide encoding an influenza virus antigen. Influenza virus RNA vaccines, as provided herein may be used to induce a balanced immune response, comprising both cellular and humoral immunity, without many of the risks associated with DNA vaccination.

In some embodiments, the virus is a strain of Influenza A or Influenza B or combinations thereof. In some embodiments, the strain of Influenza A or Influenza B is associated with birds, pigs, horses, dogs, humans or non-human primates. In some embodiments, the antigenic polypeptide encodes a hemagglutinin protein or immunogenic fragment thereof. In some embodiments, the hemagglutinin protein is H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, H17, H18, or an immunogenic fragment thereof. In some embodiments, the hemagglutinin protein does not comprise a head domain. In some embodiments, the hemagglutinin protein comprises a portion of the head domain. In some embodiments, the hemagglutinin protein does not comprise a cytoplasmic domain. In some embodiments, the hemagglutinin protein comprises a portion of the cytoplasmic domain. In some embodiments, the truncated hemagglutinin protein comprises a portion of the transmembrane domain. In some embodiments, the amino acid sequence of the hemagglutinin protein or fragment thereof comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% 98%, or 99% identify with any of the amino acid sequences having an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13). In some embodiments, the virus is selected from the group consisting of H1N1, H3N2, H7N9, and H10N8. In some embodiments, the antigenic polypeptide is selected from those proteins having an amino acid sequences identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13), or immunogenic fragments thereof.

Some embodiments provide influenza vaccines comprising one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein and a pharmaceutically acceptable carrier or excipient, formulated within a cationic lipid nanoparticle. In some embodiments, the hemagglutinin protein is selected from H1, H7 and H10. In some embodiments, the RNA polynucleotide further encodes neuraminidase protein. In some embodiments, the hemagglutinin protein is derived from a strain of Influenza A virus or Influenza B virus or combinations thereof. In some embodiments, the Influenza virus is selected from H1N1, H3N2, H7N9, and H10N8.

Some embodiments provide methods of preventing or treating influenza viral infection comprising administering to a subject any of the vaccines described herein. In some embodiments, the antigen specific immune response comprises a T cell response. In some embodiments, the antigen specific immune response comprises a B cell response. In some embodiments, the antigen specific immune response comprises both a T cell response and a B cell response. In some embodiments, the method of producing an antigen specific immune response involves a single administration of the vaccine. In some embodiments, the vaccine is administered to the subject by intradermal, intramuscular injection, subcutaneous injection, intranasal inoculation, or oral administration.

In some embodiments, the RNA (e.g., mRNA) polynucleotides or portions thereof may encode one or more polypeptides or fragments thereof of an influenza strain as an antigen. Such antigens include, but are not limited to, those antigens encoded by the polynucleotides or portions thereof of the polynucleotides listed in the Tables presented herein. In the Tables, the GenBank Accession Number or GI Accession Number represents either the complete or partial CDS of the encoded antigen. The RNA (e.g., mRNA) polynucleotides may comprise a region of any of the sequences listed in the Tables or entire coding region of the mRNA listed. They may comprise hybrid or chimeric regions, or mimics or variants.

In the following embodiments, when referring to at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding for a specific influenza virus protein, the polynucleotides may comprise a coding region of the specific influenza virus protein sequence or the entire coding region of the mRNA for that specific influenza virus protein sequence.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein or immunogenic fragment thereof (e.g., at least one HA1, HA2, or a combination of both, of H1-H18).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein or immunogenic fragment thereof (e.g., at least one HA1, HA2, or a combination of both, of H1-H18) and at least one protein, or immunogenic fragment thereof, selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, (e.g., at least one of H1-H18) and at least two proteins, or immunogenic fragments thereof, selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, (e.g., at least one of H1-H18) and at least three proteins, or immunogenic fragments thereof, selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, (e.g., at least one of H1-H18) and at least four proteins, or immunogenic fragments thereof, selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, (e.g., at least one of H1-H18) and at least five proteins, or immunogenic fragments thereof, selected from a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein and a NS2 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein or immunogenic fragment thereof (e.g., at least one of H1-H18), a NP protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, a M2 protein, or immunogenic fragment thereof, a NS1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a NA protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment, thereof, a NP protein and a NA protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, a NP protein, or immunogenic fragment, thereof and a M protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NA protein and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, a M1 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a M2 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a M2 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NS1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, and a NA protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a NA protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NP protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a M protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NA protein and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NA protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a M1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a M2 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a M2 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA1 protein, or immunogenic fragment thereof, a NS1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), and a NA protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), and a NS1 protein obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NP protein, or immunogenic fragment thereof, and a NA protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NP protein, or immunogenic fragment thereof, and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NP protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NP protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NP protein and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NA protein, or immunogenic fragment thereof, and a M1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NA protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NA protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NA protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a M1 protein, or immunogenic fragment thereof, and a M2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a M1 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a M1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a M2 protein, or immunogenic fragment thereof, and a NS1 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a H HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a M2 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a HA protein (HA or derivatives thereof comprising antigenic sequences from HA1 and/or HA2), a NS1 protein, or immunogenic fragment thereof, and a NS2 protein, or immunogenic fragment thereof, obtained from influenza virus.

It should be understood that the present disclosure is not intended to be limited by a particular strain of influenza virus. The strain of influenza virus used, as provided herein, may be any strain of influenza virus. Examples of preferred strains of influenza virus and preferred influenza antigens are provided in Tables 7-13 below.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H1/PuertoRico/8/1934.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H1/New Caledonia/20/1999.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H1/California/04/2009.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H5/Vietnam/1194/2004.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H2/Japan/305/1957.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H9/Hong Kong/1073/99.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H3/Aichi/2/1968.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H3/Brisbane/10/2007.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H7/Anhui/1/2013.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H10/Jiangxi-Donghu/346/2013.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H3/Wisconsin/67/2005.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza antigenic polypeptide (e.g., a HA protein, a NP protein, a NA protein, a M1 protein, a M2 protein, a NS1 protein, a NS2 protein, an immunogenic fragment of any of the foregoing influenza antigens, a variant or homolog of any of the foregoing influenza antigens, or any combination of two or more of the foregoing influenza antigens, variants or homologs) obtained from H1/Vietnam/850/2009.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding influenza H7N9 HA1 protein, ferritin and a dendritic cell targeting peptide (see, e.g., Ren X et al. Emerg Infect Dis 2013; 19(11):1881-84; Steel J et al. mBio 2010; 1(1):e00018-10; Kanekiyo M. et al. Nature 2013; 499:102-6, each of which is incorporated herein by reference).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an avian influenza H7 HA protein.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding influenza H7 HA1 protein (see, e.g., Steel J et al. mBio 2010; 1(1):e00018-10).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding influenza H7N9 HA1 protein and ferritin (see, e.g., Kanekiyo M. et al. Nature 2013; 499:102-6).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza H5N1 protein. In some embodiments, the influenza H5N1 protein is from a human strain.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza HIN1 protein.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza protein from an influenza A strain, such as human H1N1, H5N1, H9N2 or H3N2.

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an influenza H1N1HA having a nanoscaffold (see, e.g., Walker A et al. Sci Rep 2011:1(5):1-8, incorporated herein by reference).

In some embodiments, a vaccine comprises at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding an aglycosylated influenza H1N1 HA (see, e.g., Chen J et al. PNAS USA 2014; 111(7):2476-81, incorporated herein by reference).

An influenza vaccine may comprise, for example, at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one influenza HA2 stem antigen selected from the influenza HA2 stem antigens, provided herein, for example, those listed in Table 16, comprising an amino acid sequence identified by any one of SEQ ID NO: 394-412.

The present disclosure also encompasses an influenza vaccine comprising, for example, at least one RNA (e.g., mRNA) polynucleotide having a nucleic acid sequence selected from the influenza sequences listed in SEQ ID NO: 491-503 (see also: Mallajosyula V V et al., Front Immunol. 2015 Jun. 26; 6:329.; Mallajosyula V V et al., Proc Natl Acad Sci USA. 2014 Jun. 24; 111(25):E2514-23.; Bommakanti G, et al., J Virol. 2012 December; 86(24):13434-44; Bommakanti G et al., Proc Natl Acad Sci USA. 2010 Aug. 3; 107(31): 13701-6 and Yassine et al., Nat Med. 2015 September; 21(9):1065-70; Impagliazzo et al., Science, 2015 Sep. 18; 349(6254)).

The entire contents of International Application No. PCT/US2015/02740 is incorporated herein by reference.

In some embodiments the vaccines described herein are consensus sequences. A “consensus sequence” as used herein refers to a polypeptide sequence based on analysis of an alignment of multiple subtypes of a particular influenza antigen. mRNA sequences that encode a consensus polypeptide sequence may be prepared and used to induce broad immunity against multiple subtypes or serotypes of a particular influenza antigen.

The mRNA encoding influenza antigens provided herein can be arranged as a vaccine that causes seroconversion in vaccinated mammals and provides cross-reactivity against a broad range of seasonal strains of influenza and also pandemic strains of influenza. The seroconversion and broad cross-reactivity can be determined by measuring inhibiting titers against different hemagglutinin strains of influenza. Preferred combinations include at least two antigens from each of the influenza antigens described herein.

It has been discovered that the mRNA vaccines described herein are superior to current vaccines in several ways. First, the lipid nanoparticle (LNP) delivery is superior to other formulations including a protamine base approach described in the literature and no additional adjuvants are to be necessary. The use of LNPs enables the effective delivery of chemically modified or unmodified mRNA vaccines. Additionally it has been demonstrated herein that both modified and unmodified LNP formulated mRNA vaccines were superior to conventional vaccines by a significant degree. In some embodiments the mRNA vaccines of the invention are superior to conventional vaccines by a factor of at least 10 fold, 20 fold, 40 fold, 50 fold, 100 fold, 500 fold or 1,000 fold.

Although attempts have been made to produce functional RNA vaccines, including mRNA vaccines and self-replicating RNA vaccines, the therapeutic efficacy of these RNA vaccines have not yet been fully established. Quite surprisingly, the inventors have discovered, according to aspects of the invention a class of formulations for delivering mRNA vaccines in vivo that results in significantly enhanced, and in many respects synergistic, immune responses including enhanced antigen generation and functional antibody production with neutralization capability. These results can be achieved even when significantly lower doses of the mRNA are administered in comparison with mRNA doses used in other classes of lipid based formulations. The formulations of the invention have demonstrated significant unexpected in vivo immune responses sufficient to establish the efficacy of functional mRNA vaccines as prophylactic and therapeutic agents. Additionally, self-replicating RNA vaccines rely on viral replication pathways to deliver enough RNA to a cell to produce an immunogenic response. The formulations of the invention do not require viral replication to produce enough protein to result in a strong immune response. Thus, the mRNA of the invention are not self-replicating RNA and do not include components necessary for viral replication.

The invention involves, in some aspects, the surprising finding that lipid nanoparticle (LNP) formulations significantly enhance the effectiveness of mRNA vaccines, including chemically modified and unmodified mRNA vaccines. The efficacy of mRNA vaccines formulated in LNP was examined in vivo using several distinct antigens. The results presented herein demonstrate the unexpected superior efficacy of the mRNA vaccines formulated in LNP over other commercially available vaccines.

In addition to providing an enhanced immune response, the formulations of the invention generate a more rapid immune response with fewer doses of antigen than other vaccines tested. The mRNA-LNP formulations of the invention also produce quantitatively and qualitatively better immune responses than vaccines formulated in a different carriers.

The data described herein demonstrate that the formulations of the invention produced significant unexpected improvements over existing antigen vaccines. Additionally, the mRNA-LNP formulations of the invention are superior to other vaccines even when the dose of mRNA is lower than other vaccines. mRNA encoding HA protein sequences such as HA stem sequences from different strains have been demonstrated to induce serum antibodies that bind to diverse panel of recombinant HA (rHA) proteins. The vaccine efficacy in mice was similar at all vaccine doses, as well as with all co-formulation and co-delivery methods assessed.

The LNP used in the studies described herein has been used previously to deliver siRNA in various animal models as well as in humans. In view of the observations made in association with the siRNA delivery of LNP formulations, the fact that LNP is useful in vaccines is quite surprising. It has been observed that therapeutic delivery of siRNA formulated in LNP causes an undesirable inflammatory response associated with a transient IgM response, typically leading to a reduction in antigen production and a compromised immune response. In contrast to the findings observed with siRNA, the LNP-mRNA formulations of the invention are demonstrated herein to generate enhanced IgG levels, sufficient for prophylactic and therapeutic methods rather than transient IgM responses.

Nucleic Acids/Polynucleotides

Influenza virus vaccines, as provided herein, comprise at least one (one or more) ribonucleic acid (RNA) (e.g., mRNA) polynucleotide having an open reading frame encoding at least one Influenza antigenic polypeptide. The term “nucleic acid” includes any compound and/or substance that comprises a polymer of nucleotides (nucleotide monomer). These polymers are referred to as polynucleotides. Thus, the terms “nucleic acid” and “polynucleotide” are used interchangeably.

Nucleic acids may be or may include, for example, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs, including LNA having a β-D-ribo configuration, α-LNA having an α-L-ribo configuration (a diastereomer of LNA), 2′-amino-LNA having a 2′-amino functionalization, and 2′-amino-α-LNA having a 2′-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA) or chimeras or combinations thereof.

In some embodiments, polynucleotides of the present disclosure function as messenger RNA (mRNA). “Messenger RNA” (mRNA) refers to any polynucleotide that encodes a (at least one) polypeptide (a naturally-occurring, non-naturally-occurring, or modified polymer of amino acids) and can be translated to produce the encoded polypeptide in vitro, in vivo, in situ or ex vivo. The skilled artisan will appreciate that, except where otherwise noted, polynucleotide sequences set forth in the instant application will recite “T”s in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the “T”s would be substituted for “U” s. Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each “T” of the DNA sequence is substituted with “U.”

The basic components of an mRNA molecule typically include at least one coding region, a 5′ untranslated region (UTR), a 3′ UTR, a 5′ cap and a poly-A tail. Polynucleotides of the present disclosure may function as mRNA but can be distinguished from wild-type mRNA in their functional and/or structural design features, which serve to overcome existing problems of effective polypeptide expression using nucleic-acid based therapeutics.

In some embodiments, a RNA polynucleotide of an RNA (e.g., mRNA) vaccine encodes 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9 or 9-10 antigenic polypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide of an influenza vaccine encodes at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 antigenic polypeptides. In some embodiments, a RNA (e.g., mRNA) polynucleotide of an influenza vaccine encodes at least 100 or at least 200 antigenic polypeptides. In some embodiments, a RNA polynucleotide of an influenza vaccine encodes 1-10, 5-15, 10-20, 15-25, 20-30, 25-35, 30-40, 35-45, 40-50, 1-50, 1-100, 2-50 or 2-100 antigenic polypeptides.

Polynucleotides of the present disclosure, in some embodiments, are codon optimized. Codon optimization methods are known in the art and may be used as provided herein. Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias GC content to increase mRNA stability or reduce secondary structures; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove/add post translation modification sites in encoded protein (e.g. glycosylation sites); add, remove or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of the protein to fold properly; or to reduce or eliminate problem secondary structures within the polynucleotide. Codon optimization tools, algorithms and services are known in the art non-limiting examples include services from GeneArt (Life Technologies), DNA2.0 (Menlo Park Calif.) and/or proprietary methods. In some embodiments, the open reading frame (ORF) sequence is optimized using optimization algorithms.

In some embodiments, a codon optimized sequence shares less than 95% sequence identity, less than 90% sequence identity, less than 85% sequence identity, less than 80% sequence identity, or less than 75% sequence identity to a naturally-occurring or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or antigenic polypeptide)).

In some embodiments, a codon-optimized sequence shares between 65% and 85% (e.g., between about 67% and about 85%, or between about 67% and about 80%) sequence identity to a naturally-occurring sequence or a wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)). In some embodiments, a codon-optimized sequence shares between 65% and 75%, or about 80% sequence identity to a naturally-occurring sequence or wild-type sequence (e.g., a naturally-occurring or wild-type mRNA sequence encoding a polypeptide or protein of interest (e.g., an antigenic protein or polypeptide)).

In some embodiments a codon-optimized RNA (e.g., mRNA) may, for instance, be one in which the levels of G/C are enhanced. The G/C-content of nucleic acid molecules may influence the stability of the RNA. RNA having an increased amount of guanine (G) and/or cytosine (C) residues may be functionally more stable than nucleic acids containing a large amount of adenine (A) and thymine (T) or uracil (U) nucleotides. WO02/098443 discloses a pharmaceutical composition containing an mRNA stabilized by sequence modifications in the translated region. Due to the degeneracy of the genetic code, the modifications work by substituting existing codons for those that promote greater RNA stability without changing the resulting amino acid. The approach is limited to coding regions of the RNA.

Antigens/Antigenic Polypeptides

In some embodiments, an antigenic polypeptide (e.g., at least one Influenza antigenic polypeptide) is longer than 25 amino acids and shorter than 50 amino acids. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing. A polypeptide may be a single molecule or may be a multi-molecular complex such as a dimer, trimer or tetramer. Polypeptides may also comprise single chain polypeptides or multichain polypeptides, such as antibodies or insulin, and may be associated or linked to each other. Most commonly, disulfide linkages are found in multichain polypeptides. The term “polypeptide” may also apply to amino acid polymers in which at least one amino acid residue is an artificial chemical analogue of a corresponding naturally-occurring amino acid.

A “polypeptide variant” is a molecule that differs in its amino acid sequence relative to a native sequence or a reference sequence. Amino acid sequence variants may possess substitutions, deletions, insertions, or a combination of any two or three of the foregoing, at certain positions within the amino acid sequence, as compared to a native sequence or a reference sequence. Ordinarily, variants possess at least 50% identity to a native sequence or a reference sequence. In some embodiments, variants share at least 80% identity or at least 90% identity with a native sequence or a reference sequence.

In some embodiments “variant mimics” are provided. A “variant mimic” contains at least one amino acid that would mimic an activated sequence. For example, glutamate may serve as a mimic for phosphoro-threonine and/or phosphoro-serine. Alternatively, variant mimics may result in deactivation or in an inactivated product containing the mimic. For example, phenylalanine may act as an inactivating substitution for tyrosine, or alanine may act as an inactivating substitution for serine.

“Orthologs” refers to genes in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same function in the course of evolution. Identification of orthologs is important for reliable prediction of gene function in newly sequenced genomes.

“Analogs” is meant to include polypeptide variants that differ by one or more amino acid alterations, for example, substitutions, additions or deletions of amino acid residues that still maintain one or more of the properties of the parent or starting polypeptide.

The present disclosure provides several types of compositions that are polynucleotide or polypeptide based, including variants and derivatives. These include, for example, substitutional, insertional, deletion and covalent variants and derivatives. The term “derivative” is synonymous with the term “variant” and generally refers to a molecule that has been modified and/or changed in any way relative to a reference molecule or a starting molecule.

As such, polynucleotides encoding peptides or polypeptides containing substitutions, insertions and/or additions, deletions and covalent modifications with respect to reference sequences, in particular the polypeptide sequences disclosed herein, are included within the scope of this disclosure. For example, sequence tags or amino acids, such as one or more lysines, can be added to peptide sequences (e.g., at the N-terminal or C-terminal ends). Sequence tags can be used for peptide detection, purification or localization. Lysines can be used to increase peptide solubility or to allow for biotinylation. Alternatively, amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences. Certain amino acids (e.g., C-terminal residues or N-terminal residues) alternatively may be deleted depending on the use of the sequence, as for example, expression of the sequence as part of a larger sequence that is soluble, or linked to a solid support.

“Substitutional variants” when referring to polypeptides are those that have at least one amino acid residue in a native or starting sequence removed and a different amino acid inserted in its place at the same position. Substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more (e.g., 3, 4 or 5) amino acids have been substituted in the same molecule.

As used herein the term “conservative amino acid substitution” refers to the substitution of an amino acid that is normally present in the sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine and leucine for another non-polar residue. Likewise, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another acidic residue are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, methionine for a polar (hydrophilic) residue such as cysteine, glutamine, glutamic acid or lysine and/or a polar residue for a non-polar residue.

“Features” when referring to polypeptide or polynucleotide are defined as distinct amino acid sequence-based or nucleotide-based components of a molecule respectively. Features of the polypeptides encoded by the polynucleotides include surface manifestations, local conformational shape, folds, loops, half-loops, domains, half-domains, sites, termini and any combination(s) thereof.

As used herein when referring to polypeptides the term “domain” refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding capacity, serving as a site for protein-protein interactions).

As used herein when referring to polypeptides the terms “site” as it pertains to amino acid based embodiments is used synonymously with “amino acid residue” and “amino acid side chain.” As used herein when referring to polynucleotides the terms “site” as it pertains to nucleotide based embodiments is used synonymously with “nucleotide.” A site represents a position within a peptide or polypeptide or polynucleotide that may be modified, manipulated, altered, derivatized or varied within the polypeptide-based or polynucleotide-based molecules.

As used herein the terms “termini” or “terminus” when referring to polypeptides or polynucleotides refers to an extremity of a polypeptide or polynucleotide respectively. Such extremity is not limited only to the first or final site of the polypeptide or polynucleotide but may include additional amino acids or nucleotides in the terminal regions. Polypeptide-based molecules may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH2)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). Proteins are in some cases made up of multiple polypeptide chains brought together by disulfide bonds or by non-covalent forces (multimers, oligomers). These proteins have multiple N- and C-termini. Alternatively, the termini of the polypeptides may be modified such that they begin or end, as the case may be, with a non-polypeptide based moiety such as an organic conjugate.

As recognized by those skilled in the art, protein fragments, functional protein domains, and homologous proteins are also considered to be within the scope of polypeptides of interest. For example, provided herein is any protein fragment (meaning a polypeptide sequence at least one amino acid residue shorter than a reference polypeptide sequence but otherwise identical) of a reference protein having a length of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or longer than 100 amino acids. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 (contiguous) amino acids that are 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% identical to any of the sequences described herein can be utilized in accordance with the disclosure. In some embodiments, a polypeptide includes 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations as shown in any of the sequences provided herein or referenced herein. In another example, any protein that includes a stretch of 20, 30, 40, 50, or 100 amino acids that are greater than 80%, 90%, 95%, or 100% identical to any of the sequences described herein, wherein the protein has a stretch of 5, 10, 15, 20, 25, or 30 amino acids that are less than 80%, 75%, 70%, 65% to 60% identical to any of the sequences described herein can be utilized in accordance with the disclosure.

Polypeptide or polynucleotide molecules of the present disclosure may share a certain degree of sequence similarity or identity with the reference molecules (e.g., reference polypeptides or reference polynucleotides), for example, with art-described molecules (e.g., engineered or designed molecules or wild-type molecules). The term “identity,” as known in the art, refers to a relationship between the sequences of two or more polypeptides or polynucleotides, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between two sequences as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., “algorithms”). Identity of related peptides can be readily calculated by known methods. “% identity” as it applies to polypeptide or polynucleotide sequences is defined as the percentage of residues (amino acid residues or nucleic acid residues) in the candidate amino acid or nucleic acid sequence that are identical with the residues in the amino acid sequence or nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Methods and computer programs for the alignment are well known in the art. Identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation. Generally, variants of a particular polynucleotide or polypeptide have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference polynucleotide or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al. (1997).” Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. 25:3389-3402). Another popular local alignment technique is based on the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981) “Identification of common molecular subsequences.” J. Mol. Biol. 147:195-197). A general global alignment technique based on dynamic programming is the Needleman-Wunsch algorithm (Needleman, S. B. & Wunsch, C. D. (1970) “A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443-453). More recently, a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) was developed that purportedly produces global alignment of nucleotide and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Other tools are described herein, specifically in the definition of “identity” below.

As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g. between nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Polymeric molecules (e.g. nucleic acid molecules (e.g. DNA molecules and/or RNA molecules) and/or polypeptide molecules) that share a threshold level of similarity or identity determined by alignment of matching residues are termed homologous. Homology is a qualitative term that describes a relationship between molecules and can be based upon the quantitative similarity or identity. Similarity or identity is a quantitative term that defines the degree of sequence match between two compared sequences. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term “homologous” necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). Two polynucleotide sequences are considered homologous if the polypeptides they encode are at least 50%, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. Two protein sequences are considered homologous if the proteins are at least 50%, 60%, 70%, 80%, or 90% identical for at least one stretch of at least 20 amino acids.

Homology implies that the compared sequences diverged in evolution from a common origin. The term “homolog” refers to a first amino acid sequence or nucleic acid sequence (e.g., gene (DNA or RNA) or protein sequence) that is related to a second amino acid sequence or nucleic acid sequence by descent from a common ancestral sequence. The term “homolog” may apply to the relationship between genes and/or proteins separated by the event of speciation or to the relationship between genes and/or proteins separated by the event of genetic duplication. “Orthologs” are genes (or proteins) in different species that evolved from a common ancestral gene (or protein) by speciation. Typically, orthologs retain the same function in the course of evolution. “Paralogs” are genes (or proteins) related by duplication within a genome. Orthologs retain the same function in the course of evolution, whereas paralogs evolve new functions, even if these are related to the original one.

The term “identity” refers to the overall relatedness between polymeric molecules, for example, between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleic acid sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleic acid sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleic acid sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12, 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).

Multiprotein and Multicomponent Vaccines

The present disclosure encompasses influenza vaccines comprising multiple RNA (e.g., mRNA) polynucleotides, each encoding a single antigenic polypeptide, as well as influenza vaccines comprising a single RNA polynucleotide encoding more than one antigenic polypeptide (e.g., as a fusion polypeptide). Thus, a vaccine composition comprising a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a first antigenic polypeptide and a RNA (e.g., mRNA) polynucleotide having an open reading frame encoding a second antigenic polypeptide encompasses (a) vaccines that comprise a first RNA polynucleotide encoding a first antigenic polypeptide and a second RNA polynucleotide encoding a second antigenic polypeptide, and (b) vaccines that comprise a single RNA polynucleotide encoding a first and second antigenic polypeptide (e.g., as a fusion polypeptide). RNA (e.g., mRNA) vaccines of the present disclosure, in some embodiments, comprise 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10), or more, RNA polynucleotides having an open reading frame, each of which encodes a different antigenic polypeptide (or a single RNA polynucleotide encoding 2-10, or more, different antigenic polypeptides). The antigenic polypeptides may be selected from any of the influenza antigenic polypeptides described herein.

In some embodiments, a multicomponent vaccine comprises at least one RNA (e.g., mRNA) polynucleotide encoding at least one influenza antigenic polypeptide fused to a signal peptide (e.g., SEQ ID NO: 488-490). The signal peptide may be fused at the N-terminus or the C-terminus of an antigenic polypeptide.

Signal Peptides

In some embodiments, antigenic polypeptides encoded by influenza RNA (e.g., mRNA) polynucleotides comprise a signal peptide. Signal peptides, comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway. Signal peptides generally include three regions: an N-terminal region of differing length, which usually comprises positively charged amino acids; a hydrophobic region; and a short carboxy-terminal peptide region. In eukaryotes, the signal peptide of a nascent precursor protein (pre-protein) directs the ribosome to the rough endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it for processing. ER processing produces mature proteins, wherein the signal peptide is cleaved from precursor proteins, typically by a ER-resident signal peptidase of the host cell, or they remain uncleaved and function as a membrane anchor. A signal peptide may also facilitate the targeting of the protein to the cell membrane. The signal peptide, however, is not responsible for the final destination of the mature protein. Secretory proteins devoid of additional address tags in their sequence are by default secreted to the external environment. During recent years, a more advanced view of signal peptides has evolved, showing that the functions and immunodominance of certain signal peptides are much more versatile than previously anticipated.

Influenza vaccines of the present disclosure may comprise, for example, RNA (e.g., mRNA) polynucleotides encoding an artificial signal peptide, wherein the signal peptide coding sequence is operably linked to and is in frame with the coding sequence of the antigenic polypeptide. Thus, influenza vaccines of the present disclosure, in some embodiments, produce an antigenic polypeptide fused to a signal peptide. In some embodiments, a signal peptide is fused to the N-terminus of the antigenic polypeptide. In some embodiments, a signal peptide is fused to the C-terminus of the antigenic polypeptide.

In some embodiments, the signal peptide fused to the antigenic polypeptide is an artificial signal peptide. In some embodiments, an artificial signal peptide fused to the antigenic polypeptide encoded by the RNA (e.g., mRNA) vaccine is obtained from an immunoglobulin protein, e.g., an IgE signal peptide or an IgG signal peptide. In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine is an Ig heavy chain epsilon-1 signal peptide (IgE HC SP) having the sequence of: MDWTWILFLVAAATRVHS; SEQ ID NO: 481. In some embodiments, a signal peptide fused to the antigenic polypeptide encoded by the (e.g., mRNA) RNA (e.g., mRNA) vaccine is an IgGk chain V-III region HAH signal peptide (IgGk SP) having the sequence of METPAQLLFLLLLWLPDTTG; SEQ ID NO: 480. In some embodiments, the signal peptide is selected from: Japanese encephalitis PRM signal sequence (MLGSNSGQRVVFTILLLLVAPAYS; SEQ ID NO: 482), VSVg protein signal sequence (MKCLLYLAFLFIGVNCA; SEQ ID NO: 483) and Japanese encephalitis JEV signal sequence (MWLVSLAIVTACAGA; SEQ ID NO: 484).

In some embodiments, the antigenic polypeptide encoded by a RNA (e.g., mRNA) vaccine comprises an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479 (see also Tables 7-13) fused to a signal peptide identified by any one of SEQ ID NO: 480-484. The examples disclosed herein are not meant to be limiting and any signal peptide that is known in the art to facilitate targeting of a protein to ER for processing and/or targeting of a protein to the cell membrane may be used in accordance with the present disclosure.

A signal peptide may have a length of 15-60 amino acids. For example, a signal peptide may have a length of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 amino acids. In some embodiments, a signal peptide has a length of 20-60, 25-60, 30-60, 35-60, 40-60, 45-60, 50-60, 55-60, 15-55, 20-55, 25-55, 30-55, 35-55, 40-55, 45-55, 50-55, 15-50, 20-50, 25-50, 30-50, 35-50, 40-50, 45-50, 15-45, 20-45, 25-45, 30-45, 35-45, 40-45, 15-40, 20-40, 25-40, 30-40, 35-40, 15-35, 20-35, 25-35, 30-35, 15-30, 20-30, 25-30, 15-25, 20-25, or 15-20 amino acids.

A signal peptide is typically cleaved from the nascent polypeptide at the cleavage junction during ER processing. The mature antigenic polypeptide produce by an influenza RNA (e.g., mRNA) vaccine of the present disclosure typically does not comprise a signal peptide.

Chemical Modifications

Influenza vaccines of the present disclosure, in some embodiments, comprise at least RNA (e.g. mRNA) polynucleotide having an open reading frame encoding at least one antigenic polypeptide that comprises at least one chemical modification.

The terms “chemical modification” and “chemically modified” refer to modification with respect to adenosine (A), guanosine (G), uridine (U), thymidine (T) or cytidine (C) ribonucleosides or deoxyribonucleosides in at least one of their position, pattern, percent or population. Generally, these terms do not refer to the ribonucleotide modifications in naturally occurring 5′-terminal mRNA cap moieties. With respect to a polypeptide, the term “modification” refers to a modification relative to the canonical set 20 amino acids. Polypeptides, as provided herein, are also considered “modified” of they contain amino acid substitutions, insertions or a combination of substitutions and insertions.

Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise various (more than one) different modifications. In some embodiments, a particular region of a polynucleotide contains one, two or more (optionally different) nucleoside or nucleotide modifications. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced to a cell or organism, exhibits reduced degradation in the cell or organism, respectively, relative to an unmodified polynucleotide. In some embodiments, a modified RNA polynucleotide (e.g., a modified mRNA polynucleotide), introduced into a cell or organism, may exhibit reduced immunogenicity in the cell or organism, respectively (e.g., a reduced innate response).

Modifications of polynucleotides include, without limitation, those described herein. Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) may comprise modifications that are naturally-occurring, non-naturally-occurring or the polynucleotide may comprise a combination of naturally-occurring and non-naturally-occurring modifications. Polynucleotides may include any useful modification, for example, of a sugar, a nucleobase, or an internucleoside linkage (e.g., to a linking phosphate, to a phosphodiester linkage or to the phosphodiester backbone).

Polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides), in some embodiments, comprise non-natural modified nucleotides that are introduced during synthesis or post-synthesis of the polynucleotides to achieve desired functions or properties. The modifications may be present on an internucleotide linkages, purine or pyrimidine bases, or sugars. The modification may be introduced with chemical synthesis or with a polymerase enzyme at the terminal of a chain or anywhere else in the chain. Any of the regions of a polynucleotide may be chemically modified.

The present disclosure provides for modified nucleosides and nucleotides of a polynucleotide (e.g., RNA polynucleotides, such as mRNA polynucleotides). A “nucleoside” refers to a compound containing a sugar molecule (e.g., a pentose or ribose) or a derivative thereof in combination with an organic base (e.g., a purine or pyrimidine) or a derivative thereof (also referred to herein as “nucleobase”). A nucleotide” refers to a nucleoside, including a phosphate group. Modified nucleotides may by synthesized by any useful method, such as, for example, chemically, enzymatically, or recombinantly, to include one or more modified or non-natural nucleosides. Polynucleotides may comprise a region or regions of linked nucleosides. Such regions may have variable backbone linkages. The linkages may be standard phosphodioester linkages, in which case the polynucleotides would comprise regions of nucleotides.

Modified nucleotide base pairing encompasses not only the standard adenosine-thymine, adenosine-uracil, or guanosine-cytosine base pairs, but also base pairs formed between nucleotides and/or modified nucleotides comprising non-standard or modified bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. Any combination of base/sugar or linker may be incorporated into polynucleotides of the present disclosure.

Modifications of polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) that are useful in the vaccines of the present disclosure include, but are not limited to the following: 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine; 2-methylthio-N6-methyladenosine; 2-methylthio-N6-threonyl carbamoyladenosine; N6-glycinylcarbamoyladenosine; N6-isopentenyladenosine; N6-methyladenosine; N6-threonylcarbamoyladenosine; 1,2′-O-dimethyladenosine; 1-methyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); 2-methyladenosine; 2-methylthio-N6 isopentenyladenosine; 2-methylthio-N6-hydroxynorvalyl carbamoyladenosine; 2′-O-methyladenosine; 2′-O-ribosyladenosine (phosphate); Isopentenyladenosine; N6-(cis-hydroxyisopentenyl)adenosine; N6,2′-O-dimethyladenosine; N6,2′-O-dimethyladenosine; N6,N6,2′-O-trimethyladenosine; N6,N6-dimethyladenosine; N6-acetyladenosine; N6-hydroxynorvalylcarbamoyladenosine; N6-methyl-N6-threonylcarbamoyladenosine; 2-methyladenosine; 2-methylthio-N6-isopentenyladenosine; 7-deaza-adenosine; N1-methyl-adenosine; N6,N6 (dimethyl)adenine; N6-cis-hydroxy-isopentenyl-adenosine; α-thio-adenosine; 2 (amino)adenine; 2 (aminopropyl)adenine; 2 (methylthio) N6 (isopentenyl)adenine; 2-(alkyl)adenine; 2-(aminoalkyl)adenine; 2-(aminopropyl)adenine; 2-(halo)adenine; 2-(halo)adenine; 2-(propyl)adenine; 2′-Amino-2′-deoxy-ATP; 2′-Azido-2′-deoxy-ATP; 2′-Deoxy-2′-a-aminoadenosine TP; 2′-Deoxy-2′-a-azidoadenosine TP; 6 (alkyl)adenine; 6 (methyl)adenine; 6-(alkyl)adenine; 6-(methyl)adenine; 7 (deaza)adenine; 8 (alkenyl)adenine; 8 (alkynyl)adenine; 8 (amino)adenine; 8 (thioalkyl)adenine; 8-(alkenyl)adenine; 8-(alkyl)adenine; 8-(alkynyl)adenine; 8-(amino)adenine; 8-(halo)adenine; 8-(hydroxyl)adenine; 8-(thioalkyl)adenine; 8-(thiol)adenine; 8-azido-adenosine; aza adenine; deaza adenine; N6 (methyl)adenine; N6-(isopentyl)adenine; 7-deaza-8-aza-adenosine; 7-methyladenine; 1-Deazaadenosine TP; 2′Fluoro-N6-Bz-deoxyadenosine TP; 2′-OMe-2-Amino-ATP; 2′O-methyl-N6-Bz-deoxyadenosine TP; 2′-a-Ethynyladenosine TP; 2-aminoadenine; 2-Aminoadenosine TP; 2-Amino-ATP; 2′-a-Trifluoromethyladenosine TP; 2-Azidoadenosine TP; 2′-b-Ethynyladenosine TP; 2-Bromoadenosine TP; 2′-b-Trifluoromethyladenosine TP; 2-Chloroadenosine TP; 2′-Deoxy-2′,2′-difluoroadenosine TP; 2′-Deoxy-2′-a-mercaptoadenosine TP; 2′-Deoxy-2′-a-thiomethoxyadenosine TP; 2′-Deoxy-2′-b-aminoadenosine TP; 2′-Deoxy-2′-b-azidoadenosine TP; 2′-Deoxy-2′-b-bromoadenosine TP; 2′-Deoxy-2′-b-chloroadenosine TP; 2′-Deoxy-2′-b-fluoroadenosine TP; 2′-Deoxy-2′-b-iodoadenosine TP; 2′-Deoxy-2′-b-mercaptoadenosine TP; 2′-Deoxy-2′-b-thiomethoxyadenosine TP; 2-Fluoroadenosine TP; 2-Iodoadenosine TP; 2-Mercaptoadenosine TP; 2-methoxy-adenine; 2-methylthio-adenine; 2-Trifluoromethyladenosine TP; 3-Deaza-3-bromoadenosine TP; 3-Deaza-3-chloroadenosine TP; 3-Deaza-3-fluoroadenosine TP; 3-Deaza-3-iodoadenosine TP; 3-Deazaadenosine TP; 4′-Azidoadenosine TP; 4′-Carbocyclic adenosine TP; 4′-Ethynyladenosine TP; 5′-Homo-adenosine TP; 8-Aza-ATP; 8-bromo-adenosine TP; 8-Trifluoromethyladenosine TP; 9-Deazaadenosine TP; 2-aminopurine; 7-deaza-2,6-diaminopurine; 7-deaza-8-aza-2,6-diaminopurine; 7-deaza-8-aza-2-aminopurine; 2,6-diaminopurine; 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine; 2-thiocytidine; 3-methylcytidine; 5-formylcytidine; 5-hydroxymethylcytidine; 5-methylcytidine; N4-acetylcytidine; 2′-O-methylcytidine; 2′-O-methylcytidine; 5,2′-O-dimethylcytidine; 5-formyl-2′-O-methylcytidine; Lysidine; N4,2′-O-dimethylcytidine; N4-acetyl-2′-O-methylcytidine; N4-methylcytidine; N4,N4-Dimethyl-2′-OMe-Cytidine TP; 4-methylcytidine; 5-aza-cytidine; Pseudo-iso-cytidine; pyrrolo-cytidine; α-thio-cytidine; 2-(thio)cytosine; 2′-Amino-2′-deoxy-CTP; 2′-Azido-2′-deoxy-CTP; 2′-Deoxy-2′-a-aminocytidine TP; 2′-Deoxy-2′-a-azidocytidine TP; 3 (deaza) 5 (aza)cytosine; 3 (methyl)cytosine; 3-(alkyl)cytosine; 3-(deaza) 5 (aza)cytosine; 3-(methyl)cytidine; 4,2′-O-dimethylcytidine; 5 (halo)cytosine; 5 (methyl)cytosine; 5 (propynyl)cytosine; 5 (trifluoromethyl)cytosine; 5-(alkyl)cytosine; 5-(alkynyl)cytosine; 5-(halo)cytosine; 5-(propynyl)cytosine; 5-(trifluoromethyl)cytosine; 5-bromo-cytidine; 5-iodo-cytidine; 5-propynyl cytosine; 6-(azo)cytosine; 6-aza-cytidine; aza cytosine; deaza cytosine; N4 (acetyl)cytosine; 1-methyl-1-deaza-pseudoisocytidine; 1-methyl-pseudoisocytidine; 2-methoxy-5-methyl-cytidine; 2-methoxy-cytidine; 2-thio-5-methyl-cytidine; 4-methoxy-1-methyl-pseudoisocytidine; 4-methoxy-pseudoisocytidine; 4-thio-1-methyl-1-deaza-pseudoisocytidine; 4-thio-1-methyl-pseudoisocytidine; 4-thio-pseudoisocytidine; 5-aza-zebularine; 5-methyl-zebularine; pyrrolo-pseudoisocytidine; Zebularine; (E)-5-(2-Bromo-vinyl)cytidine TP; 2,2′-anhydro-cytidine TP hydrochloride; 2′Fluor-N4-Bz-cytidine TP; 2′Fluoro-N4-Acetyl-cytidine TP; 2′-O-Methyl-N4-Acetyl-cytidine TP; 2′O-methyl-N4-Bz-cytidine TP; 2′-a-Ethynylcytidine TP; 2′-a-Trifluoromethylcytidine TP; 2′-b-Ethynylcytidine TP; 2′-b-Trifluoromethylcytidine TP; 2′-Deoxy-2′,2′-difluorocytidine TP; 2′-Deoxy-2′-a-mercaptocytidine TP; 2′-Deoxy-2′-a-thiomethoxycytidine TP; 2′-Deoxy-2′-b-aminocytidine TP; 2′-Deoxy-2′-b-azidocytidine TP; 2′-Deoxy-2′-b-bromocytidine TP; 2′-Deoxy-2′-b-chlorocytidine TP; 2′-Deoxy-2′-b-fluorocytidine TP; 2′-Deoxy-2′-b-iodocytidine TP; 2′-Deoxy-2′-b-mercaptocytidine TP; 2′-Deoxy-2′-b-thiomethoxycytidine TP; 2′-O-Methyl-5-(1-propynyl)cytidine TP; 3′-Ethynylcytidine TP; 4′-Azidocytidine TP; 4′-Carbocyclic cytidine TP; 4′-Ethynylcytidine TP; 5-(1-Propynyl)ara-cytidine TP; 5-(2-Chloro-phenyl)-2-thiocytidine TP; 5-(4-Amino-phenyl)-2-thiocytidine TP; 5-Aminoallyl-CTP; 5-Cyanocytidine TP; 5-Ethynylara-cytidine TP; 5-Ethynylcytidine TP; 5′-Homo-cytidine TP; 5-Methoxycytidine TP; 5-Trifluoromethyl-Cytidine TP; N4-Amino-cytidine TP; N4-Benzoyl-cytidine TP; Pseudoisocytidine; 7-methylguanosine; N2,2′-O-dimethylguanosine; N2-methylguanosine; Wyosine; 1,2′-O-dimethylguanosine; 1-methylguanosine; 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate); 2′-O-methylguanosine; 2′-O-ribosylguanosine (phosphate); 7-aminomethyl-7-deazaguanosine; 7-cyano-7-deazaguanosine; Archaeosine; Methylwyosine; N2,7-dimethylguanosine; N2,N2,2′-O-trimethylguanosine; N2,N2,7-trimethylguanosine; N2,N2-dimethylguanosine; N2,7,2′-O-trimethylguanosine; 6-thio-guanosine; 7-deaza-guanosine; 8-oxo-guanosine; N1-methyl-guanosine; α-thio-guanosine; 2 (propyl)guanine; 2-(alkyl)guanine; 2′-Amino-2′-deoxy-GTP; 2′-Azido-2′-deoxy-GTP; 2′-Deoxy-2′-a-aminoguanosine TP; 2′-Deoxy-2′-a-azidoguanosine TP; 6 (methyl)guanine; 6-(alkyl)guanine; 6-(methyl)guanine; 6-methyl-guanosine; 7 (alkyl)guanine; 7 (deaza)guanine; 7 (methyl)guanine; 7-(alkyl)guanine; 7-(deaza)guanine; 7-(methyl)guanine; 8 (alkyl)guanine; 8 (alkynyl)guanine; 8 (halo)guanine; 8 (thioalkyl)guanine; 8-(alkenyl)guanine; 8-(alkyl)guanine; 8-(alkynyl)guanine; 8-(amino)guanine; 8-(halo)guanine; 8-(hydroxyl)guanine; 8-(thioalkyl)guanine; 8-(thiol)guanine; aza guanine; deaza guanine; N (methyl)guanine; N-(methyl)guanine; 1-methyl-6-thio-guanosine; 6-methoxy-guanosine; 6-thio-7-deaza-8-aza-guanosine; 6-thio-7-deaza-guanosine; 6-thio-7-methyl-guanosine; 7-deaza-8-aza-guanosine; 7-methyl-8-oxo-guanosine; N2,N2-dimethyl-6-thio-guanosine; N2-methyl-6-thio-guanosine; 1-Me-GTP; 2′Fluoro-N2-isobutyl-guanosine TP; 2′O-methyl-N2-isobutyl-guanosine TP; 2′-a-Ethynylguanosine TP; 2′-a-Trifluoromethylguanosine TP; 2′-b-Ethynylguanosine TP; 2′-b-Trifluoromethylguanosine TP; 2′-Deoxy-2′,2′-difluoroguanosine TP; 2′-Deoxy-2′-a-mercaptoguanosine TP; 2′-Deoxy-2′-a-thiomethoxyguanosine TP; 2′-Deoxy-2′-b-aminoguanosine TP; 2′-Deoxy-2′-b-azidoguanosine TP; 2′-Deoxy-2′-b-bromoguanosine TP; 2′-Deoxy-2′-b-chloroguanosine TP; 2′-Deoxy-2′-b-fluoroguanosine TP; 2′-Deoxy-2′-b-iodoguanosine TP; 2′-Deoxy-2′-b-mercaptoguanosine TP; 2′-Deoxy-2′-b-thiomethoxyguanosine TP; 4′-Azidoguanosine TP; 4′-Carbocyclic guanosine TP; 4′-Ethynylguanosine TP; 5′-Homo-guanosine TP; 8-bromo-guanosine TP; 9-Deazaguanosine TP; N2-isobutyl-guanosine TP; 1-methylinosine; Inosine; 1,2′-O-dimethylinosine; 2′-O-methylinosine; 7-methylinosine; 2′-O-methylinosine; Epoxyqueuosine; galactosyl-queuosine; Mannosylqueuosine; Queuosine; allyamino-thymidine; aza thymidine; deaza thymidine; deoxy-thymidine; 2′-O-methyluridine; 2-thiouridine; 3-methyluridine; 5-carboxymethyluridine; 5-hydroxyuridine; 5-methyluridine; 5-taurinomethyl-2-thiouridine; 5-taurinomethyluridine; Dihydrouridine; Pseudouridine; (3-(3-amino-3-carboxypropyl)uridine; 1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine; 1-methylpseduouridine; 1-methyl-pseudouridine; 2′-O-methyluridine; 2′-O-methylpseudouridine; 2′-O-methyluridine; 2-thio-2′-O-methyluridine; 3-(3-amino-3-carboxypropyl)uridine; 3,2′-O-dimethyluridine; 3-Methyl-pseudo-Uridine TP; 4-thiouridine; 5-(carboxyhydroxymethyl)uridine; 5-(carboxyhydroxymethyl)uridine methyl ester; 5,2′-O-dimethyluridine; 5,6-dihydro-uridine; 5-aminomethyl-2-thiouridine; 5-carbamoylmethyl-2′-O-methyluridine; 5-carbamoylmethyluridine; 5-carboxyhydroxymethyluridine; 5-carboxyhydroxymethyluridine methyl ester; 5-carboxymethylaminomethyl-2′-O-methyluridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyl-2-thiouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyluridine; 5-Carbamoylmethyluridine TP; 5-methoxycarbonylmethyl-2′-O-methyluridine; 5-methoxycarbonylmethyl-2-thiouridine; 5-methoxycarbonylmethyluridine; 5-methoxyuridine; 5-methyl-2-thiouridine; 5-methylaminomethyl-2-selenouridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyluridine; 5-Methyldihydrouridine; 5-Oxyacetic acid-Uridine TP; 5-Oxyacetic acid-methyl ester-Uridine TP; N1-methyl-pseudo-uridine; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 3-(3-Amino-3-carboxypropyl)-Uridine TP; 5-(iso-Pentenylaminomethyl)-2-thiouridine TP; 5-(iso-Pentenylaminomethyl)-2′-O-methyluridine TP; 5-(iso-Pentenylaminomethyl)uridine TP; 5-propynyl uracil; α-thio-uridine; 1 (aminoalkylamino-carbonylethylenyl)-2(thio)-pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminoalkylaminocarbonylethylenyl)-pseudouracil; 1 (aminocarbonylethylenyl)-2(thio)-pseudouracil; 1 (aminocarbonylethylenyl)-2,4-(dithio)pseudouracil; 1 (aminocarbonylethylenyl)-4 (thio)pseudouracil; 1 (aminocarbonylethylenyl)-pseudouracil; 1 substituted 2(thio)-pseudouracil; 1 substituted 2,4-(dithio)pseudouracil; 1 substituted 4 (thio)pseudouracil; 1 substituted pseudouracil; 1-(aminoalkylamino-carbonylethylenyl)-2-(thio)-pseudouracil; 1-Methyl-3-(3-amino-3-carboxypropyl) pseudouridine TP; 1-Methyl-3-(3-amino-3-carboxypropyl)pseudo-UTP; 1-Methyl-pseudo-UTP; 2 (thio)pseudouracil; 2′ deoxy uridine; 2′ fluorouridine; 2-(thio)uracil; 2,4-(dithio)psuedouracil; 2′ methyl, 2′amino, 2′azido, 2′fluro-guanosine; 2′-Amino-2′-deoxy-UTP; 2′-Azido-2′-deoxy-UTP; 2′-Azido-deoxyuridine TP; 2′-O-methylpseudouridine; 2′ deoxy uridine; 2′ fluorouridine; 2′-Deoxy-2′-a-aminouridine TP; 2′-Deoxy-2′-a-azidouridine TP; 2-methylpseudouridine; 3 (3 amino-3 carboxypropyl)uracil; 4 (thio)pseudouracil; 4-(thio)pseudouracil; 4-(thio)uracil; 4-thiouracil; 5 (1,3-diazole-1-alkyl)uracil; 5 (2-aminopropyl)uracil; 5 (aminoalkyl)uracil; 5 (dimethylaminoalkyl)uracil; 5 (guanidiniumalkyl)uracil; 5 (methoxycarbonylmethyl)-2-(thio)uracil; 5 (methoxycarbonyl-methyl)uracil; 5 (methyl) 2 (thio)uracil; 5 (methyl) 2,4 (dithio)uracil; 5 (methyl) 4 (thio)uracil; 5 (methylaminomethyl)-2 (thio)uracil; 5 (methylaminomethyl)-2,4 (dithio)uracil; 5 (methylaminomethyl)-4 (thio)uracil; 5 (propynyl)uracil; 5 (trifluoromethyl)uracil; 5-(2-aminopropyl)uracil; 5-(alkyl)-2-(thio)pseudouracil; 5-(alkyl)-2,4 (dithio)pseudouracil; 5-(alkyl)-4 (thio)pseudouracil; 5-(alkyl)pseudouracil; 5-(alkyl)uracil; 5-(alkynyl)uracil; 5-(allylamino)uracil; 5-(cyanoalkyl)uracil; 5-(dialkylaminoalkyl)uracil; 5-(dimethylaminoalkyl)uracil; 5-(guanidiniumalkyl)uracil; 5-(halo)uracil; 5-(1,3-diazole-1-alkyl)uracil; 5-(methoxy)uracil; 5-(methoxycarbonylmethyl)-2-(thio)uracil; 5-(methoxycarbonyl-methyl)uracil; 5-(methyl) 2(thio)uracil; 5-(methyl) 2,4 (dithio)uracil; 5-(methyl) 4 (thio)uracil; 5-(methyl)-2-(thio)pseudouracil; 5-(methyl)-2,4 (dithio)pseudouracil; 5-(methyl)-4 (thio)pseudouracil; 5-(methyl)pseudouracil; 5-(methylaminomethyl)-2 (thio)uracil; 5-(methylaminomethyl)-2,4(dithio)uracil; 5-(methylaminomethyl)-4-(thio)uracil; 5-(propynyl)uracil; 5-(trifluoromethyl)uracil; 5-aminoallyl-uridine; 5-bromo-uridine; 5-iodo-uridine; 5-uracil; 6 (azo)uracil; 6-(azo)uracil; 6-aza-uridine; allyamino-uracil; aza uracil; deaza uracil; N3 (methyl)uracil; Pseudo-UTP-1-2-ethanoic acid; Pseudouracil; 4-Thio-pseudo-UTP; 1-carboxymethyl-pseudouridine; 1-methyl-1-deaza-pseudouridine; 1-propynyl-uridine; 1-taurinomethyl-1-methyl-uridine; 1-taurinomethyl-4-thio-uridine; 1-taurinomethyl-pseudouridine; 2-methoxy-4-thio-pseudouridine; 2-thio-1-methyl-1-deaza-pseudouridine; 2-thio-1-methyl-pseudouridine; 2-thio-5-aza-uridine; 2-thio-dihydropseudouridine; 2-thio-dihydrouridine; 2-thio-pseudouridine; 4-methoxy-2-thio-pseudouridine; 4-methoxy-pseudouridine; 4-thio-1-methyl-pseudouridine; 4-thio-pseudouridine; 5-aza-uridine; Dihydropseudouridine; (±) 1-(2-Hydroxypropyl)pseudouridine TP; (2R)-1-(2-Hydroxypropyl)pseudouridine TP; (2S)-1-(2-Hydroxypropyl)pseudouridine TP; (E)-5-(2-Bromo-vinyl)ara-uridine TP; (E)-5-(2-Bromo-vinyl)uridine TP; (Z)-5-(2-Bromo-vinyl)ara-uridine TP; (Z)-5-(2-Bromo-vinyl)uridine TP; 1-(2,2,2-Trifluoroethyl)-pseudo-UTP; 1-(2,2,3,3,3-Pentafluoropropyl)pseudouridine TP; 1-(2,2-Diethoxyethyl)pseudouridine TP; 1-(2,4,6-Trimethylbenzyl)pseudouridine TP; 1-(2,4,6-Trimethyl-benzyl)pseudo-UTP; 1-(2,4,6-Trimethyl-phenyl)pseudo-UTP; 1-(2-Amino-2-carboxyethyl)pseudo-UTP; 1-(2-Amino-ethyl)pseudo-UTP; 1-(2-Hydroxyethyl)pseudouridine TP; 1-(2-Methoxyethyl)pseudouridine TP; 1-(3,4-Bis-trifluoromethoxybenzyl)pseudouridine TP; 1-(3,4-Dimethoxybenzyl)pseudouridine TP; 1-(3-Amino-3-carboxypropyl)pseudo-UTP; 1-(3-Amino-propyl)pseudo-UTP; 1-(3-Cyclopropyl-prop-2-ynyl)pseudouridine TP; 1-(4-Amino-4-carboxybutyl)pseudo-UTP; 1-(4-Amino-benzyl)pseudo-UTP; 1-(4-Amino-butyl)pseudo-UTP; 1-(4-Amino-phenyl)pseudo-UTP; 1-(4-Azidobenzyl)pseudouridine TP; 1-(4-Bromobenzyl)pseudouridine TP; 1-(4-Chlorobenzyl)pseudouridine TP; 1-(4-Fluorobenzyl)pseudouridine TP; 1-(4-Iodobenzyl)pseudouridine TP; 1-(4-Methanesulfonylbenzyl)pseudouridine TP; 1-(4-Methoxybenzyl)pseudouridine TP; 1-(4-Methoxy-benzyl)pseudo-UTP; 1-(4-Methoxy-phenyl)pseudo-UTP; 1-(4-Methylbenzyl)pseudouridine TP; 1-(4-Methyl-benzyl)pseudo-UTP; 1-(4-Nitrobenzyl)pseudouridine TP; 1-(4-Nitro-benzyl)pseudo-UTP; 1(4-Nitro-phenyl)pseudo-UTP; 1-(4-Thiomethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethoxybenzyl)pseudouridine TP; 1-(4-Trifluoromethylbenzyl)pseudouridine TP; 1-(5-Amino-pentyl)pseudo-UTP; 1-(6-Amino-hexyl)pseudo-UTP; 1,6-Dimethyl-pseudo-UTP; 1-[3-(2-{2-[2-(2-Aminoethoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl]pseudouridine TP; 1-{3-[2-(2-Aminoethoxy)-ethoxy]-propionyl} pseudouridine TP; 1-Acetylpseudouridine TP; 1-Alkyl-6-(1-propynyl)-pseudo-UTP; 1-Alkyl-6-(2-propynyl)-pseudo-UTP; 1-Alkyl-6-allyl-pseudo-UTP; 1-Alkyl-6-ethynyl-pseudo-UTP; 1-Alkyl-6-homoallyl-pseudo-UTP; 1-Alkyl-6-vinyl-pseudo-UTP; 1-Allylpseudouridine TP; 1-Aminomethyl-pseudo-UTP; 1-Benzoylpseudouridine TP; 1-Benzyloxymethylpseudouridine TP; 1-Benzyl-pseudo-UTP; 1-Biotinyl-PEG2-pseudouridine TP; 1-Biotinylpseudouridine TP; 1-Butyl-pseudo-UTP; 1-Cyanomethylpseudouridine TP; 1-Cyclobutylmethyl-pseudo-UTP; 1-Cyclobutyl-pseudo-UTP; 1-Cycloheptylmethyl-pseudo-UTP; 1-Cycloheptyl-pseudo-UTP; 1-Cyclohexylmethyl-pseudo-UTP; 1-Cyclohexyl-pseudo-UTP; 1-Cyclooctylmethyl-pseudo-UTP; 1-Cyclooctyl-pseudo-UTP; 1-Cyclopentylmethyl-pseudo-UTP; 1-Cyclopentyl-pseudo-UTP; 1-Cyclopropylmethyl-pseudo-UTP; 1-Cyclopropyl-pseudo-UTP; 1-Ethyl-pseudo-UTP; 1-Hexyl-pseudo-UTP; 1-Homoallylpseudouridine TP; 1-Hydroxymethylpseudouridine TP; 1-iso-propyl-pseudo-UTP; 1-Me-2-thio-pseudo-UTP; 1-Me-4-thio-pseudo-UTP; 1-Me-alpha-thio-pseudo-UTP; 1-Methanesulfonylmethylpseudouridine TP; 1-Methoxymethylpseudouridine TP; 1-Methyl-6-(2,2,2-Trifluoroethyl)pseudo-UTP; 1-Methyl-6-(4-morpholino)-pseudo-UTP; 1-Methyl-6-(4-thiomorpholino)-pseudo-UTP; 1-Methyl-6-(substituted phenyl)pseudo-UTP; 1-Methyl-6-amino-pseudo-UTP; 1-Methyl-6-azido-pseudo-UTP; 1-Methyl-6-bromo-pseudo-UTP; 1-Methyl-6-butyl-pseudo-UTP; 1-Methyl-6-chloro-pseudo-UTP; 1-Methyl-6-cyano-pseudo-UTP; 1-Methyl-6-dimethylamino-pseudo-UTP; 1-Methyl-6-ethoxy-pseudo-UTP; 1-Methyl-6-ethylcarboxylate-pseudo-UTP; 1-Methyl-6-ethyl-pseudo-UTP; 1-Methyl-6-fluoro-pseudo-UTP; 1-Methyl-6-formyl-pseudo-UTP; 1-Methyl-6-hydroxyamino-pseudo-UTP; 1-Methyl-6-hydroxy-pseudo-UTP; 1-Methyl-6-iodo-pseudo-UTP; 1-Methyl-6-iso-propyl-pseudo-UTP; 1-Methyl-6-methoxy-pseudo-UTP; 1-Methyl-6-methylamino-pseudo-UTP; 1-Methyl-6-phenyl-pseudo-UTP; 1-Methyl-6-propyl-pseudo-UTP; 1-Methyl-6-tert-butyl-pseudo-UTP; 1-Methyl-6-trifluoromethoxy-pseudo-UTP; 1-Methyl-6-trifluoromethyl-pseudo-UTP; 1-Morpholinomethylpseudouridine TP; 1-Pentyl-pseudo-UTP; 1-Phenyl-pseudo-UTP; 1-Pivaloylpseudouridine TP; 1-Propargylpseudouridine TP; 1-Propyl-pseudo-UTP; 1-propynyl-pseudouridine; 1-p-tolyl-pseudo-UTP; 1-tert-Butyl-pseudo-UTP; 1-Thiomethoxymethylpseudouridine TP; 1-Thiomorpholinomethylpseudouridine TP; 1-Trifluoroacetylpseudouridine TP; 1-Trifluoromethyl-pseudo-UTP; 1-Vinylpseudouridine TP; 2,2′-anhydro-uridine TP; 2′-bromo-deoxyuridine TP; 2′-F-5-Methyl-2′-deoxy-UTP; 2′-OMe-5-Me-UTP; 2′-OMe-pseudo-UTP; 2′-a-Ethynyluridine TP; 2′-a-Trifluoromethyluridine TP; 2′-b-Ethynyluridine TP; 2′-b-Trifluoromethyluridine TP; 2′-Deoxy-2′,2′-difluorouridine TP; 2′-Deoxy-2′-a-mercaptouridine TP; 2′-Deoxy-2′-a-thiomethoxyuridine TP; 2′-Deoxy-2′-b-aminouridine TP; 2′-Deoxy-2′-b-azidouridine TP; 2′-Deoxy-2′-b-bromouridine TP; 2′-Deoxy-2′-b-chlorouridine TP; 2′-Deoxy-2′-b-fluorouridine TP; 2′-Deoxy-2′-b-iodouridine TP; 2′-Deoxy-2′-b-mercaptouridine TP; 2′-Deoxy-2′-b-thiomethoxyuridine TP; 2-methoxy-4-thio-uridine; 2-methoxyuridine; 2′-O-Methyl-5-(1-propynyl)uridine TP; 3-Alkyl-pseudo-UTP; 4′-Azidouridine TP; 4′-Carbocyclic uridine TP; 4′-Ethynyluridine TP; 5-(1-Propynyl)ara-uridine TP; 5-(2-Furanyl)uridine TP; 5-Cyanouridine TP; 5-Dimethylaminouridine TP; 5′-Homo-uridine TP; 5-iodo-2′-fluoro-deoxyuridine TP; 5-Phenylethynyluridine TP; 5-Trideuteromethyl-6-deuterouridine TP; 5-Trifluoromethyl-Uridine TP; 5-Vinylarauridine TP; 6-(2,2,2-Trifluoroethyl)-pseudo-UTP; 6-(4-Morpholino)-pseudo-UTP; 6-(4-Thiomorpholino)-pseudo-UTP; 6-(Substituted-Phenyl)-pseudo-UTP; 6-Amino-pseudo-UTP; 6-Azido-pseudo-UTP; 6-Bromo-pseudo-UTP; 6-Butyl-pseudo-UTP; 6-Chloro-pseudo-UTP; 6-Cyano-pseudo-UTP; 6-Dimethylamino-pseudo-UTP; 6-Ethoxy-pseudo-UTP; 6-Ethylcarboxylate-pseudo-UTP; 6-Ethyl-pseudo-UTP; 6-Fluoro-pseudo-UTP; 6-Formyl-pseudo-UTP; 6-Hydroxyamino-pseudo-UTP; 6-Hydroxy-pseudo-UTP; 6-Iodo-pseudo-UTP; 6-iso-Propyl-pseudo-UTP; 6-Methoxy-pseudo-UTP; 6-Methylamino-pseudo-UTP; 6-Methyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Phenyl-pseudo-UTP; 6-Propyl-pseudo-UTP; 6-tert-Butyl-pseudo-UTP; 6-Trifluoromethoxy-pseudo-UTP; 6-Trifluoromethyl-pseudo-UTP; Alpha-thio-pseudo-UTP; Pseudouridine 1-(4-methylbenzenesulfonic acid) TP; Pseudouridine 1-(4-methylbenzoic acid) TP; Pseudouridine TP 1-[3-(2-ethoxy)]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-(2-ethoxy)-ethoxy]-ethoxy)-ethoxy} ]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-{2(2-ethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-[2-ethoxy]-ethoxy)-ethoxy}]propionic acid; Pseudouridine TP 1-[3-{2-(2-ethoxy)-ethoxy}] propionic acid; Pseudouridine TP 1-methylphosphonic acid; Pseudouridine TP 1-methylphosphonic acid diethyl ester; Pseudo-UTP-N1-3-propionic acid; Pseudo-UTP-N1-4-butanoic acid; Pseudo-UTP-N1-5-pentanoic acid; Pseudo-UTP-N1-6-hexanoic acid; Pseudo-UTP-N1-7-heptanoic acid; Pseudo-UTP-N1-methyl-p-benzoic acid; Pseudo-UTP-N1-p-benzoic acid; Wybutosine; Hydroxywybutosine; Isowyosine; Peroxywybutosine; undermodified hydroxywybutosine; 4-demethylwyosine; 2,6-(diamino)purine; 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl: 1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 1,3,5-(triaza)-2,6-(dioxa)-naphthalene; 2 (amino)purine; 2,4,5-(trimethyl)phenyl; 2′ methyl, 2′amino, 2′azido, 2′fluro-cytidine; 2′ methyl, 2′amino, 2′azido, 2′fluro-adenine; 2′methyl, 2′amino, 2′azido, 2′fluro-uridine; 2′-amino-2′-deoxyribose; 2-amino-6-Chloro-purine; 2-aza-inosinyl; 2′-azido-2′-deoxyribose; 2′fluoro-2′-deoxyribose; 2′-fluoro-modified bases; 2′-O-methyl-ribose; 2-oxo-7-aminopyridopyrimidin-3-yl; 2-oxo-pyridopyrimidine-3-yl; 2-pyridinone; 3 nitropyrrole; 3-(methyl)-7-(propynyl)isocarbostyrilyl; 3-(methyl)isocarbostyrilyl; 4-(fluoro)-6-(methyl)benzimidazole; 4-(methyl)benzimidazole; 4-(methyl)indolyl; 4,6-(dimethyl)indolyl; 5 nitroindole; 5 substituted pyrimidines; 5-(methyl)isocarbostyrilyl; 5-nitroindole; 6-(aza)pyrimidine; 6-(azo)thymine; 6-(methyl)-7-(aza)indolyl; 6-chloro-purine; 6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(aza)indolyl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazinl-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(guanidiniumalkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenthiazin-1-yl; 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 7-(propynyl)isocarbostyrilyl; 7-(propynyl)isocarbostyrilyl, propynyl-7-(aza)indolyl; 7-deaza-inosinyl; 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazin-1-yl; 7-substituted 1,3-(diaza)-2-(oxo)-phenoxazin-1-yl; 9-(methyl)-imidizopyridinyl; Aminoindolyl; Anthracenyl; bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Difluorotolyl; Hypoxanthine; Imidizopyridinyl; Inosinyl; Isocarbostyrilyl; Isoguanisine; N2-substituted purines; N6-methyl-2-amino-purine; N6-substituted purines; N-alkylated derivative; Napthalenyl; Nitrobenzimidazolyl; Nitroimidazolyl; Nitroindazolyl; Nitropyrazolyl; Nubularine; 06-substituted purines; O-alkylated derivative; ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; ortho-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Oxoformycin TP; para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; para-substituted-6-phenyl-pyrrolo-pyrimidin-2-on-3-yl; Pentacenyl; Phenanthracenyl; Phenyl; propynyl-7-(aza)indolyl; Pyrenyl; pyridopyrimidin-3-yl; pyridopyrimidin-3-yl, 2-oxo-7-amino-pyridopyrimidin-3-yl; pyrrolo-pyrimidin-2-on-3-yl; Pyrrolopyrimidinyl; Pyrrolopyrizinyl; Stilbenzyl; substituted 1,2,4-triazoles; Tetracenyl; Tubercidine; Xanthine; Xanthosine-5′-TP; 2-thio-zebularine; 5-aza-2-thio-zebularine; 7-deaza-2-amino-purine; pyridin-4-one ribonucleoside; 2-Amino-riboside-TP; Formycin A TP; Formycin B TP; Pyrrolosine TP; 2′-OH-ara-adenosine TP; 2′-OH-ara-cytidine TP; 2′-OH-ara-uridine TP; 2′-OH-ara-guanosine TP; 5-(2-carbomethoxyvinyl)uridine TP; and N6-(19-Amino-pentaoxanonadecyl)adenosine TP.

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of pseudouridine (ψ), N1-methylpseudouridine (mly), 2-thiouridine, N1-ethylpseudouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine. In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) include a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

In some embodiments, modified nucleobases in polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are selected from the group consisting of 1-methyl-pseudouridine (m¹ψ), 5-methoxy-uridine (mo⁵U), 5-methyl-cytidine (m⁵C), pseudouridine (ψ), α-thio-guanosine and α-thio-adenosine. In some embodiments, polynucleotides includes a combination of at least two (e.g., 2, 3, 4 or more) of the aforementioned modified nucleobases.

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise pseudouridine (ψ) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 1-methyl-pseudouridine (m¹ψ) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine (s²U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2-thiouridine and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise methoxy-uridine (mo⁵U). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 5-methoxy-uridine (mo⁵U) and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2′-O-methyl uridine. In some embodiments polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise 2′-O-methyl uridine and 5-methyl-cytidine (m⁵C). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m⁶A). In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) comprise N6-methyl-adenosine (m⁶A) and 5-methyl-cytidine (m⁵C).

In some embodiments, polynucleotides (e.g., RNA polynucleotides, such as mRNA polynucleotides) are uniformly modified (e.g., fully modified, modified throughout the entire sequence) for a particular modification. For example, a polynucleotide can be uniformly modified with 5-methyl-cytidine (m⁵C), meaning that all cytosine residues in the mRNA sequence are replaced with 5-methyl-cytidine (m⁵C). Similarly, a polynucleotide can be uniformly modified for any type of nucleoside residue present in the sequence by replacement with a modified residue such as those set forth above.

Exemplary nucleobases and nucleosides having a modified cytosine include N4-acetyl-cytidine (ac4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, 2-thio-cytidine (s2C), and 2-thio-5-methyl-cytidine.

In some embodiments, a modified nucleobase is a modified uridine. Exemplary nucleobases and In some embodiments, a modified nucleobase is a modified cytosine. nucleosides having a modified uridine include 5-cyano uridine, and 4′-thio uridine.

In some embodiments, a modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 7-deaza-adenine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), and N6-methyl-adenosine (m6A).

In some embodiments, a modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 7-deaza-guanosine, 7-cyano-7-deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), 7-methyl-guanosine (m7G), 1-methyl-guanosine (m1G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine.

The polynucleotides of the present disclosure may be partially or fully modified along the entire length of the molecule. For example, one or more or all or a given type of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may be uniformly modified in a polynucleotide of the invention, or in a given predetermined sequence region thereof (e.g., in the mRNA including or excluding the polyA tail). In some embodiments, all nucleotides X in a polynucleotide of the present disclosure (or in a given sequence region thereof) are modified nucleotides, wherein X may any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.

The polynucleotide may contain from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%). Any remaining percentage is accounted for by the presence of unmodified A, G, U, or C.

The polynucleotides may contain at a minimum 1% and at maximum 100% modified nucleotides, or any intervening percentage, such as at least 5% modified nucleotides, at least 10% modified nucleotides, at least 25% modified nucleotides, at least 50% modified nucleotides, at least 80% modified nucleotides, or at least 90% modified nucleotides. For example, the polynucleotides may contain a modified pyrimidine such as a modified uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in the polynucleotide is replaced with a modified uracil (e.g., a 5-substituted uracil). The modified uracil can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures). n some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine in the polynucleotide is replaced with a modified cytosine (e.g., a 5-substituted cytosine). The modified cytosine can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).

Thus, in some embodiments, the RNA (e.g., mRNA) vaccines comprise a 5′UTR element, an optionally codon optimized open reading frame, and a 3′UTR element, a poly(A) sequence and/or a polyadenylation signal wherein the RNA is not chemically modified.

In some embodiments, the modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s²U), 4-thio-uridine (s⁴U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho⁵U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridineor 5-bromo-uridine), 3-methyl-uridine (m³U), 5-methoxy-uridine (mo⁵U), uridine 5-oxyacetic acid (cmo⁵U), uridine 5-oxyacetic acid methyl ester (mcmo⁵U), 5-carboxymethyl-uridine (cm⁵U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm⁵U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm⁵U), 5-methoxycarbonylmethyl-uridine (mcm⁵U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm⁵s2U), 5-aminomethyl-2-thio-uridine (nm s²U), 5-methylaminomethyl-uridine (mnm⁵U), 5-methylaminomethyl-2-thio-uridine (mnm⁵s⁵U), 5-methylaminomethyl-2-seleno-uridine (mnm⁵se²U), 5-carbamoylmethyl-uridine (ncm⁵U), 5-carboxymethylaminomethyl-uridine (cmnm⁵U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm⁵s²U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyl-uridine (τm⁵U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine(τm⁵s²U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m⁵U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m¹ψ), 5-methyl-2-thio-uridine (m⁵s²U), 1-methyl-4-thio-pseudouridine (m¹s⁴ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m³J), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m⁵D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp³U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp³ψ), 5-(isopentenylaminomethyl)uridine (inm⁵U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm⁵s²U), α-thio-uridine, 2′-O-methyl-uridine (Um), 5,2′-O-dimethyl-uridine (m⁵Um), 2′-O-methyl-pseudouridine (ψm), 2-thio-2′-O-methyl-uridine (s²Um), 5-methoxycarbonylmethyl-2′-O-methyl-uridine (mcm⁵Um), 5-carbamoylmethyl-2′-O-methyl-uridine (ncm⁵Um), 5-carboxymethylaminomethyl-2′-O-methyl-uridine (cmnm⁵Um), 3,2′-O-dimethyl-uridine (m³Um), and 5-(isopentenylaminomethyl)-2′-O-methyl-uridine (inm⁵Um), 1-thio-uridine, deoxythymidine, 2′-F-ara-uridine, 2′-F-uridine, 2′-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and 5-[3-(1-E-propenylamino)]uridine.

In some embodiments, the modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m³C), N4-acetyl-cytidine (ac⁴C), 5-formyl-cytidine (f⁵C), N4-methyl-cytidine (m⁴C), 5-methyl-cytidine (m⁵C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm⁵C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine (s²C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k₂C), α-thio-cytidine, 2′-O-methyl-cytidine (Cm), 5,2′-O-dimethyl-cytidine (m⁵Cm), N4-acetyl-2′-O-methyl-cytidine (ac⁴Cm), N4,2′-O-dimethyl-cytidine (m⁴Cm), 5-formyl-2′-O-methyl-cytidine (f⁵Cm), N4,N4,2′-O-trimethyl-cytidine (m⁴²Cm), 1-thio-cytidine, 2′-F-ara-cytidine, 2′-F-cytidine, and 2′-OH-ara-cytidine.

In some embodiments, the modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m¹A), 2-methyl-adenine (m²A), N6-methyl-adenosine (m⁶A), 2-methylthio-N6-methyl-adenosine (ms²m6A), N6-isopentenyl-adenosine (i⁶A), 2-methylthio-N6-isopentenyl-adenosine (ms²i⁶A), N6-(cis-hydroxyisopentenyl)adenosine (io⁶A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms²io⁶A), N6-glycinylcarbamoyl-adenosine (g⁶A), N6-threonylcarbamoyl-adenosine (t⁶A), N6-methyl-N6-threonylcarbamoyl-adenosine (m⁶t⁶A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms²g⁶A), N6,N6-dimethyl-adenosine (m⁶₂A), N6-hydroxynorvalylcarbamoyl-adenosine (hn⁶A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine (ms²hn⁶A), N6-acetyl-adenosine (ac⁶A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine, 2′-O-methyl-adenosine (Am), N6,2′-O-dimethyl-adenosine (m⁶Am), N6,N6,2′-O-trimethyl-adenosine (m⁶₂Am), 1,2′-O-dimethyl-adenosine (m¹Am), 2′-O-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine, 8-azido-adenosine, 2′-F-ara-adenosine, 2′-F-adenosine, 2′-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

In some embodiments, the modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m¹I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o₂yW), hydroxywybutosine (OhyW), undermodified hydroxywybutosine (OhyW*), 7-deaza-guanosine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanosine (preQ₀), 7-aminomethyl-7-deaza-guanosine (preQ₁), archaeosine (G⁺), 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine (m⁷G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine (m G), N2-methyl-guanosine (m²G), N2,N2-dimethyl-guanosine (m²₂G), N2,7-dimethyl-guanosine (m^2,7G), N2,N2,7-dimethyl-guanosine (m^2,2,7G), 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, α-thio-guanosine, 2′-O-methyl-guanosine (Gm), N2-methyl-2′-O-methyl-guanosine (m²Gm), N2,N2-dimethyl-2′-O-methyl-guanosine (m²₂Gm), 1-methyl-2′-O-methyl-guanosine (m Gm), N2,7-dimethyl-2′-O-methyl-guanosine (m^2,7Gm), 2′-O-methyl-inosine (Im), 1,2′-O-dimethyl-inosine (m¹Im), 2′-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine, 06-methyl-guanosine, 2′-F-ara-guanosine, and 2′-F-guanosine.

In Vitro Transcription of RNA (e.g., mRNA)

Influenza virus vaccines of the present disclosure comprise at least one RNA polynucleotide, such as a mRNA (e.g., modified mRNA). mRNA, for example, is transcribed in vitro from template DNA, referred to as an “in vitro transcription template.” In some embodiments, an in vitro transcription template encodes a 5′ untranslated (UTR) region, contains an open reading frame, and encodes a 3′ UTR and a polyA tail. The particular nucleic acid sequence composition and length of an in vitro transcription template will depend on the mRNA encoded by the template.

A “5′ untranslated region” (5′UTR) refers to a region of an mRNA that is directly upstream (i.e., 5′) from the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide.

A “3′ untranslated region” (3′UTR) refers to a region of an mRNA that is directly downstream (i.e., 3′) from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide.

An “open reading frame” is a continuous stretch of DNA beginning with a start codon (e.g., methionine (ATG)), and ending with a stop codon (e.g., TAA, TAG or TGA) and encodes a polypeptide.

A “polyA tail” is a region of mRNA that is downstream, e.g., directly downstream (i.e., 3′), from the 3′ UTR that contains multiple, consecutive adenosine monophosphates. A polyA tail may contain 10 to 300 adenosine monophosphates. For example, a polyA tail may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates. In some embodiments, a polyA tail contains 50 to 250 adenosine monophosphates. In a relevant biological setting (e.g., in cells, in vivo) the poly(A) tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus and translation.

In some embodiments, a polynucleotide includes 200 to 3,000 nucleotides. For example, a polynucleotide may include 200 to 500, 200 to 1000, 200 to 1500, 200 to 3000, 500 to 1000, 500 to 1500, 500 to 2000, 500 to 3000, 1000 to 1500, 1000 to 2000, 1000 to 3000, 1500 to 3000, or 2000 to 3000 nucleotides.

Flagellin Adjuvants

Flagellin is an approximately 500 amino acid monomeric protein that polymerizes to form the flagella associated with bacterial motion. Flagellin is expressed by a variety of flagellated bacteria (Salmonella typhimurium for example) as well as non-flagellated bacteria (such as Escherichia coli). Sensing of flagellin by cells of the innate immune system (dendritic cells, macrophages, etc.) is mediated by the Toll-like receptor 5 (TLR5) as well as by Nod-like receptors (NLRs) Ipaf and Naip5. TLRs and NLRs have been identified as playing a role in the activation of innate immune response and adaptive immune response. As such, flagellin provides an adjuvant effect in a vaccine.

The nucleotide and amino acid sequences encoding known flagellin polypeptides are publicly available in the NCBI GenBank database. The flagellin sequences from S. Typhimurium, H. Pylori, V. Cholera, S. marcesens, S. flexneri, T. Pallidum, L. pneumophila, B. burgdorferei, C. difficile, R. meliloti, A. tumefaciens, R. lupini, B. clarridgeiae, P. Mirabilis, B. subtilus, L. monocytogenes, P. aeruginosa, and E. coli, among others are known.

A flagellin polypeptide, as used herein, refers to a full length flagellin protein, immunogenic fragments thereof, and peptides having at least 50% sequence identify to a flagellin protein or immunogenic fragments thereof. Exemplary flagellin proteins include flagellin from Salmonella typhi (UniPro Entry number: Q56086), Salmonella typhimurium (A0A0C9DG09), Salmonella enteritidis (A0A0C9BAB7), and Salmonella choleraesuis (Q6V2X8), and proteins having an amino acid sequence identified by any one of SEQ ID NO 1-444, 458, 460, 462-479 (see also Tables 7-13). In some embodiments, the flagellin polypeptide has at least 60%, 70%, 75%, 80%, 90%, 95%, 97%, 98%, or 99% sequence identify to a flagellin protein or immunogenic fragments thereof.

In some embodiments, the flagellin polypeptide is an immunogenic fragment. An immunogenic fragment is a portion of a flagellin protein that provokes an immune response. In some embodiments, the immune response is a TLR5 immune response. An example of an immunogenic fragment is a flagellin protein in which all or a portion of a hinge region has been deleted or replaced with other amino acids. For example, an antigenic polypeptide may be inserted in the hinge region. Hinge regions are the hypervariable regions of a flagellin. Hinge regions of a flagellin are also referred to as “D3 domain or region, “propeller domain or region,” “hypervariable domain or region” and “variable domain or region.” “At least a portion of a hinge region,” as used herein, refers to any part of the hinge region of the flagellin, or the entirety of the hinge region. In other embodiments an immunogenic fragment of flagellin is a 20, 25, 30, 35, or 40 amino acid C-terminal fragment of flagellin.

The flagellin monomer is formed by domains DO through D3. DO and D1, which form the stem, are composed of tandem long alpha helices and are highly conserved among different bacteria. The D1 domain includes several stretches of amino acids that are useful for TLR5 activation. The entire D1 domain or one or more of the active regions within the domain are immunogenic fragments of flagellin. Examples of immunogenic regions within the D1 domain include residues 88-114 and residues 411-431 (in Salmonella typhimurium FliC flagellin. Within the 13 amino acids in the 88-100 region, at least 6 substitutions are permitted between Salmonella flagellin and other flagellins that still preserve TLR5 activation. Thus, immunogenic fragments of flagellin include flagellin like sequences that activate TLR5 and contain a 13 amino acid motif that is 53% or more identical to the Salmonella sequence in 88-100 of FliC (LQRVRELAVQSAN; SEQ ID NO: 504).

In some embodiments, the RNA (e.g., mRNA) vaccine includes an RNA that encodes a fusion protein of flagellin and one or more antigenic polypeptides. A “fusion protein” as used herein, refers to a linking of two components of the construct. In some embodiments, a carboxy-terminus of the antigenic polypeptide is fused or linked to an amino terminus of the flagellin polypeptide. In other embodiments, an amino-terminus of the antigenic polypeptide is fused or linked to a carboxy-terminus of the flagellin polypeptide. The fusion protein may include, for example, one, two, three, four, five, six or more flagellin polypeptides linked to one, two, three, four, five, six or more antigenic polypeptides. When two or more flagellin polypeptides and/or two or more antigenic polypeptides are linked such a construct may be referred to as a “multimer.”

Each of the components of a fusion protein may be directly linked to one another or they may be connected through a linker. For instance, the linker may be an amino acid linker. The amino acid linker encoded for by the RNA (e.g., mRNA) vaccine to link the components of the fusion protein may include, for instance, at least one member selected from the group consisting of a lysine residue, a glutamic acid residue, a serine residue and an arginine residue. In some embodiments the linker is 1-30, 1-25, 1-25, 5-10, 5, 15, or 5-20 amino acids in length.

In other embodiments the RNA (e.g., mRNA) vaccine includes at least two separate RNA polynucleotides, one encoding one or more antigenic polypeptides and the other encoding the flagellin polypeptide. The at least two RNA polynucleotides may be co-formulated in a carrier such as a lipid nanoparticle.

Methods of Treatment

Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention and/or treatment of influenza virus in humans and other mammals. Influenza virus RNA vaccines can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat infectious disease. In exemplary aspects, the influenza virus RNA vaccines of the present disclosure are used to provide prophylactic protection from influenza virus. Prophylactic protection from influenza virus can be achieved following administration of an influenza virus RNA vaccine of the present disclosure. Vaccines can be administered once, twice, three times, four times or more. It is possible, although less desirable, to administer the vaccine to an infected individual to achieve a therapeutic response. Dosing may need to be adjusted accordingly.

In some embodiments, the influenza virus vaccines of the present disclosure can be used as a method of preventing an influenza virus infection in a subject, the method comprising administering to said subject at least one influenza virus vaccine as provided herein. In some embodiments, the influenza virus vaccines of the present disclosure can be used as a method of inhibiting a primary influenza virus infection in a subject, the method comprising administering to said subject at least one influenza virus vaccine as provided herein. In some embodiments, the influenza virus vaccines of the present disclosure can be used as a method of treating an influenza virus infection in a subject, the method comprising administering to said subject at least one influenza virus vaccine as provided herein. In some embodiments, the influenza virus vaccines of the present disclosure can be used as a method of reducing an incidence of influenza virus infection in a subject, the method comprising administering to said subject at least one influenza virus vaccine as provided herein. In come embodiments, the influenza virus vaccines of the present disclosure can be used as a method of inhibiting spread of influenza virus from a first subject infected with influenza virus to a second subject not infected with influenza virus, the method comprising administering to at least one of said first subject sand said second subject at least one influenza virus vaccine as provided herein.

A method of eliciting an immune response in a subject against an influenza virus is provided in aspects of the invention. The method involves administering to the subject an influenza virus RNA vaccine comprising at least one RNA polynucleotide having an open reading frame encoding at least one influenza virus antigenic polypeptide or an immunogenic fragment thereof, thereby inducing in the subject an immune response specific to influenza virus antigenic polypeptide or an immunogenic fragment thereof, wherein anti-antigenic polypeptide antibody titer in the subject is increased following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the influenza virus. An “anti-antigenic polypeptide antibody” is a serum antibody the binds specifically to the antigenic polypeptide.

A prophylactically effective dose is a therapeutically effective dose that prevents infection with the virus at a clinically acceptable level. In some embodiments the therapeutically effective dose is a dose listed in a package insert for the vaccine. A traditional vaccine, as used herein, refers to a vaccine other than the mRNA vaccines of the present disclosure. For instance, a traditional vaccine includes, but is not limited to, live microorganism vaccines, killed microorganism vaccines, subunit vaccines, protein antigen vaccines, DNA vaccines, VLP vaccines, etc. In exemplary embodiments, a traditional vaccine is a vaccine that has achieved regulatory approval and/or is registered by a national drug regulatory body, for example the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA).

In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log to 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against the influenza virus.

In some embodiments the anti-antigenic polypeptide antibody titer in the subject is increased 1 log, 2 log, 3 log, 5 log or 10 log following vaccination relative to anti-antigenic polypeptide antibody titer in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against influenza.

A method of eliciting an immune response in a subject against an influenza virus is provided in other aspects of the present disclosure. The method involves administering to the subject an influenza virus RNA vaccine comprising at least one RNA polynucleotide having an open reading frame encoding at least one influenza virus antigenic polypeptide or an immunogenic fragment thereof, thereby inducing in the subject an immune response specific to influenza virus antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine against the influenza virus at 2 times to 100 times the dosage level relative to the RNA vaccine.

In some embodiments, the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the influenza vaccine.

In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 10-100 times, or 100-1000 times, the dosage level relative to the influenza vaccine.

In some embodiments the immune response is assessed by determining [protein] antibody titer in the subject.

Some embodiments provide a method of inducing an immune response in a subject by administering to the subject an influenza RNA (e.g., mRNA) vaccine comprising at least one RNA (e.g., mRNA) polynucleotide having an open reading frame encoding at least one influenza antigenic polypeptide, thereby inducing in the subject an immune response specific to the antigenic polypeptide or an immunogenic fragment thereof, wherein the immune response in the subject is induced 2 days to 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine against influenza. In some embodiments, the immune response in the subject is induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine at 2 times to 100 times the dosage level relative to the influenza RNA (e.g., mRNA) vaccine.

In some embodiments the immune response in the subject is equivalent to an immune response in a subject vaccinated with a traditional vaccine at 2, 3, 4, 5, 10, 50, 100 times the dosage level relative to the influenza RNA (e.g., mRNA) vaccine.

In some embodiments, the immune response in the subject is induced 2 days earlier, or 3 days earlier, relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.

In some embodiments the immune response in the subject is induced 1 week, 2 weeks, 3 weeks, 5 weeks, or 10 weeks earlier relative to an immune response induced in a subject vaccinated with a prophylactically effective dose of a traditional vaccine.

Therapeutic and Prophylactic Compositions

Provided herein are compositions (e.g., pharmaceutical compositions), methods, kits and reagents for prevention, treatment or diagnosis of influenza in humans and other mammals, for example. Influenza RNA (e.g. mRNA) vaccines can be used as therapeutic or prophylactic agents. They may be used in medicine to prevent and/or treat infectious disease. In some embodiments, the respiratory RNA (e.g., mRNA) vaccines of the present disclosure are used fin the priming of immune effector cells, for example, to activate peripheral blood mononuclear cells (PBMCs) ex vivo, which are then infused (re-infused) into a subject.

In some embodiments, influenza vaccine containing RNA (e.g., mRNA) polynucleotides as described herein can be administered to a subject (e.g., a mammalian subject, such as a human subject), and the RNA (e.g., mRNA) polynucleotides are translated in vivo to produce an antigenic polypeptide.

The influenza RNA (e.g., mRNA) vaccines may be induced for translation of a polypeptide (e.g., antigen or immunogen) in a cell, tissue or organism. In some embodiments, such translation occurs in vivo, although such translation may occur ex vivo, in culture or in vitro. In some embodiments, the cell, tissue or organism is contacted with an effective amount of a composition containing an influenza RNA (e.g., mRNA) vaccine that contains a polynucleotide that has at least one a translatable region encoding an antigenic polypeptide.

An “effective amount” of an influenza RNA (e.g. mRNA) vaccine is provided based, at least in part, on the target tissue, target cell type, means of administration, physical characteristics of the polynucleotide (e.g., size, and extent of modified nucleosides) and other components of the vaccine, and other determinants. In general, an effective amount of the influenza RNA (e.g., mRNA) vaccine composition provides an induced or boosted immune response as a function of antigen production in the cell, preferably more efficient than a composition containing a corresponding unmodified polynucleotide encoding the same antigen or a peptide antigen. Increased antigen production may be demonstrated by increased cell transfection (the percentage of cells transfected with the RNA, e.g., mRNA, vaccine), increased protein translation from the polynucleotide, decreased nucleic acid degradation (as demonstrated, for example, by increased duration of protein translation from a modified polynucleotide), or altered antigen specific immune response of the host cell.

In some embodiments, RNA (e.g. mRNA) vaccines (including polynucleotides their encoded polypeptides) in accordance with the present disclosure may be used for treatment of Influenza.

Influenza RNA (e.g. mRNA) vaccines may be administered prophylactically or therapeutically as part of an active immunization scheme to healthy individuals or early in infection during the incubation phase or during active infection after onset of symptoms. In some embodiments, the amount of RNA (e.g., mRNA) vaccine of the present disclosure provided to a cell, a tissue or a subject may be an amount effective for immune prophylaxis.

Influenza RNA (e.g. mRNA) vaccines may be administrated with other prophylactic or therapeutic compounds. As a non-limiting example, a prophylactic or therapeutic compound may be an adjuvant or a booster. As used herein, when referring to a prophylactic composition, such as a vaccine, the term “booster” refers to an extra administration of the prophylactic (vaccine) composition. A booster (or booster vaccine) may be given after an earlier administration of the prophylactic composition. The time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 10 days, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 18 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25 years, 30 years, 35 years, 40 years, 45 years, 50 years, 55 years, 60 years, 65 years, 70 years, 75 years, 80 years, 85 years, 90 years, 95 years or more than 99 years. In some embodiments, the time of administration between the initial administration of the prophylactic composition and the booster may be, but is not limited to, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months or 1 year.

In some embodiments, influenza RNA (e.g. mRNA) vaccines may be administered intramuscularly, intradermally, or intranasally, similarly to the administration of inactivated vaccines known in the art. In some embodiments, influenza RNA (e.g. mRNA) vaccines are administered intramuscularly.

Influenza RNA (e.g. mRNA) vaccines may be utilized in various settings depending on the prevalence of the infection or the degree or level of unmet medical need. As a non-limiting example, the RNA (e.g., mRNA) vaccines may be utilized to treat and/or prevent a variety of influenzas. RNA (e.g., mRNA) vaccines have superior properties in that they produce much larger antibody titers and produce responses early than commercially available anti-viral agents/compositions.

Provided herein are pharmaceutical compositions including influenza RNA (e.g. mRNA) vaccines and RNA (e.g. mRNA) vaccine compositions and/or complexes optionally in combination with one or more pharmaceutically acceptable excipients.

Influenza RNA (e.g. mRNA) vaccines may be formulated or administered alone or in conjunction with one or more other components. For instance, Influenza RNA (e.g., mRNA) vaccines (vaccine compositions) may comprise other components including, but not limited to, adjuvants.

In some embodiments, influenza (e.g. mRNA) vaccines do not include an adjuvant (they are adjuvant free).

Influenza RNA (e.g. mRNA) vaccines may be formulated or administered in combination with one or more pharmaceutically-acceptable excipients. In some embodiments, vaccine compositions comprise at least one additional active substances, such as, for example, a therapeutically-active substance, a prophylactically-active substance, or a combination of both. Vaccine compositions may be sterile, pyrogen-free or both sterile and pyrogen-free. General considerations in the formulation and/or manufacture of pharmaceutical agents, such as vaccine compositions, may be found, for example, in Remington: The Science and Practice of Pharmacy 21st ed., Lippincott Williams & Wilkins, 2005 (incorporated herein by reference in its entirety).

In some embodiments, influenza RNA (e.g. mRNA) vaccines are administered to humans, human patients or subjects. For the purposes of the present disclosure, the phrase “active ingredient” generally refers to the RNA (e.g., mRNA) vaccines or the polynucleotides contained therein, for example, RNA polynucleotides (e.g., mRNA polynucleotides) encoding antigenic polypeptides.

Formulations of the influenza vaccine compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient (e.g., mRNA polynucleotide) into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.

Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the disclosure will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

Influenza RNA (e.g. mRNA) vaccines can be formulated using one or more excipients to: increase stability; increase cell transfection; permit the sustained or delayed release (e.g., from a depot formulation); alter the biodistribution (e.g., target to specific tissues or cell types); increase the translation of encoded protein in vivo; and/or alter the release profile of encoded protein (antigen) in vivo. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with influenza RNA (e.g. mRNA)vaccines (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof.

Stabilizing Elements

Naturally-occurring eukaryotic mRNA molecules have been found to contain stabilizing elements, including, but not limited to untranslated regions (UTR) at their 5′-end (5′UTR) and/or at their 3′-end (3′UTR), in addition to other structural features, such as a 5′-cap structure or a 3′-poly(A) tail. Both the 5′UTR and the 3′UTR are typically transcribed from the genomic DNA and are elements of the premature mRNA. Characteristic structural features of mature mRNA, such as the 5′-cap and the 3′-poly(A) tail are usually added to the transcribed (premature) mRNA during mRNA processing. The 3′-poly(A) tail is typically a stretch of adenine nucleotides added to the 3′-end of the transcribed mRNA. It can comprise up to about 400 adenine nucleotides. In some embodiments the length of the 3′-poly(A) tail may be an essential element with respect to the stability of the individual mRNA.

In some embodiments the RNA (e.g., mRNA) vaccine may include one or more stabilizing elements. Stabilizing elements may include for instance a histone stem-loop. A stem-loop binding protein (SLBP), a 32 kDa protein has been identified. It is associated with the histone stem-loop at the 3′-end of the histone messages in both the nucleus and the cytoplasm. Its expression level is regulated by the cell cycle; it is peaks during the S-phase, when histone mRNA levels are also elevated. The protein has been shown to be essential for efficient 3′-end processing of histone pre-mRNA by the U7 snRNP. SLBP continues to be associated with the stem-loop after processing, and then stimulates the translation of mature histone mRNAs into histone proteins in the cytoplasm. The RNA binding domain of SLBP is conserved through metazoa and protozoa; its binding to the histone stem-loop depends on the structure of the loop. The minimum binding site includes at least three nucleotides 5′ and two nucleotides 3′ relative to the stem-loop.

In some embodiments, the RNA (e.g., mRNA) vaccines include a coding region, at least one histone stem-loop, and optionally, a poly(A) sequence or polyadenylation signal. The poly(A) sequence or polyadenylation signal generally should enhance the expression level of the encoded protein. The encoded protein, in some embodiments, is not a histone protein, a reporter protein (e.g. Luciferase, GFP, EGFP, β-Galactosidase, EGFP), or a marker or selection protein (e.g. alpha-Globin, Galactokinase and Xanthine:guanine phosphoribosyl transferase (GPT)).

In some embodiments, the combination of a poly(A) sequence or polyadenylation signal and at least one histone stem-loop, even though both represent alternative mechanisms in nature, acts synergistically to increase the protein expression beyond the level observed with either of the individual elements. It has been found that the synergistic effect of the combination of poly(A) and at least one histone stem-loop does not depend on the order of the elements or the length of the poly(A) sequence.

In some embodiments, the RNA (e.g., mRNA) vaccine does not comprise a histone downstream element (HDE). “Histone downstream element” (HDE) includes a purine-rich polynucleotide stretch of approximately 15 to 20 nucleotides 3′ of naturally occurring stem-loops, representing the binding site for the U7 snRNA, which is involved in processing of histone pre-mRNA into mature histone mRNA. Ideally, the inventive nucleic acid does not include an intron.

In some embodiments, the RNA (e.g., mRNA) vaccine may or may not contain a enhancer and/or promoter sequence, which may be modified or unmodified or which may be activated or inactivated. In some embodiments, the histone stem-loop is generally derived from histone genes, and includes an intramolecular base pairing of two neighbored partially or entirely reverse complementary sequences separated by a spacer, including (e.g., consisting of) a short sequence, which forms the loop of the structure. The unpaired loop region is typically unable to base pair with either of the stem loop elements. It occurs more often in RNA, as is a key component of many RNA secondary structures, but may be present in single-stranded DNA as well. Stability of the stem-loop structure generally depends on the length, number of mismatches or bulges, and base composition of the paired region. In some embodiments, wobble base pairing (non-Watson-Crick base pairing) may result. In some embodiments, the at least one histone stem-loop sequence comprises a length of 15 to 45 nucleotides.

In other embodiments the RNA (e.g., mRNA) vaccine may have one or more AU-rich sequences removed. These sequences, sometimes referred to as AURES are destabilizing sequences found in the 3′UTR. The AURES may be removed from the RNA (e.g., mRNA) vaccines. Alternatively the AURES may remain in the RNA (e.g., mRNA) vaccine.

Nanoparticle Formulations

In some embodiments, influenza RNA (e.g. mRNA) vaccines are formulated in a nanoparticle. In some embodiments, influenza RNA (e.g. mRNA) vaccines are formulated in a lipid nanoparticle. In some embodiments, influenza RNA (e.g. mRNA) vaccines are formulated in a lipid-polycation complex, referred to as a cationic lipid nanoparticle. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, influenza RNA (e.g., mRNA) vaccines are formulated in a lipid nanoparticle that includes a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).

A lipid nanoparticle formulation may be influenced by, but not limited to, the selection of the cationic lipid component, the degree of cationic lipid saturation, the nature of the PEGylation, ratio of all components and biophysical parameters such as size. In one example by Semple et al. (Nature Biotech. 2010 28:172-176), the lipid nanoparticle formulation is composed of 57.1% cationic lipid, 7.1% dipalmitoylphosphatidylcholine, 34.3% cholesterol, and 1.4% PEG-c-DMA. As another example, changing the composition of the cationic lipid can more effectively deliver siRNA to various antigen presenting cells (Basha et al. Mol Ther. 2011 19:2186-2200).

In some embodiments, lipid nanoparticle formulations may comprise 35 to 45% cationic lipid, 40% to 50% cationic lipid, 50% to 60% cationic lipid and/or 55% to 65% cationic lipid. In some embodiments, the ratio of lipid to RNA (e.g., mRNA) in lipid nanoparticles may be 5:1 to 20:1, 10:1 to 25:1, 15:1 to 30:1 and/or at least 30:1.

In some embodiments, the ratio of PEG in the lipid nanoparticle formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the lipid nanoparticle formulations. As a non-limiting example, lipid nanoparticle formulations may contain 0.5% to 3.0%, 1.0% to 3.5%, 1.5% to 4.0%, 2.0% to 4.5%, 2.5% to 5.0% and/or 3.0% to 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(ω-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.

In some embodiments, an influenza RNA (e.g. mRNA) vaccine formulation is a nanoparticle that comprises at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In some embodiments, the lipid may be a cationic lipid such as, but not limited to, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy] methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy] methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.

Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.

In some embodiments, a lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.

In some embodiments, a lipid nanoparticle formulation includes 25% to 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., 35 to 65%, 45 to 65%, 60%, 57.5%, 50% or 40% on a molar basis.

In some embodiments, a lipid nanoparticle formulation includes 0.5% to 15% on a molar basis of the neutral lipid, e.g., 3 to 12%, 5 to 10% or 15%, 10%, or 7.5% on a molar basis. Examples of neutral lipids include, without limitation, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes 5% to 50% on a molar basis of the sterol (e.g., 15 to 45%, 20 to 40%, 40%, 38.5%, 35%, or 31% on a molar basis. A non-limiting example of a sterol is cholesterol. In some embodiments, a lipid nanoparticle formulation includes 0.5% to 20% on a molar basis of the PEG or PEG-modified lipid (e.g., 0.5 to 10%, 0.5 to 5%, 1.5%, 0.5%, 1.5%, 3.5%, or 5% on a molar basis. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In some embodiments, a PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Non-limiting examples of PEG-modified lipids include PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety).

In some embodiments, lipid nanoparticle formulations include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.5% of the neutral lipid, 31% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 38.5% of the sterol, and 1.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 10% of the neutral lipid, 35% of the sterol, 4.5% or 5% of the PEG or PEG-modified lipid, and 0.5% of the targeting lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 15% of the neutral lipid, 40% of the sterol, and 5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 7.1% of the neutral lipid, 34.3% of the sterol, and 1.4% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations include 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), 7.5% of the neutral lipid, 31.5% of the sterol, and 3.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in molar ratios of 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid. In some embodiments, lipid nanoparticle formulations consists essentially of a lipid mixture in a molar ratio of 20-60% cationic lipid: 5-25% neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.

In some embodiments, the molar lipid ratio is 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

Non-limiting examples of lipid nanoparticle compositions and methods of making them are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, lipid nanoparticle formulations may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, a lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, a lipid nanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise 40-60% of cationic lipid, 5-15% of a non-cationic lipid, 1-2% of a PEG lipid and 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise 50% cationic lipid, 10% non-cationic lipid, 1.5% PEG lipid and 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise 55% cationic lipid, 10% non-cationic lipid, 2.5% PEG lipid and 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-KC2-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DOMG and 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise 50% of the cationic lipid DLin-MC3-DMA, 10% of the non-cationic lipid DSPC, 1.5% of the PEG lipid PEG-DMG and 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise 55% of the cationic lipid L319, 10% of the non-cationic lipid DSPC, 2.5% of the PEG lipid PEG-DMG and 32.5% of the structural lipid cholesterol.

Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a vaccine composition may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

In some embodiments, the influenza RNA (e.g. mRNA) vaccine composition may comprise the polynucleotide described herein, formulated in a lipid nanoparticle comprising MC3, Cholesterol, DSPC and PEG2000-DMG, the buffer trisodium citrate, sucrose and water for injection. As a non-limiting example, the composition comprises: 2.0 mg/mL of drug substance, 21.8 mg/mL of MC3, 10.1 mg/mL of cholesterol, 5.4 mg/mL of DSPC, 2.7 mg/mL of PEG2000-DMG, 5.16 mg/mL of trisodium citrate, 71 mg/mL of sucrose and 1.0 mL of water for injection.

In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 10-500 nm, 20-400 nm, 30-300 nm, 40-200 nm. In some embodiments, a nanoparticle (e.g., a lipid nanoparticle) has a mean diameter of 50-150 nm, 50-200 nm, 80-100 nm or 80-200 nm.

Liposomes, Lipoplexes, and Lipid Nanoparticles

The RNA (e.g., mRNA) vaccines of the disclosure can be formulated using one or more liposomes, lipoplexes, or lipid nanoparticles. In some embodiments, pharmaceutical compositions of RNA (e.g., mRNA) vaccines include liposomes. Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of nutrients and pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the pharmaceutical formulations.

The formation of liposomes may depend on the physicochemical characteristics such as, but not limited to, the pharmaceutical formulation entrapped and the liposomal ingredients, the nature of the medium in which the lipid vesicles are dispersed, the effective concentration of the entrapped substance and its potential toxicity, any additional processes involved during the application and/or delivery of the vesicles, the optimization size, polydispersity and the shelf-life of the vesicles for the intended application, and the batch-to-batch reproducibility and possibility of large-scale production of safe and efficient liposomal products.

In some embodiments, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), and MC3 (US20100324120; herein incorporated by reference in its entirety) and liposomes which may deliver small molecule drugs such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).

In some embodiments, pharmaceutical compositions described herein may include, without limitation, liposomes such as those formed from the synthesis of stabilized plasmid-lipid particles (SPLP) or stabilized nucleic acid lipid particle (SNALP) that have been previously described and shown to be suitable for oligonucleotide delivery in vitro and in vivo (see Wheeler et al. Gene Therapy. 1999 6:271-281; Zhang et al. Gene Therapy. 1999 6:1438-1447; Jeffs et al. Pharm Res. 2005 22:362-372; Morrissey et al., Nat Biotechnol. 2005 2:1002-1007; Zimmermann et al., Nature. 2006 441:111-114; Heyes et al. J Contr Rel. 2005 107:276-287; Semple et al. Nature Biotech. 2010 28:172-176; Judge et al. J Clin Invest. 2009 119:661-673; deFougerolles Hum Gene Ther. 2008 19:125-132; U.S. Patent Publication No US20130122104; all of which are incorporated herein in their entireties). The original manufacture method by Wheeler et al. was a detergent dialysis method, which was later improved by Jeffs et al. and is referred to as the spontaneous vesicle formation method. The liposome formulations are composed of 3 to 4 lipid components in addition to the polynucleotide. As an example a liposome can contain, but is not limited to, 55% cholesterol, 20% disteroylphosphatidyl choline (DSPC), 10% PEG-S-DSG, and 15% 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), as described by Jeffs et al. As another example, certain liposome formulations may contain, but are not limited to, 48% cholesterol, 20% DSPC, 2% PEG-c-DMA, and 30% cationic lipid, where the cationic lipid can be 1,2-distearloxy-N,N-dimethylaminopropane (DSDMA), DODMA, DLin-DMA, or 1,2-dilinolenyloxy-3-dimethylaminopropane (DLenDMA), as described by Heyes et al.

In some embodiments, liposome formulations may comprise from about 25.0% cholesterol to about 40.0% cholesterol, from about 30.0% cholesterol to about 45.0% cholesterol, from about 35.0% cholesterol to about 50.0% cholesterol and/or from about 48.5% cholesterol to about 60% cholesterol. In some embodiments, formulations may comprise a percentage of cholesterol selected from the group consisting of 28.5%, 31.5%, 33.5%, 36.5%, 37.0%, 38.5%, 39.0% and 43.5%. In some embodiments, formulations may comprise from about 5.0% to about 10.0% DSPC and/or from about 7.0% to about 15.0% DSPC.

In some embodiments, the RNA (e.g., mRNA) vaccine pharmaceutical compositions may be formulated in liposomes such as, but not limited to, DiLa2 liposomes (Marina Biotech, Bothell, Wash.), SMARTICLES® (Marina Biotech, Bothell, Wash.), neutral DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) based liposomes (e.g., siRNA delivery for ovarian cancer (Landen et al. Cancer Biology & Therapy 2006 5(12)1708-1713); herein incorporated by reference in its entirety) and hyaluronan-coated liposomes (Quiet Therapeutics, Israel).

In some embodiments, the cationic lipid may be a low molecular weight cationic lipid such as those described in U.S. Patent Application No. 20130090372, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid vesicle, which may have crosslinks between functionalized lipid bilayers.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex. The formation of the lipid-polycation complex may be accomplished by methods known in the art and/or as described in U.S. Pub. No. 20120178702, herein incorporated by reference in its entirety. As a non-limiting example, the polycation may include a cationic peptide or a polypeptide such as, but not limited to, polylysine, polyornithine and/or polyarginine. In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid-polycation complex, which may further include a non-cationic lipid such as, but not limited to, cholesterol or dioleoyl phosphatidylethanolamine (DOPE).

In some embodiments, the ratio of PEG in the lipid nanoparticle (LNP) formulations may be increased or decreased and/or the carbon chain length of the PEG lipid may be modified from C14 to C18 to alter the pharmacokinetics and/or biodistribution of the LNP formulations. As a non-limiting example, LNP formulations may contain from about 0.5% to about 3.0%, from about 1.0% to about 3.5%, from about 1.5% to about 4.0%, from about 2.0% to about 4.5%, from about 2.5% to about 5.0% and/or from about 3.0% to about 6.0% of the lipid molar ratio of PEG-c-DOMG (R-3-[(w-methoxy-poly(ethyleneglycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine) (also referred to herein as PEG-DOMG) as compared to the cationic lipid, DSPC and cholesterol. In some embodiments, the PEG-c-DOMG may be replaced with a PEG lipid such as, but not limited to, PEG-DSG (1,2-Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn-glycerol) and/or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol). The cationic lipid may be selected from any lipid known in the art such as, but not limited to, DLin-MC3-DMA, DLin-DMA, C12-200 and DLin-KC2-DMA.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a lipid nanoparticle.

In some embodiments, the RNA (e.g., mRNA) vaccine formulation comprising the polynucleotide is a nanoparticle which may comprise at least one lipid. The lipid may be selected from, but is not limited to, DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids and amino alcohol lipids. In another aspect, the lipid may be a cationic lipid such as, but not limited to, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. The amino alcohol cationic lipid may be the lipids described in and/or made by the methods described in U.S. Patent Publication No. US20130150625, herein incorporated by reference in its entirety. As a non-limiting example, the cationic lipid may be 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,2Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 1 in US20130150625); 2-amino-3-[(9Z)-octadec-9-en-1-yloxy]-2-{[(9Z)-octadec-9-en-1-yloxy]methyl}propan-1-ol (Compound 2 in US20130150625); 2-amino-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-[(octyloxy)methyl]propan-1-ol (Compound 3 in US20130150625); and 2-(dimethylamino)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-2-{[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]methyl}propan-1-ol (Compound 4 in US20130150625); or any pharmaceutically acceptable salt or stereoisomer thereof.

Lipid nanoparticle formulations typically comprise a lipid, in particular, an ionizable cationic lipid, for example, 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), or di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), and further comprise a neutral lipid, a sterol and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid.

In some embodiments, the lipid nanoparticle formulation consists essentially of (i) at least one lipid selected from the group consisting of 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); (ii) a neutral lipid selected from DSPC, DPPC, POPC, DOPE and SM; (iii) a sterol, e.g., cholesterol; and (iv) a PEG-lipid, e.g., PEG-DMG or PEG-cDMA, in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; 0.5-15% PEG-lipid.

In some embodiments, the formulation includes from about 25% to about 75% on a molar basis of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), e.g., from about 35 to about 65%, from about 45 to about 65%, about 60%, about 57.5%, about 50% or about 40% on a molar basis.

In some embodiments, the formulation includes from about 0.5% to about 15% on a molar basis of the neutral lipid e.g., from about 3 to about 12%, from about 5 to about 10% or about 15%, about 10%, or about 7.5% on a molar basis. Examples of neutral lipids include, but are not limited to, DSPC, POPC, DPPC, DOPE and SM. In some embodiments, the formulation includes from about 5% to about 50% on a molar basis of the sterol (e.g., about 15 to about 45%, about 20 to about 40%, about 40%, about 38.5%, about 35%, or about 31% on a molar basis. An exemplary sterol is cholesterol. In some embodiments, the formulation includes from about 0.5% to about 20% on a molar basis of the PEG or PEG-modified lipid (e.g., about 0.5 to about 10%, about 0.5 to about 5%, about 1.5%, about 0.5%, about 1.5%, about 3.5%, or about 5% on a molar basis. In some embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of 2,000 Da. In other embodiments, the PEG or PEG modified lipid comprises a PEG molecule of an average molecular weight of less than 2,000, for example around 1,500 Da, around 1,000 Da, or around 500 Da. Examples of PEG-modified lipids include, but are not limited to, PEG-distearoyl glycerol (PEG-DMG) (also referred herein as PEG-C14 or C14-PEG), PEG-cDMA (further discussed in Reyes et al. J. Controlled Release, 107, 276-287 (2005) the contents of which are herein incorporated by reference in their entirety)

In some embodiments, the formulations of the present disclosure include 25-75% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 0.5-15% of the neutral lipid, 5-50% of the sterol, and 0.5-20% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include 35-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 3-12% of the neutral lipid, 15-45% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include 45-65% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), 5-10% of the neutral lipid, 25-40% of the sterol, and 0.5-10% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 60% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.5% of the neutral lipid, about 31% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 38.5% of the sterol, and about 1.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 50% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 10% of the neutral lipid, about 35% of the sterol, about 4.5% or about 5% of the PEG or PEG-modified lipid, and about 0.5% of the targeting lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 40% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 15% of the neutral lipid, about 40% of the sterol, and about 5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 57.2% of a cationic lipid selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319), about 7.1% of the neutral lipid, about 34.3% of the sterol, and about 1.4% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, the formulations of the present disclosure include about 57.5% of a cationic lipid selected from the PEG lipid is PEG-cDMA (PEG-cDMA is further discussed in Reyes et al. (J. Controlled Release, 107, 276-287 (2005), the contents of which are herein incorporated by reference in their entirety), about 7.5% of the neutral lipid, about 31.5% of the sterol, and about 3.5% of the PEG or PEG-modified lipid on a molar basis.

In some embodiments, lipid nanoparticle formulation consists essentially of a lipid mixture in molar ratios of about 20-70% cationic lipid: 5-45% neutral lipid: 20-55% cholesterol: 0.5-15% PEG-modified lipid; more preferably in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% cholesterol: 0.5-15% PEG-modified lipid.

In some embodiments, the molar lipid ratio is approximately 50/10/38.5/1.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG, PEG-DSG or PEG-DPG), 57.2/7.1134.3/1.4 (mol % cationic lipid/neutral lipid, e.g., DPPC/Chol/PEG-modified lipid, e.g., PEG-cDMA), 40/15/40/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 50/10/35/4.5/0.5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DSG), 50/10/35/5 (cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG), 40/10/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA), 35/15/40/10 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA) or 52/13/30/5 (mol % cationic lipid/neutral lipid, e.g., DSPC/Chol/PEG-modified lipid, e.g., PEG-DMG or PEG-cDMA).

Examples of lipid nanoparticle compositions and methods of making same are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28:172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51: 8529-8533; and Maier et al. (2013) Molecular Therapy 21, 1570-1578 (the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a PEG lipid and a structural lipid and optionally comprise a non-cationic lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

In some embodiments, the lipid nanoparticle formulations described herein may be 4 component lipid nanoparticles. The lipid nanoparticle may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle may comprise about 40-60% of cationic lipid, about 5-15% of a non-cationic lipid, about 1-2% of a PEG lipid and about 30-50% of a structural lipid. As another non-limiting example, the lipid nanoparticle may comprise about 50% cationic lipid, about 10% non-cationic lipid, about 1.5% PEG lipid and about 38.5% structural lipid. As yet another non-limiting example, the lipid nanoparticle may comprise about 55% cationic lipid, about 10% non-cationic lipid, about 2.5% PEG lipid and about 32.5% structural lipid. In some embodiments, the cationic lipid may be any cationic lipid described herein such as, but not limited to, DLin-KC2-DMA, DLin-MC3-DMA and L319.

In some embodiments, the lipid nanoparticle formulations described herein may comprise a cationic lipid, a non-cationic lipid, a PEG lipid and a structural lipid. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-KC2-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DOMG and about 38.5% of the structural lipid cholesterol. As a non-limiting example, the lipid nanoparticle comprise about 50% of the cationic lipid DLin-MC3-DMA, about 10% of the non-cationic lipid DSPC, about 1.5% of the PEG lipid PEG-DMG and about 38.5% of the structural lipid cholesterol. As yet another non-limiting example, the lipid nanoparticle comprise about 55% of the cationic lipid L319, about 10% of the non-cationic lipid DSPC, about 2.5% of the PEG lipid PEG-DMG and about 32.5% of the structural lipid cholesterol.

As a non-limiting example, the cationic lipid may be selected from (20Z,23Z)—N,N-dimethylnonacosa-20,23-dien-10-amine, (17Z,20Z)—N,N-dimemylhexacosa-17,20-dien-9-amine, (1Z,19Z)—N5N-dimethylpentacosa-16,19-dien-8-amine, (13Z,16Z)—N,N-dimethyldocosa-13,16-dien-5-amine, (12Z,15Z)—N,N-dimethylhenicosa-12,15-dien-4-amine, (14Z,17Z)—N,N-dimethyltricosa-14,17-dien-6-amine, (15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-7-amine, (18Z,21Z)—N,N-dimethylheptacosa-18,21-dien-10-amine, (15Z,18Z)—N,N-dimethyltetracosa-15,18-dien-5-amine, (14Z,17Z)—N,N-dimethyltricosa-14,17-dien-4-amine, (19Z,22Z)—N,N-dimeihyloctacosa-19,22-dien-9-amine, (18Z,21 Z)—N,N-dimethylheptacosa-18,21-dien-8-amine, (17Z,20Z)—N,N-dimethylhexacosa-17,20-dien-7-amine, (16Z,19Z)—N,N-dimethylpentacosa-16,19-dien-6-amine, (22Z,25Z)—N,N-dimethylhentriaconta-22,25-dien-10-amine, (21 Z,24Z)—N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)—N,N-dimetylheptacos-18-en-10-amine, (17Z)—N,N-dimethylhexacos-17-en-9-amine, (19Z,22Z)—N,N-dimethyloctacosa-19,22-dien-7-amine, N,N-dimethylheptacosan-10-amine, (20Z,23Z)—N-ethyl-N-methylnonacosa-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl] pyrrolidine, (20Z)—N,N-dimethylheptacos-20-en-10-amine, (15Z)—N,N-dimethyl eptacos-15-en-10-amine, (14Z)—N,N-dimethylnonacos-14-en-10-amine, (17Z)—N,N-dimethylnonacos-17-en-10-amine, (24Z)—N,N-dimethyltritriacont-24-en-10-amine, (20Z)—N,N-dimethylnonacos-20-en-10-amine, (22Z)—N,N-dimethylhentriacont-22-en-10-amine, (16Z)—N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine, (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl] eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl] nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine, N,N-dimethyl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl} cyclopropyl]nonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecyIcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl} dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, S—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}pyrrolidine, (2S)—N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azetidine, (2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-amine; (2S)—N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(octyloxy)propan-2-amine, (2S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propan-2-amine, (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethylpropan-2-amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amine, 1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)—N,N-dimethyl-H(1-methyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl} cyclopropyl] octyl}oxy)propan-2-amine, N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-amine and (11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,2-trien-10-amine or a pharmaceutically acceptable salt or stereoisomer thereof.

In some embodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines may contain PEG-c-DOMG at 3% lipid molar ratio. In some embodiments, the LNP formulations of the RNA (e.g., mRNA) vaccines may contain PEG-c-DOMG at 1.5% lipid molar ratio.

In some embodiments, the pharmaceutical compositions of the RNA (e.g., mRNA) vaccines may include at least one of the PEGylated lipids described in International Publication No. WO2012099755, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the LNP formulation may contain PEG-DMG 2000 (1,2-dimyristoyl-sn-glycero-3-phophoethanolamine-N-[methoxy(polyethylene glycol)-2000). In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art and at least one other component. In some embodiments, the LNP formulation may contain PEG-DMG 2000, a cationic lipid known in the art, DSPC and cholesterol. As a non-limiting example, the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol. As another non-limiting example the LNP formulation may contain PEG-DMG 2000, DLin-DMA, DSPC and cholesterol in a molar ratio of 2:40:10:48 (see e.g., Geall et al., Nonviral delivery of self-amplifying RNA (e.g., mRNA) vaccines, PNAS 2012; PMID: 22908294, the contents of each of which are herein incorporated by reference in their entirety).

The lipid nanoparticles described herein may be made in a sterile environment.

In some embodiments, the LNP formulation may be formulated in a nanoparticle such as a nucleic acid-lipid particle. As a non-limiting example, the lipid particle may comprise one or more active agents or therapeutic agents; one or more cationic lipids comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

The nanoparticle formulations may comprise a phosphate conjugate. The phosphate conjugate may increase in vivo circulation times and/or increase the targeted delivery of the nanoparticle. As a non-limiting example, the phosphate conjugates may include a compound of any one of the formulas described in International Application No. WO2013033438, the contents of which are herein incorporated by reference in its entirety.

The nanoparticle formulation may comprise a polymer conjugate. The polymer conjugate may be a water soluble conjugate. The polymer conjugate may have a structure as described in U.S. Patent Application No. 20130059360, the contents of which are herein incorporated by reference in its entirety. In some embodiments, polymer conjugates with the polynucleotides of the present disclosure may be made using the methods and/or segmented polymeric reagents described in U.S. Patent Application No. 20130072709, the contents of which are herein incorporated by reference in its entirety. In some embodiments, the polymer conjugate may have pendant side groups comprising ring moieties such as, but not limited to, the polymer conjugates described in U.S. Patent Publication No. US20130196948, the contents which are herein incorporated by reference in its entirety.

The nanoparticle formulations may comprise a conjugate to enhance the delivery of nanoparticles of the present disclosure in a subject. Further, the conjugate may inhibit phagocytic clearance of the nanoparticles in a subject. In one aspect, the conjugate may be a “self” peptide designed from the human membrane protein CD47 (e.g., the “self” particles described by Rodriguez et al. (Science 2013 339, 971-975), herein incorporated by reference in its entirety). As shown by Rodriguez et al., the self peptides delayed macrophage-mediated clearance of nanoparticles which enhanced delivery of the nanoparticles. In another aspect, the conjugate may be the membrane protein CD47 (e.g., see Rodriguez et al. Science 2013 339, 971-975, herein incorporated by reference in its entirety). Rodriguez et al. showed that, similarly to “self” peptides, CD47 can increase the circulating particle ratio in a subject as compared to scrambled peptides and PEG coated nanoparticles.

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure are formulated in nanoparticles which comprise a conjugate to enhance the delivery of the nanoparticles of the present disclosure in a subject. The conjugate may be the CD47 membrane or the conjugate may be derived from the CD47 membrane protein, such as the “self” peptide described previously. In some embodiments, the nanoparticle may comprise PEG and a conjugate of CD47 or a derivative thereof. In some embodiments, the nanoparticle may comprise both the “self” peptide described above and the membrane protein CD47.

In some embodiments, a “self” peptide and/or CD47 protein may be conjugated to a virus-like particle or pseudovirion, as described herein for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure.

In some embodiments, RNA (e.g., mRNA) vaccine pharmaceutical compositions comprising the polynucleotides of the present disclosure and a conjugate that may have a degradable linkage. Non-limiting examples of conjugates include an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. As a non-limiting example, pharmaceutical compositions comprising a conjugate with a degradable linkage and methods for delivering such pharmaceutical compositions are described in U.S. Patent Publication No. US20130184443, the contents of which are herein incorporated by reference in their entirety.

The nanoparticle formulations may be a carbohydrate nanoparticle comprising a carbohydrate carrier and a RNA (e.g., mRNA) vaccine. As a non-limiting example, the carbohydrate carrier may include, but is not limited to, an anhydride-modified phytoglycogen or glycogen-type material, phytoglycogen octenyl succinate, phytoglycogen beta-dextrin, anhydride-modified phytoglycogen beta-dextrin. (See e.g., International Publication No. WO2012109121; the contents of which are herein incorporated by reference in their entirety).

Nanoparticle formulations of the present disclosure may be coated with a surfactant or polymer in order to improve the delivery of the particle. In some embodiments, the nanoparticle may be coated with a hydrophilic coating such as, but not limited to, PEG coatings and/or coatings that have a neutral surface charge. The hydrophilic coatings may help to deliver nanoparticles with larger payloads such as, but not limited to, RNA (e.g., mRNA) vaccines within the central nervous system. As a non-limiting example nanoparticles comprising a hydrophilic coating and methods of making such nanoparticles are described in U.S. Patent Publication No. US20130183244, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophilic polymer particles. Non-limiting examples of hydrophilic polymer particles and methods of making hydrophilic polymer particles are described in U.S. Patent Publication No. US20130210991, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the lipid nanoparticles of the present disclosure may be hydrophobic polymer particles.

Lipid nanoparticle formulations may be improved by replacing the cationic lipid with a biodegradable cationic lipid which is known as a rapidly eliminated lipid nanoparticle (reLNP). Ionizable cationic lipids, such as, but not limited to, DLinDMA, DLin-KC2-DMA, and DLin-MC3-DMA, have been shown to accumulate in plasma and tissues over time and may be a potential source of toxicity. The rapid metabolism of the rapidly eliminated lipids can improve the tolerability and therapeutic index of the lipid nanoparticles by an order of magnitude from a 1 mg/kg dose to a 10 mg/kg dose in rat. Inclusion of an enzymatically degraded ester linkage can improve the degradation and metabolism profile of the cationic component, while still maintaining the activity of the reLNP formulation. The ester linkage can be internally located within the lipid chain or it may be terminally located at the terminal end of the lipid chain. The internal ester linkage may replace any carbon in the lipid chain.

In some embodiments, the internal ester linkage may be located on either side of the saturated carbon.

In some embodiments, an immune response may be elicited by delivering a lipid nanoparticle which may include a nanospecies, a polymer and an immunogen. (U.S. Publication No. 20120189700 and International Publication No. WO2012099805; each of which is herein incorporated by reference in their entirety). The polymer may encapsulate the nanospecies or partially encapsulate the nanospecies. The immunogen may be a recombinant protein, a modified RNA and/or a polynucleotide described herein. In some embodiments, the lipid nanoparticle may be formulated for use in a vaccine such as, but not limited to, against a pathogen.

Lipid nanoparticles may be engineered to alter the surface properties of particles so the lipid nanoparticles may penetrate the mucosal barrier. Mucus is located on mucosal tissue such as, but not limited to, oral (e.g., the buccal and esophageal membranes and tonsil tissue), ophthalmic, gastrointestinal (e.g., stomach, small intestine, large intestine, colon, rectum), nasal, respiratory (e.g., nasal, pharyngeal, tracheal and bronchial membranes), genital (e.g., vaginal, cervical and urethral membranes). Nanoparticles larger than 10-200 nm which are preferred for higher drug encapsulation efficiency and the ability to provide the sustained delivery of a wide array of drugs have been thought to be too large to rapidly diffuse through mucosal barriers. Mucus is continuously secreted, shed, discarded or digested and recycled so most of the trapped particles may be removed from the mucosa tissue within seconds or within a few hours. Large polymeric nanoparticles (200 nm-500 nm in diameter) which have been coated densely with a low molecular weight polyethylene glycol (PEG) diffused through mucus only 4 to 6-fold lower than the same particles diffusing in water (Lai et al. PNAS 2007 104:1482-487; Lai et al. Adv Drug Deliv Rev. 2009 61: 158-171; each of which is herein incorporated by reference in their entirety). The transport of nanoparticles may be determined using rates of permeation and/or fluorescent microscopy techniques including, but not limited to, fluorescence recovery after photobleaching (FRAP) and high resolution multiple particle tracking (MPT). As a non-limiting example, compositions which can penetrate a mucosal barrier may be made as described in U.S. Pat. No. 8,241,670 or International Patent Publication No. WO2013110028, the contents of each of which are herein incorporated by reference in its entirety.

The lipid nanoparticle engineered to penetrate mucus may comprise a polymeric material (i.e. a polymeric core) and/or a polymer-vitamin conjugate and/or a tri-block co-polymer. The polymeric material may include, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, poly(styrenes), polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. The polymeric material may be biodegradable and/or biocompatible. Non-limiting examples of biocompatible polymers are described in International Patent Publication No. WO2013116804, the contents of which are herein incorporated by reference in their entirety. The polymeric material may additionally be irradiated. As a non-limiting example, the polymeric material may be gamma irradiated (see e.g., International App. No. WO201282165, herein incorporated by reference in its entirety). Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacralate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), PEG-PLGA-PEG and trimethylene carbonate, polyvinylpyrrolidone. The lipid nanoparticle may be coated or associated with a co-polymer such as, but not limited to, a block co-polymer (such as a branched polyether-polyamide block copolymer described in International Publication No. WO2013012476, herein incorporated by reference in its entirety), and (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer (see e.g., U.S. Publication 20120121718 and U.S. Publication 20100003337 and U.S. Pat. No. 8,263,665, the contents of each of which is herein incorporated by reference in their entirety). The co-polymer may be a polymer that is generally regarded as safe (GRAS) and the formation of the lipid nanoparticle may be in such a way that no new chemical entities are created. For example, the lipid nanoparticle may comprise poloxamers coating PLGA nanoparticles without forming new chemical entities which are still able to rapidly penetrate human mucus (Yang et al. Angew. Chem. Int. Ed. 2011 50:2597-2600; the contents of which are herein incorporated by reference in their entirety). A non-limiting scalable method to produce nanoparticles which can penetrate human mucus is described by Xu et al. (see, e.g., J Control Release 2013, 170:279-86; the contents of which are herein incorporated by reference in their entirety).

The vitamin of the polymer-vitamin conjugate may be vitamin E. The vitamin portion of the conjugate may be substituted with other suitable components such as, but not limited to, vitamin A, vitamin E, other vitamins, cholesterol, a hydrophobic moiety, or a hydrophobic component of other surfactants (e.g., sterol chains, fatty acids, hydrocarbon chains and alkylene oxide chains).

The lipid nanoparticle engineered to penetrate mucus may include surface altering agents such as, but not limited to, polynucleotides, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as for example dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol and poloxamer), mucolytic agents (e.g., N-acetylcysteine, mugwort, bromelain, papain, clerodendrum, acetylcysteine, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin β4 dornase alfa, neltenexine, erdosteine) and various DNases including rhDNase. The surface altering agent may be embedded or enmeshed in the particle's surface or disposed (e.g., by coating, adsorption, covalent linkage, or other process) on the surface of the lipid nanoparticle. (see e.g., U.S. Publication 20100215580 and U.S. Publication 20080166414 and US20130164343; the contents of each of which are herein incorporated by reference in their entirety).

In some embodiments, the mucus penetrating lipid nanoparticles may comprise at least one polynucleotide described herein. The polynucleotide may be encapsulated in the lipid nanoparticle and/or disposed on the surface of the particle. The polynucleotide may be covalently coupled to the lipid nanoparticle. Formulations of mucus penetrating lipid nanoparticles may comprise a plurality of nanoparticles. Further, the formulations may contain particles which may interact with the mucus and alter the structural and/or adhesive properties of the surrounding mucus to decrease mucoadhesion, which may increase the delivery of the mucus penetrating lipid nanoparticles to the mucosal tissue.

In some embodiments, the mucus penetrating lipid nanoparticles may be a hypotonic formulation comprising a mucosal penetration enhancing coating. The formulation may be hypotonic for the epithelium to which it is being delivered. Non-limiting examples of hypotonic formulations may be found in International Patent Publication No. WO2013110028, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, in order to enhance the delivery through the mucosal barrier the RNA (e.g., mRNA) vaccine formulation may comprise or be a hypotonic solution.

Hypotonic solutions were found to increase the rate at which mucoinert particles such as, but not limited to, mucus-penetrating particles, were able to reach the vaginal epithelial surface (see e.g., Ensign et al. Biomaterials 2013 34(28):6922-9, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a lipoplex, such as, without limitation, the ATUPLEX™ system, the DACC system, the DBTC system and other siRNA-lipoplex technology from Silence Therapeutics (London, United Kingdom), STEMFECT™ from STEMGENT® (Cambridge, Mass.), and polyethylenimine (PEI) or protamine-based targeted and non-targeted delivery of nucleic acids (Aleku et al. Cancer Res. 2008 68:9788-9798; Strumberg et al. Int J Clin Pharmacol Ther 2012 50:76-78; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 2010 23:334-344; Kaufmann et al. Microvasc Res 2010 80:286-293Weide et al. J Immunother. 2009 32:498-507; Weide et al. J Immunother. 2008 31:180-188; Pascolo Expert Opin. Biol. Ther. 4:1285-1294; Fotin-Mleczek et al., 2011 J. Immunother. 34:1-15; Song et al., Nature Biotechnol. 2005, 23:709-717; Peer et al., Proc Natl Acad Sci USA. 2007 6; 104:4095-4100; deFougerolles Hum Gene Ther. 2008 19:125-132, the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, such formulations may also be constructed or compositions altered such that they passively or actively are directed to different cell types in vivo, including but not limited to hepatocytes, immune cells, tumor cells, endothelial cells, antigen presenting cells, and leukocytes (Akinc et al. Mol Ther. 2010 18:1357-1364; Song et al., Nat Biotechnol. 2005 23:709-717; Judge et al., J Clin Invest. 2009 119:661-673; Kaufmann et al., Microvasc Res 2010 80:286-293; Santel et al., Gene Ther 2006 13:1222-1234; Santel et al., Gene Ther 2006 13:1360-1370; Gutbier et al., Pulm Pharmacol. Ther. 2010 23:334-344; Basha et al., Mol. Ther. 2011 19:2186-2200; Fenske and Cullis, Expert Opin Drug Deliv. 2008 5:25-44; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety). One example of passive targeting of formulations to liver cells includes the DLin-DMA, DLin-KC2-DMA and DLin-MC3-DMA-based lipid nanoparticle formulations, which have been shown to bind to apolipoprotein E and promote binding and uptake of these formulations into hepatocytes in vivo (Akinc et al. Mol Ther. 2010 18:1357-1364, the contents of which are incorporated herein by reference in their entirety). Formulations can also be selectively targeted through expression of different ligands on their surface as exemplified by, but not limited by, folate, transferrin, N-acetylgalactosamine (GalNAc), and antibody targeted approaches (Kolhatkar et al., Curr Drug Discov Technol. 2011 8:197-206; Musacchio and Torchilin, Front Biosci. 2011 16:1388-1412; Yu et al., Mol Membr Biol. 2010 27:286-298; Patil et al., Crit Rev Ther Drug Carrier Syst. 2008 25:1-61; Benoit et al., Biomacromolecules. 2011 12:2708-2714; Zhao et al., Expert Opin Drug Deliv. 2008 5:309-319; Akinc et al., Mol Ther. 2010 18:1357-1364; Srinivasan et al., Methods Mol Biol. 2012 820:105-116; Ben-Arie et al., Methods Mol Biol. 2012 757:497-507; Peer 2010 J Control Release. 20:63-68; Peer et al., Proc Natl Acad Sci USA. 2007 104:4095-4100; Kim et al., Methods Mol Biol. 2011 721:339-353; Subramanya et al., Mol Ther. 2010 18:2028-2037; Song et al., Nat Biotechnol. 2005 23:709-717; Peer et al., Science. 2008 319:627-630; Peer and Lieberman, Gene Ther. 2011 18:1127-1133, the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccine is formulated as a solid lipid nanoparticle. A solid lipid nanoparticle (SLN) may be spherical with an average diameter between 10 to 1000 nm. SLN possess a solid lipid core matrix that can solubilize lipophilic molecules and may be stabilized with surfactants and/or emulsifiers. In some embodiments, the lipid nanoparticle may be a self-assembly lipid-polymer nanoparticle (see Zhang et al., ACS Nano, 2008, 2, pp 1696-1702; the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the SLN may be the SLN described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the SLN may be made by the methods or processes described in International Patent Publication No. WO2013105101, the contents of which are herein incorporated by reference in their entirety.

Liposomes, lipoplexes, or lipid nanoparticles may be used to improve the efficacy of polynucleotides directed protein production as these formulations may be able to increase cell transfection by the RNA (e.g., mRNA) vaccine; and/or increase the translation of encoded protein. One such example involves the use of lipid encapsulation to enable the effective systemic delivery of polyplex plasmid DNA (Heyes et al., Mol Ther. 2007 15:713-720; the contents of which are incorporated herein by reference in their entirety). The liposomes, lipoplexes, or lipid nanoparticles may also be used to increase the stability of the polynucleotide.

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure can be formulated for controlled release and/or targeted delivery. As used herein, “controlled release” refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome. In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a delivery agent described herein and/or known in the art for controlled release and/or targeted delivery. As used herein, the term “encapsulate” means to enclose, surround or encase. As it relates to the formulation of the compounds of the disclosure, encapsulation may be substantial, complete or partial. The term “substantially encapsulated” means that at least greater than 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.9 or greater than 99.999% of the pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. “Partially encapsulation” means that less than 10, 10, 20, 30, 40 50 or less of the pharmaceutical composition or compound of the disclosure may be enclosed, surrounded or encased within the delivery agent. Advantageously, encapsulation may be determined by measuring the escape or the activity of the pharmaceutical composition or compound of the disclosure using fluorescence and/or electron micrograph. For example, at least 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the pharmaceutical composition or compound of the disclosure are encapsulated in the delivery agent.

In some embodiments, the controlled release formulation may include, but is not limited to, tri-block co-polymers. As a non-limiting example, the formulation may include two different types of tri-block co-polymers (International Pub. No. WO2012131104 and WO2012131106, the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccines may be encapsulated into a lipid nanoparticle or a rapidly eliminated lipid nanoparticle and the lipid nanoparticles or a rapidly eliminated lipid nanoparticle may then be encapsulated into a polymer, hydrogel and/or surgical sealant described herein and/or known in the art. As a non-limiting example, the polymer, hydrogel or surgical sealant may be PLGA, ethylene vinyl acetate (EVAc), poloxamer, GELSITE® (Nanotherapeutics, Inc. Alachua, Fla.), HYLENEX® (Halozyme Therapeutics, San Diego Calif.), surgical sealants such as fibrinogen polymers (Ethicon Inc. Cornelia, Ga.), TISSELL® (Baxter International, Inc Deerfield, Ill.), PEG-based sealants, and COSEAL® (Baxter International, Inc Deerfield, Ill.).

In some embodiments, the lipid nanoparticle may be encapsulated into any polymer known in the art which may form a gel when injected into a subject. As another non-limiting example, the lipid nanoparticle may be encapsulated into a polymer matrix which may be biodegradable.

In some embodiments, the RNA (e.g., mRNA) vaccine formulation for controlled release and/or targeted delivery may also include at least one controlled release coating. Controlled release coatings include, but are not limited to, OPADRY®, polyvinylpyrrolidone/vinyl acetate copolymer, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, EUDRAGIT RL®, EUDRAGIT RS® and cellulose derivatives such as ethylcellulose aqueous dispersions (AQUACOAT® and SURELEASE®).

In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation may comprise at least one degradable polyester which may contain polycationic side chains. Degradable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

In some embodiments, the RNA (e.g., mRNA) vaccine controlled release and/or targeted delivery formulation comprising at least one polynucleotide may comprise at least one PEG and/or PEG related polymer derivatives as described in U.S. Pat. No. 8,404,222, the contents of which are incorporated herein by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine controlled release delivery formulation comprising at least one polynucleotide may be the controlled release polymer system described in US20130130348, the contents of which are incorporated herein by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be encapsulated in a therapeutic nanoparticle, referred to herein as “therapeutic nanoparticle RNA (e.g., mRNA) vaccines.” Therapeutic nanoparticles may be formulated by methods described herein and known in the art such as, but not limited to, International Pub Nos. WO2010005740, WO2010030763, WO2010005721, WO2010005723, WO2012054923, U.S. Publication Nos. US20110262491, US20100104645, US20100087337, US20100068285, US20110274759, US20100068286, US20120288541, US20130123351 and US20130230567 and U.S. Pat. Nos. 8,206,747, 8,293,276, 8,318,208 and 8,318,211; the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, therapeutic polymer nanoparticles may be identified by the methods described in US Pub No. US20120140790, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccine may be formulated for sustained release. As used herein, “sustained release” refers to a pharmaceutical composition or compound that conforms to a release rate over a specific period of time. The period of time may include, but is not limited to, hours, days, weeks, months and years. As a non-limiting example, the sustained release nanoparticle may comprise a polymer and a therapeutic agent such as, but not limited to, the polynucleotides of the present disclosure (see International Pub No. 2010075072 and US Pub No. US20100216804, US20110217377 and US20120201859, the contents of each of which are incorporated herein by reference in their entirety). In another non-limiting example, the sustained release formulation may comprise agents which permit persistent bioavailability such as, but not limited to, crystals, macromolecular gels and/or particulate suspensions (see U.S. Patent Publication No US20130150295, the contents of each of which are incorporated herein by reference in their entirety).

In some embodiments, the therapeutic nanoparticle RNA (e.g., mRNA) vaccines may be formulated to be target specific. As a non-limiting example, the therapeutic nanoparticles may include a corticosteroid (see International Pub. No. WO2011084518, the contents of which are incorporated herein by reference in their entirety). As a non-limiting example, the therapeutic nanoparticles may be formulated in nanoparticles described in International Pub No. WO2008121949, WO2010005726, WO2010005725, WO2011084521 and US Pub No. US20100069426, US20120004293 and US20100104655, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiments, the nanoparticles of the present disclosure may comprise a polymeric matrix. As a non-limiting example, the nanoparticle may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof.

In some embodiments, the therapeutic nanoparticle comprises a diblock copolymer. In some embodiments, the diblock copolymer may include PEG in combination with a polymer such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polylysine, poly(ethylene imine), poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester) or combinations thereof. In yet another embodiment, the diblock copolymer may be a high-X diblock copolymer such as those described in International Patent Publication No. WO2013120052, the contents of which are incorporated herein by reference in their entirety.

As a non-limiting example the therapeutic nanoparticle comprises a PLGA-PEG block copolymer (see U.S. Publication No. US20120004293 and U.S. Pat. No. 8,236,330, each of which is herein incorporated by reference in their entirety). In another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle comprising a diblock copolymer of PEG and PLA or PEG and PLGA (see U.S. Pat. No. 8,246,968 and International Publication No. WO2012166923, the contents of each of which are herein incorporated by reference in their entirety). In yet another non-limiting example, the therapeutic nanoparticle is a stealth nanoparticle or a target-specific stealth nanoparticle as described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are herein incorporated by reference in their entirety).

In yet another non-limiting example, the lipid nanoparticle comprises the block copolymer PEG-PLGA-PEG (see e.g., the thermosensitive hydrogel (PEG-PLGA-PEG) was used as a TGF-beta1 gene delivery vehicle in Lee et al. Thermosensitive Hydrogel as a TGF-β1 Gene Delivery Vehicle Enhances Diabetic Wound Healing. Pharmaceutical Research, 2003 20(12): 1995-2000; as a controlled gene delivery system in Li et al. Controlled Gene Delivery System Based on Thermosensitive Biodegradable Hydrogel. Pharmaceutical Research 2003 20:884-888; and Chang et al., Non-ionic amphiphilic biodegradable PEG-PLGA-PEG copolymer enhances gene delivery efficiency in rat skeletal muscle. J Controlled Release. 2007 118:245-253, the contents of each of which are herein incorporated by reference in their entirety). The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles comprising the PEG-PLGA-PEG block copolymer.

In some embodiments, the therapeutic nanoparticle may comprise a multiblock copolymer (see e.g., U.S. Pat. Nos. 8,263,665 and 8,287,910 and U.S. Patent Pub. No. US20130195987, the contents of each of which are herein incorporated by reference in their entirety).

In some embodiments, the block copolymers described herein may be included in a polyion complex comprising a non-polymeric micelle and the block copolymer. (see e.g., U.S. Publication No. 20120076836, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the therapeutic nanoparticle may comprise at least one acrylic polymer. Acrylic polymers include but are not limited to, acrylic acid, methacrylic acid, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, amino alkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), polycyanoacrylates and combinations thereof.

In some embodiments, the therapeutic nanoparticles may comprise at least one poly(vinyl ester) polymer. The poly(vinyl ester) polymer may be a copolymer such as a random copolymer. As a non-limiting example, the random copolymer may have a structure such as those described in International Application No. WO2013032829 or U.S. Patent Publication No US20130121954, the contents of each of which are herein incorporated by reference in their entirety. In some embodiments, the poly(vinyl ester) polymers may be conjugated to the polynucleotides described herein.

In some embodiments, the therapeutic nanoparticle may comprise at least one diblock copolymer. The diblock copolymer may be, but it not limited to, a poly(lactic) acid-poly(ethylene)glycol copolymer (see, e.g., International Patent Publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the therapeutic nanoparticle may be used to treat cancer (see International publication No. WO2013044219, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the therapeutic nanoparticles may comprise at least one cationic polymer described herein and/or known in the art.

In some embodiments, the therapeutic nanoparticles may comprise at least one amine-containing polymer such as, but not limited to polylysine, polyethylene imine, poly(amidoamine) dendrimers, poly(beta-amino esters) (see, e.g., U.S. Pat. No. 8,287,849, the contents of which are herein incorporated by reference in their entirety) and combinations thereof.

In some embodiments, the nanoparticles described herein may comprise an amine cationic lipid such as those described in International Patent Application No. WO2013059496, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the cationic lipids may have an amino-amine or an amino-amide moiety.

In some embodiments, the therapeutic nanoparticles may comprise at least one degradable polyester which may contain polycationic side chains. Degradable polyesters include, but are not limited to, poly(serine ester), poly(L-lactide-co-L-lysine), poly(4-hydroxy-L-proline ester), and combinations thereof. In some embodiments, the degradable polyesters may include a PEG conjugation to form a PEGylated polymer.

In some embodiments, the synthetic nanocarriers may contain an immunostimulatory agent to enhance the immune response from delivery of the synthetic nanocarrier. As a non-limiting example, the synthetic nanocarrier may comprise a Th1 immunostimulatory agent, which may enhance a Th1-based response of the immune system (see International Pub No. WO2010123569 and U.S. Publication No. US20110223201, the contents of each of which are herein incorporated by reference in their entirety).

In some embodiments, the synthetic nanocarriers may be formulated for targeted release. In some embodiments, the synthetic nanocarrier is formulated to release the polynucleotides at a specified pH and/or after a desired time interval. As a non-limiting example, the synthetic nanoparticle may be formulated to release the RNA (e.g., mRNA) vaccines after 24 hours and/or at a pH of 4.5 (see International Publication Nos. WO2010138193 and WO2010138194 and US Pub Nos. US20110020388 and US20110027217, each of which is herein incorporated by reference in their entireties).

In some embodiments, the synthetic nanocarriers may be formulated for controlled and/or sustained release of the polynucleotides described herein. As a non-limiting example, the synthetic nanocarriers for sustained release may be formulated by methods known in the art, described herein and/or as described in International Pub No. WO2010138192 and US Pub No. 20100303850, each of which is herein incorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated for controlled and/or sustained release wherein the formulation comprises at least one polymer that is a crystalline side chain (CYSC) polymer. CYSC polymers are described in U.S. Pat. No. 8,399,007, herein incorporated by reference in its entirety.

In some embodiments, the synthetic nanocarrier may be formulated for use as a vaccine. In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide which encode at least one antigen. As a non-limiting example, the synthetic nanocarrier may include at least one antigen and an excipient for a vaccine dosage form (see International Publication No. WO2011150264 and U.S. Publication No. US20110293723, the contents of each of which are herein incorporated by reference in their entirety). As another non-limiting example, a vaccine dosage form may include at least two synthetic nanocarriers with the same or different antigens and an excipient (see International Publication No. WO2011150249 and U.S. Publication No. US20110293701, the contents of each of which are herein incorporated by reference in their entirety). The vaccine dosage form may be selected by methods described herein, known in the art and/or described in International Publication No. WO2011150258 and U.S. Publication No. US20120027806, the contents of each of which are herein incorporated by reference in their entirety).

In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide which encodes at least one adjuvant. As non-limiting example, the adjuvant may comprise dimethyldioctadecylammonium-bromide, dimethyldioctadecylammonium-chloride, dimethyldioctadecylammonium-phosphate or dimethyldioctadecylammonium-acetate (DDA) and an apolar fraction or part of said apolar fraction of a total lipid extract of a mycobacterium (see, e.g., U.S. Pat. No. 8,241,610, the content of which is herein incorporated by reference in its entirety). In some embodiments, the synthetic nanocarrier may comprise at least one polynucleotide and an adjuvant. As a non-limiting example, the synthetic nanocarrier comprising and adjuvant may be formulated by the methods described in International Publication No. WO2011150240 and U.S. Publication No. US20110293700, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiments, the synthetic nanocarrier may encapsulate at least one polynucleotide that encodes a peptide, fragment or region from a virus. As a non-limiting example, the synthetic nanocarrier may include, but is not limited to, any of the nanocarriers described in International Publication No. WO2012024621, WO201202629, WO2012024632 and U.S. Publication No. US20120064110, US20120058153 and US20120058154, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiments, the synthetic nanocarrier may be coupled to a polynucleotide which may be able to trigger a humoral and/or cytotoxic T lymphocyte (CTL) response (see, e.g., International Publication No. WO2013019669, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccine may be encapsulated in, linked to and/or associated with zwitterionic lipids. Non-limiting examples of zwitterionic lipids and methods of using zwitterionic lipids are described in U.S. Patent Publication No. US20130216607, the contents of which are herein incorporated by reference in their entirety. In some aspects, the zwitterionic lipids may be used in the liposomes and lipid nanoparticles described herein.

In some embodiments, the RNA (e.g., mRNA) vaccine may be formulated in colloid nanocarriers as described in U.S. Patent Publication No. US20130197100, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the nanoparticle may be optimized for oral administration. The nanoparticle may comprise at least one cationic biopolymer such as, but not limited to, chitosan or a derivative thereof. As a non-limiting example, the nanoparticle may be formulated by the methods described in U.S. Publication No. 20120282343, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, LNPs comprise the lipid KL52 (an amino-lipid disclosed in U.S. Application Publication No. 2012/0295832, the contents of which are herein incorporated by reference in their entirety. Activity and/or safety (as measured by examining one or more of ALT/AST, white blood cell count and cytokine induction, for example) of LNP administration may be improved by incorporation of such lipids. LNPs comprising KL52 may be administered intravenously and/or in one or more doses. In some embodiments, administration of LNPs comprising KL52 results in equal or improved mRNA and/or protein expression as compared to LNPs comprising MC3.

In some embodiments, RNA (e.g., mRNA) vaccine may be delivered using smaller LNPs. Such particles may comprise a diameter from below 0.1 um up to 100 nm such as, but not limited to, less than 0.1 um, less than 1.0 um, less than 5 um, less than 10 um, less than 15 um, less than 20 um, less than 25 um, less than 30 um, less than 35 um, less than 40 um, less than 50 um, less than 55 um, less than 60 um, less than 65 um, less than 70 um, less than 75 um, less than 80 um, less than 85 um, less than 90 um, less than 95 um, less than 100 um, less than 125 um, less than 150 um, less than 175 um, less than 200 um, less than 225 um, less than 250 um, less than 275 um, less than 300 um, less than 325 um, less than 350 um, less than 375 um, less than 400 um, less than 425 um, less than 450 um, less than 475 um, less than 500 um, less than 525 um, less than 550 um, less than 575 um, less than 600 um, less than 625 um, less than 650 um, less than 675 um, less than 700 um, less than 725 um, less than 750 um, less than 775 um, less than 800 um, less than 825 um, less than 850 um, less than 875 um, less than 900 um, less than 925 um, less than 950 um, less than 975 um, or less than 1000 um.

In some embodiments, RNA (e.g., mRNA) vaccines may be delivered using smaller LNPs, which may comprise a diameter from about 1 nm to about 100 nm, from about 1 nm to about 10 nm, about 1 nm to about 20 nm, from about 1 nm to about 30 nm, from about 1 nm to about 40 nm, from about 1 nm to about 50 nm, from about 1 nm to about 60 nm, from about 1 nm to about 70 nm, from about 1 nm to about 80 nm, from about 1 nm to about 90 nm, from about 5 nm to about from 100 nm, from about 5 nm to about 10 nm, about 5 nm to about 20 nm, from about 5 nm to about 30 nm, from about 5 nm to about 40 nm, from about 5 nm to about 50 nm, from about 5 nm to about 60 nm, from about 5 nm to about 70 nm, from about 5 nm to about 80 nm, from about 5 nm to about 90 nm, about 10 to about 50 nm, from about 20 to about 50 nm, from about 30 to about 50 nm, from about 40 to about 50 nm, from about 20 to about 60 nm, from about 30 to about 60 nm, from about 40 to about 60 nm, from about 20 to about 70 nm, from about 30 to about 70 nm, from about 40 to about 70 nm, from about 50 to about 70 nm, from about 60 to about 70 nm, from about 20 to about 80 nm, from about 30 to about 80 nm, from about 40 to about 80 nm, from about 50 to about 80 nm, from about 60 to about 80 nm, from about 20 to about 90 nm, from about 30 to about 90 nm, from about 40 to about 90 nm, from about 50 to about 90 nm, from about 60 to about 90 nm and/or from about 70 to about 90 nm.

In some embodiments, such LNPs are synthesized using methods comprising microfluidic mixers. Examples of microfluidic mixers may include, but are not limited to, a slit interdigital micromixer including, but not limited to those manufactured by Microinnova (Allerheiligen bei Wildon, Austria) and/or a staggered herringbone micromixer (SHM) (Zhigaltsev, I. V. et al., Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing have been published (Langmuir. 2012. 28:3633-40; Belliveau, N. M. et al., Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Molecular Therapy-Nucleic Acids. 2012. 1:e37; Chen, D. et al., Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012. 134(16):6948-51, the contents of each of which are herein incorporated by reference in their entirety). In some embodiments, methods of LNP generation comprising SHM, further comprise the mixing of at least two input streams wherein mixing occurs by microstructure-induced chaotic advection (MICA). According to this method, fluid streams flow through channels present in a herringbone pattern causing rotational flow and folding the fluids around each other. This method may also comprise a surface for fluid mixing wherein the surface changes orientations during fluid cycling. Methods of generating LNPs using SHM include those disclosed in U.S. Application Publication Nos. 2004/0262223 and 2012/0276209, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccine of the present disclosure may be formulated in lipid nanoparticles created using a micromixer such as, but not limited to, a Slit Interdigital Microstructured Mixer (SIMM-V2) or a Standard Slit Interdigital Micro Mixer (SSIMM) or Caterpillar (CPMM) or Impinging-jet (IJMM) from the Institut fiir Mikrotechnik Mainz GmbH, Mainz Germany).

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using microfluidic technology (see, e.g., Whitesides, George M. The Origins and the Future of Microfluidics. Nature, 2006 442: 368-373; and Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651; each of which is herein incorporated by reference in its entirety). As a non-limiting example, controlled microfluidic formulation includes a passive method for mixing streams of steady pressure-driven flows in micro channels at a low Reynolds number (see, e.g., Abraham et al. Chaotic Mixer for Microchannels. Science, 2002 295: 647-651, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in lipid nanoparticles created using a micromixer chip such as, but not limited to, those from Harvard Apparatus (Holliston, Mass.) or Dolomite Microfluidics (Royston, UK). A micromixer chip can be used for rapid mixing of two or more fluid streams with a split and recombine mechanism.

In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated for delivery using the drug encapsulating microspheres described in International Patent Publication No. WO2013063468 or U.S. Pat. No. 8,440,614, the contents of each of which are herein incorporated by reference in their entirety. The microspheres may comprise a compound of the formula (I), (II), (III), (IV), (V) or (VI) as described in International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety. In some embodiments, the amino acid, peptide, polypeptide, lipids (APPL) are useful in delivering the RNA (e.g., mRNA) vaccines of the disclosure to cells (see International Patent Publication No. WO2013063468, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the RNA (e.g., mRNA) vaccines of the disclosure may be formulated in lipid nanoparticles having a diameter from about 10 to about 100 nm such as, but not limited to, about 10 to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm, about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about 70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20 to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm, about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about 80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30 to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm, about 30 to about 70 nm, about 30 to about 80 nm, about 30 to about 90 nm, about 30 to about 100 nm, about 40 to about 50 nm, about 40 to about 60 nm, about 40 to about 70 nm, about 40 to about 80 nm, about 40 to about 90 nm, about 40 to about 100 nm, about 50 to about 60 nm, about 50 to about 70 nm about 50 to about 80 nm, about 50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70 nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to about 100 nm, about 70 to about 80 nm, about 70 to about 90 nm, about 70 to about 100 nm, about 80 to about 90 nm, about 80 to about 100 nm and/or about 90 to about 100 nm.

In some embodiments, the lipid nanoparticles may have a diameter from about 10 to 500 nm.

In some embodiments, the lipid nanoparticle may have a diameter greater than 100 nm, greater than 150 nm, greater than 200 nm, greater than 250 nm, greater than 300 nm, greater than 350 nm, greater than 400 nm, greater than 450 nm, greater than 500 nm, greater than 550 nm, greater than 600 nm, greater than 650 nm, greater than 700 nm, greater than 750 nm, greater than 800 nm, greater than 850 nm, greater than 900 nm, greater than 950 nm or greater than 1000 nm.

In some embodiments, the lipid nanoparticle may be a limit size lipid nanoparticle described in International Patent Publication No. WO2013059922, the contents of which are herein incorporated by reference in their entirety. The limit size lipid nanoparticle may comprise a lipid bilayer surrounding an aqueous core or a hydrophobic core; where the lipid bilayer may comprise a phospholipid such as, but not limited to, diacylphosphatidylcholine, a diacylphosphatidylethanolamine, a ceramide, a sphingomyelin, a dihydrosphingomyelin, a cephalin, a cerebroside, a C8-C20 fatty acid diacylphophatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC). In some embodiments, the limit size lipid nanoparticle may comprise a polyethylene glycol-lipid such as, but not limited to, DLPE-PEG, DMPE-PEG, DPPC-PEG and DSPE-PEG.

In some embodiments, the RNA (e.g., mRNA) vaccines may be delivered, localized and/or concentrated in a specific location using the delivery methods described in International Patent Publication No. WO2013063530, the contents of which are herein incorporated by reference in their entirety. As a non-limiting example, a subject may be administered an empty polymeric particle prior to, simultaneously with or after delivering the RNA (e.g., mRNA) vaccines to the subject. The empty polymeric particle undergoes a change in volume once in contact with the subject and becomes lodged, embedded, immobilized or entrapped at a specific location in the subject.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in an active substance release system (see, e.g., U.S. Patent Publication No. US20130102545, the contents of which are herein incorporated by reference in their entirety). The active substance release system may comprise 1) at least one nanoparticle bonded to an oligonucleotide inhibitor strand which is hybridized with a catalytically active nucleic acid and 2) a compound bonded to at least one substrate molecule bonded to a therapeutically active substance (e.g., polynucleotides described herein), where the therapeutically active substance is released by the cleavage of the substrate molecule by the catalytically active nucleic acid.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in a nanoparticle comprising an inner core comprising a non-cellular material and an outer surface comprising a cellular membrane. The cellular membrane may be derived from a cell or a membrane derived from a virus. As a non-limiting example, the nanoparticle may be made by the methods described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the nanoparticle described in International Patent Publication No. WO2013052167, the contents of which are herein incorporated by reference in their entirety, may be used to deliver the RNA (e.g., mRNA) vaccines described herein.

In some embodiments, the RNA (e.g., mRNA) vaccines may be formulated in porous nanoparticle-supported lipid bilayers (protocells). Protocells are described in International Patent Publication No. WO2013056132, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in polymeric nanoparticles as described in or made by the methods described in U.S. Pat. Nos. 8,420,123 and 8,518,963 and European Patent No. EP2073848B1, the contents of each of which are herein incorporated by reference in their entirety. As a non-limiting example, the polymeric nanoparticle may have a high glass transition temperature such as the nanoparticles described in or nanoparticles made by the methods described in U.S. Pat. No. 8,518,963, the contents of which are herein incorporated by reference in their entirety. As another non-limiting example, the polymer nanoparticle for oral and parenteral formulations may be made by the methods described in European Patent No. EP2073848B 1, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the RNA (e.g., mRNA) vaccines described herein may be formulated in nanoparticles used in imaging. The nanoparticles may be liposome nanoparticles such as those described in U.S. Patent Publication No US20130129636, herein incorporated by reference in its entirety. As a non-limiting example, the liposome may comprise gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N′-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid and a neutral, fully saturated phospholipid component (see, e.g., U.S. Patent Publication No US20130129636, the contents of which are herein incorporated by reference in their entirety).

In some embodiments, the nanoparticles which may be used in the present disclosure are formed by the methods described in U.S. Patent Application No. US20130130348, the contents of which are herein incorporated by reference in their entirety.

The nanoparticles of the present disclosure may further include nutrients such as, but not limited to, those which deficiencies can lead to health hazards from anemia to neural tube defects (see, e.g., the nanoparticles described in International Patent Publication No WO2013072929, the contents of which are herein incorporated by reference in their entirety). As a non-limiting example, the nutrient may be iron in the form of ferrous, ferric salts or elemental iron, iodine, folic acid, vitamins or micronutrients.

In some embodiments, the RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in a swellable nanoparticle. The swellable nanoparticle may be, but is not limited to, those described in U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety. As a non-limiting embodiment, the swellable nanoparticle may be used for delivery of the RNA (e.g., mRNA) vaccines of the present disclosure to the pulmonary system (see, e.g., U.S. Pat. No. 8,440,231, the contents of which are herein incorporated by reference in their entirety).

The RNA (e.g., mRNA) vaccines of the present disclosure may be formulated in polyanhydride nanoparticles such as, but not limited to, those described in U.S. Pat. No. 8,449,916, the contents of which are herein incorporated by reference in their entirety.

The nanoparticles and microparticles of the present disclosure may be geometrically engineered to modulate macrophage and/or the immune response. In some embodiments, the geometrically engineered particles may have varied shapes, sizes and/or surface charges in order to incorporated the polynucleotides of the present disclosure for targeted delivery such as, but not limited to, pulmonary delivery (see, e.g., International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety). Other physical features the geometrically engineering particles may have include, but are not limited to, fenestrations, angled arms, asymmetry and surface roughness, charge which can alter the interactions with cells and tissues. As a non-limiting example, nanoparticles of the present disclosure may be made by the methods described in International Publication No WO2013082111, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the nanoparticles of the present disclosure may be water soluble nanoparticles such as, but not limited to, those described in International Publication No. WO2013090601, the contents of which are herein incorporated by reference in their entirety. The nanoparticles may be inorganic nanoparticles which have a compact and zwitterionic ligand in order to exhibit good water solubility. The nanoparticles may also have small hydrodynamic diameters (HD), stability with respect to time, pH, and salinity and a low level of non-specific protein binding.

In some embodiments the nanoparticles of the present disclosure may be developed by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the nanoparticles of the present disclosure are stealth nanoparticles or target-specific stealth nanoparticles such as, but not limited to, those described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety. The nanoparticles of the present disclosure may be made by the methods described in U.S. Patent Publication No. US20130172406, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the stealth or target-specific stealth nanoparticles may comprise a polymeric matrix. The polymeric matrix may comprise two or more polymers such as, but not limited to, polyethylenes, polycarbonates, polyanhydrides, polyhydroxyacids, polypropylfumerates, polycaprolactones, polyamides, polyacetals, polyethers, polyesters, poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes, polyphosphazenes, polyacrylates, polymethacrylates, polycyanoacrylates, polyureas, polystyrenes, polyamines, polyesters, polyanhydrides, polyethers, polyurethanes, polymethacrylates, polyacrylates, polycyanoacrylates or combinations thereof.

In some embodiments, the nanoparticle may be a nanoparticle-nucleic acid hybrid structure having a high density nucleic acid layer. As a non-limiting example, the nanoparticle-nucleic acid hybrid structure may made by the methods described in U.S. Patent Publication No. US20130171646, the contents of which are herein incorporated by reference in their entirety. The nanoparticle may comprise a nucleic acid such as, but not limited to, polynucleotides described herein and/or known in the art.

At least one of the nanoparticles of the present disclosure may be embedded in in the core a nanostructure or coated with a low density porous 3-D structure or coating which is capable of carrying or associating with at least one payload within or on the surface of the nanostructure. Non-limiting examples of the nanostructures comprising at least one nanoparticle are described in International Patent Publication No. WO2013123523, the contents of which are herein incorporated by reference in their entirety.

In some embodiments the RNA (e.g., mRNA) vaccine may be associated with a cationic or polycationic compounds, including protamine, nucleoline, spermine or spermidine, or other cationic peptides or proteins, such as poly-L-lysine (PLL), polyarginine, basic polypeptides, cell penetrating peptides (CPPs), including HIV-binding peptides, HIV-1 Tat (HIV), Tat-derived peptides, Penetratin, VP²² derived or analog peptides, Pestivirus Erns, HSV, VP²² (Herpes simplex), MAP, KALA or protein transduction domains (PTDs), PpT620, prolin-rich peptides, arginine-rich peptides, lysine-rich peptides, MPG-peptide(s), Pep-1, L-oligomers, Calcitonin peptide(s), Antennapedia-derived peptides (particularly from Drosophila antennapedia), pAntp, pIs1, FGF, Lactoferrin, Transportan, Buforin-2, Bac715-24, SynB, SynB, pVEC, hCT-derived peptides, SAP, histones, cationic polysaccharides, for example chitosan, polybrene, cationic polymers, e.g. polyethyleneimine (PEI), cationic lipids, e.g. DOTMA: [1-(2,3-sioleyloxy)propyl)]-N,N,N-trimethylammonium chloride, DMRIE, di-C14-amidine, DOTIM, SAINT, DC-Chol, BGTC, CTAP, DOPC, DODAP, DOPE: Dioleyl phosphatidylethanol-amine, DOSPA, DODAB, DOIC, DMEPC, DOGS: Dioctadecylamidoglicylspermin, DIMRI: Dimyristooxypropyl dimethyl hydroxyethyl ammonium bromide, DOTAP: dioleoyloxy-3-(trimethylammonio)propane, DC-6-14: O,O-ditetradecanoyl-N-.alpha.-trimethylammonioacetyl)diethanolamine chloride, CLIP 1: rac-[(2,3-dioctadecyloxypropyl)(2-hydroxyethyl)]-dimethylammonium chloride, CLIP6: rac-[2(2,3-dihexadecyloxypropyloxymethyloxy)ethyl]-trimethylammonium, CLIP9: rac-[2(2,3-dihexadecyloxypropyloxysuccinyloxy)ethyl]-trimethylammonium, oligofectamine, or cationic or polycationic polymers, e.g. modified polyaminoacids, such as beta-aminoacid-polymers or reversed polyamides, etc., modified polyethylenes, such as PVP (poly(N-ethyl-4-vinylpyridinium bromide)), etc., modified acrylates, such as pDMAEMA (poly(dimethylaminoethyl methylacrylate)), etc., modified amidoamines such as pAMAM (poly(amidoamine)), etc., modified polybetaminoester (PBAE), such as diamine end modified 1,4 butanediol diacrylate-co-5-amino-1-pentanol polymers, etc., dendrimers, such as polypropylamine dendrimers or pAMAM based dendrimers, etc., polyimine(s), such as PEI: poly(ethyleneimine), poly(propyleneimine), etc., polyallylamine, sugar backbone based polymers, such as cyclodextrin based polymers, dextran based polymers, chitosan, etc., silan backbone based polymers, such as PMOXA-PDMS copolymers, etc., blockpolymers consisting of a combination of one or more cationic blocks (e.g. selected from a cationic polymer as mentioned above) and of one or more hydrophilic or hydrophobic blocks (e.g. polyethyleneglycole), etc.

In other embodiments the RNA (e.g., mRNA) vaccine is not associated with a cationic or polycationic compounds.

Modes of Vaccine Administration

Influenza RNA (e.g. mRNA) vaccines may be administered by any route which results in a therapeutically effective outcome. These include, but are not limited, to intradermal, intramuscular, intranasal and/or subcutaneous administration. The present disclosure provides methods comprising administering RNA (e.g., mRNA) vaccines to a subject in need thereof. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. Influenza RNA (e.g., mRNA) vaccines compositions are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of RNA (e.g., mRNA) vaccine compositions may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or appropriate imaging dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.

In some embodiments, influenza disease RNA (e.g. mRNA) vaccines compositions may be administered at dosage levels sufficient to deliver 0.0001 mg/kg to 100 mg/kg, 0.001 mg/kg to 0.05 mg/kg, 0.005 mg/kg to 0.05 mg/kg, 0.001 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5 mg/kg, 0.01 mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.5 mg/kg to 30 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.1 mg/kg to 10 mg/kg, or 1 mg/kg to 25 mg/kg, of subject body weight per day, one or more times a day, per week, per month, etc. to obtain the desired therapeutic, diagnostic, prophylactic, or imaging effect (see, e.g., the range of unit doses described in International Publication No WO2013078199, the contents of which are herein incorporated by reference in their entirety). The desired dosage may be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, every four weeks, every 2 months, every three months, every 6 months, etc. In some embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). When multiple administrations are employed, split dosing regimens such as those described herein may be used. In exemplary embodiments, influenza RNA (e.g., mRNA) vaccines compositions may be administered at dosage levels sufficient to deliver 0.0005 mg/kg to 0.01 mg/kg, e.g., about 0.0005 mg/kg to about 0.0075 mg/kg, e.g., about 0.0005 mg/kg, about 0.001 mg/kg, about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg or about 0.005 mg/kg.

In some embodiments, influenza disease RNA (e.g., mRNA) vaccine compositions may be administered once or twice (or more) at dosage levels sufficient to deliver 0.025 mg/kg to 0.250 mg/kg, 0.025 mg/kg to 0.500 mg/kg, 0.025 mg/kg to 0.750 mg/kg, or 0.025 mg/kg to 1.0 mg/kg.

In some embodiments, influenza disease RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.0100 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg, 0.125 mg, 0.150 mg, 0.175 mg, 0.200 mg, 0.225 mg, 0.250 mg, 0.275 mg, 0.300 mg, 0.325 mg, 0.350 mg, 0.375 mg, 0.400 mg, 0.425 mg, 0.450 mg, 0.475 mg, 0.500 mg, 0.525 mg, 0.550 mg, 0.575 mg, 0.600 mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700 mg, 0.725 mg, 0.750 mg, 0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875 mg, 0.900 mg, 0.925 mg, 0.950 mg, 0.975 mg, or 1.0 mg. Higher and lower dosages and frequency of administration are encompassed by the present disclosure. For example, an influenza RNA (e.g., mRNA) vaccine composition may be administered three or four times.

In some embodiments, influenza RNA (e.g., mRNA) vaccine compositions may be administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and 6 months later, Day 0 and 9 months later, Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0 and 5 years later, or Day 0 and 10 years later) at a total dose of or at dosage levels sufficient to deliver a total dose of 0.010 mg, 0.025 mg, 0.100 mg or 0.400 mg.

In some embodiments, the influenza RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 μg/kg and 400 μg/kg of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments the RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of between 10 μg and 400 μg of the nucleic acid vaccine (in an effective amount to vaccinate the subject). In some embodiments, an influenza RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as a single dosage of 25-1000 μg. In some embodiments, an influenza RNA (e.g., mRNA) vaccine is administered to the subject as a single dosage of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 μg. For example, an influenza RNA (e.g., mRNA) vaccine may be administered to a subject as a single dose of 25-100, 25-500, 50-100, 50-500, 50-1000, 100-500, 100-1000, 250-500, 250-1000, or 500-1000 μg. In some embodiments, an influenza RNA (e.g., mRNA) vaccine for use in a method of vaccinating a subject is administered to the subject as two dosages, the combination of which equals 25-1000 μg of the influenza RNA (e.g., mRNA) vaccine.

An influenza RNA (e.g. mRNA) vaccine pharmaceutical composition described herein can be formulated into a dosage form described herein, such as an intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, intranasal and subcutaneous).

Influenza Virus RNA (e.g., mRNA) Vaccine Formulations and Methods of Use

Some aspects of the present disclosure provide formulations of the influenza RNA (e.g., mRNA) vaccine, wherein the RNA (e.g., mRNA) vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject (e.g., production of antibodies specific to an influenza antigenic polypeptide). “An effective amount” is a dose of an RNA (e.g., mRNA) vaccine effective to produce an antigen-specific immune response. Also provided herein are methods of inducing an antigen-specific immune response in a subject.

In some embodiments, the antigen-specific immune response is characterized by measuring an anti-influenza antigenic polypeptide antibody titer produced in a subject administered an influenza RNA (e.g., mRNA) vaccine as provided herein. An antibody titer is a measurement of the amount of antibodies within a subject, for example, antibodies that are specific to a particular antigen (e.g., an influenza antigenic polypeptide) or epitope of an antigen. Antibody titer is typically expressed as the inverse of the greatest dilution that provides a positive result. Enzyme-linked immunosorbent assay (ELISA) is a common assay for determining antibody titers, for example.

In some embodiments, an antibody titer is used to assess whether a subject has had an infection or to determine whether immunizations are required. In some embodiments, an antibody titer is used to determine the strength of an autoimmune response, to determine whether a booster immunization is needed, to determine whether a previous vaccine was effective, and to identify any recent or prior infections. In accordance with the present disclosure, an antibody titer may be used to determine the strength of an immune response induced in a subject by the influenza RNA (e.g., mRNA) vaccine.

In some embodiments, an anti-influenza antigenic polypeptide antibody titer produced in a subject is increased by at least 1 log relative to a control. For example, anti-antigenic polypeptide antibody titer produced in a subject may be increased by at least 1.5, at least 2, at least 2.5, or at least 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1, 1.5, 2, 2.5 or 3 log relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased by 1-1.5, 1-2, 1-2.5, 1-3, 1.5-2, 1.5-2.5, 1.5-3, 2-2.5, 2-3, or 2.5-3 log relative to a control.

In some embodiments, the anti-influenza antigenic polypeptide antibody titer produced in a subject is increased at least 2 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is increased 2, 3, 4, 5, 6, 7, 8, 9, or 10 times relative to a control. In some embodiments, the anti-antigenic polypeptide antibody titer produced in a subject is increased 2-10 times relative to a control. For example, the anti-antigenic polypeptide antibody titer produced in a subject may be increased 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 times relative to a control.

A control, in some embodiments, is the anti-influenza antigenic polypeptide antibody titer produced in a subject who has not been administered an influenza RNA (e.g., mRNA) vaccine of the present disclosure. In some embodiments, a control is an anti-influenza antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated influenza vaccine. An attenuated vaccine is a vaccine produced by reducing the virulence of a viable (live). An attenuated virus is altered in a manner that renders it harmless or less virulent relative to live, unmodified virus. In some embodiments, a control is an anti-influenza antigenic polypeptide antibody titer produced in a subject administered inactivated influenza vaccine. In some embodiments, a control is an anti-influenza antigenic polypeptide antibody titer produced in a subject administered a recombinant or purified influenza protein vaccine. Recombinant protein vaccines typically include protein antigens that either have been produced in a heterologous expression system (e.g., bacteria or yeast) or purified from large amounts of the pathogenic organism. In some embodiments, a control is an anti-influenza antigenic polypeptide antibody titer produced in a subject who has been administered an influenza virus-like particle (VLP) vaccine.

In some embodiments, an effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose that is reduced compared to the standard of care dose of a recombinant influenza protein vaccine. A “standard of care,” as provided herein, refers to a medical or psychological treatment guideline and can be general or specific. “Standard of care” specifies appropriate treatment based on scientific evidence and collaboration between medical professionals involved in the treatment of a given condition. It is the diagnostic and treatment process that a physician/clinician should follow for a certain type of patient, illness or clinical circumstance. A “standard of care dose,” as provided herein, refers to the dose of a recombinant or purified influenza protein vaccine, or a live attenuated or inactivated influenza vaccine, that a physician/clinician or other medical professional would administer to a subject to treat or prevent influenza, or a related condition, while following the standard of care guideline for treating or preventing influenza, or a related condition.

In some embodiments, the anti-influenza antigenic polypeptide antibody titer produced in a subject administered an effective amount of an influenza RNA (e.g., mRNA) vaccine is equivalent to an anti-influenza antigenic polypeptide antibody titer produced in a control subject administered a standard of care dose of a recombinant or purified influenza protein vaccine or a live attenuated or inactivated influenza vaccine.

In some embodiments, an effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose equivalent to an at least 2-fold reduction in a standard of care dose of a recombinant or purified influenza protein vaccine. For example, an effective amount of an influenza RNA (e.g., mRNA) vaccine may be a dose equivalent to an at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold reduction in a standard of care dose of a recombinant or purified influenza protein vaccine. In some embodiments, an effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose equivalent to an at least at least 100-fold, at least 500-fold, or at least 1000-fold reduction in a standard of care dose of a recombinant or purified influenza protein vaccine. In some embodiments, an effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 50-, 100-, 250-, 500-, or 1000-fold reduction in a standard of care dose of a recombinant or purified influenza protein vaccine. In some embodiments, the anti-influenza antigenic polypeptide antibody titer produced in a subject administered an effective amount of an influenza RNA (e.g., mRNA) vaccine is equivalent to an anti-influenza antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or protein influenza protein vaccine or a live attenuated or inactivated influenza vaccine. In some embodiments, an effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose equivalent to a 2-fold to 1000-fold (e.g., 2-fold to 100-fold, 10-fold to 1000-fold) reduction in the standard of care dose of a recombinant or purified influenza protein vaccine, wherein the anti-influenza antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-influenza antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified influenza protein vaccine or a live attenuated or inactivated influenza vaccine.

In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose equivalent to a 2 to 1000-, 2 to 900-, 2 to 800-, 2 to 700-, 2 to 600-, 2 to 500-, 2 to 400-, 2 to 300-, 2 to 200-, 2 to 100-, 2 to 90-, 2 to 80-, 2 to 70-, 2 to 60-, 2 to 50-, 2 to 40-, 2 to 30-, 2 to 20-, 2 to 10-, 2 to 9-, 2 to 8-, 2 to 7-, 2 to 6-, 2 to 5-, 2 to 4-, 2 to 3-, 3 to 1000-, 3 to 900-, 3 to 800-, 3 to 700-, 3 to 600-, 3 to 500-, 3 to 400-, 3 to 3 to 00-, 3 to 200-, 3 to 100-, 3 to 90-, 3 to 80-, 3 to 70-, 3 to 60-, 3 to 50-, 3 to 40-, 3 to 30-, 3 to 20-, 3 to 10-, 3 to 9-, 3 to 8-, 3 to 7-, 3 to 6-, 3 to 5-, 3 to 4-, 4 to 1000-, 4 to 900-, 4 to 800-, 4 to 700-, 4 to 600-, 4 to 500-, 4 to 400-, 4 to 4 to 00-, 4 to 200-, 4 to 100-, 4 to 90-, 4 to 80-, 4 to 70-, 4 to 60-, 4 to 50-, 4 to 40-, 4 to 30-, 4 to 20-, 4 to 10-, 4 to 9-, 4 to 8-, 4 to 7-, 4 to 6-, 4 to 5-, 4 to 4-, 5 to 1000-, 5 to 900-, 5 to 800-, 5 to 700-, 5 to 600-, 5 to 500-, 5 to 400-, 5 to 300-, 5 to 200-, 5 to 100-, 5 to 90-, 5 to 80-, 5 to 70-, 5 to 60-, 5 to 50-, 5 to 40-, 5 to 30-, 5 to 20-, 5 to 10-, 5 to 9-, 5 to 8-, 5 to 7-, 5 to 6-, 6 to 1000-, 6 to 900-, 6 to 800-, 6 to 700-, 6 to 600-, 6 to 500-, 6 to 400-, 6 to 300-, 6 to 200-, 6 to 100-, 6 to 90-, 6 to 80-, 6 to 70-, 6 to 60-, 6 to 50-, 6 to 40-, 6 to 30-, 6 to 20-, 6 to 10-, 6 to 9-, 6 to 8-, 6 to 7-, 7 to 1000-, 7 to 900-, 7 to 800-, 7 to 700-, 7 to 600-, 7 to 500-, 7 to 400-, 7 to 300-, 7 to 200-, 7 to 100-, 7 to 90-, 7 to 80-, 7 to 70-, 7 to 60-, 7 to 50-, 7 to 40-, 7 to 30-, 7 to 20-, 7 to 10-, 7 to 9-, 7 to 8-, 8 to 1000-, 8 to 900-, 8 to 800-, 8 to 700-, 8 to 600-, 8 to 500-, 8 to 400-, 8 to 300-, 8 to 200-, 8 to 100-, 8 to 90-, 8 to 80-, 8 to 70-, 8 to 60-, 8 to 50-, 8 to 40-, 8 to 30-, 8 to 20-, 8 to 10-, 8 to 9-, 9 to 1000-, 9 to 900-, 9 to 800-, 9 to 700-, 9 to 600-, 9 to 500-, 9 to 400-, 9 to 300-, 9 to 200-, 9 to 100-, 9 to 90-, 9 to 80-, 9 to 70-, 9 to 60-, 9 to 50-, 9 to 40-, 9 to 30-, 9 to 20-, 9 to 10-, 10 to 1000-, 10 to 900-, 10 to 800-, 10 to 700-, 10 to 600-, 10 to 500-, 10 to 400-, 10 to 300-, 10 to 200-, 10 to 100-, 10 to 90-, 10 to 80-, 10 to 70-, 10 to 60-, 10 to 50-, 10 to 40-, 10 to 30-, 10 to 20-, 20 to 1000-, 20 to 900-, 20 to 800-, 20 to 700-, 20 to 600-, 20 to 500-, 20 to 400-, 20 to 300-, 20 to 200-, 20 to 100-, 20 to 90-, 20 to 80-, 20 to 70-, 20 to 60-, 20 to 50-, 20 to 40-, 20 to 30-, 30 to 1000-, 30 to 900-, 30 to 800-, 30 to 700-, 30 to 600-, 30 to 500-, 30 to 400-, 30 to 300-, 30 to 200-, 30 to 100-, 30 to 90-, 30 to 80-, 30 to 70-, 30 to 60-, 30 to 50-, 30 to 40-, 40 to 1000-, 40 to 900-, 40 to 800-, 40 to 700-, 40 to 600-, 40 to 500-, 40 to 400-, 40 to 300-, 40 to 200-, 40 to 100-, 40 to 90-, 40 to 80-, 40 to 70-, 40 to 60-, 40 to 50-, 50 to 1000-, 50 to 900-, 50 to 800-, 50 to 700-, 50 to 600-, 50 to 500-, 50 to 400-, 50 to 300-, 50 to 200-, 50 to 100-, 50 to 90-, 50 to 80-, 50 to 70-, 50 to 60-, 60 to 1000-, 60 to 900-, 60 to 800-, 60 to 700-, 60 to 600-, 60 to 500-, 60 to 400-, 60 to 300-, 60 to 200-, 60 to 100-, 60 to 90-, 60 to 80-, 60 to 70-, 70 to 1000-, 70 to 900-, 70 to 800-, 70 to 700-, 70 to 600-, 70 to 500-, 70 to 400-, 70 to 300-, 70 to 200-, 70 to 100-, 70 to 90-, 70 to 80-, 80 to 1000-, 80 to 900-, 80 to 800-, 80 to 700-, 80 to 600-, 80 to 500-, 80 to 400-, 80 to 300-, 80 to 200-, 80 to 100-, 80 to 90-, 90 to 1000-, 90 to 900-, 90 to 800-, 90 to 700-, 90 to 600-, 90 to 500-, 90 to 400-, 90 to 300-, 90 to 200-, 90 to 100-, 100 to 1000-, 100 to 900-, 100 to 800-, 100 to 700-, 100 to 600-, 100 to 500-, 100 to 400-, 100 to 300-, 100 to 200-, 200 to 1000-, 200 to 900-, 200 to 800-, 200 to 700-, 200 to 600-, 200 to 500-, 200 to 400-, 200 to 300-, 300 to 1000-, 300 to 900-, 300 to 800-, 300 to 700-, 300 to 600-, 300 to 500-, 300 to 400-, 400 to 1000-, 400 to 900-, 400 to 800-, 400 to 700-, 400 to 600-, 400 to 500-, 500 to 1000-, 500 to 900-, 500 to 800-, 500 to 700-, 500 to 600-, 600 to 1000-, 600 to 900-, 600 to 800-, 600 to 700-, 700 to 1000-, 700 to 900-, 700 to 800-, 800 to 1000-, 800 to 900-, or 900 to 1000-fold reduction in the standard of care dose of a recombinant influenza protein vaccine. In some embodiments, the anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified influenza protein vaccine or a live attenuated or inactivated influenza vaccine. In some embodiments, the effective amount is a dose equivalent to (or equivalent to an at least) 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 20-, 30-, 40-, 50-, 60-, 70-, 80-, 90-, 100-, 110-, 120-, 130-, 140-, 150-, 160-, 170-, 1280-, 190-, 200-, 210-, 220-, 230-, 240-, 250-, 260-, 270-, 280-, 290-, 300-, 310-, 320-, 330-, 340-, 350-, 360-, 370-, 380-, 390-, 400-, 410-, 420-, 430-, 440-, 450-, 4360-, 470-, 480-, 490-, 500-, 510-, 520-, 530-, 540-, 550-, 560-, 5760-, 580-, 590-, 600-, 610-, 620-, 630-, 640-, 650-, 660-, 670-, 680-, 690-, 700-, 710-, 720-, 730-, 740-, 750-, 760-, 770-, 780-, 790-, 800-, 810-, 820--, 830-, 840-, 850-, 860-, 870-, 880-, 890-, 900-, 910-, 920-, 930-, 940-, 950-, 960-, 970-, 980-, 990-, or 1000-fold reduction in the standard of care dose of a recombinant influenza protein vaccine. In some embodiments, an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant or purified influenza protein vaccine or a live attenuated or inactivated an influenza vaccine.

In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a total dose of 50-1000 μg. In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a total dose of 50-1000, 50-900, 50-800, 50-700, 50-600, 50-500, 50-400, 50-300, 50-200, 50-100, 50-90, 50-80, 50-70, 50-60, 60-1000, 60-900, 60-800, 60-700, 60-600, 60-500, 60-400, 60-300, 60-200, 60-100, 60-90, 60-80, 60-70, 70-1000, 70-900, 70-800, 70-700, 70-600, 70-500, 70-400, 70-300, 70-200, 70-100, 70-90, 70-80, 80-1000, 80-900, 80-800, 80-700, 80-600, 80-500, 80-400, 80-300, 80-200, 80-100, 80-90, 90-1000, 90-900, 90-800, 90-700, 90-600, 90-500, 90-400, 90-300, 90-200, 90-100, 100-1000, 100-900, 100-800, 100-700, 100-600, 100-500, 100-400, 100-300, 100-200, 200-1000, 200-900, 200-800, 200-700, 200-600, 200-500, 200-400, 200-300, 300-1000, 300-900, 300-800, 300-700, 300-600, 300-500, 300-400, 400-1000, 400-900, 400-800, 400-700, 400-600, 400-500, 500-1000, 500-900, 500-800, 500-700, 500-600, 600-1000, 600-900, 600-900, 600-700, 700-1000, 700-900, 700-800, 800-1000, 800-900, or 900-1000 μg. In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a total dose of 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000 μg. In some embodiments, the effective amount is a dose of 25-500 μg administered to the subject a total of two times. In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a dose of 25-500, 25-400, 25-300, 25-200, 25-100, 25-50, 50-500, 50-400, 50-300, 50-200, 50-100, 100-500, 100-400, 100-300, 100-200, 150-500, 150-400, 150-300, 150-200, 200-500, 200-400, 200-300, 250-500, 250-400, 250-300, 300-500, 300-400, 350-500, 350-400, 400-500 or 450-500 μg administered to the subject a total of two times. In some embodiments, the effective amount of an influenza RNA (e.g., mRNA) vaccine is a total dose of 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 μg administered to the subject a total of two times.

Additional Embodiments

1. An influenza virus vaccine or composition or immunogenic composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap, an open reading frame encoding at least one influenza antigenic polypeptide, and a 3′ polyA tail.

2. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by SEQ ID NO: 447-457, 459, 461.3. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by SEQ ID NO: 491-503.4. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by SEQ ID NO: 1-444, 458, 460, 462-479.5. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by SEQ ID NO: 457.6. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by SEQ ID NO: 501.7. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by SEQ ID NO: 458.8. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by SEQ ID NO: 459.9. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by SEQ ID NO: 502.10. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by SEQ ID NO: 460.11. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide is encoded by a sequence identified by SEQ ID NO: 461.12. The vaccine of paragraph 1, wherein the at least one mRNA polynucleotide comprises a sequence identified by SEQ ID NO: 503.13. The vaccine of paragraph 1, wherein the at least one antigenic polypeptide comprises a sequence identified by SEQ ID NO: 462.14. The vaccine of any one of paragraphs 1-13, wherein the 5′ terminal cap is or comprises 7mG(5′)ppp(5′)NlmpNp.15. The vaccine of any one of paragraphs 1-14, wherein 100% of the uracil in the open reading frame is modified to include N1-methyl pseudouridine at the 5-position of the uracil.16. The vaccine of any one of paragraphs 1-15, wherein the vaccine is formulated in a lipid nanoparticle comprising: DLin-MC3-DMA; cholesterol; 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC); and polyethylene glycol (PEG)2000-DMG.17. The vaccine of paragraph 16, wherein the lipid nanoparticle further comprises trisodium citrate buffer, sucrose and water.18. A influenza virus vaccine or composition or immunogenic composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 501 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 501 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.

19. A influenza virus vaccine, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 502 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 502 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.

20. A influenza virus vaccine or composition or immunogenic composition, comprising:

at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp, a sequence identified by SEQ ID NO: 503 and a 3′ polyA tail, wherein the uracil nucleotides of the sequence identified by SEQ ID NO: 503 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.

21. The vaccine of any one of paragraphs 18-20 formulated in a lipid nanoparticle comprising DLin-MC3-DMA, cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and polyethylene glycol (PEG)2000-DMG.

This invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

EXAMPLES

Example 1: Manufacture of Polynucleotides

According to the present disclosure, the manufacture of polynucleotides and/or parts or regions thereof may be accomplished utilizing the methods taught in International Publication WO2014/152027, entitled “Manufacturing Methods for Production of RNA Transcripts,” the contents of which is incorporated herein by reference in its entirety.

Purification methods may include those taught in International Publication WO2014/152030 and International Publication WO2014/152031, each of which is incorporated herein by reference in its entirety.

Detection and characterization methods of the polynucleotides may be performed as taught in International Publication WO2014/144039, which is incorporated herein by reference in its entirety.

Characterization of the polynucleotides of the disclosure may be accomplished using polynucleotide mapping, reverse transcriptase sequencing, charge distribution analysis, detection of RNA impurities, or any combination of two or more of the foregoing. “Characterizing” comprises determining the RNA transcript sequence, determining the purity of the RNA transcript, or determining the charge heterogeneity of the RNA transcript, for example. Such methods are taught in, for example, International Publication WO2014/144711 and International Publication WO2014/144767, the content of each of which is incorporated herein by reference in its entirety.

Example 2: Chimeric Polynucleotide Synthesis

According to the present disclosure, two regions or parts of a chimeric polynucleotide may be joined or ligated using triphosphate chemistry. A first region or part of 100 nucleotides or less is chemically synthesized with a 5′ monophosphate and terminal 3′desOH or blocked OH, for example. If the region is longer than 80 nucleotides, it may be synthesized as two strands for ligation.

If the first region or part is synthesized as a non-positionally modified region or part using in vitro transcription (IVT), conversion the 5′monophosphate with subsequent capping of the 3′ terminus may follow.

Monophosphate protecting groups may be selected from any of those known in the art.

The second region or part of the chimeric polynucleotide may be synthesized using either chemical synthesis or IVT methods. IVT methods may include an RNA polymerase that can utilize a primer with a modified cap. Alternatively, a cap of up to 130 nucleotides may be chemically synthesized and coupled to the IVT region or part.

For ligation methods, ligation with DNA T4 ligase, followed by treatment with DNase should readily avoid concatenation.

The entire chimeric polynucleotide need not be manufactured with a phosphate-sugar backbone. If one of the regions or parts encodes a polypeptide, then such region or part may comprise a phosphate-sugar backbone.

Ligation is then performed using any known click chemistry, orthoclick chemistry, solulink, or other bioconjugate chemistries known to those in the art.

Synthetic Route

The chimeric polynucleotide may be made using a series of starting segments. Such segments include:

(a) a capped and protected 5′ segment comprising a normal 3′OH (SEG. 1)

(b) a 5′ triphosphate segment, which may include the coding region of a polypeptide and a normal 3′OH (SEG. 2)

(c) a 5′ monophosphate segment for the 3′ end of the chimeric polynucleotide (e.g., the tail) comprising cordycepin or no 3′OH (SEG. 3)

After synthesis (chemical or IVT), segment 3 (SEG. 3) may be treated with cordycepin and then with pyrophosphatase to create the 5′ monophosphate.

Segment 2 (SEG. 2) may then be ligated to SEG. 3 using RNA ligase. The ligated polynucleotide is then purified and treated with pyrophosphatase to cleave the diphosphate. The treated SEG.2-SEG. 3 construct may then be purified and SEG. 1 is ligated to the 5′ terminus. A further purification step of the chimeric polynucleotide may be performed.

Where the chimeric polynucleotide encodes a polypeptide, the ligated or joined segments may be represented as: 5′UTR (SEG. 1), open reading frame or ORF (SEG. 2) and 3′UTR+PolyA (SEG. 3).

The yields of each step may be as much as 90-95%.

Example 3: PCR for cDNA Production

PCR procedures for the preparation of cDNA may be performed using 2×KAPA HIFI™ HotStart ReadyMix by Kapa Biosystems (Woburn, Mass.). This system includes 2× KAPA ReadyMix 12.5 μl; Forward Primer (10 μM) 0.75 μl; Reverse Primer (10 μM) 0.75 μl; Template cDNA 100 ng; and dH₂0 diluted to 25.0 μl. The reaction conditions may be at 95° C. for 5 min. The reaction may be performed for 25 cycles of 98° C. for 20 sec, then 58° C. for 15 sec, then 72° C. for 45 sec, then 72° C. for 5 min, then 4° C. to termination.

The reaction may be cleaned up using Invitrogen's PURELINK™ PCR Micro Kit (Carlsbad, Calif.) per manufacturer's instructions (up to 5 μg). Larger reactions may require a cleanup using a product with a larger capacity. Following the cleanup, the cDNA may be quantified using the NANODROP™ and analyzed by agarose gel electrophoresis to confirm that the cDNA is the expected size. The cDNA may then be submitted for sequencing analysis before proceeding to the in vitro transcription reaction.

Example 4: In Vitro Transcription (IVT)

The in vitro transcription reaction generates RNA polynucleotides. Such polynucleotides may comprise a region or part of the polynucleotides of the disclosure, including chemically modified RNA (e.g., mRNA) polynucleotides. The chemically modified RNA polynucleotides can be uniformly modified polynucleotides. The in vitro transcription reaction utilizes a custom mix of nucleotide triphosphates (NTPs). The NTPs may comprise chemically modified NTPs, or a mix of natural and chemically modified NTPs, or natural NTPs.

A typical in vitro transcription reaction includes the following:

1)	Template cDNA	1.0	μg
2)	10× transcription buffer	2.0	μl
	(400 mM Tris-HCl pH 8.0, 190 mM
	MgCl2, 50 mM DTT, 10 mM Spermidine)
3)	Custom NTPs (25 mM each)	0.2	μl
4)	RNase Inhibitor	20	U
5)	T7 RNA polymerase	3000	U
6)	dH2O	up to 20.0 μl. and
7)	Incubation at 37° C. for 3 hr-5 hrs.

The crude IVT mix may be stored at 4° C. overnight for cleanup the next day. 1 U of RNase-free DNase may then be used to digest the original template. After 15 minutes of incubation at 37° C., the mRNA may be purified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following the manufacturer's instructions. This kit can purify up to 500 μg of RNA. Following the cleanup, the RNA polynucleotide may be quantified using the NANODROP™ and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred.

Example 5: Enzymatic Capping

Capping of a RNA polynucleotide is performed as follows where the mixture includes: IVT RNA 60 μg-180 μg and dH₂0 up to 72 yl. The mixture is incubated at 65° C. for 5 minutes to denature RNA, and then is transferred immediately to ice.

The protocol then involves the mixing of 10× Capping Buffer (0.5 M Tris-HCl (pH 8.0), 60 mM KCl, 12.5 mM MgCl₂) (10.0 μl); 20 mM GTP (5.0 μl); 20 mM S-Adenosyl Methionine (2.5 μl); RNase Inhibitor (100 U); 2′-O-Methyltransferase (400U); Vaccinia capping enzyme (Guanylyl transferase) (40 U); dH₂0 (Up to 28 μl); and incubation at 37° C. for 30 minutes for 60 μg RNA or up to 2 hours for 180 μg of RNA.

The RNA polynucleotide may then be purified using Ambion's MEGACLEAR™ Kit (Austin, Tex.) following the manufacturer's instructions. Following the cleanup, the RNA may be quantified using the NANODROP™ (ThermoFisher, Waltham, Mass.) and analyzed by agarose gel electrophoresis to confirm the RNA polynucleotide is the proper size and that no degradation of the RNA has occurred. The RNA polynucleotide product may also be sequenced by running a reverse-transcription-PCR to generate the cDNA for sequencing.

Example 6: PolyA Tailing Reaction

Without a poly-T in the cDNA, a poly-A tailing reaction must be performed before cleaning the final product. This is done by mixing capped IVT RNA (100 yl); RNase Inhibitor (20 U); 10× Tailing Buffer (0.5 M Tris-HCl (pH 8.0), 2.5 M NaCl, 100 mM MgCl₂) (12.0 μl); 20 mM ATP (6.0 μl); Poly-A Polymerase (20 U); dH₂0 up to 123.5 μl and incubation at 37° C. for 30 min. If the poly-A tail is already in the transcript, then the tailing reaction may be skipped and proceed directly to cleanup with Ambion's MEGACLEAR™ kit (Austin, Tex.) (up to 500 μg). Poly-A Polymerase may be a recombinant enzyme expressed in yeast.

It should be understood that the processivity or integrity of the polyA tailing reaction may not always result in an exact size polyA tail. Hence, polyA tails of approximately between 40-200 nucleotides, e.g., about 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 150-165, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164 or 165 are within the scope of the present disclosure.

Example 7: Natural 5′ Caps and 5′ Cap Analogues

5′-capping of polynucleotides may be completed concomitantly during the in vitro-transcription reaction using the following chemical RNA cap analogs to generate the 5′-guanosine cap structure according to manufacturer protocols: 3′-O-Me-m7G(5′)ppp(5′) G [the ARCA cap]; G(5′)ppp(5′)A; G(5′)ppp(5′)G; m7G(5′)ppp(5′)A; m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). 5′-capping of modified RNA may be completed post-transcriptionally using a Vaccinia Virus Capping Enzyme to generate the “Cap 0” structure: m7G(5′)ppp(5′)G (New England BioLabs, Ipswich, Mass.). Cap 1 structure may be generated using both Vaccinia Virus Capping Enzyme and a 2′-O methyl-transferase to generate: m7G(5′)ppp(5′)G-2′-O-methyl. Cap 2 structure may be generated from the Cap 1 structure followed by the 2′-O-methylation of the 5′-antepenultimate nucleotide using a 2′-O methyl-transferase. Cap 3 structure may be generated from the Cap 2 structure followed by the 2′-O-methylation of the 5′-preantepenultimate nucleotide using a 2′-0 methyl-transferase. Enzymes are preferably derived from a recombinant source.

When transfected into mammalian cells, the modified mRNAs have a stability of between 12-18 hours or more than 18 hours, e.g., 24, 36, 48, 60, 72 or greater than 72 hours.

Example 8: Capping Assays

Protein Expression Assay

Polynucleotides (e.g., mRNA) encoding a polypeptide, containing any of the caps taught herein, can be transfected into cells at equal concentrations. The amount of protein secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. Synthetic polynucleotides that secrete higher levels of protein into the medium correspond to a synthetic polynucleotide with a higher translationally-competent cap structure.

Purity Analysis Synthesis

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be compared for purity using denaturing Agarose-Urea gel electrophoresis or HPLC analysis. RNA polynucleotides with a single, consolidated band by electrophoresis correspond to the higher purity product compared to polynucleotides with multiple bands or streaking bands. Chemically modified RNA polynucleotides with a single HPLC peak also correspond to a higher purity product. The capping reaction with a higher efficiency provides a more pure polynucleotide population.

Cytokine Analysis

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be transfected into cells at multiple concentrations. The amount of pro-inflammatory cytokines, such as TNF-alpha and IFN-beta, secreted into the culture medium can be assayed by ELISA at 6, 12, 24 and/or 36 hours post-transfection. RNA polynucleotides resulting in the secretion of higher levels of pro-inflammatory cytokines into the medium correspond to a polynucleotides containing an immune-activating cap structure.

Capping Reaction Efficiency

RNA (e.g., mRNA) polynucleotides encoding a polypeptide, containing any of the caps taught herein can be analyzed for capping reaction efficiency by LC-MS after nuclease treatment. Nuclease treatment of capped polynucleotides yield a mixture of free nucleotides and the capped 5′-5-triphosphate cap structure detectable by LC-MS. The amount of capped product on the LC-MS spectra can be expressed as a percent of total polynucleotide from the reaction and correspond to capping reaction efficiency. The cap structure with a higher capping reaction efficiency has a higher amount of capped product by LC-MS.

Example 9: Agarose Gel Electrophoresis of Modified RNA or RT PCR Products

Individual RNA polynucleotides (200-400 ng in a 20 μl volume) or reverse transcribed PCR products (200-400 ng) may be loaded into a well on a non-denaturing 1.2% Agarose E-Gel (Invitrogen, Carlsbad, Calif.) and run for 12-15 minutes, according to the manufacturer protocol.

Example 10: NANODROP™ Modified RNA Quantification and UV Spectral Data

Chemically modified RNA polynucleotides in TE buffer (1 μl) are used for NANODROP™ UV absorbance readings to quantitate the yield of each polynucleotide from an chemical synthesis or in vitro transcription reaction.

Example 11: Formulation of Modified mRNA Using Lipidoids

RNA (e.g., mRNA) polynucleotides may be formulated for in vitro experiments by mixing the polynucleotides with the lipidoid at a set ratio prior to addition to cells. In vivo formulation may require the addition of extra ingredients to facilitate circulation throughout the body. To test the ability of these lipidoids to form particles suitable for in vivo work, a standard formulation process used for siRNA-lipidoid formulations may be used as a starting point. After formation of the particle, polynucleotide is added and allowed to integrate with the complex. The encapsulation efficiency is determined using a standard dye exclusion assays.

Example 12: Mouse Immunogenicity Studies

Comparison of HA Stem Antigens

In this example, assays were carried out to evaluate the immune response to influenza virus vaccine antigens delivered using an mRNA/LNP platform in comparison to protein antigens. The instant study was designed to test the immunogenicity in mice of candidate influenza virus vaccines comprising an mRNA polynucleotide encoding HA stem protein obtained from different strains of influenza virus. Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: stem of H1/Puerto Rico/8/1934 (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem of H1/New Caledonia/20/1999 (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem of H1/California/04/2009 (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem of H5/Vietnam/1194/2004 (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23), stem of H10/Jiangxi-Donghu/346/2013, and full-length H10/Jiangxi-Donghu/346/2013.

Protein vaccines tested in this study included the pH1HA10-Foldon protein, as described in Mallajosyula et al. Proc Natl Acad Sci USA. 2014; 111(25):E2514-23. Additional controls included MC3 (control for effects of LNP) and PR8 influenza virus.

Mice were immunized intramuscularly with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep, except for administration of the PR8 influenza virus control which was delivered intranasally in a volume of 20 μL while the animals were sedated with a mixture of Ketamine and Xylazine. The group numbers for each test vaccine along with the vaccine dose are outlined in the table below:

TABLE 1
RNA Test Vaccines
Group #	Antigen	dose	formulation
1	H10/Jiangxi-	10	μg	MC3
	Donghu/346/2013 full-
	length RNA
2	H10N8 A/JX346/2013	10	μg	MC3
	stem RNA
3	H1N1 A/Puerto Rico/8/	10	μg	MC3
	1934 stem RNA
4	H1N1 A/New	10	μg	MC3
	Caledonia/20/99 stem
	RNA
5	H1N1 A/California/04/	10	μg	MC3
	2009 stem RNA
6	H5N1 A/Vietnam/1203/	10	μg	MC3
	2004 stem RNA
7	pH1HA10-Foldon protein	20	μg	CpG 7909
8	MC3	0	μg	MC3
9	0.1 LD90 PR8 virus	0.1	LD90	None

Mice were immunized with two doses of the various influenza virus RNA vaccine formulations at weeks 0 and 3, and serum was collected two weeks after immunization with the second dose.

To test the sera for the presence of antibodies capable of binding to hemagglutinin (HA) from a wide variety of influenza strains, ELISA plates were coated with 100 ng of the following recombinant HAs obtained from Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99), cat #11683-V08H; Influenza A H3N2 (A/Aichi/2/1968), cat #11707-V08H; Influenza A H1N1 (A/California/04/2009) cat #11055-V08H; Influenza A H1N1 (A/Puerto Rico/8/34) cat #11684-V08H; Influenza A H3N2 (A/Brisbane/10/2007), cat #11056-V08H; Influenza A H2N2 (A/Japan/305/1957) cat #11088-V08H; Influenza A H7N9 (A/Anhui/l/2013) cat #40103-V08H; Influenza H5N1 (A/Vietnam/1194/2004) cat #11062-V08H1; Influenza H9N2 (A/Hong Kong/1073/99) cat #11229-V08H and Influenza A H10N8 (A/Jiangxi-Donghu/346/2013) cat #40359-V08B. After coating, the plates were washed, blocked with Phosphate Buffered Saline with 0.05% Tween-20 (PBST)+3% milk, and 100 μL of control antibodies or sera from immunized mice (diluted in PBST+3% milk) were added to the top well of each plate and serially diluted. Plates were sealed and incubated at room temperature for 2 hours. Plates were washed, and goat anti-mouse IgG (H+L)-HRP conjugate (Novex, diluted 1:2000 in PBST/3% milk) was added to each well containing mouse sera. Plates were incubated at room temperature for 1 hr, washed, and incubated with TMB substrate (Thermo Scientific). The color was allowed to develop for 10 minutes and then quenched with 100 μL of 2N sulfuric acid. The plates were read at 450 nM on a microplate reader. Endpoint titers (2.5-fold above background) were calculated.

In FIG. 1, the vaccines tested are shown on the y-axis and the endpoint titer to HA from each of the different strains of influenza are plotted. HAs from group 1 (H1, H2, H5, H9) strains of influenza are indicated by filled circles while HAs from group 2 (H3, H7, H10) strains of influenza are indicated by open circles. FIG. 1 illustrates that mRNA based vaccines encoding HA-based antigens that are encapsulated in the MC3 lipid nanoparticle induced high antibody binding titers to HA. FIG. 1 also illustrates that mRNA vaccines designed to express a portion of the stem domain from different H1N1 or H5N1 strains of influenza elicited high antibody titers that were capable of binding all strains of group 1 HA tested as well as several group 2 strains. FIG. 1 also illustrates that mRNA vaccines designed to express a portion of the H1N1 A/California/04/2009 stem domain induced higher titers than a protein vaccine of the same stem domain.

In another mouse immunogenicity study, the immune response to additional influenza virus vaccine antigens delivered using an mRNA/LNP platform was evaluated. The purpose of this study was to evaluate the ability of a second set of mRNA vaccine antigens to elicit cross-protective immune responses in the mouse and to assess the potential for mRNA vaccines encoding influenza HA antigens to be co-dosed. Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: H1HA6 (based on Bommakanti G et al. J Virol. 2012 December; 86(24):13434-44); H3HA6 (based on Bommakanti G et al. PNAS 2010 Aug. 3; 107(31):13701-6); H1HA10-Foldon_delta Ngly; eH1HA (ectodomain of HA from H1N1 A/Puerto Rico/8/34); eH1HA_native signal seq (eH1HA with its native signal sequence); H3N2 A/Wisconsin/67/2005 stem; H3N2 A/Hong Kong/1/1968 stem (based on Mallajosyula V et al. Front Immunol. 2015 Jun. 26; 6:329); H7N9 A/Anhui/l/2013 stem; H1N1 A/California/04/2009 stem RNA (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23); and H1N1 A/Puerto Rico/8/1934 stem RNA (based on Mallajosyula V et al. PNAS 2014 Jun. 24; 111(25):E2514-23).

Controls included: MC3 (control for effects of LNP); Naïve (unvaccinated animals); and vaccination with H1N1 A/PR/8/34 and H3N2 A/HK/1/68 influenza viruses (positive controls).

Mice were immunized intramuscularly with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep, except for administration of the H1N1 A/PR/8/34 and H3N2 A/HK/1/68 virus influenza virus controls which were delivered intranasally in a volume of 20 μL while the animals were sedated with a mixture of Ketamine and Xylazine. The group numbers for each test vaccine along with the vaccine dose are outlined in the table below:

TABLE 2
Test Vaccines
		Antigen	Formu-	Volume,
Group #	Antigen	dose	lation	Route
1	H1HA6 RNA	10	μg	MC3	100
					μl, i.m.
2	H3HA6 RNA	10	μg	MC3	100
					μl, i.m.
3	H1HA10-Foldon_delta	10	μg	MC3	100
	Ngly				μl, i.m.
4	eH1HA	10	μg	MC3	100
					μl, i.m.
5	eH1HA_native signal	10	μg	MC3	100
	seq				μl, i.m.
6	H3N2 A/Wisconsin/67/	10	μg	MC3	100
	2005 stem RNA				μl, i.m.
7	H3N2 A/Hong Kong/1/	10	μg	MC3	100
	1968 stem RNA				μl, i.m.
8	H7N9 A/Anhui/1/2013	10	μg	MC3	100
	stem RNA				μl, i.m.
9	H1N1 A/Puerto Rico/8/	10	μg	MC3	100
	1934 stem RNA AND				μl, i.m.
	H3N2 A/Wisconsin/67/
	2005 stem RNA (RNAs
	mixed prior to
	formulation)
10	H1N1 A/Puerto Rico/8/	10	μg	MC3	100
	1934 stem RNA AND				μl, i.m.
	H3N2 A/Wisconsin/67/
	2005 stem RNA (RNAs
	formulated and then
	mixed
11	H1N1 A/California/04/	10	μg	MC3	100
	2009 stem RNA				μl, i.m.
12	H1N1 A/Puerto Rico/8/	10	μg	MC3	100
	1934 stem RNA				μl, i.m.
13	MC3	0	μg	MC3	100
					μl, i.m.
14	Naïve	0	μg	None	None
15	H3N2 A/HK/1/68 virus	0.1	LD90	None	20
					μl, i.n.
16	H1N1 A/PR/8/34 virus	0.1	LD90	None	20
					μl, i.n.

Animals were immunized on the study start day and then again three weeks after the initial immunization. Sera were collected from the animals two weeks after the second dose. To test the sera for the presence of antibodies capable of binding to hemagglutinin (HA) from a wide variety of influenza strains, ELISA plates were coated with 100 ng of the following recombinant HAs obtained from Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99), cat #11683-V08H; Influenza A H3N2 (A/Aichi/2/1968), cat #11707-V08H; Influenza A H1N1 (A/California/04/2009) cat #11055-V08H; Influenza A H1N1 (A/Puerto Rico/8/34) cat #11684-V08H; Influenza A H3N2 (A/Brisbane/10/2007), cat #11056-V08H; Influenza A H2N2 (A/Japan/305/1957) cat #11088-V08H; Influenza A H7N9 (A/Anhui/l/2013) cat #40103-V08H and Influenza A H3N2 (A/Moscow/10/99) cat #40154-V08. The ELISA assay was performed and endpoint titers were calculated as described above. FIGS. 2 and 3 show the endpoint anti-HA antibody titers following the second immunization with the test vaccines. The vaccines tested are shown on the x-axis and the binding to HA from each of the different strains of influenza is plotted. All mRNA vaccines encoding HA stem were immunogenic and elicited a robust antibody response recognizing HA from a diverse set of influenza A virus strains. The H1HA6, eH1HA, and eH1HA_native-signal-sequence mRNAs elicited the highest overall binding titers across the panel of group 1 HAs, while the H3HA6 RNA elicited the highest overall binding titers across group 2 Has (FIG. 2). Immunogenicity of combinations of stem mRNA vaccines was also tested. In this study, individual mRNAs were mixed prior to formulation with LNP (Group 9, co-form) or individual mRNAs were formulated with LNP prior to mixing (Group 10, mix-form). As shown in FIG. 3, combining H1 and H3 stem-based mRNAs did not result in interference in the immune response to either antigen, regardless of the method of formulation.

Example 13: Mouse Efficacy Studies

Influenza A Challenge #1

This study was designed to test the immunogenicity and efficacy in mice of candidate influenza virus vaccines. Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: NIHGen6HASS-foldon mRNA (based on Yassine et al. Nat. Med. 2015 September; 21(9):1065-70), an mRNA encoding the nucleoprotein NP from an H3N2 strain, or one of several combinations of NIHGen6HASS-foldon and NP mRNAs. Several methods of vaccine antigen co-delivery were tested including: mixing individual mRNAs prior to formulation with LNP (co-form), formulation of individual mRNAs prior to mixing (mix ind LNPs), and formulating mRNAs individually and injecting distal sites (opposite legs) (ind LNPs remote). Control animals were vaccinated with an RNA encoding the ectodomain of the HA from H1N1 A/Puerto Rico/8/1934 (eH1HA, positive control) or empty MC3 LNP (to control for effects of the LNP) or were not vaccinated (naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep. Candidate influenza virus vaccines evaluated in this study were described above and are outlined in the table below. Sera were collected from all animals two weeks after the second dose. At week 6, spleens were harvested from a subset of the animals (n=4). The remaining animals (n=6) were challenged intranasally while sedated with a mixture of Ketamine and Xylazine with a lethal dose of mouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934. Mortality was recorded and individual mouse weight was assessed daily for 20 days post-infection.

TABLE 3
Test Vaccines
		Antigen		Volume,
Group #	Antigen	dose	Formulation	Route
1	NIHGen6HASS-	10 μg	MC3	100 μl,
	foldon RNA			i.m.
2	NIHGen6HASS-	5 μg	MC3	100 μl,
	foldon RNA			i.m.
3	NIHGen6HASS-	2 μg	MC3	100 μl,
	foldon RNA			i.m.
4	NP RNA	5 μg	MC3	100 μl,
				i.m.
5	NIHGen6HASS-	5 μg of each	MC3	100 μl,
	foldon RNA +	RNA mixed,		i.m.
	NP RNA	then formulated
6	NIHGen6HASS-	5 μg of each	MC3	100 μl,
	foldon RNA +	RNA		i.m.
	NP RNA	formulated,
		then mixed
7	NIHGen6HASS-	5 μg of each	MC3	100 μl,
	foldon RNA +	RNA		i.m.
	NP RNA	formulated and
		injected into
		separate legs
8	NIHGen6HASS-	5 μg of NP +	MC3	100 μl,
	foldon RNA +	2 μg of		i.m.
	NP RNA	NIHGen6HASS-
		foldon RNA
		mixed, then
		formulated
9	eH1HA RNA	10 μg	MC3	100 μl,
				i.m.
10	MC3	0 μg	MC3	100 μl,
				i.m.
11	Naïve	0 μg	None	None

To test the sera for the presence of antibodies capable of binding to hemagglutinin (HA) from a wide variety of influenza strains or nucleoprotein (NP), ELISA plates were coated with 100 ng of the following recombinant proteins obtained from Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99) HA, cat #11683-V08H; Influenza A H3N2 (A/Aichi/2/1968) HA, cat #11707-V08H; Influenza A H1N1 (A/California/04/2009) HA, cat #11055-V08H; Influenza A HIN1 (A/Puerto Rico/8/34) HA, cat #11684-V08H; Influenza A H1N1 (A/Brisbane/59/2007) HA, cat #11052-V08H; Influenza A H2N2 (A/Japan/305/1957) HA, cat #11088-V08H; Influenza A H7N9 (A/Anhui/1/2013) HA, cat #40103-V08H, Influenza A H3N2 (A/Moscow/10/99) HA, cat #40154-V08 and Influenza A H3N2 (A/Aichi/2/1968) Nucleoprotein cat #40207-V08B. The ELISA assay was performed and endpoint titers were calculated as described above. FIG. 4 depicts the endpoint titers of the pooled serum from animals vaccinated with the test vaccines. The vaccines tested are shown on the x-axis of FIG. 4A and the binding to HA from each of the different strains of influenza is plotted. The NIHGen6HASS-foldon mRNA vaccine elicited high titers of antibodies that bound all H1, H2 and H7 HAs tested. Combining the NIHGen6HASS-foldon mRNA with one that encodes NP did not negatively affect the observed anti-HA response, regardless of the method of mRNA co-formulation or co-delivery. In serum collected from identical groups from a separate study, a robust antibody response to NP protein was also detected in serum from animals vaccinated with NP mRNA containing vaccines, either NP alone or co-formulated with NIHGen6HASS-foldon mRNA (FIG. 4B).

To probe the functional antibody response, the ability of serum to neutralize a panel of HA-pseudotyped viruses was assessed (FIG. 5). Briefly, 293 cells were co-transfected with a replication-defective retroviral vector containing a firefly luciferase gene, an expression vector encoding a human airway serine protease, and expression vectors encoding influenza hemagglutinin (HA) and neuraminidase (NA) proteins. The resultant pseudoviruses were harvested from the culture supernatant, filtered, and titered. Serial dilutions of serum were incubated in 96 well plates at 37° C. for one hour with pseudovirus stocks (30,000-300,000 relative light units per well) before 293 cells were added to each well. The cultures were incubated at 37° C. for 72 hours, luciferase substrate and cell lysing reagents were added, and relative light units (RLU) were measured on a luminometer. Neutralization titers are expressed as the reciprocal of the serum dilution that inhibited 50% of pseudovirus infection (IC50).

For each sample tested (listed along the x-axis), each bar represents the IC50 for neutralization of a different virus pseudotype. While the serum from naïve or NP RNA vaccinated mice was unable to inhibit pseudovirus infection, the serum from mice vaccinated with 10 μg or 5 μg of NIHGen6HASS-foldon mRNA or with a combination of NIHGen6HASS-foldon and NP mRNAs neutralized, to a similar extent, all H1 and H5 virus pseudotypes tested.

The ability of NIHGen6HASS-foldon antisera to mediate antibody-dependent cell cytotoxicity (ADCC) surrogate activity in vitro was also assessed. Briefly, serially titrated mouse serum samples were incubated with A549 cells stably expressing HA from H1N1 A/Puerto Rico/8/1934 on the cell surface. Subsequently, ADCC Bioassay Effector cells (Promega, mouse FcgRIV NFAT-Luc effector cells) were added to the serum/target cell mixture. Approximately 6 hours later, Bio-glo reagent (Promega) was added to sample wells and luminescence was measured. Data was plotted as fold induction (sample luminescence/background luminescence) versus serum concentration (FIG. 6). When incubated with the appropriate target cells, serum from NIHGen6HASS-foldon mRNA vaccinated mice was able to stimulate the surrogate ADCC effector cell line, suggesting that the vaccine may induce antibodies capable of mediating in vivo ADCC activity.

Three weeks after the administration of the second vaccine dose, spleens were harvested from a subset of animals in each group and splenocytes from animals in the same group were pooled. Splenic lymphocytes were stimulated with a pool of HA or NP peptides, and IFN-γ, IL-2 or TNF-α production was measured by intracellular staining and flow cytometry. FIG. 7 is a representation of responses following stimulation with a pool of NP peptides, and FIG. 8 is a representation of responses following stimulation with a pool of H1 HA peptides. Following vaccination with NP mRNA, either in the presence or absence of NIHGen6HASS-foldon mRNA, antigen-specific CD4 and CD8 T cells were found in the spleen. Following vaccination with NIHGen6HASS-foldon RNA or delivery of NIHGen6HASS-foldon and NP RNAs to distal injections sites (dist. site), only HA-specific CD4 cells were observed. However, when NIHGen6HASS-foldon and NP RNAs were co-administered to the same injection site (co-form, mix), an HA-specific CD8 T cell response was detected.

Following lethal challenge with mouse-adapted H1N1 A/Puerto Rico/8/1934, all naïve animals succumbed to infection by day 12 post-infection (FIG. 9). In contrast, all animals vaccinated with NIHGen6HASS-foldon mRNA, NP mRNA, any combination of NIHGen6HASS-foldon and NP mRNAs, or eH1HA mRNA survived the challenge. As seen in FIG. 9, although there was no mortality, mice that were vaccinated with an H3N2 NP mRNA and challenged with H1N1 virus lost a significant amount (˜15%) of weight prior to recovery. Those vaccinated with NIHGen6HASS-foldon RNA also lost ˜5% body weight. In contrast, mice vaccinated with a combination of NIHGen6HASS-foldon and NP mRNAs appeared to be completely protected from lethal influenza virus challenge, similar to those vaccinated with mRNA expressing an HA antigen homologous to that of the challenge virus (eH1HA). Vaccine efficacy was similar at all vaccine doses, as well as with all co-formulation and co-delivery methods assessed (FIG. 10).

Influenza A Challenge #2

This study was designed to test the immunogenicity and efficacy in mice of candidate influenza virus vaccines. Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: NIHGen6HASS-foldon mRNA (based on Yassine et al. Nat. Med. 2015 September; 21(9):1065-70) and NIHGen6HASS-TM2 mRNA. Control animals were vaccinated with an mRNA encoding the ectodomain of the HA from H1N1 A/Puerto Rico/8/1934 (eH1HA, positive control) or were not vaccinated (naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep. Candidate influenza virus vaccines evaluated in this study were described above and outlined in the table below. Sera were collected from all animals two weeks after the second dose. At week 6, all animals were challenged intranasally while sedated with a mixture of Ketamine and Xylazine with a lethal dose of mouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934. Mortality was recorded and group mouse weight was assessed daily for 20 days post-infection.

TABLE 4
Test Vaccines
		Antigen		Volume,
Group #	Antigen	dose	Formulation	Route
1	NIHGen6HASS-	5 μg	MC3	100 μl,
	foldon RNA			i.m.
2	NIHGen6HASS-	5 μg	MC3	100 μl,
	foldon-TM2 RNA			i.m.
3	eH1HA RNA	10 μg	MC3	100 μl,
				i.m.
4	Naïve	0 μg	None	None

To test the sera for the presence of antibody capable of binding to hemagglutinin (HA) from a wide variety of influenza strains, ELISA plates were coated with 100 ng of the following recombinant HAs obtained from Sino Biological Inc.: Influenza A H1N1 (A/New Caledonia/20/99), cat #11683-V08H; Influenza A H3N2 (A/Aichi/2/1968), cat #11707-V08H; Influenza A H1N1 (A/California/04/2009) cat #11055-V08H; Influenza A H1N1 (A/Puerto Rico/8/34) cat #11684-V08H; Influenza A H1N1 (A/Brisbane/59/2007), cat #11052-V08H; Influenza A H2N2 (A/Japan/305/1957) cat #11088-V08H; Influenza A H7N9 (A/Anhui/1l/2013) cat #40103-V08H and Influenza A H3N2 (A/Moscow/10/99) cat #40154-V08. The ELISA assay was performed and endpoint titers were calculated as described above. FIG. 11A depicts the endpoint titers of the pooled serum from animals vaccinated with the test vaccines. The vaccines tested are shown on the x-axis and the binding to HA from each of the different strains of influenza is plotted. The NIHGen6HASS-foldon mRNA vaccine elicited high titers of antibodies that bound all H1, H2 and H7 HAs tested. The binding titers from NIHGen6HASS-TM2 mRNA vaccinated mice were reduced as compared to those from NIHGen6HASS-foldon mRNA vaccinated mice.

Following lethal challenge with mouse-adapted H1N1 A/Puerto Rico/8/1934, all naïve animals succumbed to infection by day 16 post-infection (FIG. 11B). In contrast, all animals vaccinated with NIHGen6HASS-foldon mRNA, NIHGen6HASS-TM2 mRNA, or eH1HA RNA survived the challenge. As shown in FIG. 11B, the efficacy of the NIHGen6HASS-TM2 vaccine was equivalent to that of the NIHGen6HASS-foldon vaccine.

Influenza A Challenge #3

In this example, two animal studies and assays were carried out to evaluate the immune response to influenza virus consensus hemagglutinin (HA) vaccine antigens delivered using an mRNA/LNP platform. The purpose of these studies was to evaluate the ability of consensus HA mRNA vaccine antigens to elicit cross-protective immune responses in the mouse.

To generate consensus HA sequences, 2415 influenza A serotype H1 HA sequences were obtained from the NIAID Influenza Research Database (IRD) (Squires et al., Influenza Other Respir Viruses. 2012 November; 6(6): 404-416.) through the web site at http://www.fludb.org. After removal of duplicate sequences and lab strains, 2385 entries remained, including 1735 H1 sequences from pandemic H1N1 strains (pH1N1) and 650 from seasonal H1N1 strains (sHIN1). Pandemic and seasonal H1 sequences were separately aligned and a consensus sequence was generated for each group using the Matlab 9.0 Bioinformatics toolbox (MathWorks, Natick, Mass.). Sequence profiles were generated for both groups separately using a modified Seq2Logo program (Thomsen et al., Nucleic Acids Res. 2012 July; 40 (Web Server issue):W281-7).

Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: ConH1 and ConH3 (based on Webby et al., PLoS One. 2015 Oct. 15; 10(10):e0140702.); Cobra_P1 and Cobra_X3 (based on Carter et al., J Virol. 2016 Apr. 14; 90(9):4720-34); MRK_pH_Con and MRK_sH1_Con (pandemic and seasonal consensus sequences described above); and each of the above mentioned six antigens with a ferritin fusion sequence for potential particle formation.

Controls included: MC3 (control for effects of LNP); Naïve (unvaccinated animals); and vaccination with eH1HA RNA, which encode the ectodomain of HA from strain H1N1 A/PR/8/34 (positive control for the virus challenge).

At week 0 and week 3, animals were immunized intramuscularly (IM) with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep. Candidate influenza virus vaccines evaluated in this study were described above and are outlined in the table below. Sera were collected from all animals two weeks after the second dose (week 5). At week 6, the animals were challenged intranasally while sedated with a mixture of Ketamine and Xylazine with a lethal dose of mouse-adapted influenza virus strain H1N1 A/Puerto Rico/8/1934 (PR8). Mortality was recorded and group weight was assessed daily for 20 days post-infection.

TABLE 5
Test Vaccines
		Antigen		Volume,
Group #	Antigen	dose	Formulation	Route
1	Con_H1 RNA	10 μg	MC3	100 μl,
				i.m.
2	Con_H3 RNA	10 μg	MC3	100 μl,
				i.m.
3	Merck_pH1_Con RNA	10 μg	MC3	100 μl,
				i.m.
4	Merck_sH1_Con RNA	10 μg	MC3	100 μl,
				i.m.
5	Cobra_P1 RNA	10 μg	MC3	100 μl,
				i.m.
6	Cobra_X3 RNA	10 μg	MC3	100 μl,
				i.m.
7	ConH1_ferritin RNA	10 μg	MC3	100 μl,
				i.m.
8	ConH3_ferritin RNA	10 μg	MC3	100 μl,
				i.m.
9	Merck_pH1_Con_ferritin	10 μg	MC3	100 μl,
	RNA			i.m.
10	Merck_sH1_Con_ferritin	10 μg	MC3	100 μl,
	RNA			i.m.
11	Cobra_P1_ferritin RNA	10 μg	MC3	100 μl,
				i.m.
12	Cobra_X3_ferritin RNA	10 μg	MC3	100 μl,
				i.m.
13	eH1HA	10 μg	MC3	100 μl,
				i.m.
14	MC3	0 μg	MC3	100 μl,
				i.m.
15	Naïve	0 μg	None	None

To test the ability of the serum antibodies to neutralize the challenge virus strain, a microneutralization assay using a modified PR8 virus with a Gaussia luciferase reporter gene (Pan et al., Nat Commun. 2013; 4:2369) was performed. Briefly, PR8 luciferase virus was diluted in virus diluent with TPCK-treated trypsin. Serum samples were diluted 1:10 and then serially diluted 3-fold in 96-well cell culture plates. 50 μL of each diluted serum sample and an equal volume of diluted virus were mixed in the well and incubated at 37° C. with 5% CO₂ for 1 hr before 100 μL of MDCK cells at 1.5×10≡cells/mL were added. Plates were then incubated at 37° C. with 5% CO₂ for 72 hrs. Luminescence signal was read with a Gaussia Luciferase Glow Assay Kit (Pierce) on an EnVision reader (Perkin Elmer). As shown in FIG. 12A, serum from mice immunized with mRNA encoding consensus HA antigens from the H1 subtype was able to detectably neutralize the PR8 luciferase virus, even though the HA sequences of these antigens were 8-19% different from that of the PR8 strain. The HA sequence-matched antigen (eH1HA) elicited a much higher serum neutralizing antibody response against this virus. Serum from mice vaccinated with RNA encoding the consensus H3 antigen (ConH3), in contrast, was not able to neutralize the PR8 luciferase virus, suggesting that the consensus sequences from different subtypes (H1 and H3, for example) may not cross-react. Similarly, serum from mice immunized with mRNA encoding H1 subtype consensus HA antigens with a ferritin fusion sequence was able to detectably neutralize the PR8 luciferase virus, except for the Merck_pH1_Con_ferritin mRNA, while serum from mice vaccinated with an mRNA encoding the consensus H3 antigen with a ferritin fusion sequence was not able to neutralize the PR8 luciferase virus (FIG. 12B). Consistent with the serum neutralization data, mice immunized with the consensus H1 HA antigens (with or without ferritin fusion) survived the lethal PR8 virus challenge and showed no weight loss, except for the Merck_pH1_Con_ferritin mRNA group, while mice in the ConH3, naïve and LNP only control groups rapidly lost weight upon challenge (FIG. 13). Mice immunized with Merck_pH1_Con_ferritin mRNA survived the lethal PR8 virus challenge and showed 5-10% weight loss, suggesting that partial protection may be mediated by mechanism(s) other than virus neutralization.

To assess the breadth of the serum neutralizing activity elicited by the consensus HA antigens, neutralization assays were performed on a panel of pseudoviruses as described above (FIG. 14). As expected, serum from mice immunized with influenza virus H1N1 A/Puerto Rico/8/1934 (from studies described in Example 12) was only able to neutralize a matched pseudovirus strain (PR8). In contrast, serum from mice immunized with the consensus H1 HA antigens, as well as the eH1HA antigen, were able to neutralize a panel of diverse group 1 pseudoviruses, including strains from subtypes H1 and H5, but not a strain from group 2 (subtype H3). Consistently, serum from mice immunized with the consensus H3 HA antigen was able to neutralize a strain from group 2 (subtype H3) but not any of the group 1 pseudoviruses.

Influenza B Challenge

This study was designed to test the immunogenicity and efficacy in mice of candidate influenza virus vaccines. Animals tested were 6-8 week old female BALB/c mice obtained from Charles River Laboratories. Test vaccines included the following mRNAs formulated in MC3 LNP: B/Phuket/3073/2013 sHA (soluble HA), B/Phuket/3073/2013 mHA (full-length HA with membrane anchor), B/Brisbane/60/2008 sHA, B/Victoria/02/1987 sHA, B/Victoria/02/1987 mHA, B/Yamagata/16/1988 mHA, or BHA10 (HA stem design). Control animals were vaccinated with a nonlethal dose of mouse-adapted B/Ann Arbor/1954 (positive control) or empty MC3 LNP (to control for effects of the LNP) or were not vaccinated (naïve).

At week 0 and week 3, animals were immunized intramuscularly (IM) with a total volume of 100 μL of each test vaccine, which was administered in a 50 μL immunization to each quadricep. Candidate influenza virus vaccines evaluated in this study were described above and are outlined in the table below. Sera were collected from all animals two weeks after the second dose. At week 6, all animals (n=10 per group) were challenged intranasally while sedated with a mixture of Ketamine and Xylazine with a lethal dose of mouse-adapted influenza virus strain B/Ann Arbor/1954. Mortality was recorded and group mouse weight was assessed daily for 20 days post-infection.

Each of the sequences described herein encompasses a chemically modified sequence or an unmodified sequence which includes no nucleotide modifications.

TABLE 6
Test Vaccines
		Antigen		Volume,
Group #	Antigen	dose	Formulation	Route
1	B/Phuket/3073/2013	10	μg	MC3	100 μl,
	sHA RNA				i.m.
2	B/Phuket/3073/2013	10	μg	MC3	100 μl,
	mHA RNA				i.m.
3	B/Brisbane/60/2008	10	μg	MC3	100 μl,
	sHA RNA				i.m.
4	B/Victoria/02/1987	10	μg	MC3	100 μl,
	sHA RNA				i.m.
5	B/Victoria/02/1987	10	μg	MC3	100 μl,
	mHA RNA				i.m.
6	B/Yamagata/16/1988	10	μg	MC3	100 μl,
	mHA RNA				i.m.
7	BHA10 RNA	10	μg	MC3	100 μl,
					i.m.
8	MC3	0	μg	MC3	100 μl,
					i.m.
9	Naïve	0	μg	None	100 μl,
					i.m.
10	B/Ann Arbor/1954	0.1	LD90	None	20 μl, i.n.

FIG. 15A depicts the ELISA endpoint anti-HA antibody titers of the pooled serum from animals vaccinated with the test vaccines. The vaccines tested are shown on the x-axis and the binding to HA from each of the different strains of influenza is plotted. All vaccines tested, except for those derived from B/Phuket/3073/2013 were immunogenic, and serum antibody bound to HA from both B/Yamagata/16/1988 (Yamagata lineage) and B/Florida/4/2006 (Victoria lineage).

Following lethal challenge with mouse-adapted B/Ann Arbor/1954, 90% of MC3-vaccinated and naïve animals succumbed to infection by day 16 post-infection (FIG. 15B). The B/Phuket/3073/2013 sHA and mHA mRNA vaccines showed no efficacy against lethal challenge, and the BHA10 stem mRNA vaccine protected only half of the animals. All other vaccines tested protected mice completely from mortality (FIG. 15B), but only the B/Yamagata/16/1988 mHA RNA vaccine was able to prevent lethality and weight loss in animals challenged with a heterologous virus strain (FIG. 15B).

Example 14: Non-Human Primate Immunogenicity

This study was designed to test the immunogenicity in rhesus macaques of candidate influenza virus vaccines. Test vaccines included the following mRNAs formulated in MC3 LNP: NIHGen6HASS-foldon mRNA (based on Yassine et al. Nat. Med. 2015 September; 21(9):1065-70) and NP mRNA encoding NP protein from an H3N2 influenza strain.

Animals in Group 1 had been previously vaccinated with seasonal inactivated influenza vaccine (FLUZONE®) and were boosted intramuscularly (IM) at day 0 with 300 μg of NIHGen6HASS-foldon mRNA. Animals in Groups 2 and 3 were influenza naïve at the study start and were vaccinated at days 0, 28 and 56 with 300 μg of NIHGen6HASS-foldon mRNA or 300 μg of NP mRNA, respectively. Serum was collected from all animals prior to the study start (day −8) as well as at days 14, 28, 42, 56, 70, 84, 112, 140 and 168.

The NIHGen6HASS-foldon vaccine elicited a robust antibody response as measured by ELISA assay (plates coated with recombinantly-expressed NIHGen6HASS-foldon [HA stem] or NP proteins), and the data is depicted in FIG. 16. FIG. 16A shows titers to HA stem, over time, for four rhesus macaques previously vaccinated with FLUZONE® and boosted a single time with NIHGen6HASS-foldon mRNA vaccine. FIG. 16B depicts titers to HA stem, over time, from four rhesus macaques vaccinated at days 0, 28 and 56 with the same NIHGen6HASS-foldon RNA vaccine. The NIHGen6HASS-foldon RNA vaccine was able to boost anti-HA stem antibody binding titers in animal previously vaccinated with inactivated influenza vaccine as well as elicited a robust response in naïve animals. In both groups, HA stem titers remained elevated over baseline to at least study day 168. FIG. 16C illustrates antibody titers to NP, over time, for four rhesus macaques vaccinated at days 0, 28 and 56 with the NP mRNA vaccine and shows that the vaccine elicited a robust antibody response to NP.

To test the Group 1 and 2 sera for the presence of antibody capable of binding to hemagglutinin (HA) from a wide variety of influenza strains, ELISA plates were coated with recombinant HAs from a diverse set of influenza strains as described above. EC10 titers were calculated as the reciprocal of the serum dilution that reached 10% of the maximal signal. For animals in Group 1 (FIG. 17A), a single dose of NIHGen6HASS-foldon vaccine boosted titers to H1 HAs ˜40-60 fold, and titers peaked approximately 28 days post-vaccination. Titers decreased from days 28-70, but day 70 titers were still ˜10-30-fold above the titers measured prior to vaccination. The NIHGen6HASS-foldon mRNA vaccine did not boost titers to HAs from H3 or H7 influenza strains. For animals in Group 2 (FIG. 17B), antibody titers to H1 and H2 HAs rose after each dose of NIHGen6HASS-foldon mRNA vaccine, and titers appeared to rise most dramatically after dose 2.

In addition to robust antibody responses, the NP mRNA vaccine also elicited cell-mediated immunity in rhesus. On study day 0, 42, 70 and 140, PBMCs were collected from Group 3 NP mRNA vaccinated rhesus macaques. Lymphocytes were stimulated with a pool of NP peptides, and IFN-γ, IL-2 or TNF-α production were measured by intracellular staining and flow cytometry. FIG. 18 is a representation of responses following NP peptide pool stimulation. Following vaccination with NP mRNA, antigen-specific CD4 and CD8 T cells were found in the peripheral blood, and these cells were maintained above baseline to at least study day 140.

Example 15: H7N9 Immunogenicity Studies

The instant study was designed to test H7N9 immunogenicity. Intramuscular immunizations of 25 μM were administered on days 1 and 22 to 40 animals, and blood was collected on days 1, 8, 22, and 43. Hemagglutination inhibition (HAI) and microneutralization tests were conducted using the blood samples.

The HAI test showed a geometric mean titer (GMT) of 45 for all of the animals, including the placebo group. The GMT of the responders only was 116 (FIG. 19). The HAI kinetics for each individual subject are given in FIG. 20.

The microneutralization (MN) test showed a geometric mean titer (GMT) of 36 for all of the animals, including the placebo group. The GMT of the responders only was 84 (FIG. 21). The MN test kinetics for each subject are given in FIG. 22.

HAI and MN showed a very strong correlation (FIG. 23). Only one subject had a protective titer in one assay, but not in the other. Also, 10 subjects had no detectable HAI or MN titer at Day 43.

TABLE 7
Influenza H1N1 Antigens
		GenBank/GI
Strain/Protein	Length	Accession No.
Influenza A virus (A/Bayern/7/95(H1N1)) NA	1,459 bp	AJ518104.1
gene for neuraminidase, genomic RNA	linear mRNA	GI: 31096418
Influenza A virus (A/Brazil/11/1978(X-	1,072 bp	X86654.1
71)(H1N1)) mRNA for hemagglutinin HA1,	linear mRNA	GI: 995549
escape variant 1
Influenza A virus (A/Brazil/11/1978(X-	1,072 bp	X86655.1
71)(H1N1)) mRNA for hemagglutinin HA1,	linear mRNA	GI: 995550
escape variant 2
Influenza A virus (A/Brazil/11/1978(X-	1,072 bp	X86656.1
71)(H1N1)) mRNA for hemagglutinin HA1,	linear mRNA	GI: 995551
escape variant 3
Influenza A virus (A/Brazil/11/1978(X-	1,072 bp	X86657.1
71)(H1N1)) mRNA for hemagglutinin HA1,	linear mRNA	GI: 995552
escape variant 4
Influenza A virus	1,220 bp	AF116575.1
(A/Brevig_Mission/1/18(H1N1)) hemagglutinin	linear mRNA	GI: 4325017
(HA) mRNA, partial cds
Influenza A virus	1,410 bp	AF250356.2
(A/Brevig_Mission/1/18(H1N1)) neuraminidase	linear mRNA	GI: 13260556
(NA) gene, complete cds
Influenza A virus (A/Brevig	1,497 bp	AY744935.1
Mission/1/1918(H1N1)) nucleoprotein (np)	linear mRNA	GI: 55273940
mRNA, complete cds
Influenza A virus (A/Brevig	2,280 bp	DQ208309.1
Mission/1/1918(H1N1)) polymerase PB2 (PB2)	linear mRNA	GI: 76786704
mRNA, complete cds
Influenza A virus (A/Brevig	2,274 bp	DQ208310.1
Mission/1/1918(H1N1)) polymerase PB1 (PB1)	linear mRNA	GI: 76786706
mRNA, complete cds
Influenza A virus (A/Brevig	2,151 bp	DQ208311.1
Mission/1/1918(H1N1)) polymerase PA (PA)	linear mRNA	GI: 76786708
mRNA, complete cds
Influenza A virus	366 bp	M73975.1
(A/camel/Mongolia/1982(H1N1)) hemagglutinin	linear mRNA	GI: 324242
mRNA, partial cds
Influenza A virus	460 bp	M73978.1
(A/camel/Mongolia/1982(H1N1)) matrix protein	linear mRNA	GI: 324402
mRNA, partial cds
Influenza A virus	310 bp	M73976.1
(A/camel/Mongolia/1982(H1N1)) neuraminidase	linear mRNA	GI: 324579
(NA) mRNA, partial cds
Influenza A Virus A/camel/Mongolia/82 NS1	273 bp	M73977.1
protein mRNA, partial cds	linear mRNA	GI: 324768
Influenza A virus	227 bp	M73974.1
(A/camel/Mongolia/1982(H1N1)) PA polymerase	linear mRNA	GI: 324931
mRNA, partial cds
Influenza A virus	531 bp	M73973.1
(A/camel/Mongolia/1982(H1N1)) PB1 protein	linear mRNA	GI: 324971
mRNA, partial cds
Influenza A Virus (A/camel/Mongolia/82(H1N1))	379 bp	M73972.1
polymerase 2 (P2) mRNA, partial cds	linear mRNA	GI: 324993
Influenza A virus (A/chicken/Hong	1,169 bp	U46782.1
Kong/14/1976(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912328
(HA) mRNA, partial cds
Influenza A virus (A/Chonnam/07/2002(H1N1))	1,452 bp	AY297141.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871990
Influenza A virus (A/Chonnam/07/2002(H1N1))	1,137 bp	AY297154.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140347
Influenza A virus (A/Chonnam/18/2002(H1N1))	1,458 bp	AY297143.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871994
Influenza A virus (A/Chonnam/18/2002(H1N1))	1,176 bp	AY297156.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140355
Influenza A virus (A/Chonnam/19/2002(H1N1))	1,458 bp	AY310410.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872389
Influenza A virus (A/Chonnam/19/2002(H1N1))	1,167 bp	AY299502.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140392
Influenza A virus (A/Chonnam/51/2002(H1N1))	1,443 bp	AY310412.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31873090
Influenza A virus (A/Chonnam/51/2002(H1N1))	1,161 bp	AY299498.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140384
Influenza A virus (A/Chungbuk/50/2002(H1N1))	1,425 bp	AY297150.1
neuraminidase (NA) mRNA, partial cds	linear mRNA	GI: 31872010
Influenza A virus (A/Chungbuk/50/2002(H1N1))	1,161 bp	AY299506.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140400
Influenza A virus (A/Denmark/40/2000(H1N1))	1,458 bp	AJ518095.1
NA gene for neuraminidase, genomic RNA	linear mRNA	GI: 31096400
Influenza A virus (A/Denver/1/57(H1N1))	379 bp	AF305216.1
neuraminidase mRNA, partial cds	linear mRNA	GI: 10732818
Influenza A virus (A/Denver/1/57(H1N1))	442 bp	AF305217.1
matrix protein gene, partial cds	linear mRNA	GI: 10732820
Influenza A virus (A/Denver/1/57(H1N1))	215 bp	AF305218.1
hemagglutinin gene, partial cds	linear mRNA	GI: 10732822
Influenza A virus	981 bp	U47309.1
(A/duck/Australia/749/80(H1N1)) hemagglutinin	linear mRNA	GI: 1912348
precursor (HA) mRNA, partial cds
Influenza A virus	1,777 bp	AF091312.1
(A/duck/Australia/749/80(H1N1)) segment 4	linear mRNA	GI: 4585166
hemagglutinin precursor (HA) mRNA,
complete cds
Influenza A virus (A/duck/Bavaria/1/77	1,777 bp	AF091313.1
(H1N1)) segment 4 hemagglutinin precursor	linear mRNA	GI: 4585168
(HA) mRNA, complete cds
Influenza A virus (A/duck/Bavaria/2/77(H1N1))	981 bp	U47308.1
hemagglutinin precursor (HA) mRNA, partial	linear mRNA	GI: 1912346
cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429749.1
China/103/2003(H1N1)) segment 6 neuraminidase	linear mRNA	GI: 167859463
(NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,461 bp	EU429751.1
China/152/2003(H1N1)) segment 6 neuraminidase	linear mRNA	GI: 167859467
(NA) mRNA, complete cds
Influenza A virus (A/Duck/Ohio/1180/93	1,410 bp	AF250361.2
(H1N1)) neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260576
Influenza A virus (A/Duck/Ohio/175/86(H1N1))	1,410 bp	AF250358.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260565
Influenza A virus (A/Duck/Ohio/194/86(H1N1))	1,410 bp	AF250360.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260573
Influenza A virus (A/Duck/Ohio/30/86(H1N1))	1,410 bp	AF250359.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260570
Influenza A virus strain	1,460 bp	AJ006954.1
A/Fiji/15899/83(H1N1) mRNA for neuraminidase	linear mRNA	GI: 4210707
Influenza A Virus (A/Fiji/15899/83(H1N1))	2,341 bp	AJ564805.1
mRNA for PB2 protein	linear mRNA	GI: 31442134
Influenza A Virus (A/Fiji/15899/83(H1N1))	2,113 bp	AJ564807.1
partial mRNA for PB1 protein	linear mRNA	GI: 31442138
Influenza A virus (A/FM/1/47(H1N1))	1,395 bp	AF250357.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260561
Influenza A virus (A/goose/Hong	1,091 bp	U46021.1
Kong/8/1976(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912326
(HA) mRNA, partial cds
Influenza A virus (A/goose/Hong	261 bp	U48284.1
Kong/8/1976(H1N1)) polymerase (PB1)	linear mRNA	GI: 1912372
mRNA, partial cds
Influenza A virus (A/goose/Hong	1,395 bp	U49093.1
Kong/8/1976(H1N1)) nucleoprotein (NP)	linear mRNA	GI: 1912384
mRNA, partial cds
Influenza A virus	1,775 bp	EU382986.1
(A/Guangzhou/1561/2006(H1N1)) segment 4	linear mRNA	GI: 170762603
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382993.1
(A/Guangzhou/1561/2006(H1N1)) segment 6	linear mRNA	GI: 170762617
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382987.1
(A/Guangzhou/1684/2006(H1N1)) segment 4	linear mRNA	GI: 170762605
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382994.1
(A/Guangzhou/1684/2006(H1N1)) segment 6	linear mRNA	GI: 170762619
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382981.1
(A/Guangzhou/483/2006(H1N1)) segment 4	linear mRNA	GI: 170762593
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382988.1
(A/Guangzhou/483/2006(H1N1)) segment 6	linear mRNA	GI: 170762607
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382982.1
(A/Guangzhou/506/2006(H1N1)) segment 4	linear mRNA	GI: 170762595
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,461 bp	EU382989.1
(A/Guangzhou/506/2006(H1N1)) segment 6	linear mRNA	GI: 170762609
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382983.1
(A/Guangzhou/555/2006(H1N1)) segment 4	linear mRNA	GI: 170762597
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382990.1
(A/Guangzhou/555/2006(H1N1)) segment 6	linear mRNA	GI: 170762611
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382984.1
(A/Guangzhou/657/2006(H1N1)) segment 4	linear mRNA	GI: 170762599
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382991.1
(A/Guangzhou/657/2006(H1N1)) segment 6	linear mRNA	GI: 170762613
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,775 bp	EU382985.1
(A/Guangzhou/665/2006(H1N1)) segment 4	linear mRNA	GI: 170762601
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,462 bp	EU382992.1
(A/Guangzhou/665/2006(H1N1)) segment 6	linear mRNA	GI: 170762615
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/Gwangju/55/2002(H1N1))	1,431 bp	AY297151.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872012
Influenza A virus (A/Gwangju/55/2002(H1N1))	1,179 bp	AY299507.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140402
Influenza A virus (A/Gwangju/57/2002(H1N1))	1,446 bp	AY297152.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872014
Influenza A virus (A/Gwangju/57/2002(H1N1))	1,167 bp	AY299508.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140404
Influenza A virus (A/Gwangju/58/2002(H1N1))	1,434 bp	AY297153.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872016
Influenza A virus (A/Gwangju/58/2002(H1N1))	1,176 bp	AY299509.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140406
Influenza A virus (A/Gwangju/90/2002(H1N1))	1,446 bp	AY297147.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872002
Influenza A virus (A/Gwangju/90/2002(H1N1))	1,164 bp	AY299499.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140386
Influenza A virus (A/Hong	1,403 bp	AJ518101.1
Kong/437/2002(H1N1)) partial NA gene for	linear mRNA	GI: 31096412
neuraminidase, genomic RNA
Influenza A virus (A/Hong	1,352 bp	AJ518102.1
Kong/747/2001(H1N1)) partial NA gene for	linear mRNA	GI: 31096414
neuraminidase, genomic RNA
Influenza A virus (A/London/1/1918(H1N1))	563 bp	AY184805.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32395285
Influenza A virus (A/London/1/1919(H1N1))	563 bp	AY184806.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32395287
Influenza A virus (A/Loygang/4/1957(H1N1))	1,565 bp	M76604.1
nucleoprotein mRNA, complete cds	linear mRNA	GI: 324255
Influenza A virus (A/Lyon/651/2001(H1N1))	1,318 bp	AJ518103.1
partial NA gene for neuraminidase, genomic	linear mRNA	GI: 31096416
RNA
Influenza A virus (A/mallard/Alberta/119/98	947 bp	AY664487.1
(H1N1)) nonfunctional matrix protein mRNA,	linear mRNA	GI: 51011891
partial sequence
Influenza A virus	981 bp	U47310.1
(A/duck/Alberta/35/76(H1N1)) hemagglutinin	linear mRNA	GI: 1912350
precursor (HA) mRNA, partial cds
Influenza A virus	1,777 bp	AF091309.1
(A/duck/Alberta/35/76(H1N1)) segment 4	linear mRNA	GI: 4585160
hemagglutinin precursor (HA) mRNA,
complete cds
Influenza A virus	1,410 bp	AF250362.2
(A/duck/Alberta/35/76(H1N1)) neuraminidase	linear mRNA	GI: 13260579
(NA) gene, complete cds
Influenza A virus	981 bp	U47307.1
(A/mallard/Tennessee/11464/85(H1N1))	linear mRNA	GI: 1912344
hemagglutinin precursor (HA) mRNA,
partial cds
Influenza A virus	1,777 bp	AF091311.1
(A/mallard/Tennessee/11464/85(H1N1))	linear mRNA	GI: 4585164
segment 4 hemagglutinin precursor (HA)
mRNA, complete cds
Influenza A virus (A/New	294 bp	HQ008884.1
Caledonia/20/1999(H1N1)) segment 7 matrix	linear mRNA	GI: 302566794
protein 2 (M2) mRNA, complete cds
Influenza A virus (A/New Jersey/4/1976(H1N1))	1,565 bp	M76605.1
nucleoprotein mRNA, complete cds	linear mRNA	GI: 324581
Influenza A virus (A/New Jersey/8/1976(H1N1))	1,565 bp	M76606.1
nucleoprotein mRNA, complete cds	linear mRNA	GI: 324583
Influenza A virus (A/New_York/1/18(H1N1))	1,220 bp	AF116576.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 4325019
Influenza A virus (A/Ohio/3523/1988(H1N1))	1,565 bp	M76602.1
nucleoprotein mRNA, complete cds	linear mRNA	GI: 324889
Influenza A virus (A/Pusan/22/2002(H1N1))	1,455 bp	AY310411.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872391
Influenza A virus (A/Pusan/22/2002(H1N1))	1,149 bp	AY299503.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140394
Influenza A virus (A/Pusan/23/2002(H1N1))	1,440 bp	AY297144.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871996
Influenza A virus (A/Pusan/23/2002(H1N1))	1,158 bp	AY297157.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140357
Influenza A virus (A/Pusan/24/2002(H1N1))	1,449 bp	AY297145.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871998
Influenza A virus (A/Pusan/24/2002(H1N1))	1,128 bp	AY299494.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140376
Influenza A virus (A/Pusan/44/2002(H1N1))	1,431 bp	AY297148.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872004
Influenza A virus (A/Pusan/44/2002(H1N1))	1,167 bp	AY299504.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140396
Influenza A virus (A/Pusan/45/2002(H1N1))	1,434 bp	AY297146.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872000
Influenza A virus (A/Pusan/45/2002(H1N1))	1,167 bp	AY299496.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140380
Influenza A virus (A/Pusan/46/2002(H1N1))	1,422 bp	AY310408.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872385
Influenza A virus (A/Pusan/46/2002(H1N1))	1,176 bp	AY299497.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140382
Influenza A virus (A/Pusan/47/2002(H1N1))	1,437 bp	AY297149.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872008
Influenza A virus (A/Pusan/47/2002(H1N1))	1,170 bp	AY299505.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140398
Influenza A virus (A/Saudi	789 bp	AJ519463.1
Arabia/7971/2000(H1N1)) partial NS1 gene for	linear mRNA	GI: 31096450
non structural protein 1 and partial NS2 gene
for non structural protein 2, genomic RNA
Influenza A virus (A/Seoul/11/2002(H1N1))	1,452 bp	AY297142.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871992
Influenza A virus (A/Seoul/11/2002(H1N1))	1,176 bp	AY297155.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140349
Influenza A virus (A/Seoul/13/2002(H1N1))	1,452 bp	AY310409.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872387
Influenza A virus (A/Seoul/13/2002(H1N1))	1,167 bp	AY299500.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140388
Influenza A virus (A/Seoul/15/2002(H1N1))	1,449 bp	AY297140.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31871988
Influenza A virus (A/Seoul/15/2002(H1N1))	1,149 bp	AY299501.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140390
Influenza A virus (A/Seoul/33/2002(H1N1))	1,437 bp	AY310407.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 31872383
Influenza A virus (A/Seoul/33/2002(H1N1))	1,167 bp	AY299495.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32140378
Influenza A virus	1,050 bp	Z46437.1
(A/swine/Arnsberg/6554/1979(H1N1))	linear mRNA	GI: 565609
mRNA for hemagglutinin HA1
Influenza A virus	1,595 bp	U46783.1
(A/swine/Beijing/47/1991(H1N1)) hemagglutinin	linear mRNA	GI: 1912330
precursor (HA) mRNA, partial cds
Influenza A virus	1,565 bp	U49091.1
(A/swine/Beijing/94/1991(H1N1)) nucleoprotein	linear mRNA	GI: 1912380
(NP) mRNA, complete cds
Influenza A virus	1,778 bp	AF091316.1
(A/swine/Belgium/1/83(H1N1)) segment 4	linear mRNA	GI: 4585174
hemagglutinin precursor (HA) mRNA,
complete cds
Influenza A virus (A/swine/Cotes	1,116 bp	AM490219.1
d'Armor/0118/2006(H1N1)) partial mRNA for	linear mRNA	GI: 222062898
haemagglutinin precursor (HA1 gene)
Influenza A virus (A/swine/Cotes	1,043 bp	AM490223.1
d'Armor/0136_18/2006(H1N1)) partial mRNA for	linear mRNA	GI: 222062906
haemagglutinin precursor (HA1 gene)
Influenza A virus (A/swine/Cotes	1,089 bp	AM490220.1
d'Armor/0184/2006(H1N1)) partial mRNA for	linear mRNA	GI: 222062900
haemagglutinin precursor (HA1 gene)
Influenza A virus (A/swine/Cotes	1,068 bp	AM490221.1
d'Armor/0227/2005(H1N1)) partial mRNA for	linear mRNA	GI: 222062902
haemagglutinin precursor (HA1 gene)
Influenza A virus (A/swine/Cotes	1,024 bp	AM490222.1
d'Armor/0250/2006(H1N1)) partial mRNA for	linear mRNA	GI: 222062904
haemagglutinin precursor (HA1 gene)
Influenza A virus (A/swine/Cotes	1,011 bp	AJ517820.1
d'Armor/736/2001(H1N1)) partial HA gene for	linear mRNA	GI: 38422533
Haemagglutinin, genomic RNA
Influenza A virus (A/Swine/England/195852/92	1,410 bp	AF250366.2
(H1N1)) neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260593
Influenza A virus PB2 gene for Polymerase 2	2,268 bp	AJ311457.1
protein, genomic RNA, strain	linear mRNA	GI: 13661037
A/Swine/Finistere/2899/82
Influenza A virus PB1 gene for Polymerase 1	2,341 bp	AJ311462.1
protein, genomic RNA, strain	linear mRNA	GI: 13661047
A/Swine/Finistere/2899/82
Influenza A virus PA gene for Polymerase A	2,233 bp	AJ311463.1
protein, genomic RNA, strain	linear mRNA	GI: 13661049
A/Swine/Finistere/2899/82
Influenza A virus	1,002 bp	AJ316059.1
(A/swine/Finistere/2899/82(H1N1) M1 gene for	linear mRNA	GI: 20068128
matrix protein 1 and M2 gene for matrix
protein 2, genomic RNA
Influenza A virus	864 bp	AJ344037.1
(A/swine/Finistere/2899/82(H1N1)) NS1 gene	linear mRNA	GI: 20068185
for non structural protein 1 and NS2 gene for
non structural protein 2, genomic RNA
Influenza A virus	838 bp	X75786.1
(A/swine/Germany/2/1981(H1N1)) mRNA for	linear mRNA	GI: 438106
PA polymerase
Influenza A virus	305 bp	Z30277.1
(A/swine/Germany/2/1981(H1N1)) mRNA for	linear mRNA	GI: 530399
neuraminidase (partial)
Influenza A virus	1,730 bp	Z30276.1
(A/swine/Germany/2/1981(H1N1)) mRNA for	linear mRNA	GI: 563490
hemagglutinin
165. Influenza A virus	1,730 bp	Z46434.1
(A/swine/Germany/8533/1991(H1N1)) mRNA for	linear mRNA	GI: 565611
hemagglutinin precursor
Influenza A virus	1,690 bp	AY852271.1
(A/swine/Guangdong/711/2001(H1N1))	linear mRNA	GI: 60327789
nonfunctional hemagglutinin (HA) mRNA,
partial sequence
Influenza A virus	1,809 bp	EU163946.1
(A/swine/Haseluenne/IDT2617/03(H1N1))	linear mRNA	GI: 157679548
hemagglutinin mRNA, complete cds
Influenza A virus (A/swine/Hokkaido/2/81	981 bp	U47306.1
(H1N1)) hemagglutinin precursor (HA) mRNA,	linear mRNA	GI: 1912342
partial cds
Influenza A virus (A/swine/Hokkaido/2/81	1,778 bp	AF091306.1
(H1N1)) segment 4 hemagglutinin precursor	linear mRNA	GI: 4585154
(HA) mRNA, complete cds
Influenza A virus (A/swine/Hong	1,113 bp	U44482.1
Kong/168/1993(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912318
(HA) mRNA, partial cds
Influenza A virus (A/swine/Hong	416 bp	U47817.1
Kong/168/1993(H1N1)) neuraminidase (NA)	linear mRNA	GI: 1912354
mRNA, partial cds
Influenza A virus (A/swine/Hong	286 bp	U48286.1
Kong/168/1993(H1N1)) polymerase (PB2)	linear mRNA	GI: 1912358
mRNA, partial cds
Influenza A virus (A/swine/Hong	379 bp	U48283.1
Kong/168/1993(H1N1)) polymerase (PB1)	linear mRNA	GI: 1912370
mRNA, partial cds
Influenza A virus (A/swine/Hong	308 bp	U48850.1
Kong/168/1993(H1N1)) polymerase (PA)	linear mRNA	GI: 1912376
mRNA, partial cds
Influenza A virus (A/swine/Hong	1,397 bp	U49096.1
Kong/168/1993(H1N1)) nucleoprotein (NP)	linear mRNA	GI: 1912390
mRNA, partial cds
Influenza A virus (A/swine/Hong	1,315 bp	U46020.1
Kong/172/1993(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912324
(HA) mRNA, partial cds
Influenza A virus (A/swine/Hong	1,113 bp	U45451.1
Kong/176/1993(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912320
(HA) mRNA, partial cds
Influenza A virus (A/swine/Hong	1,330 bp	U45452.1
Kong/273/1994(H1N1)) hemagglutinin precursor	linear mRNA	GI: 1912322
(HA) mRNA, partial cds
Influenza A virus (A/swine/Hong	241 bp	U47818.1
Kong/273/1994(H1N1)) neuraminidase (NA)	linear mRNA	GI: 1912356
mRNA, partial cds
Influenza A virus (A/swine/Hong	328 bp	U48287.1
Kong/273/1994(H1N1)) polymerase (PB2)	linear mRNA	GI: 1912360
mRNA, partial cds
Influenza A virus (A/swine/Hong	240 bp	U48282.1
Kong/273/1994(H1N1)) polymerase (PB1)	linear mRNA	GI: 1912368
mRNA, partial cds
Influenza A virus (A/swine/Hong	336 bp	U48851.1
Kong/273/1994(H1N1)) polymerase (PA)	linear mRNA	GI: 1912378
mRNA, partial cds
Influenza A virus (A/swine/Hong	1,422 bp	U49092.1
Kong/273/1994(H1N1)) nucleoprotein (NP) mRNA,	linear mRNA	GI: 1912382
partial cds
Influenza A virus	1,761 bp	EU163947.1
(A/swine/IDT/Re230/92hp(H1N1)) hemagglutinin	linear mRNA	GI: 157679550
mRNA, complete cds
Influenza A virus	1,550 bp	L46849.1
(A/swine/IN/1726/1988(H1N1)) nucleoprotein	linear mRNA	GI: 954755
(segment 5) mRNA, complete cds
Influenza A virus (A/swine/Iowa/15/30(H1N1))	981 bp	U47305.1
hemagglutinin precursor (HA) mRNA, partial	linear mRNA	GI: 1912340
cds
Influenza A virus (A/swine/Iowa/15/30(H1N1))	1,778 bp	AF091308.1
segment 4 hemagglutinin precursor (HA) mRNA,	linear mRNA	GI: 4585158
complete cds
Influenza A virus (A/Swine/Iowa/30(H1N1))	1,410 bp	AF250364.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260586
Influenza A virus (A/swine/Iowa/17672/	981 bp	U47304.1
88(H1N1)) hemagglutinin precursor (HA)	linear mRNA	GI: 1912338
mRNA, partial cds
Influenza A virus	864 bp	AJ519462.1
(A/swine/Italy/3364/00(H1N1)) partial NS1	linear mRNA	GI: 31096447
gene for non structural protein 1 and partial
NS2 gene for non structural protein 2,
genomic RNA
Influenza A virus (A/swine/Italy-	1,777 bp	AF091315.1
Virus/671/87(H1N1)) segment 4 hemagglutinin	linear mRNA	GI: 4585172
precursor (HA) mRNA, complete cds
Influenza A Virus	1,028 bp	Z46436.1
(A/swine/Italy/v.147/1981(H1N1)) mRNA for	linear mRNA	GI: 854214
hemagglutinin HA1
Influenza A virus	1,118 bp	AM490218.1
(A/swine/Morbihan/0070/2005(H1N1)) partial	linear mRNA	GI: 222062896
mRNA for haemagglutinin precursor (HA1 gene)
Influenza A virus	1,770 bp	L09063.1
(A/swine/Nebraska/1/92(H1N1)) HA protein	linear mRNA	GI: 290722
mRNA, complete cds
Influenza A virus	1,550 bp	L11164.1
(A/swine/Nebraska/1/1992(H1N1)) segment 5	linear mRNA	GI: 290724
nucleoprotein (NP) mRNA, complete cds
Influenza A virus	981 bp	U46943.1
(A/swine/Netherlands/12/1985(H1N1))	linear mRNA	GI: 1912336
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	1,776 bp	AF091317.1
(A/swine/Netherlands/12/85(H1N1)) segment 4	linear mRNA	GI: 4585176
hemagglutinin precursor (HA) mRNA, complete
cds
Influenza A virus	539 bp	X75791.1
(A/swine/Netherlands/25/1980(H1N1)) mRNA	linear mRNA	GI: 438105
for nucleoprotein
Influenza A virus	981 bp	U46942.1
(A/swine/Netherlands/3/1980(H1N1))	linear mRNA	GI: 1912334
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	1,778 bp	AF091314.1
(A/swine/Netherlands/3/80(H1N1)) segment 4	linear mRNA	GI: 4585170
hemagglutinin precursor (HA) mRNA, complete
cds
Influenza A virus (A/NJ/11/76(H1N1))	1,410 bp	AF250363.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260583
Influenza A virus (A/Swine/Quebec/192/81	1,438 bp	U86144.1
(SwQc81)) neuraminidase mRNA, complete cds	linear mRNA	GI: 4099318
Influenza A virus (A/Swine/Quebec/5393/91	1,438 bp	U86145.1
(SwQc91)) neuraminidase mRNA, complete cds	linear mRNA	GI: 4099320
Influenza A virus (A/swine/Schleswig-	1,730 bp	Z46435.1
Holstein/1/1992(H1N1)) mRNA for	linear mRNA	GI: 854216
hemagglutinin precursor
Influenza A Virus (A/swine/Schleswig-	1,554 bp	Z46438.1
Holstein/1/1993(H1N1)) mRNA for nucleoprotein	linear mRNA	GI: 854222
Influenza A virus	1,778 bp	AF091307.1
(A/swine/Wisconsin/1/61(H1N1)) segment 4	linear mRNA	GI: 4585156
hemagglutinin precursor (HA) mRNA, complete
cds
212. Influenza A virus	1,565 bp	M76607.1
(A/swine/Wisconsin/1/1967(H1N1))	linear mRNA	GI: 325086
nucleoprotein mRNA, complete cds
Influenza A virus	1,565 bp	M76608.1
(A/swine/Wisconsin/1915/1988(H1N1))	linear mRNA	GI: 325088
nucleoprotein mRNA, complete cds
Influenza A virus	1,550 bp	L46850.1
(A/swine/WI/1915/1988(H1N1)) nucleoprotein	linear mRNA	GI: 954757
(segment 5) mRNA, complete cds
Influenza A virus	729 bp	AJ532568.1
(A/Switzerland/8808/2002(H1N1)) partial m1	linear mRNA	GI: 31096461
gene for matrix protein 1 and partial m2 gene
for matrix protein 2, genomic RNA
Influenza A virus	561 bp	AF362803.1
(A/human/Taiwan/0012/00(H1N1))	linear mRNA	GI: 14571975
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	561 bp	AF362779.1
(A/human/Taiwan/0016/00(H1N1))	linear mRNA	GI: 14571927
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0016/2000(H1N1))	303 bp	AY303752.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330993
partial cds
Influenza A virus	561 bp	AF362780.1
(A/human/Taiwan/0030/00(H1N1))	linear mRNA	GI: 14571929
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0030/2000(H1N1))	303 bp	AY303704.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330897
partial cds
Influenza A virus (A/Taiwan/0032/2002(H1N1))	494 bp	AY604804.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727488
Influenza A virus (A/Taiwan/0061/2002(H1N1))	494 bp	AY604795.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727470
Influenza A virus (A/Taiwan/0069/2002(H1N1))	494 bp	AY604803.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727486
Influenza A virus (A/Taiwan/0078/2002(H1N1))	494 bp	AY604805.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727490
Influenza A virus (A/Taiwan/0094/2002(H1N1))	494 bp	AY604797.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727474
Influenza A virus (A/Taiwan/0116/2002(H1N1))	494 bp	AY604796.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727472
Influenza A virus	564 bp	AF362781.1
(A/human/Taiwan/0130/96(H1N1))	linear mRNA	GI: 14571931
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0130/96(H1N1))	303 bp	AY303707.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330903
partial cds
Influenza A virus	564 bp	AF362782.1
(A/human/Taiwan/0132/96(H1N1))	linear mRNA	GI: 14571933
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0132/96(H1N1))	303 bp	AY303708.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330905
partial cds
Influenza A virus	564 bp	AF362783.1
(A/human/Taiwan/0211/96(H1N1))	linear mRNA	GI: 14571935
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0211/96(H1N1))	303 bp	AY303709.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330907
partial cds
Influenza A virus	564 bp	AF362784.1
(A/human/Taiwan/0235/96(H1N1))	linear mRNA	GI: 14571937
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0235/96(H1N1))	303 bp	AY303710.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330909
partial cds
Influenza A virus	564 bp	AF362785.1
(A/human/Taiwan/0255/96(H1N1))	linear mRNA	GI: 14571939
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0255/96(H1N1))	303 bp	AY303711.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330911
partial cds
Influenza A virus	564 bp	AF362786.1
(A/human/Taiwan/0337/96(H1N1))	linear mRNA	GI: 14571941
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	564 bp	AF362787.1
(A/human/Taiwan/0342/96(H1N1))	linear mRNA	GI: 14571943
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0342/96(H1N1))	303 bp	AY303714.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330917
partial cds
Influenza A virus	561 bp	AF362788.1
(A/human/Taiwan/0464/99(H1N1))	linear mRNA	GI: 14571945
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	564 bp	AF362789.1
(A/human/Taiwan/0562/95(H1N1))	linear mRNA	GI: 14571947
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0562/95(H1N1))	303 bp	AY303720.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330929
partial cds
Influenza A virus	564 bp	AF362790.1
(A/human/Taiwan/0563/95(H1N1))	linear mRNA	GI: 14571949
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0563/95(H1N1))	303 bp	AY303721.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330931
partial cds
Influenza A virus	564 bp	AF362791.1
(A/human/Taiwan/0657/95(H1N1))	linear mRNA	GI: 14571951
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0657/95(H1N1))	303 bp	AY303724.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330937
partial cds
Influenza A virus (A/Taiwan/0859/2002(H1N1))	494 bp	AY604801.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727482
Influenza A virus	561 bp	AF362792.1
(A/human/Taiwan/0892/99(H1N1))	linear mRNA	GI: 14571953
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/0983/2002(H1N1))	494 bp	AY604800.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727480
Influenza A virus (A/Taiwan/1007/2006(H1N1))	507 bp	EU068163.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	0GI: 158452199
Influenza A virus (A/Taiwan/1015/2006(H1N1))	507 bp	EU068171.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452215
Influenza A virus (A/Taiwan/112/1996-1(H1N1))	1,176 bp	AF026153.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554950
Influenza A virus (A/Taiwan/112/1996-2(H1N1))	1,176 bp	AF026154.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554952
Influenza A virus (A/Taiwan/117/1996-1(H1N1))	1,176 bp	AF026155.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554954
Influenza A virus (A/Taiwan/117/1996-2(H1N1))	1,176 bp	AF026156.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554956
Influenza A virus (A/Taiwan/117/1996-3(H1N1))	1,176 bp	AF026157.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554958
Influenza A virus (A/Taiwan/118/1996-1(H1N1))	1,176 bp	AF026158.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554960
Influenza A virus (A/Taiwan/118/1996-2(H1N1))	1,176 bp	AF026159.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554962
Influenza A virus (A/Taiwan/118/1996-3(H1N1))	1,176 bp	AF026160.1
haemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 2554964
Influenza A virus	561 bp	AF362793.1
(A/human/Taiwan/1184/99(H1N1))	linear mRNA	GI: 14571955
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/1184/99(H1N1))	303 bp	AY303726.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330941
partial cds
Influenza A virus	564 bp	AF362794.1
(A/human/Taiwan/1190/95(H1N1))	linear mRNA	GI: 14571957
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/1190/95(H1N1))	303 bp	AY303727.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330943
partial cds
Influenza A virus (A/Taiwan/1523/2003(H1N1))	494 bp	AY604808.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727496
Influenza A virus (A/Taiwan/1566/2003(H1N1))	494 bp	AY604806.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727492
Influenza A virus (A/Taiwan/1769/96(H1N1))	875 bp	AF138710.2
matrix protein M1 (M) mRNA, partial cds	linear mRNA	GI: 4996871
Influenza A virus (A/Taiwan/1906/2002(H1N1))	494 bp	AY604799.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727478
Influenza A virus (A/Taiwan/1922/2002(H1N1))	494 bp	AY604802.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727484
Influenza A virus (A/Taiwan/2069/2006(H1N1))	507 bp	EU068168.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452209
Influenza A virus (A/Taiwan/2157/2001(H1N1))	303 bp	AY303733.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330955
partial cds
Influenza A virus (A/Taiwan/2175/2001(H1N1))	561 bp	AY303734.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32330957
Influenza A virus	564 bp	AF362795.1
(A/human/Taiwan/2200/95(H1N1))	linear mRNA	GI: 14571959
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/2200/95(H1N1))	303 bp	AY303737.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330963
partial cds
Influenza A virus (A/Taiwan/2966/2006(H1N1))	507 bp	EU068170.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452213
Influenza A virus (A/Taiwan/3168/2005(H1N1))	507 bp	EU068174.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452221
Influenza A virus	561 bp	AF362796.1
(A/human/Taiwan/3355/97(H1N1))	linear mRNA	GI: 14571961
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/3355/97(H1N1))	303 bp	AY303739.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330967
partial cds
Influenza A virus (A/Taiwan/3361/2001(H1N1))	303 bp	AY303740.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330969
partial cds
Influenza A virus (A/Taiwan/3361/2001(H1N1))	561 bp	AY303741.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32330971
Influenza A virus (A/Taiwan/3518/2006(H1N1))	507 bp	EU068169.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452211
Influenza A virus	581 bp	AF362797.1
(A/human/Taiwan/3825/00(H1N1))	linear mRNA	GI: 14571963
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/3896/2001(H1N1))	303 bp	AY303746.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330981
partial cds
Influenza A virus (A/Taiwan/3896/2001(H1N1))	561 bp	AY303747.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 32330983
Influenza A virus (A/Taiwan/4050/2003(H1N1))	494 bp	AY604807.1
hemagglutinin mRNA, partial cds	linear mRNA	GI: 50727494
Influenza A virus (A/Taiwan/4054/2006(H1N1))	507 bp	EU068160.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452193
Influenza A virus	561 bp	AF362798.1
(A/human/Taiwan/4360/99(H1N1))	linear mRNA	GI: 14571965
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/4360/99(H1N1))	303 bp	AY303748.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330985
partial cds
Influenza A virus	561 bp	AF362799.1
(A/human/Taiwan/4415/99(H1N1))	linear mRNA	GI: 14571967
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/4415/99(H1N1))	303 bp	AY303749.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330987
partial cds
Influenza A virus (A/Taiwan/4509/2006(H1N1))	507 bp	EU068165.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452203
Influenza A virus	561 bp	AF362800.1
(A/human/Taiwan/4845/99(H1N1))	linear mRNA	GI: 14571969
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/4845/99(H1N1))	303 bp	AY303750.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330989
partial cds
Influenza A virus	561 bp	AF362801.1
(A/human/Taiwan/4943/99(H1N1))	linear mRNA	GI: 14571971
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/5010/2006(H1N1))	507 bp	EU068167.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452207
Influenza A virus	561 bp	AF362802.1
(A/human/Taiwan/5063/99(H1N1))	linear mRNA	GI: 14571973
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/5063/99(H1N1))	303 bp	AY303751.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330991
partial cds
Influenza A virus (A/Taiwan/5084/2006(H1N1))	507 bp	EU068166.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452205
Influenza A virus (A/Taiwan/511/96(H1N1))	875 bp	AF138708.2
matrix protein M1 (M) mRNA, partial cds	linear mRNA	GI: 4996867
Influenza A virus (A/Taiwan/557/2006(H1N1))	507 bp	EU068156.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452185
Influenza A virus (A/Taiwan/562/2006(H1N1))	507 bp	EU068159.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452191
Influenza A virus	561 bp	AF362778.1
(A/human/Taiwan/5779/98(H1N1))	linear mRNA	GI: 14571925
hemagglutinin (HA) mRNA, partial cds
Influenza A virus (A/Taiwan/5779/98(H1N1))	303 bp	AY303702.1
polymerase basic protein 1 (PB1) mRNA,	linear mRNA	GI: 32330893
partial cds
Influenza A virus (A/Taiwan/6025/2005(H1N1))	507 bp	EU068172.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452217
Influenza A virus (A/Taiwan/607/2006(H1N1))	507 bp	EU068157.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452187
Influenza A virus (A/Taiwan/615/2006(H1N1))	507 bp	EU068162.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452197
Influenza A virus (A/Taiwan/645/2006(H1N1))	507 bp	EU068164.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452201
Influenza A virus (A/Taiwan/680/2005(H1N1))	507 bp	EU068173.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452219
Influenza A virus (A/Taiwan/719/2006(H1N1))	507 bp	EU068158.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 158452189
Influenza A virus	1,410 bp	EU021285.1
(A/Thailand/CU124/2006(H3N2))	linear mRNA	GI: 154224724
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021265.1
(A/Thailand/CU32/2006(H1N1))	linear mRNA	GI: 154224704
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021264.1
(A/Thailand/CU32/2006(H1N1))	linear mRNA	GI: 154224775
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021247.1
(A/Thailand/CU41/2006(H1N1))	linear mRNA	GI: 154224686
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021246.1
(A/Thailand/CU41/2006(H1N1))	linear mRNA	GI: 154224757
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021259.1
(A/Thailand/CU44/2006(H1N1))	linear mRNA	GI: 154224698
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021258.1
(A/Thailand/CU44/2006(H1N1))	linear mRNA	GI: 154224769
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021255.1
(A/Thailand/CU51/2006(H1N1))	linear mRNA	GI: 154224694
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021254.1
(A/Thailand/CU51/2006(H1N1))	linear mRNA	GI: 154224765
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021249.1
(A/Thailand/CU53/2006(H1N1))	linear mRNA	GI: 154224688
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021248.1
(A/Thailand/CU53/2006(H1N1))	linear mRNA	GI: 154224759
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021257.1
(A/Thailand/CU57/2006(H1N1))	linear mRNA	GI: 154224696
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021256.1
(A/Thailand/CU57/2006(H1N1))	linear mRNA	GI: 154224767
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021251.1
(A/Thailand/CU67/2006(H1N1))	linear mRNA	GI: 154224690
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021250.1
(A/Thailand/CU67/2006(H1N1))	linear mRNA	GI: 154224761
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021261.1
(A/Thailand/CU68/2006(H1N1))	linear mRNA	GI: 154224700
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021260.1
(A/Thailand/CU68/2006(H1N1))	linear mRNA	GI: 154224771
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021263.1
(A/Thailand/CU75/2006(H1N1))	linear mRNA	GI: 154224702
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021262.1
(A/Thailand/CU75/2006(H1N1))	linear mRNA	GI: 154224773
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,413 bp	EU021253.1
(A/Thailand/CU88/2006(H1N1))	linear mRNA	GI: 154224692
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,698 bp	EU021252.1
(A/Thailand/CU88/2006(H1N1))	linear mRNA	GI: 154224763
hemagglutinin (HA) mRNA, complete cds
Influenza A virus	1,565 bp	M76603.1
(A/turkey/England/647/1977(H1N1))	linear mRNA	GI: 325094
nucleoprotein mRNA, complete cds
Influenza A virus	1,445 bp	AJ416626.1
(A/turkey/France/87075/87(H1N1)) N1 gene	linear mRNA	GI: 39840719
for neuraminidase, genomic RNA
Influenza A virus	394 bp	Z30272.1
(A/turkey/Germany/3/91(H1N1)) mRNA for	linear mRNA	GI: 456652
PB2 polymerase (partial)
Influenza A virus	97 bp	Z30275.1
(A/turkey/Germany/3/91(H1N1)) mRNA	linear mRNA	GI: 530398
for neuraminidase (UTR)
Influenza A virus	264 bp	Z30274.1
(A/turkey/Germany/3/91(H1N1)) mRNA	linear mRNA	GI: 530401
for PA polymerase
Influenza A virus	247 bp	Z30273.1
(A/turkey/Germany/3/91(H1N1)) mRNA	linear mRNA	GI: 530403
for PBI polymerase (partial)
Influenza A virus	1,038 bp	Z46441.1
(A/turkey/Germany/3/91(H1N1)) mRNA	linear mRNA	GI: 854218
for hemagglutinin HA1
Influenza A virus	981 bp	U46941.1
(A/turkey/Minnesota/1661/1981(H1N1))	linear mRNA	GI: 1912332
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	1,777 bp	AF091310.1
(A/turkey/Minnesota/1661/81(H1N1))	linear mRNA	GI: 4585162
segment 4 hemagglutinin precursor (HA)
mRNA, complete cds
Influenza A virus (A/turkey/North	1,565 bp	M76609.1
Carolina/1790/1988(H1N1)) nucleoprotein	linear mRNA	GI: 325096
mRNA, complete cds
Influenza A virus (A/Weiss/43(H1N1))	1,410 bp	AF250365.2
neuraminidase (NA) gene, complete cds	linear mRNA	GI: 13260589
Influenza A virus (A/Wilson-Smith/1933(H1N1))	1,497 bp	EU330203.1
nucleocapsid protein (NP) mRNA, complete cds	linear mRNA	GI: 167989512
Influenza A virus	241 bp	U47816.1
(A/Wisconsin/3523/1988(H1N1))	linear mRNA	GI: 1912352
neuraminidase (NA) mRNA, partial cds
Influenza A virus	1,565 bp	M76610.1
(A/Wisconsin/3623/1988(H1N1))	linear mRNA	GI: 325103
nucleoprotein mRNA, complete cds
Influenza A virus (A/WI/4754/1994(H1N1))	235 bp	U53156.1
PB1 (PB1) mRNA, partial cds	linear mRNA	GI: 1399590
Influenza A virus (A/WI/4754/1994(H1N1))	168 bp	U53158.1
PB2 (PB2) mRNA, partial cds	linear mRNA	GI: 1399594
Influenza A virus (A/WI/4754/1994(H1N1))	621 bp	U53160.1
PA (PA) mRNA, partial cds	linear mRNA	GI: 1399598
Influenza A virus (A/WI/4754/1994(H1N1))	1,778 bp	U53162.1
hemagglutinin (HA) mRNA, complete cds	linear mRNA	GI: 1399602
Influenza A virus (A/WI/4754/1994(H1N1))	200 bp	U53164.1
NP (NP) mRNA, partial cds	linear mRNA	GI: 1399606
Influenza A virus (A/WI/4754/1994(H1N1))	1,458 bp	U53166.1
neuraminidase (NA) mRNA, complete cds	linear mRNA	GI: 1399610
Influenza A virus (A/WI/4754/1994(H1N1)) M	1,027 bp	U53168.1
(M) mRNA, complete cds	linear mRNA	GI: 1399614
Influenza A virus (A/WI/4754/1994(H1N1))	890 bp	U53170.1
NS (NS) mRNA, complete cds	linear mRNA	GI: 1399618
Influenza A virus (A/WI/4755/1994(H1N1))	203 bp	U53157.1
PB1 (PB1) mRNA, partial cds	linear mRNA	GI: 1399592
Influenza A virus (A/WI/4755/1994(H1N1))	173 bp	U53159.1
PB2 (PB2) mRNA, partial cds	linear mRNA	GI: 1399596
Influenza A virus (A/WI/4755/1994(H1N1))	621 bp	U53161.1
PA (PA) mRNA, partial cds	linear mRNA	GI: 1399600
Influenza A virus (A/WI/4755/1994(H1N1))	1,778 bp	U53163.1
hemagglutinin (HA) mRNA, complete cds	linear mRNA	GI: 1399604
Influenza A virus (A/WI/4755/1994(H1N1))	215 bp	U53165.1
NP (NP) mRNA, partial cds	linear mRNA	GI: 1399608
Influenza A virus (A/WI/4755/1994(H1N1))	209 bp	U53167.1
neuraminidase (NA) mRNA, partial cds	linear mRNA	GI: 1399612
Influenza A virus (A/WI/4755/1994(H1N1)) M	1,027 bp	U53169.1
(M) mRNA, complete cds	linear mRNA	GI: 1399616
Influenza A virus (A/WI/4755/1994(H1N1))	890 bp	U53171.1
NS (NS) mRNA, complete cds	linear mRNA	GI: 1399620
Influenza A virus (A/WSN/33) segment 5	543 bp	AF306656.1
nucleocapsid protein (NP) mRNA, partial cds	linear mRNA	GI: 11935089

TABLE 8
Influenza H3N2 Antigens
		GenBank/GI
Strain/Protein	Length	Accession No.
1. Influenza A virus (A/Aichi/2/1968(H3N2))	1,704 bp	EF614248.1
hemagglutinin (HA) mRNA, complete cds	linear mRNA	GI: 148910819
2. Influenza A virus (A/Aichi/2/1968(H3N2))	1,698 bp	EF614249.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 148910821
3. Influenza A virus (A/Aichi/2/1968(H3N2))	1,698 bp	EF614250.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 148910823
4. Influenza A virus (A/Aichi/2/1968(H3N2))	1,698 bp	EF614251.1
hemagglutinin (HA) mRNA, partial cds	linear mRNA	GI: 148910825
5. Influenza A virus (A/Akita/1/1995(H3N2))	1,032 bp	U48444.1
haemagglutinin mRNA, partial cds	linear mRNA	GI: 1574989
6. Influenza A virus	1,041 bp	Z46392.1
(A/Beijing/32/1992(H3N2)) mRNA for	linear mRNA	GI: 609020
haemagglutinin
7. Influenza A virus	987 bp	AF501516.1
(A/Canada/33312/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314288
(HA) mRNA, partial cds
8. Influenza A virus	987 bp	AF297094.1
(A/Charlottesville/10/99(H3N2))	linear mRNA	GI: 11228917
hemagglutinin mRNA, partial cds
9. Influenza A virus	987 bp	AF297096.1
(A/Charlottesville/49/99(H3N2))	linear mRNA	GI: 11228921
hemagglutinin mRNA, partial cds
10. Influenza A virus	987 bp	AF297097.1
(A/Charlottesville/69/99(H3N2))	linear mRNA	GI: 11228923
hemagglutinin mRNA, partial cds
11. Influenza A virus	987 bp	AF297095.1
(A/Charlottesville/73/99(H3N2))	linear mRNA	GI: 11228919
hemagglutinin mRNA, partial cds
12. Influenza A virus	1,041 bp	Z46393.1
(A/England/1/1993(H3N2)) mRNA for	linear mRNA	GI: 609024
haemagglutinin
13. Influenza A virus	1,041 bp	Z46394.1
(A/England/247/1993(H3N2)) mRNA for	linear mRNA	GI: 609025
haemagglutinin
14. Influenza A virus	1,041 bp	Z46395.1
(A/England/269/93(H3N2)) mRNA for	linear mRNA	GI: 609027
haemagglutinin
15. Influenza A virus	1,041 bp	Z46396.1
(A/England/284/1993(H3N2)) mRNA for	linear mRNA	GI: 609029
haemagglutinin
16. Influenza A virus	1,041 bp	Z46397.1
(A/England/286/1993(H3N2)) mRNA for	linear mRNA	GI: 609031
haemagglutinin
17. Influenza A virus	1,041 bp	Z46398.1
(A/England/289/1993(H3N2)) mRNA for	linear mRNA	GI: 609033
haemagglutinin
18. Influenza A virus	1,041 bp	Z46399.1
(A/England/328/1993(H3N2)) mRNA for	linear mRNA	GI: 609035
haemagglutinin
19. Influenza A virus	1,041 bp	Z46400.1
(A/England/346/1993(H3N2)) mRNA for	linear mRNA	GI: 609037
haemagglutinin
20. Influenza A virus	1,041 bp	Z46401.1
(A/England/347/1993(H3N2)) mRNA for	linear mRNA	GI: 609039
haemagglutinin
21. Influenza A virus	1,091 bp	AF201875.1
(A/England/42/72(H3N2)) hemagglutinin	linear mRNA	GI: 6470274
mRNA, partial cds
22. Influenza A virus	1,041 bp	Z46402.1
(A/England/471/1993(H3N2)) mRNA for	linear mRNA	GI: 609041
haemagglutinin
23. Influenza A virus	1,041 bp	Z46403.1
(A/England/67/1994(H3N2)) mRNA for	linear mRNA	GI: 609043
haemagglutinin
24. Influenza A virus	1,041 bp	Z46404.1
(A/England/68/1994(H3N2)) mRNA for	linear mRNA	GI: 609045
haemagglutinin
25. Influenza A virus	1,041 bp	Z46405.1
(A/England/7/1994(H3N2)) mRNA for	linear mRNA	GI: 609047
haemagglutinin
28. Influenza A virus	1,041 bp	Z46406.1
(A/Guangdong/25/1993(H3N2)) mRNA for	linear mRNA	GI: 609049
haemagglutinin
29. Influenza A virus (A/Hong	1,091 bp	AF201874.1
Kong/1/68(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 6470272
partial cds
30. Influenza A virus (A/Hong	1,041 bp	Z46407.1
Kong/1/1994(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609051
31. Influenza A virus (A/Hong	1,762 bp	AF382319.1
Kong/1143/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487957
complete cds
32. Influenza A virus (A/Hong	1,762 bp	AF382320.1
Kong/1143/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487959
complete cds
33. Influenza A virus (A/Hong	1,466 bp	AF382329.1
Kong/1143/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487977
complete cds
34. Influenza A virus (A/Hong	1,466 bp	AF382330.1
Kong/1143/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487979
complete cds
35. Influenza A virus (A/Hong	1,762 bp	AY035589.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486403
complete cds
36. Influenza A virus (A/Hong	1,762 bp	AF382321.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487961
complete cds
37. Influenza A virus (A/Hong	1,762 bp	AF382322.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487963
complete cds
38. Influenza A virus (A/Hong	1,466 bp	AF382331.1
Kong/1144/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487981
complete cds
39. Influenza A virus (A/Hong	1,466 bp	AF382332.1
Kong/1144/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487983
complete cds
40. Influenza A virus (A/Hong	1,762 bp	AY035590.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486405
complete cds
41. Influenza A virus (A/Hong	1,762 bp	AF382323.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487965
complete cds
42. Influenza A virus (A/Hong	1,762 bp	AF382324.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487967
complete cds
43. Influenza A virus (A/Hong	1,762 bp	AY035591.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486407
complete cds
44. Influenza A virus (A/Hong	1,762 bp	AF382325.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487969
complete cds
45. Influenza A virus (A/Hong	1,762 bp	AF382326.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487971
complete cds
46. Influenza A virus (A/Hong	1,762 bp	AF382327.1
Kong/1182/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487973
complete cds
47. Influenza A virus (A/Hong	1,762 bp	AF382328.1
Kong/1182/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487975
complete cds
48. Influenza A virus (A/Hong	1,041 bp	Z46408.1
Kong/2/1994(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609055
49. Influenza A virus (A/Hong	1,041 bp	Z46410.1
Kong/23/1992(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609053
50. Influenza A virus (A/Hong	1,041 bp	Z46409.1
Kong/34/1990(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609057
51. Influenza A virus	1,041 bp	Z46397.1
(A/England/286/1993(H3N2)) mRNA for	linear mRNA	GI: 609031
haemagglutinin
52. Influenza A virus	1,041 bp	Z46398.1
(A/England/289/1993(H3N2)) mRNA for	linear mRNA	GI: 609033
haemagglutinin
53. Influenza A virus	1,041 bp	Z46399.1
(A/England/328/1993(H3N2)) mRNA for	linear mRNA	GI: 609035
haemagglutinin
54. Influenza A virus	1,041 bp	Z46400.1
(A/England/346/1993(H3N2)) mRNA for	linear mRNA	GI: 609037
haemagglutinin
55. Influenza A virus	1,041 bp	Z46401.1
(A/England/347/1993(H3N2)) mRNA for	linear mRNA	GI: 609039
haemagglutinin
56. Influenza A virus	1,091 bp	AF201875.1
(A/England/42/72(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 6470274
partial cds
57. Influenza A virus	1,041 bp	Z46402.1
(A/England/471/1993(H3N2)) mRNA for	linear mRNA	GI: 609041
haemagglutinin
58. Influenza A virus	1,041 bp	Z46403.1
(A/England/67/1994(H3N2)) mRNA for	linear mRNA	GI: 609043
haemagglutinin
59. Influenza A virus	1,041 bp	Z46404.1
(A/England/68/1994(H3N2)) mRNA for	linear mRNA	GI: 609045
haemagglutinin
60. Influenza A virus	1,041 bp	Z46405.1
(A/England/7/1994(H3N2)) mRNA for	linear mRNA	GI: 609047
haemagglutinin
63. Influenza A virus	1,032 bp	U48442.1
(A/Guandong/28/1994(H3N2)) haemagglutinin	linear mRNA	GI: 1574985
mRNA, partial cds
64. Influenza A virus	1,041 bp	Z46406.1
(A/Guangdong/25/1993(H3N2)) mRNA for	linear mRNA	GI: 609049
haemagglutinin
65. Influenza A virus	1,032 bp	U48447.1
(A/Hebei/19/1995(H3N2)) haemagglutinin mRNA,	linear mRNA	GI: 1574995
partial cds
66. Influenza A virus	1,032 bp	U48441.1
(A/Hebei/41/1994(H3N2)) haemagglutinin mRNA,	linear mRNA	GI: 1574983
partial cds
67. Influenza A virus (A/Hong	1,091 bp	AF201874.1
Kong/1/68(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 6470272
partial cds
68. Influenza A virus (A/Hong	1,041 bp	Z46407.1
Kong/1/1994(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609051
69. Influenza A virus (A/Hong	1,762 bp	AY035588.1
Kong/1143/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486401
complete cds
70. Influenza A virus (A/Hong	1,762 bp	AF382319.1
Kong/1143/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487957
complete cds
71. Influenza A virus (A/Hong	1,762 bp	AF382320.1
Kong/1143/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487959
complete cds
72. Influenza A virus (A/Hong	1,466 bp	AF382329.1
Kong/1143/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487977
complete cds
73. Influenza A virus (A/Hong	1,466 bp	AF382330.1
Kong/1143/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487979
complete cds
74. Influenza A virus (A/Hong	1,762 bp	AY035589.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486403
complete cds
75. Influenza A virus (A/Hong	1,762 bp	AF382321.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487961
complete cds
76. Influenza A virus (A/Hong	1,762 bp	AF382322.1
Kong/1144/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487963
complete cds
77. Influenza A virus (A/Hong	1,466 bp	AF382331.1
Kong/1144/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487981
complete cds
78. Influenza A virus (A/Hong	1,466 bp	AF382332.1
Kong/1144/99(H3N2)) neuraminidase mRNA,	linear mRNA	GI: 14487983
complete cds
79. Influenza A virus (A/Hong	1,762 bp	AY035590.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486405
complete cds
80. Influenza A virus (A/Hong	1,762 bp	AF382323.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487965
complete cds
81. Influenza A virus (A/Hong	1,762 bp	AF382324.1
Kong/1179/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487967
complete cds
82. Influenza A virus (A/Hong	1,762 bp	AY035591.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486407
complete cds
83. Influenza A virus (A/Hong	1,762 bp	AF382325.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487969
complete cds
84. Influenza A virus (A/Hong	1,762 bp	AF382326.1
Kong/1180/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487971
complete cds
85. Influenza A virus (A/Hong	1,762 bp	AY035592.1
Kong/1182/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14486409
complete cds
86. Influenza A virus (A/Hong	1,762 bp	AF382327.1
Kong/1182/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487973
complete cds
87. Influenza A virus (A/Hong	1,762 bp	AF382328.1
Kong/1182/99(H3N2)) hemagglutinin mRNA,	linear mRNA	GI: 14487975
complete cds
88. Influenza A virus (A/Hong	1,041 bp	Z46408.1
Kong/2/1994(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609055
89. Influenza A virus (A/Hong	1,041 bp	Z46410.1
Kong/23/1992(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609053
90. Influenza A virus (A/Hong	1,041 bp	Z46409.1
Kong/34/1990(H3N2)) mRNA for haemagglutinin	linear mRNA	GI: 609057
91. Influenza A virus	987 bp	AF501534.1
(A/Indiana/28170/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314324
(HA) mRNA, partial cds
92. Influenza A virus	529 bp	AY961997.1
(A/Kinmen/618/03(H3N2)) hemagglutinin	linear mRNA	GI: 68138151
(HA) mRNA, partial cds
93. Influenza A virus	383 bp	AY973325.1
(A/Kinmen/618/03(H3N2)) neuraminidase	linear mRNA	GI: 70673206
(NA) mRNA, partial cds
94. Influenza A virus	882 bp	AY986986.1
(A/Kinmen/618/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728099
(NP) mRNA, partial cds
95. Influenza A virus	545 bp	AY962017.1
(A/Kinmen/621/03(H3N2)) hemagglutinin	linear mRNA	GI: 68138191
(HA) mRNA, partial cds
96. Influenza A virus	386 bp	AY973326.1
(A/Kinmen/621/03(H3N2)) neuraminidase	linear mRNA	GI: 70673208
(NA) mRNA, partial cds
97. Influenza A virus	882 bp	AY986987.1
(A/Kinmen/621/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728101
(NP) mRNA, partial cds
98. Influenza A virus	786 bp	AY962008.1
(A/Kinmen/639/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138173
(HA) mRNA, partial cds
99. Influenza A virus	381 bp	AY973327.1
(A/Kinmen/639/04(H3N2)) neuraminidase	linear mRNA	GI: 70673210
(NA) mRNA, partial cds
100. Influenza A virus	882 bp	AY986988.1
(A/Kinmen/639/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728103
(NP) mRNA, partial cds
101. Influenza A virus	596 bp	AY962004.1
(A/Kinmen/641/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138165
(HA) mRNA, partial cds
102. Influenza A virus	785 bp	AY973328.1
(A/Kinmen/641/04(H3N2)) neuraminidase	linear mRNA	GI: 70673212
(NA) mRNA, partial cds
103. Influenza A virus	576 bp	AY962001.1
(A/Kinmen/642/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138159
(HA) mRNA, partial cds
104. Influenza A virus	580 bp	AY973329.1
(A/Kinmen/642/04(H3N2)) neuraminidase	linear mRNA	GI: 70673214
(NA) mRNA, partial cds
105. Influenza A virus	882 bp	AY986989.1
(A/Kinmen/642/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728105
(NP) mRNA, partial cds
106. Influenza A virus	789 bp	AY962009.1
(A/Kinmen/645/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138175
(HA) mRNA, partial cds
107. Influenza A virus	581 bp	AY973330.1
(A/Kinmen/645/04(H3N2)) neuraminidase	linear mRNA	GI: 70673216
(NA) mRNA, partial cds
108. Influenza A virus	981 bp	AY986990.1
(A/Kinmen/645/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728107
(NP) mRNA, partial cds
109. Influenza A virus	2,341 bp	U62543.1
(A/LosAngeles/2/1987(H3N2)) polymerase	linear mRNA	GI: 1480737
protein basic 2 (PB2) mRNA, complete cds
110. Influenza A virus	1,041 bp	Z46411.1
(A/Madrid/252/1993(H3N2)) mRNA for	linear mRNA	GI: 609067
haemagglutinin
111. Influenza A virus	987 bp	AF501531.1
(A/Michigan/22568/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314318
(HA) mRNA, partial cds
112. Influenza A virus	987 bp	AF501518.1
(A/Michigan/22692/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314292
(HA) mRNA, partial cds
113. Influenza A virus	754 bp	AJ519454.1
(A/Moscow/10/99(H3N2)) partial NS1 gene	linear mRNA	GI: 31096423
for non structural protein 1 and partial NS2
gene for non structural protein 2, genomic
RNA
114. Influenza A virus	987 bp	AY138518.1
(A/ningbo/17/2002(H3N2)) hemagglutinin	linear mRNA	GI: 24895178
(HA) mRNA, partial cds
115. Influenza A virus	987 bp	AY138517.1
(A/ningbo/25/2002(H3N2)) hemagglutinin	linear mRNA	GI: 24895169
(HA) mRNA, partial cds
116. Influenza A virus	1,765 bp	V01103.1
(A/NT/60/68/29C(H3N2)) mRNA for	linear mRNA	GI: 60800
haemagglutinin (HA1 and HA2 genes)
117. Influenza A virus	1,701 bp	DQ059385.1
(A/Oklahoma/323/03(H3N2)) hemagglutinin	linear mRNA	GI: 66933143
mRNA, complete cds
118. Influenza A virus	1,410 bp	DQ059384.2
(A/Oklahoma/323/03(H3N2)) neuraminidase	linear mRNA	GI: 75859981
mRNA, complete cds
119. Influenza A virus	766 bp	AJ519458.1
(A/Panama/2007/99(H3N2)) partial NS1 gene	linear mRNA	GI: 31096435
for non structural protein 1 and partial NS2
gene for non structural protein 2, genomic
RNA
120. Influenza A virus	987 bp	AF501526.1
(A/Pennsylvanla/20109/99(H3N2))	linear mRNA	GI: 21314308
hemagglutinin (HA) mRNA, partial cds
121. Influenza A virus	1,091 bp	AF233691.1
(A/Phillppines/2/82(H3N2)) hemagglutinin	linear mRNA	GI: 7331124
mRNA, partial cds
122. Influenza A virus	767 bp	AY962000.1
(A/Pingtung/303/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138157
(HA) mRNA, partial cds
123. Influenza A virus	783 bp	AY973331.1
(A/Pingtung/303/04(H3N2)) neuraminidase	linear mRNA	GI: 70673218
(NA) mRNA, partial cds
124. Influenza A virus	928 bp	AY986991.1
(A/Pingtung/303/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728109
(NP) mRNA, partial cds
125. Influenza A virus	788 bp	AY961999.1
(A/Pingtung/313/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138155
(HA) mRNA, partial cds
126. Influenza A virus	787 bp	AY973332.1
(A/Pingtung/313/04(H3N2)) neuraminidase	linear mRNA	GI: 70673220
(NA) mRNA, partial cds
127. Influenza A virus	882 bp	AY986992.1
(A/Pingtung/313/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728111
(NP) mRNA, partial cds
128. Influenza A virus (A/ruddy	927 bp	AY664458.1
turnstone/Delaware/142/99(H3N2))	linear mRNA	GI: 51011862
nonfunctional matrix protein mRNA, partial
sequence
129. Influenza A virus	1,041 bp	Z46413.1
(A/Scotland/142/1993(H3N2)) mRNA for	linear mRNA	GI: 609059
haemagglutinin
130. Influenza A virus	1,041 bp	Z46414.1
(A/Scotland/160/1993(H3N2)) mRNA for	linear mRNA	GI: 609061
haemagglutinin
131. Influenza A virus	1,041 bp	Z46416.1
(A/Scotland/173/1993(H3N2)) mRNA for	linear mRNA	GI: 609063
haemagglutinin
132. Influenza A virus	1,041 bp	Z46415.1
(A/Scotland/174/1993(H3N2)) mRNA for	linear mRNA	GI: 609065
haemagglutinin
133. Influenza A virus	1,041 bp	Z46412.1
(A/Scotland/2/1993(H3N2)) mRNA for	linear mRNA	GI: 609069
haemagglutinin
134. Influenza A virus	1,032 bp	U48439.1
(A/Sendai/c182/1994(H3N2)) haemagglutinin	linear mRNA	GI: 1574979
mRNA, partial cds
135. Influenza A virus	1,032 bp	U48445.1
(A/Sendai/c373/1995(H3N2)) haemagglutinin	linear mRNA	GI: 1574991
mRNA, partial cds
136. Influenza A virus	1,032 bp	U48440.1
(A/Sendai/c384/1994(H3N2)) haemagglutinin	linear mRNA	GI: 1574981
mRNA, partial cds
137. Influenza A virus	1,041 bp	Z46417.1
(A/Shangdong/9/1993(H3N2)) mRNA for	linear mRNA	GI: 609071
haemagglutinin
138. Influenza A virus	987 bp	L19416.1
(A/Shanghai/11/1987/X99aE high yield	linear mRNA	GI: 348117
reassortant(H3N2)) hemagglutinin (HA)
mRNA, partial cds
139. Influenza A virus	2,280 bp	AF225514.1
(A/sw/Shizuoka/110/97(H3N2)) polymerase	linear mRNA	GI: 27462098
basic 2 (PB2) mRNA, complete cds
140. Influenza A virus	2,274 bp	AF225518.1
(A/sw/Shizuoka/110/97(H3N2)) polymerase	linear mRNA	GI: 27462106
basic 1 (PB1) mRNA, complete cds
141. Influenza A virus	2,151 bp	AF225522.1
(A/sw/Shizuoka/110/97(H3N2)) polymerase	linear mRNA	GI: 27462114
acidic (PA) mRNA, complete cds
142. Influenza A virus	1,497 bp	AF225534.1
(A/sw/Shizuoka/110/97(H3N2)) nucleoprotein	linear mRNA	GI: 27462146
(NP) mRNA, complete cds
143. Influenza A virus	1,410 bp	AF225538.1
(A/sw/Shizuoka/110/97(H3N2)) neuraminidase	linear mRNA	GI: 27462154
(NA) mRNA, complete cds
144. Influenza A virus	984 bp	AF225542.1
(A/sw/Shizuoka/110/97(H3N2)) hemagglutinin	linear mRNA	GI: 27462162
(HA1) mRNA, partial cds
145. Influenza A virus	2,280 bp	AF225515.1
(A/sw/Shizuoka/115/97(H3N2)) polymerase	linear mRNA	GI: 27462100
basic 2 (PB2) mRNA, complete cds
146. Influenza A virus	2,274 bp	AF225519.1
(A/sw/Shizuoka/115/97(H3N2)) polymerase	linear mRNA	GI: 27462108
basic 1 (PB1) mRNA, complete cds
147. Influenza A virus	2,151 bp	AF225523.1
(A/sw/Shizuoka/115/97(H3N2)) polymerase	linear mRNA	GI: 27462116
acidic (PA) mRNA, complete cds
148. Influenza A virus	1,497 bp	AF225535.1
(A/sw/Shizuoka/115/97(H3N2)) nucleoprotein	linear mRNA	GI: 27462148
(NP) mRNA, complete cds
149. Influenza A virus	1,410 bp	AF225539.1
(A/sw/Shizuoka/115/97(H3N2)) neuraminidase	linear mRNA	GI: 27462156
(NA) mRNA, complete cds
150. Influenza A virus	984 bp	AF225543.1
(A/sw/Shizuoka/115/97(H3N2)) hemagglutinin	linear mRNA	GI: 27462164
(HA1) mRNA, partial cds
151. Influenza A virus	2,280 bp	AF225516.1
(A/sw/Shizuoka/119/97(H3N2)) polymerase	linear mRNA	GI: 27462102
basic 2 (PB2) mRNA, complete cds
152. Influenza A virus	2,274 bp	AF225520.1
(A/sw/Shizuoka/119/97(H3N2)) polymerase	linear mRNA	GI: 27462110
basic 1 (PB1) mRNA, complete cds
153. Influenza A virus	2,151 bp	AF225524.1
(A/sw/Shizuoka/119/97(H3N2)) polymerase	linear mRNA	GI: 27462118
acidic (PA) mRNA, complete cds
154. Influenza A virus	1,497 bp	AF225536.1
(A/sw/Shizuoka/119/97(H3N2)) nucleoprotein	linear mRNA	GI: 27462150
(NP) mRNA, complete cds
155. Influenza A virus	1,410 bp	AF225540.1
(A/sw/Shizuoka/119/97(H3N2)) neuraminidase	linear mRNA	GI: 27462158
(NA) mRNA, complete cds
156. Influenza A virus	984 bp	AF225544.1
(A/sw/Shizuoka/119/97(H3N2)) hemagglutinin	linear mRNA	GI: 27462166
(HA1) mRNA, partial cds
159. Influenza A virus	1,410 bp	EU163948.1
(A/swine/Bakum/IDT1769/2003(H3N2))	linear mRNA	GI: 157679552
neuraminidase mRNA, complete cds
163. Influenza A virus	1,738 bp	AY857957.1
(A/swine/Fujian/668/01(H3N2)) nonfunctional	linear mRNA	GI: 58042507
hemagglutinin mRNA, complete sequence
164. Influenza A virus PB2 gene for	2,280 bp	AJ311459.1
Polymerase 2 protein, genomic RNA, strain	linear mRNA	GI: 13661041
A/Swine/Italy/1523/98
165. Influenza A virus PB1 gene for	2,274 bp	AJ311460.1
Polymerase 1 protein, genomic RNA, strain	linear mRNA	GI: 13661043
A/Swine/Italy/1523/98
166. Influenza A virus	821 bp	AJ344024.1
(A/swine/Italy/1523/98(H3N2)) NS1 gene for	linear mRNA	GI: 20068146
non structural protein 1 and NS2 gene for
non structural protein 2, genomic RNA
167. Influenza A virus	1,465 bp	EU163949.1
(A/swine/Re220/92hp(H3N2)) neuraminidase	linear mRNA	GI: 157679554
mRNA, complete cds
168. Influenza A virus	2,280 bp	AF225517.1
(A/sw/Shizuoka/120/97(H3N2)) polymerase	linear mRNA	GI: 27462104
basic 2 (PB2) mRNA, complete cds
169. Influenza A virus	2,274 bp	AF225521.1
(A/sw/Shizuoka/120/97(H3N2)) polymerase	linear mRNA	GI: 27462112
basic 1 (PB1) mRNA, complete cds
170. Influenza A virus	2,151 bp	AF225525.1
(A/sw/Shizuoka/120/97(H3N2)) polymerase	linear mRNA	GI: 27462120
acidic (PA) mRNA, complete cds
171. Influenza A virus	1,497 bp	AF225537.1
(A/sw/Shizuoka/120/97(H3N2)) nucleoprotein	linear mRNA	GI: 27462152
(NP) mRNA, complete cds
172. Influenza A virus	1,410 bp	AF225541.1
(A/sw/Shizuoka/120/97(H3N2)) neuraminidase	linear mRNA	GI: 27462160
(NA) mRNA, complete cds
173. Influenza A virus	984 bp	AF225545.1
(A/sw/Shizuoka/120/97(H3N2)) hemagglutinin	linear mRNA	GI: 27462168
(HA1) mRNA, partial cds
174. Influenza A virus	1,762 bp	AY032978.1
(A/Switzerland/7729/98(H3N2)) hemagglutinin	linear mRNA	GI: 14161723
mRNA, complete cds
175. Influenza A virus	1,762 bp	AF382318.1
(A/Switzerland/7729/98(H3N2)) hemagglutinin	linear mRNA	GI: 14487955
mRNA, complete cds
176. Influenza A virus	528 bp	AY962011.1
(A/Tainan/704/03(H3N2)) hemagglutinin (HA)	linear mRNA	GI: 68138179
mRNA, partial cds
177. Influenza A virus	384 bp	AY973333.1
(A/Tainan/704/03(H3N2)) neuraminidase (NA)	linear mRNA	GI: 70673222
mRNA, partial cds
178. Influenza A virus	882 bp	AY986993.1
(A/Tainan/704/03(H3N2)) nucleoprotein (NP)	linear mRNA	GI: 70728113
mRNA, partial cds
179. Influenza A virus	519 bp	AY962012.1
(A/Tainan/712/03(H3N2)) hemagglutinin (HA)	linear mRNA	GI: 68138181
mRNA, partial cds
180. Influenza A virus	383 bp	AY973334.1
(A/Tainan/712/03(H3N2)) neuraminidase (NA)	linear mRNA	GI: 70673224
mRNA, partial cds
181. Influenza A virus	882 bp	AY986994.1
(A/Tainan/712/03(H3N2)) nucleoprotein (NP)	linear mRNA	GI: 70728115
mRNA, partial cds
182. Influenza A virus	784 bp	AY962005.1
(A/Tainan/722/03(H3N2)) hemagglutinin (HA)	linear mRNA	GI: 68138167
mRNA, partial cds
183. Influenza A virus	592 bp	AY973335.1
(A/Tainan/722/03(H3N2)) neuraminidase (NA)	linear mRNA	GI: 70673226
mRNA, partial cds
184. Influenza A virus	936 bp	AY986995.1
(A/Tainan/722/03(H3N2)) nucleoprotein (NP)	linear mRNA	GI: 70728117
mRNA, partial cds
185. Influenza A virus	788 bp	AY961998.1
(A/Taipei/407/03(H3N2)) hemagglutinin (HA)	linear mRNA	GI: 68138153
mRNA, partial cds
186. Influenza A virus	787 bp	AY973336.1
(A/Taipei/407/03(H3N2)) neuraminidase (NA)	linear mRNA	GI: 70673228
mRNA, partial cds
187. Influenza A virus	882 bp	AY986996.1
(A/Taipei/407/03(H3N2)) nucleoprotein (NP)	linear mRNA	GI: 70728119
mRNA, partial cds
188. Influenza A virus	787 bp	AY962007.1
(A/Taipei/416/03(H3N2)) hemagglutinin (HA)	linear mRNA	GI: 68138171
mRNA, partial cds
189. Influenza A virus	782 bp	AY973337.1
(A/Taipei/416/03(H3N2)) neuraminidase (NA)	linear mRNA	GI: 70673230
mRNA, partial cds
190. Influenza A virus	882 bp	AY986997.1
(A/Taipei/416/03(H3N2)) nucleoprotein (NP)	linear mRNA	GI: 70728121
mRNA, partial cds
191. Influenza A virus (A/Taiwan/0020/	297 bp	AY303703.1
98(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330895
(PB1) mRNA, partial cds
192. Influenza A virus	791 bp	AY604817.1
(A/Taiwan/0040/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727514
mRNA, partial cds
193. Influenza A virus (A/Taiwan/0045/	297 bp	AY303705.1
98(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330899
(PB1) mRNA, partial cds
194. Influenza A virus	844 bp	AF362820.1
(A/human/Taiwan/0095/96(H3N2))	linear mRNA	GI: 15055140
hemagglutinin (HA) mRNA, partial cds
195. Influenza A virus	791 bp	AY604828.1
(A/Taiwan/0097/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727536
mRNA, partial cds
196. Influenza A virus (A/Taiwan/0104/	297 bp	AY303706.1
2001(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330901
(PB1) mRNA, partial cds
197. Influenza A virus	844 bp	AF362805.1
(A/human/Taiwan/0118/98(H3N2))	linear mRNA	GI: 15055110
hemagglutinin (HA) mRNA, partial cds
198. Influenza A virus	791 bp	AY604823.1
(A/Taiwan/0122/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727526
mRNA, partial cds
199. Influenza A virus	844 bp	AF362806.1
(A/human/Taiwan/0149/00(H3N2))	linear mRNA	GI: 15055112
hemagglutinin (HA) mRNA, partial cds
200. Influenza A virus (A/Taiwan/0275/	297 bp	AY303712.1
2000(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330913
(PB1) mRNA, partial cds
201. Influenza A virus (A/Taiwan/0275/	844 bp	AY303713.1
2000(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330915
partial cds
202. Influenza A virus	844 bp	AF362807.1
(A/human/Taiwan/0293/98(H3N2))	linear mRNA	GI: 15055114
hemagglutinin (HA) mRNA, partial cds
203. Influenza A virus (A/Taiwan/0346/	297 bp	AY303715.1
98(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330919
(PB1) mRNA, partial cds
204. Influenza A virus (A/Taiwan/0379/	297 bp	AY303716.1
2000(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330921
(PB1) mRNA, partial cds
205. Influenza A virus (A/Taiwan/0379/	844 bp	AY303717.1
2000(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330923
partial cds
206. Influenza A virus	791 bp	AY625729.1
(A/Taiwan/0388/2001(H3N2)) hemagglutinin	linear mRNA	GI: 50604415
(HA) mRNA, partial cds
207. Influenza A virus	844 bp	AF362808.1
(A/human/Taiwan/0389/99(H3N2))	linear mRNA	GI: 15055116
hemagglutinin (HA) mRNA, partial cds
208. Influenza A virus	844 bp	AF362809.1
(A/human/Taiwan/0423/98(H3N2))	linear mRNA	GI: 15055118
hemagglutinin (HA) mRNA, partial cds
209. Influenza A virus (A/Taiwan/0423/	297 bp	AY303718.1
98(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330925
(PB1) mRNA, partial cds
210. Influenza A virus	844 bp	AF362810.1
(A/human/Taiwan/0464/98(H3N2))	linear mRNA	GI: 15055120
hemagglutinin (HA) mRNA, partial cds
211. Influenza A virus (A/Taiwan/0464/	297 bp	AY303719.1
98(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330927
(PB1) mRNA, partial cds
212. Influenza A virus	791 bp	AY625730.1
(A/Taiwan/0568/2001(H3N2)) hemagglutinin	linear mRNA	GI: 50604440
(HA) mRNA, partial cds
213. Influenza A virus	791 bp	AY604822.1
(A/Taiwan/0570/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727524
mRNA, partial cds
214. Influenza A virus	791 bp	AY604827.1
(A/Taiwan/0572/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727534
mRNA, partial cds
215. Influenza A virus	791 bp	AY604821.1
(A/Taiwan/0578/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727522
mRNA, partial cds
216. Influenza A virus	791 bp	AY604820.1
(A/Taiwan/0583/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727520
mRNA, partial cds
217. Influenza A virus (A/Taiwan/0646/	297 bp	AY303722.1
2000(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330933
(PB1) mRNA, partial cds
218. Influenza A virus (A/Taiwan/0646/	844 bp	AY303723.1
2000(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330935
partial cds
219. Influenza A virus	844 bp	AF362811.1
(A/human/Taiwan/0830/99(H3N2))	linear mRNA	GI: 15055122
hemagglutinin (HA) mRNA, partial cds
220. Influenza A virus	791 bp	AY625731.1
(A/Taiwan/0964/2001(H3N2)) hemagglutinin	linear mRNA	GI: 50604469
(HA) mRNA, partial cds
221. Influenza A virus	844 bp	AF362812.1
(A/human/Taiwan/1008/99(H3N2))	linear mRNA	GI: 15055124
hemagglutinin (HA) mRNA, partial cds
222. Influenza A virus (A/Taiwan/1008/	297 bp	AY303725.1
99(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330939
(PB1) mRNA, partial cds
223. Influenza A virus	750 bp	EU068138.1
(A/Taiwan/1219/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452149
(HA) mRNA, partial cds
224. Influenza A virus	750 bp	EU068125.1
(A/Taiwan/1315/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452123
(HA) mRNA, partial cds
225. Influenza A virus	750 bp	EU068153.1
(A/Taiwan/1511/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452179
(HA) mRNA, partial cds
226. Influenza A virus	750 bp	EU068119.1
(A/Taiwan/1533/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452111
(HA) mRNA, partial cds
227. Influenza A virus	844 bp	AF362813.1
(A/human/Taiwan/1537/99(H3N2))	linear mRNA	GI: 15055126
hemagglutinin (HA) mRNA, partial cds
228. Influenza A virus (A/Taiwan/1537/	297 bp	AY303728.1
99(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330945
(PB1) mRNA, partial cds
229. Influenza A virus	791 bp	AY604826.1
(A/Taiwan/1566/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727532
mRNA, partial cds
230. Influenza A virus	791 bp	AY604819.1
(A/Taiwan/1568/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727518
mRNA, partial cds
231. Influenza A virus	750 bp	EU068116.1
(A/Taiwan/158/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452105
(HA) mRNA, partial cds
232. Influenza A virus	875 bp	AF138709.2
(A/Taiwan/1600/96(H3N2)) matrix protein	linear mRNA	GI: 4996869
M1 (M) mRNA, partial cds
233. Influenza A virus	750 bp	EU068117.1
(A/Taiwan/1613/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452107
(HA) mRNA, partial cds
234. Influenza A virus	750 bp	EU068148.1
(A/Taiwan/1651/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452169
(HA) mRNA, partial cds
235. Influenza A virus	844 bp	AF362814.1
(A/human/Taiwan/1748/97(H3N2))	linear mRNA	GI: 15055128
hemagglutinin (HA) mRNA, partial cds
236. Influenza A virus (A/Taiwan/1748/	297 bp	AY303729.1
97(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330947
(PB1) mRNA, partial cds
237. Influenza A virus	872 bp	AF138707.2
(A/Taiwan/179/96(H3N2)) matrix protein	linear mRNA	GI: 4996865
M1 (M) mRNA, partial cds
238. Influenza A virus	750 bp	EU068139.1
(A/Taiwan/1817/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452151
(HA) mRNA, partial cds
239. Influenza A virus	750 bp	EU068154.1
(A/Taiwan/1904/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452181
(HA) mRNA, partial cds
240. Influenza A virus	750 bp	EU068155.1
(A/Taiwan/1921/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452183
(HA) mRNA, partial cds
241. Influenza A virus	844 bp	AF362815.1
(A/human/Taiwan/1986/96(H3N2))	linear mRNA	GI: 15055130
hemagglutinin (HA) mRNA, partial cds
242. Influenza A virus (A/Taiwan/1990/	297 bp	AY303730.1
96(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330949
(PB1) mRNA, partial cds
243. Influenza A virus (A/Taiwan/1990/	844 bp	AY303731.1
96(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330951
partial cds
244. Influenza A virus	861 bp	AF139938.1
(A/Taiwan/20/98(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972940
(HA) mRNA, partial cds
245. Influenza A virus	392 bp	AF140627.1
(A/Taiwan/20/98(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972988
(NA) mRNA, partial cds
246. Influenza A virus	875 bp	AF138715.2
(A/Taiwan/20/98(H3N2)) matrix protein	linear mRNA	GI: 4996879
M1 (M) mRNA, partial cds
247. Influenza A virus	844 bp	AF362816.1
(A/human/Taiwan/2031/97(H3N2))	linear mRNA	GI: 15055132
hemagglutinin (HA) mRNA, partial cds
248. Influenza A virus	861 bp	AF139937.1
(A/Taiwan/2034/96(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972938
(HA) mRNA, partial cds
249. Influenza A virus	392 bp	AF140620.1
(A/Taiwan/2034/96(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972974
(NA) mRNA, partial cds
250. Influenza A virus	297 bp	AY303732.1
(A/Taiwan/2034/96(H3N2)) polymerase basic	linear mRNA	GI: 32330953
protein 1 (PB1) mRNA, partial cds
251. Influenza A virus	791 bp	AY604818.1
(A/Taiwan/2040/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727516
mRNA, partial cds
252. Influenza A virus	750 bp	EU068131.1
(A/Taiwan/2072/2006(H3N2)) hemagglutinin	linear mRNA	GI: 158452135
(HA) mRNA, partial cds
253. Influenza A vIrus	861 bp	AF139934.1
(A/Taiwan/21/98(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972932
(HA) mRNA, partial cds
254. Influenza A virus	392 bp	AF140624.1
(A/Taiwan/21/98(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972982
(NA) mRNA, partial cds
255. Influenza A virus	875 bp	AF138716.2
(A/Taiwan/21/98(H3N2)) matrix protein	linear mRNA	GI: 4996881
M1 (M) mRNA, partial cds
256. Influenza A virus	861 bp	AF139932.1
(A/Taiwan/2191/96(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972928
(HA) mRNA, partial cds
257. Influenza A virus	392 bp	AF140622.1
(A/Taiwan/2191/96(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972978
(NA) mRNA, partial cds
258. Influenza A virus	875 bp	AF138711.3
(A/Taiwan/2191/96(H3N2)) matrix protein	linear mRNA	GI: 156147502
M1 (M) mRNA, partial cds
259. Influenza A virus	861 bp	AF139936.1
(A/Taiwan/2192/96(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972936
(HA) mRNA, partial cds
260. Influenza A virus	392 bp	AF140626.1
(A/Taiwan/2192/96(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972986
(NA) mRNA, partial cds
261. Influenza A virus (A/Taiwan/2195/	297 bp	AY303735.1
96(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330959
(PB1) mRNA, partial cds
262. Influenza A virus (A/Taiwan/2195/	844 bp	AY303736.1
96(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330961
partial cds
263. Influenza A virus	875 bp	AF138718.2
(A/Taiwan/224/98(H3N2)) matrix protein	linear mRNA	GI: 4996885
M1 (M) mRNA, partial cds
264. Influenza A virus	844 bp	AF362817.1
(A/human/Taiwan/2548/99(H3N2))	linear mRNA	GI: 15055134
hemagglutinin (HA) mRNA, partial cds
265. Influenza A virus	750 bp	EU068120.1
(A/Taiwan/268/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452113
(HA) mRNA, partial cds
266. Influenza A virus	750 bp	EU068149.1
(A/Taiwan/3008/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452171
(HA) mRNA, partial cds
267. Influenza A virus	750 bp	EU068152.1
(A/Taiwan/3075/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452177
(HA) mRNA, partial cds
268. Influenza A virus	940 bp	AF362818.1
(A/human/Taiwan/3083/00(H3N2))	linear mRNA	GI: 15055136
hemagglutinin (HA) mRNA, partial cds
269. Influenza A virus	791 bp	AY604811.1
(A/Taiwan/3131/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727502
mRNA, partial cds
270. Influenza A virus	750 bp	EU068145.1
(A/Taiwan/3154/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452163
(HA) mRNA, partial cds
271. Influenza A virus	750 bp	EU068141.1
(A/Taiwan/3187/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452155
(HA) mRNA, partial cds
272. Influenza A virus	750 bp	EU068134.1
(A/Taiwan/3245/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452141
(HA) mRNA, partial cds
273. Influenza A virus	750 bp	EU068133.1
(A/Taiwan/3294/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452139
(HA) mRNA, partial cds
274. Influenza A virus	861 bp	AF139935.1
(A/Taiwan/3351/97(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972934
(HA) mRNA, partial cds
275. Influenza A virus	392 bp	AF140625.1
(A/Taiwan/3351/97(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972984
(NA) mRNA, partial cds
276. Influenza A virus	875 bp	AF138713.2
(A/Taiwan/3351/97(H3N2)) matrix protein	linear mRNA	GI: 4996875
M1 (M) mRNA, partial cds
277. Influenza A virus	297 bp	AY303738.1
(A/Taiwan/3351/97(H3N2)) polymerase basic	linear mRNA	GI: 32330965
protein 1 (PB1) mRNA, partial cds
278. Influenza A virus	750 bp	EU068132.1
(A/Taiwan/3387/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452137
(HA) mRNA, partial cds
279. Influenza A virus (A/Taiwan/3396/	297 bp	AY303742.1
97(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330973
(PB1) mRNA, partial cds
280. Influenza A virus (A/Taiwan/3396/	844 bp	AY303743.1
97(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330975
partial cds
281. Influenza A virus	861 bp	AF139930.1
(A/Taiwan/3427/97(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972924
(HA) mRNA, partial cds
282. Influenza A virus	392 bp	AF140619.1
(A/Taiwan/3427/97(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972972
(NA) mRNA, partial cds
283. Influenza A virus	861 bp	AF139940.1
(A/Taiwan/346/98(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972944
(HA) mRNA, partial cds
284. Influenza A virus	392 bp	AF140787.1
(A/Taiwan/346/98(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972992
(NA) mRNA, partial cds
285. Influenza A virus	875 bp	AF138719.2
(A/Taiwan/346/98(H3N2)) matrix protein	linear mRNA	GI: 4996887
M1 (M) mRNA, partial cds
286. Influenza A virus	942 bp	AF362819.1
(A/human/Taiwan/3460/00(H3N2)) truncated	linear mRNA	GI: 15055138
hemagglutinin (HA) mRNA, partial cds
287. Influenza A virus	861 bp	AF139933.1
(A/Taiwan/3469/97(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972930
(HA) mRNA, partial cds
288. Influenza A virus	392 bp	AF140623.1
(A/Taiwan/3469/97(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972980
(NA) mRNA, partial cds
289. Influenza A virus	875 bp	AF138714.2
(A/Taiwan/3469/97(H3N2)) matrix protein	linear mRNA	GI: 4996877
M1 (M) mRNA, partial cds
290. Influenza A virus (A/Taiwan/3503/	297 bp	AY303744.1
97(H3N2)) polymerase basic protein 1	linear mRNA	GI: 32330977
(PB1) mRNA, partial cds
291. Influenza A virus (A/Taiwan/3503/	844 bp	AY303745.1
97(H3N2)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330979
partial cds
292. Influenza A virus	919 bp	AF138712.1
(A/Taiwan/3513/96(H3N2)) matrix protein	linear mRNA	GI: 4928900
M1 (M) mRNA, partial cds
293. Influenza A virus	861 bp	AF139931.1
(A/Taiwan/3513/97(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972926
(HA) mRNA, partial cds
294. Influenza A virus	392 bp	AF140621.1
(A/Taiwan/3513/97(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972976
(NA) mRNA, partial cds
295. Influenza A virus	791 bp	AY604814.1
(A/Taiwan/3744/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727508
mRNA, partial cds
296. Influenza A virus	940 bp	AF362804.1
(A/human/Taiwan/3760/00(H3N2))	linear mRNA	GI: 15055108
hemagglutinin (HA) mRNA, partial cds
297. Influenza A virus (A/Taiwan/3896/	561 bp	AY303747.1
2001(H1N1)) hemagglutinin (HA) mRNA,	linear mRNA	GI: 32330983
partial cds
298. Influenza A virus	791 bp	AY604825.1
(A/Taiwan/4050/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727530
mRNA, partial cds
299. Influenza A virus	791 bp	AY604824.1
(A/Taiwan/4063/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727528
mRNA, partial cds
300. Influenza A virus	750 bp	EU068137.1
(A/Taiwan/41/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452147
(HA) mRNA, partial cds
301. Influenza A virus	861 bp	AF139939.1
(A/Taiwan/45/98(H3N2)) H3 hemagglutinin	linear mRNA	GI: 4972942
(HA) mRNA, partial cds
302. Influenza A virus	392 bp	AF140628.1
(A/Taiwan/45/98(H3N2)) N2 neuraminidase	linear mRNA	GI: 4972990
(NA) mRNA, partial cds
303. Influenza A virus	875 bp	AF138717.2
(A/Taiwan/45/98(H3N2)) matrix protein	linear mRNA	GI: 4996883
M1 (M) mRNA, partial ds
304. Influenza A virus	750 bp	EU068114.1
(A/Taiwan/4548/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452101
(HA) mRNA, partial cds
305. Influenza A virus	791 bp	AY604813.1
(A/Taiwan/4673/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727506
mRNA, partial cds
306. Influenza A virus	791 bp	AY604812.1
(A/Taiwan/4680/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727504
mRNA, partial cds
307. Influenza A virus	750 bp	EU068136.1
(A/Taiwan/4735/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452145
(HA) mRNA, partial cds
308. Influenza A virus	750 bp	EU068142.1
(A/Taiwan/4829/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452157
(HA) mRNA, partial cds
309. Influenza A virus	750 bp	EU068130.1
(A/Taiwan/4836/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452133
(HA) mRNA, partial cds
310. Influenza A virus	750 bp	EU068143.1
(A/Taiwan/4865/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452159
(HA) mRNA, partial cds
311. Influenza A virus	750 bp	EU068121.1
(A/Taiwan/4883/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452115
(HA) mRNA, partial cds
312. Influenza A virus	791 bp	AY604809.1
(A/Taiwan/4938/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727498
mRNA, partial cds
313. Influenza A virus	791 bp	AY604815.1
(A/Taiwan/4954/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727510
mRNA, partial cds
314. Influenza A virus	791 bp	AY604810.1
(A/Taiwan/4963/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727500
mRNA, partial cds
315. Influenza A virus	750 bp	EU068122.1
(A/Taiwan/4987/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452117
(HA) mRNA, partial cds
316. Influenza A virus	750 bp	EU068127.1
(A/Taiwan/4990/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452127
(HA) mRNA, partial cds
317. Influenza A virus	750 bp	EU068118.1
(A/Taiwan/5/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452109
(HA) mRNA, partial cds
318. Influenza A virus	791 bp	AY604816.1
(A/Taiwan/5153/2002(H3N2)) hemagglutinin	linear mRNA	GI: 50727512
mRNA, partial cds
319. Influenza A virus	750 bp	EU068128.1
(A/Taiwan/5267/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452129
(HA) mRNA, partial cds
320. Influenza A virus	750 bp	EU068146.1
(A/Taiwan/556/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452165
(HA) mRNA, partial cds
321. Influenza A virus	750 bp	EU068126.1
(A/Taiwan/5694/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452125
(HA) mRNA, partial cds
322. Influenza A virus	750 bp	EU068147.1
(A/Taiwan/587/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452167
(HA) mRNA, partial cds
323. Influenza A virus	750 bp	EU068151.1
(A/Taiwan/592/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452175
(HA) mRNA, partial cds
324. Influenza A virus	791 bp	AY604829.1
(A/Taiwan/7099/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727538
mRNA, partial cds
325. Influenza A virus	791 bp	AY604830.1
(A/Taiwan/7100/2003(H3N2)) hemagglutinin	linear mRNA	GI: 50727540
mRNA, partial cds
326. Influenza A virus	750 bp	EU068150.1
(A/Taiwan/7196/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452173
(HA) mRNA, partial cds
327. Influenza A virus	750 bp	EU068135.1
(A/Taiwan/7568/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452143
(HA) mRNA, partial cds
328. Influenza A virus	750 bp	EU068144.1
(A/Taiwan/7601/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452161
(HA) mRNA, partial cds
329. Influenza A virus	750 bp	EU068124.1
(A/Taiwan/7681/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452121
(HA) mRNA, partial cds
330. Influenza A virus	750 bp	EU068123.1
(A/Taiwan/7702/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452119
(HA) mRNA, partial cds
331. Influenza A virus	750 bp	EU068129.1
(A/Taiwan/7873/2005(H3N2)) hemagglutinin	linear mRNA	GI: 158452131
(HA) mRNA, partial cds
332. Influenza A virus	750 bp	EU068115.1
(A/Taiwan/8/2003(H3N2)) hemagglutinin	linear mRNA	GI: 158452103
(HA) mRNA, partial cds
333. Influenza A virus	750 bp	EU068140.1
(A/Taiwan/93/2004(H3N2)) hemagglutinin	linear mRNA	GI: 158452153
(HA) mRNA, partial cds
334. Influenza A virus	528 bp	AY962016.1
(A/Taoyuan/108/02(H3N2)) hemagglutinin	linear mRNA	GI: 68138189
(HA) mRNA, partial cds
335. Influenza A virus	754 bp	AY973338.1
(A/Taoyuan/108/02(H3N2)) neuraminidase	linear mRNA	GI: 70673232
(NA) mRNA, partial cds
336. Influenza A virus	882 bp	AY986998.1
(A/Taoyuan/108/02(H3N2)) nucleoprotein	linear mRNA	GI: 70728123
(NP) mRNA, partial cds
337. Influenza A virus	1,410 bp	EU021285.1
(A/Thailand/CU124/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224724
(NA) mRNA, complete cds
338. Influenza A virus	1,701 bp	EU021284.1
(A/Thailand/CU124/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224795
(HA) mRNA, complete cds
339. Influenza A virus	1,410 bp	EU021275.1
(A/Thailand/CU228/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224714
(NA) mRNA, complete cds
340. Influenza A virus	1,701 bp	EU021274.1
(A/Thailand/CU228/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224785
(HA) mRNA, complete cds
341. Influenza A virus	1,347 bp	EU021267.1
(A/Thailand/CU23/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224706
(NA) mRNA, partial cds
342. Influenza A virus	1,701 bp	EU021266.1
(A/Thailand/CU23/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224777
(HA) mRNA, complete cds
343. Influenza A virus	1,410 bp	EU021283.1
(A/Thailand/CU231/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224722
(NA) mRNA, complete cds
344. Influenza A virus	1,701 bp	EU021282.1
(A/Thailand/CU231/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224793
(HA) mRNA, complete cds
345. Influenza A virus	1,410 bp	EU021279.1
(A/Thailand/CU259/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224718
(NA) mRNA, complete cds
346. Influenza A virus	1,701 bp	EU021278.1
(A/Thailand/CU259/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224789
(HA) mRNA, complete cds
347. Influenza A virus	1,410 bp	EU021281.1
(A/Thailand/CU260/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224720
(NA) mRNA, complete cds
348. Influenza A virus	1,129 bp	EU021280.1
(A/Thailand/CU260/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224791
(HA) mRNA, partial cds
349. Influenza A virus	1,410 bp	EU021271.1
(A/Thailand/CU272/2007(H3N2)) neuraminidase	linear mRNA	GI: 154224710
(NA) mRNA, complete cds
350. Influenza A virus	1,701 bp	EU021270.1
(A/Thailand/CU272/2007(H3N2)) hemagglutinin	linear mRNA	GI: 154224781
(HA) mRNA, complete cds
351. Influenza A virus	1,410 bp	EU021273.1
(A/Thailand/CU280/2007(H3N2)) neuraminidase	linear mRNA	GI: 154224712
(NA) mRNA, complete cds
352. Influenza A virus	1,701 bp	EU021272.1
(A/Thailand/CU280/2007(H3N2)) hemagglutinin	linear mRNA	GI: 154224783
(HA) mRNA, complete cds
353. Influenza A virus	1,410 bp	EU021277.1
(A/Thailand/CU282/2007(H3N2)) neuraminidase	linear mRNA	GI: 154224716
(NA) mRNA, complete cds
354. Influenza A virus	1,701 bp	EU021276.1
(A/Thailand/CU282/2007(H3N2)) hemagglutinin	linear mRNA	GI: 154224787
(HA) mRNA, complete cds
355. Influenza A virus	1,413 bp	EU021265.1
(A/Thailand/CU32/2006(H1N1)) neuraminidase	linear mRNA	GI: 154224704
(NA) mRNA, complete cds
361. Influenza A virus	1,410 bp	EU021269.1
(A/Thailand/CU46/2006(H3N2)) neuraminidase	linear mRNA	GI: 154224708
(NA) mRNA, complete cds
362. Influenza A virus	1,701 bp	EU021268.1
(A/Thailand/CU46/2006(H3N2)) hemagglutinin	linear mRNA	GI: 154224779
(HA) mRNA, complete cds
377. Influenza A virus	987 bp	U77837.1
(A/Tottori/849AM1AL3/1994(H3N2))	linear mRNA	GI: 2992515
hemagglutinin (HA) mRNA, partial cds
378. Influenza A virus	987 bp	U77833.1
(A/Tottori/849AM2/1994(H3N2)) hemagglutinin	linear mRNA	GI: 2992507
(HA) mRNA, partial cds
379. Influenza A virus	987 bp	U77839.1
(A/Tottori/849AM2AL3/1994(H3N2))	linear mRNA	GI: 2992519
hemagglutinin (HA) mRNA, partial cds
380. Influenza A virus	987 bp	U77835.1
(A/Tottori/849AM4/1994(H3N2)) hemagglutinin	linear mRNA	GI: 2992511
(HA) mRNA, partial cds
382. Influenza A virus	987 bp	U77834.1
(A/Tottori/872AM2/1994(H3N2)) hemagglutinin	linear mRNA	GI: 2992509
(HA) mRNA, partial cds
383. Influenza A virus	987 bp	U77840.1
(A/Tottori/872AM2AL3/1994(H3N2))	linear mRNA	GI: 2992521
hemagglutinin (HA) mRNA, partial cds
384. Influenza A virus	987 bp	U77836.1
(A/Tottori/872AM4/1994(H3N2)) hemagglutinin	linear mRNA	GI: 2992513
(HA) mRNA, partial cds
385. Influenza A virus	987 bp	U77832.1
(A/Tottori/872K4/1994(H3N2)) hemagglutinin	linear mRNA	GI: 2992505
(HA) mRNA, partial cds
386. Influenza A virus (A/United	987 bp	AF501529.1
Kingdom/26554/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314314
(HA) mRNA, partial cds
387. Influenza A virus (A/United	987 bp	AF501527.1
Kingdom/34300/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314310
(HA) mRNA, partial cds
388. Influenza A virus	987 bp	AF501533.1
(A/Utah/20997/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314322
(HA) mRNA, partial cds
389. Influenza A virus (A/Victoria/3/75)	1,565 bp	AF072545.1
segment 5 nucleoprotein mRNA,	linear mRNA	GI: 4218933
complete cds
390. Influenza A virus	1,762 bp	AF017270.2
(A/Vienna/47/96M(H3N2)) hemagglutinin	linear mRNA	GI: 14286338
(HA) mRNA, complete cds
391. Influenza A virus	1,762 bp	AF017272.2
(A/Vienna/47/96V(H3N2)) hemagglutinin	linear mRNA	GI: 15004991
(HA) mRNA, complete cds
392. Influenza A virus	1,069 bp	AF017271.1
(A/Vienna/81/96V(H3N2)) hemagglutinin	linear mRNA	GI: 2407251
(HA) mRNA, partial cds
393. Influenza A virus	987 bp	AF501532.1
(A/Virginia/21712/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314320
(HA) mRNA, partial cds
394. Influenza A virus	987 bp	AF501515.1
(A/Virginia/21716/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314286
(HA) mRNA, partial cds
395. Influenza A virus	987 bp	AF501530.1
(A/Virginia/21735/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314316
(HA) mRNA, partial cds
396. Influenza A virus	987 bp	AF501524.1
(A/Virginia/21743/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314304
(HA) mRNA, partial cds
397. Influenza A virus	987 bp	AF501519.1
(A/Virginia/21754/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314294
(HA) mRNA, partial cds
398. Influenza A virus	987 bp	AF501523.1
(A/Virginia/21799/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314302
(HA) mRNA, partial cds
399. Influenza A virus	987 bp	AF501525.1
(A/Virginia/21817/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314306
(HA) mRNA, partial cds
400. Influenza A virus	987 bp	AF501520.1
(A/Virginia/21822/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314296
(HA) mRNA, partial cds
401. Influenza A virus	987 bp	AF501528.1
(A/Virginia/21828/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314312
(HA) mRNA, partial cds
402. Influenza A virus	987 bp	AF501517.1
(A/Virginia/21833/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314290
(HA) mRNA, partial cds
403. Influenza A virus	987 bp	AF501522.1
(A/Virginia/21845/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314300
(HA) mRNA, partial cds
404. Influenza A virus	987 bp	AF501535.1
(A/Virginia/21847/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314326
(HA) mRNA, partial cds
405. Influenza A virus	987 bp	AF501521.1
(A/Virginia/G1/99(H3N2)) hemagglutinin	linear mRNA	GI: 21314298
(HA) mRNA, partial cds
406. Influenza A virus	755 bp	AY973339.1
(A/Yilan/508/03(H3N2)) neuraminidase	linear mRNA	GI: 70673234
(NA) mRNA, partial cds
407. Influenza A virus	882 bp	AY986999.1
(A/Yilan/508/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728125
(NP) mRNA, partial cds
408. Influenza A virus	740 bp	AY962015.1
(A/Yilan/513/03(H3N2)) hemagglutinin	linear mRNA	GI: 68138187
(HA) mRNA, partial cds
409. Influenza A virus	396 bp	AY973340.1
(A/Yilan/513/03(H3N2)) neuraminidase	linear mRNA	GI: 70673236
(NA) mRNA, partial cds
410. Influenza A virus	882 bp	AY987000.1
(A/Yilan/513/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728127
(NP) mRNA, partial cds
411. Influenza A virus	511 bp	AY962010.1
(A/Yilan/515/03(H3N2)) hemagglutinin	linear mRNA	GI: 68138177
(HA) mRNA, partial cds
412. Influenza A virus	394 bp	AY973341.1
(A/Yilan/515/03(H3N2)) neuraminidase	linear mRNA	GI: 70673238
(NA) mRNA, partial cds
413. Influenza A virus	882 bp	AY987001.1
(A/Yilan/516/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728129
(NP) mRNA, partial cds
414. Influenza A virus	530 bp	AY962006.1
(A/Yilan/518/03(H3N2)) hemagglutinin	linear mRNA	GI: 68138169
(HA) mRNA, partial cds
415. Influenza A virus	397 bp	AY973342.1
(A/Yilan/518/03(H3N2)) neuraminidase	linear mRNA	GI: 70673240
(NA) mRNA, partial cds
416. Influenza A virus	882 bp	AY987002.1
(A/Yilan/518/03(H3N2)) nucleoprotein	linear mRNA	GI: 70728131
(NP) mRNA, partial cds
417. Influenza A virus	777 bp	AY962002.1
(A/Yilan/538/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138161
(HA) mRNA, partial cds
418. Influenza A virus	783 bp	AY973343.1
(A/Yilan/538/04(H3N2)) neuraminidase	linear mRNA	GI: 70673242
(NA) mRNA, partial cds
419. Influenza A virus	882 bp	AY987003.1
(A/Yilan/538/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728133
(NP) mRNA, partial cds
420. Influenza A virus	788 bp	AY962003.1
(A/Yilan/549/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138163
(HA) mRNA, partial cds
421. Influenza A virus	779 bp	AY973344.1
(A/Yilan/549/04(H3N2)) neuraminidase	linear mRNA	GI: 70673244
(NA) mRNA, partial cds
422. Influenza A virus	882 bp	AY987004.1
(A/Yilan/549/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728135
(NP) mRNA, partial cds
423. Influenza A virus	776 bp	AY962013.1
(A/Yilan/557/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138183
(HA) mRNA, partial cds
424. Influenza A virus	796 bp	AY973345.1
(A/Yilan/557/04(H3N2)) neuraminidase	linear mRNA	GI: 70673246
(NA) mRNA, partial cds
425. Influenza A virus	882 bp	AY987005.1
(A/Yilan/557/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728137
(NP) mRNA, partial cds
426. Influenza A virus	753 bp	AY962014.1
(A/Yilan/566/04(H3N2)) hemagglutinin	linear mRNA	GI: 68138185
(HA) mRNA, partial cds
427. Influenza A virus	808 bp	AY973346.1
(A/Yilan/566/04(H3N2)) neuraminidase	linear mRNA	GI: 70673248
(NA) mRNA, partial cds
428. Influenza A virus	882 bp	AY987006.1
(A/Yilan/566/04(H3N2)) nucleoprotein	linear mRNA	GI: 70728139
(NP) mRNA, partial cds
429. Influenza A virus	987 bp	AY138513.1
(A/zhejiang/06/99(H3N2)) hemagglutinin	linear mRNA	GI: 24895131
(HA) mRNA, partial cds
430. Influenza A virus	987 bp	AY138515.1
(A/zhejiang/10/98(H3N2)) hemagglutinin	linear mRNA	GI: 24895149
(HA) mRNA, partial cds
431. Influenza A virus	987 bp	AY138516.1
(A/zhejiang/11/2002(H3N2)) hemagglutinin	linear mRNA	GI: 24895159
(HA) mRNA, partial cds
432. Influenza A virus	987 bp	AY138514.1
(A/zhejiang/12/99(H3N2)) hemagglutinin-like	linear mRNA	GI: 24895141
(HA) mRNA, partial sequence
433. Influenza A virus	987 bp	AY138519.1
(A/zhejiang/8/2002(H3N2)) hemagglutinin	linear mRNA	GI: 24895188
(HA) mRNA, partial cds
434. Influenza A virus H3N2 strain	840 bp	U65670.1
A/Akita/1/94 nonstructural protein 1 and	linear mRNA	GI: 3929405
nonstructural protein 2 mRNAs,
complete cds
435. Influenza A virus H3N2 strain	840 bp	U65671.1
A/Akita/1/95 nonstructural protein 1 and	linear mRNA	GI: 3929408
nonstructural protein 2 mRNAs,
complete cds
436. Influenza A virus H3N2 strain	840 bp	U65673.1
A/Shiga/20/95 nonstructural protein 1 and	linear mRNA	GI: 3929411
nonstructural protein 2 mRNAs,
complete cds
437. Influenza A virus H3N2 strain	840 bp	U65674.1
A/Miyagi/69/95 nonstructural protein 1 and	linear mRNA	GI: 3929414
nonstructural protein 2 mRNAs,
complete cds
438. Influenza A virus H3N2 strain	840 bp	U65672.1
A/Hebei/19/95 nonstructural protein 1 and	linear mRNA	GI: 6468319
nonstructural protein 2 mRNAs,
complete cds
A/Aichi/69/1994(H3N2) haemagglutinin		U48446.1
A/Bangkok/1/1979 (H3N2) hemagglutinin (HA)		AF201843.1
A/Beijing/353/89(H3) hemagglutinin (HA)		U97740.1
A/Beijing/353/1989(H3N2) haemagglutinin		Z46391.1
A/chicken/Singapore/2002(H3N2) M2 protein		EU014143.1
A/Christ Hospital/231/82(H3N2))		U77830.1
hemagglutinin (HA)
A/duck/Eastern China/36/2002(H3N2)		EU429701.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/160/2003(H3N2)		EU429732.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/848/2003(H3N2)		EU429721.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/770/2003(H3N2)		EU429736.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/855/2003(H3N2)		EU429737.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/875/2003(H3N2)		EU429738.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/901/2003(H3N2)		EU429739.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/866/2003(H3N2)		EU429756.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/857/2003(H3N2)		EU429761.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/852/2003(H3N2)		EU429767.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/838/2003(H3N2)		EU429720.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/6/2004(H3N2)		EU429745.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/03/2005(H3N2)		EU429781.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/02/2006(H3N2)		EU429769.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/04/2006(H3N2)		EU429770.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/21/2006(H3N2)		EU429771.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/23/2006(H3N2)		EU429772.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/31/2006(H3N2)		EU429773.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/35/2006(H3N2)		EU429768.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/42/2006(H3N2)		EU429774.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/53/2006(H3N2)		EU429775.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/60/2006(H3N2)		EU429776.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/62/2006(H3N2)		EU429784.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/63/2006(H3N2)		EU429777.1
segment 6 neuraminidase (NA)
A/duck/Eastern China/142/2006(H3N2)		EU429742.1
segment 6 neuraminidase (NA)
A/Dunedin/4/1973 (H3N2) hemagglutinin		AF201842.1
(HA)

TABLE 9
Influenza H5N1 Antigens
		GenBank/GI
Strain/Protein	Length	Accession No.
1. Influenza A virus (A/chicken/Burkina	827 bp linear	AM503036.1
Faso/01.03/2006(H5N1)) mRNA for non-	mRNA	GI:147846308
structural protein (ns gene)
2. Influenza A virus (A/chicken/Burkina	990 bp linear	AM503007.1
Faso/13.1/2006(H5N1)) partial mRNA for	mRNA	GI:147846250
matrix protein 1 (m1 gene)
3. Influenza A virus (A/chicken/Burkina	1,529 bp	AM503029.1
Faso/13.1/2006(H5N1)) mRNA for nucleoprotein	linear mRNA	GI:147846294
(np gene)
4. Influenza A virus (A/chicken/Burkina	827 bp linear	AM503037.1
Faso/13.1/2006(H5N1)) mRNA for non-	mRNA	GI:147846310
structural protein (ns gene)
5. Influenza A virus (A/chicken/Burkina	2,169 bp	AM503046.1
Faso/13.1/2006(H5N1)) partial mRNA for	linear mRNA	GI:147846328
polymerase (pa gene)
6. Influenza A virus (A/chicken/Burkina	2,259 bp	AM503056.1
Faso/13.1/2006(H5N1)) partial mRNA for	linear mRNA	GI:147846348
polymerase basic protein 1 (pb1 gene)
7. Influenza A virus (A/chicken/Burkina	2,315 bp	AM503067.1
Faso/13.1/2006(H5N1)) partial mRNA for	linear mRNA	GI:147846859
polymerase basic protein 2 (pb2 gene)
8. Influenza A virus	1,736 bp	DQ023145.1
(A/chicken/China/1/02(H5N1)) hemagglutinin	linear mRNA	GI:66775624
(HA) mRNA, complete cds
9. Influenza A virus	1,509 bp	DQ023146.1
(A/chicken/China/1/02(H5N1)) nucleoprotein	linear mRNA	GI:66775626
(NP) mRNA, complete cds
10. Influenza A virus	1,379 bp	DQ023147.1
(A/chicken/China/1/02(H5N1)) neuraminidase	linear mRNA	GI:66775628
(NA) mRNA, complete cds
11. Influenza A virus	999 bp linear	DQ650660.1
(A/chicken/Crimea/04/2005(H5N1)) matrix	mRNA	GI:109692767
protein (M) mRNA, complete cds
12. Influenza A virus	850 bp linear	DQ650662.1
(A/chicken/Crimea/04/2005(H5N1))	mRNA	GI:109692771
nonstructural protein (NS) mRNA, complete cds
13 . Influenza A virus	994 bp linear	DQ650664.1
(A/chicken/Crimea/08/2005(H5N1)) matrix	mRNA	GI:109692775
protein (M) mRNA, complete cds
14. Influenza A virus	1,532 bp	DQ650666.1
(A/chicken/Crimea/08/2005(H5N1))	linear mRNA	GI:109692779
nucleoprotein (NP) mRNA, complete cds
15. Influenza A virus	850 bp linear	DQ65066 7.1
(A/chicken/Crimea/08/2005(H5N1))	mRNA	GI:109692781
nonstructural protein (NS) mRNA, complete cds
16. Influenza A virus	2,208 bp	DQ650668.1
(A/chicken/Crimea/08/2005(H5N1)) polymerase	linear mRNA	GI:109692783
acidic protein (PA) mRNA, complete cds
17. Influenza A virus	2,305 bp	DQ650670.1
(A/chicken/Crimea/08/2005(H5N1)) polymerase	linear mRNA	GI:109692787
basic protein 2 (PB2) mRNA, complete cds
18. Influenza A virus	1,015 bp	DQ676838.1
(A/chicken/Dovolnoe/03/2005(H5N1))	linear mRNA	GI:108782527
hemagglutinin (HA) mRNA, partial cds
20. Influenza A virus	2,341 bp	DQ366327.1
(A/chicken/Guangxi/12/2004(H5N1)) polymerase	linear mRNA	GI:86753731
PB2 mRNA, complete cds
21. Influenza A virus	2,341 bp	DQ366328.1
(A/chicken/Guangxi/12/2004(H5N1)) polymerase	linear mRNA	GI:86753741
PB1 mRNA, complete cds
22. Influenza A virus	2,233 bp	DQ366329.1
(A/chicken/Guangxi/12/2004(H5N1)) PA protein	linear mRNA	GI:86753751
mRNA, complete cds
23 . Influenza A virus	1,565 bp	DQ366331.1
(A/chicken/Guangxi/12/2004(H5N1))	linear mRNA	GI:86753771
nucleocapsid mRNA, complete cds
24. Influenza A virus	1,027 bp	DQ366333.1
(A/chicken/Guangxi/12/2004(H5N1)) matrix	linear mRNA	GI:86753791
protein mRNA, complete cds
25. Influenza A virus (A/chicken/Hong	1,718 bp	AF057291.1
Kong/258/97(H5N1)) hemagglutinin mRNA,	linear mRNA	GI:3068720
complete cds
26. Influenza A virus (A/chicken/Hong	1,318 bp	AF057292.1
Kong/258/97(H5N1)) neuraminidase mRNA,	linear mRNA	GI:3068722
partial cds
27. Influenza A virus (A/chicken/Hong	1,508 bp	AF057293.1
Kong/258/97(H5N1)) nucleoprotein mRNA,	linear mRNA	GI:3068724
complete cds
28. Influenza A virus (A/Chicken/Hong	1,726 bp	AF082034.1
Kong/728/97 (H5N1)) hemagglutinin H5 mRNA,	linear mRNA	GI:4240435
complete cds
29. Influenza A virus (A/Chicken/Hong	1,726 bp	AF082035.1
Kong/786/97 (H5N1)) hemagglutinin H5 mRNA,	linear mRNA	GI:4240437
complete cds
30. Influenza A virus (A/chicken/Hong	1,726 bp	AF082036.1
Kong/915/97(H5N1)) hemagglutinin H5 mRNA,	linear mRNA	GI:4240439
complete cds
31. Influenza A virus (A/chicken/Hong	1,091 bp	AF082037.1
Kong/990/97 (H5N1)) hemagglutinin H5 mRNA,	linear mRNA	GI:4240441
partial cds
32. Influenza A virus	1,002 bp	DQ676835.1
(A/chicken/Krasnodar/01/2006(H5N1)) matrix	linear mRNA	GI:108782521
protein 1 (M) mRNA, complete cds
33. Influenza A virus	850 bp linear	DQ676837.1
(A/chicken/Krasnodar/01/2006(H5N1))	mRNA	GI:108782525
nonstructural protein (NS) mRNA, complete cds
34. Influenza A virus	1,754 bp	DQ449632.1
(A/chicken/Kurgan/05/2005(H5N1))	linear mRNA	GI:90289625
hemagglutinin (HA) mRNA, complete cds
35. Influenza A virus	1,002 bp	DQ449633.1
(A/chicken/Kurgan/05/2005(H5N1)) matrix	linear mRNA	GI:90289627
protein 1 (M) mRNA, complete cds
36. Influenza A virus	1,373 bp	DQ449634.1
(A/chicken/Kurgan/05/2005(H5N1))	linear mRNA	GI:90289629
neuraminidase (NA) mRNA, complete cds
37. Influenza A virus	1,540 bp	DQ449635.1
(A/chicken/Kurgan/05/2005(H5N1))	linear mRNA	GI:90289631
nucleoprotein (NP) mRNA, complete cds
38. Influenza A virus	850 bp linear	DQ449636.1
(A/chicken/Kurgan/05/2005(H5N1))	mRNA	GI:90289633
nonstructural protein (NS) mRNA, complete cds
39. Influenza A virus	2,208 bp	DQ449637.1
(A/chicken/Kurgan/05/2005(H5N1)) polymerase	linear mRNA	GI:90289635
acidic protein (PA) mRNA, complete cds
40. Influenza A virus	2,316 bp	DQ449638.1
(A/chicken/Kurgan/05/2005(H5N1)) polymerase	linear mRNA	GI:90289637
basic protein 1 (PB1) mRNA, complete cds
41. Influenza A virus	2,316 bp	DQ449639.1
(A/chicken/Kurgan/05/2005(H5N1)) polymerase	linear mRNA	GI:90289646
basic protein 2 (PB2) mRNA, complete cds
42 . Influenza A virus	184 bp linear	EU447276.1
(A/chicken/Lobzenko/01/2008(H5N1))	mRNA	GI:168998217
hemagglutinin (HA) mRNA, partial cds
43. Influenza A virus	1,002 bp	DQ676831.1
(A/chicken/Mahachkala/05/2006(H5N1)) matrix	linear mRNA	GI:108782513
protein 1 (M) mRNA, complete cds
44. Influenza A virus	850 bp linear	DQ676833.1
(A/chicken/Mahachkala/05/2006(H5N1))	mRNA	GI:108782517
nonstructural protein (NS) mRNA, complete cds
45. Influenza A virus	1,531 bp	AM503030.1
(A/chicken/Nigeria/AB13/2006(H5N1)) mRNA for	linear mRNA	GI:147846296
nucleoprotein (np gene)
46 . Influenza A virus	827 bp linear	AM503040.1
(A/chicken/Nigeria/AB13/2006(H5N1)) mRNA for	mRNA	GI:147846316
non-structural protein (ns gene)
47. Influenza A virus	2,169 bp	AM503051.1
(A/chicken/Nigeria/AB13/2006(H5N1)) partial	linear mRNA	GI:147846338
mRNA for polymerase (pa gene)
48. Influenza A virus	2,259 bp	AM503060.1
(A/chicken/Nigeria/AB13/2006(H5N1)) partial	linear mRNA	GI:147846845
mRNA for polymerase basic protein 1 (pb1 gene)
49. Influenza A virus	2,315 bp	AM503071.1
(A/chicken/Nigeria/AB13/2006(H5N1)) partial	linear mRNA	GI:147846867
mRNA for polymerase basic protein 2 (pb2 gene)
70. Influenza A virus (A/chicken/Hong	1,055 bp	DQ250158.1
Kong/3123.1/2002(H5N1)) neuraminidase (NA)	linear mRNA	GI:82412012
mRNA, partial cds
75. Influenza A virus	1,754 bp	DQ676834.1
(A/chicken/Krasnodar/01/2006(H5N1))	linear mRNA	GI:108782519
hemagglutinin (HA) mRNA, complete cds
78. Influenza A virus	1,373 bp	DQ676836.2
(A/chicken/Krasnodar/01/2006(H5N1))	linear mRNA	GI:115520953
neuraminidase (NA) mRNA, complete cds
91. Influenza A virus	184 bp linear	EU447276.1
(A/chicken/Lobzenko/01/2008(H5N1))	mRNA	GI:168998217
hemagglutinin (HA) mRNA, partial cds
92 . Influenza A virus	1,683 bp	DQ676830.1
(A/chicken/Mahachkala/05/2006(H5N1))	linear mRNA	GI:108782511
hemagglutinin (HA) mRNA, complete cds
94. Influenza A virus	1,373 bp	DQ676832.1
(A/chicken/Mahachkala/05/2006(H5N1))	linear mRNA	GI:108782515
neuraminidase (NA) mRNA, complete cds
96 . Influenza A virus	433 bp linear	DQ096567.1
(A/chicken/Malaysia/01/2004(H5N1))	mRNA	GI:69145364
neuramidase (NA) mRNA, partial cds
97. Influenza A virus	1,722 bp	AM503002.1
(A/chicken/Nigeria/AB13/2006(H5N1)) partial	linear mRNA	GI:147846240
mRNA for hemagglutinin (ha gene)
98. Influenza A virus	1,329 bp	AM503020.1
(A/chicken/Nigeria/AB13/2006(H5N1)) partial	linear mRNA	GI:147846276
mRNA for neuraminidase (na gene)
105. Influenza A virus	1,719 bp	AM503003.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	linear mRNA	GI:147846242
mRNA for hemagglutinin (ha gene)
106. Influenza A virus	953 bp linear	AM503011.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	mRNA	GI:147846258
mRNA for matrix protein 1 (m1 gene)
107. Influenza A virus	1,343 bp	AM503025.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	linear mRNA	GI:147846286
mRNA for neuraminidase (na gene)
108. Influenza A virus	827 bp linear	AM503041.1
(A/chicken/Nigeria/AB14/2006(H5N1)) mRNA for	mRNA	GI:147846318
non-structural protein (ns gene)
109. Influenza A virus	2,169 bp	AM503054.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	linear mRNA	GI:147846344
mRNA for polymerase (pa gene)
110. Influenza A virus	2,259 bp	AM503061.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	linear mRNA	GI:147846847
mRNA for polymerase basic protein 1 (pb1 gene)
111. Influenza A virus	2,315 bp	AM503072.1
(A/chicken/Nigeria/AB14/2006(H5N1)) partial	linear mRNA	GI:147846869
mRNA for polymerase basic protein 2 (pb2 gene)
112. Influenza A virus	1,548 bp	AM503034.2
(A/chicken/Nigeria/AB14/2006(H5N1)) mRNA for	linear mRNA	GI:149773117
nucleoprotein (np gene)
113. Influenza A virus	1,342 bp	AM503022.1
(A/chicken/Nigeria/BA210/2006(H5N1)) partial	linear mRNA	GI:147846280
mRNA for neuraminidase (na gene)
114. Influenza A virus	1,321 bp	AM503021.1
(A/chicken/Nigeria/BA211/2006(H5N1)) partial	linear mRNA	GI:147846278
mRNA for neuraminidase (na gene)
115. Influenza A virus	2,315 bp	AM503073.1
(A/chicken/Nigeria/BA211/2006(H5N1)) partial	linear mRNA	GI:147846871
mRNA for polymerase basic protein 2 (pb2 gene)
116. Influenza A virus	1,717 bp	AM503004.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	linear mRNA	GI:147846244
raRNA for hemagglutinin (ha gene)
117. Influenza A virus	989 bp linear	AM503013.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	mRNA	GI:147846262
mRNA for matrix protein 1 (m1 gene)
118. Influenza A virus	1,321 bp	AM503026.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	linear mRNA	GI:147846288
mRNA for neuraminidase (na gene)
119. Influenza A virus	827 bp linear	AM503045.1
(A/chicken/Nigeria/FA4/2006(H5N1)) mRNA for	mRNA	GI:147846326
non-structural protein (ns gene)
120. Influenza A virus	2,169 bp	AM503055.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	linear mRNA	GI:147846346
mRNA for polymerase (pa gene)
121. Influenza A virus	2,259 bp	AM503064.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	linear mRNA	GI:147846853
mRNA for polymerase basic protein 1 (pb1 gene)
122. Influenza A virus	2,224 bp	AM503074.1
(A/chicken/Nigeria/FA4/2006(H5N1)) partial	linear mRNA	GI:147846873
mRNA for polymerase basic protein 2 (pb2 gene)
123. Influenza A virus	1,717 bp	AM502998.1
(A/chicken/Nigeria/FA6/2006(H5N1)) partial	linear mRNA	GI:147846232
mRNA for hemagglutinin (ha gene)
124. Influenza A virus	965 bp linear	AM503012.1
(A/chicken/Nigeria/FA6/2006(H5N1)) partial	mRNA	GI:147846260
mRNA for matrix protein 1 (m1 gene)
125. Influenza A virus	1,327 bp	AM503023.1
(A/chicken/Nigeria/FA6/2006(H5N1)) partial	linear mRNA	GI:147846282
mRNA for neuraminidase (na gene)
126. Influenza A virus	1,543 bp	AM503031.1
(A/chicken/Nigeria/FA6/2006(H5N1)) mRNA for	linear mRNA	GI:147846298
nucleoprotein (np gene)
127. Influenza A virus	2,169 bp	AM503052.1
(A/chicken/Nigeria/FA6/2006(H5N1)) partial	linear mRNA	GI:147846340
mRNA for polymerase (pa gene)
128. Influenza A virus	2,259 bp	AM503063.1
(A/chicken/Nigeria/FA6/2006(H5N1)) partial	linear mRNA	GI:147846851
mRNA for polymerase basic protein 1 (pb1 gene)
129. Influenza A virus	1,710 bp	AM502999.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846234
mRNA for hemagglutinin (ha gene)
130. Influenza A virus	1,001 bp	AM503009.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846254
mRNA for matrix protein 1 (m1 gene)
131. Influenza A virus	1,331 bp	AM503018.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846272
mRNA for neuraminidase (na gene)
132. Influenza A virus	1,531 bp	AM503035.1
(A/chicken/Nigeria/FA7/2006(H5N1)) mRNA for	linear mRNA	GI:147846306
nucleoprotein (np gene)
133. Influenza A virus	827 bp linear	AM503042.1
(A/chicken/Nigeria/FA7/2006(H5N1)) mRNA for	mRNA	GI:147846320
non-structural protein (ns gene)
134. Influenza A virus	2,169 bp	AM503049.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846334
mRNA for polymerase (pa gene)
135. Influenza A virus	2,259 bp	AM503057.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846350
raRNA for polymerase basic protein 1 (pb1 gene)
136. Influenza A virus	2,315 bp	AM503068.1
(A/chicken/Nigeria/FA7/2006(H5N1)) partial	linear mRNA	GI:147846861
mRNA for polymerase basic protein 2 (pb2 gene)
137. Influenza A virus	1,714 bp	AM503001.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	linear mRNA	GI:147846238
mRNA for hemagglutinin (ha gene)
138. Influenza A virus	990 bp linear	AM503010.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	mRNA	GI:147846256
mRNA for matrix protein 1 (m1 gene)
139. Influenza A virus	1,332 bp	AM503024.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	linear mRNA	GI:147846284
mRNA for neuraminidase (na gene)
140. Influenza A virus	827 bp linear	AM503044.1
(A/chicken/Nigeria/IF10/2006(H5N1)) mRNA for	mRNA	GI:147846324
non-structural protein (ns gene)
141. Influenza A virus	2,169 bp	AM503053.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	linear mRNA	GI:147846342
mRNA for polymerase (pa gene)
142. Influenza A virus	2,259 bp	AM503059.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	linear mRNA	GI:147846843
mRNA for polymerase basic protein 1 (pb1 gene)
143. Influenza A virus	2,315 bp	AM503069.1
(A/chicken/Nigeria/IF10/2006(H5N1)) partial	linear mRNA	GI:147846863
mRNA for polymerase basic protein 2 (pb2 gene)
144. Influenza A virus	1,550 bp	AM503033.2
(A/chicken/Nigeria/IF10/2006(H5N1)) mRNA for	linear mRNA	GI:149773115
nucleoprotein (np gene)
145. Influenza A virus	1,719 bp	AM503005.1
(A/chicken/Nigeria/OD8/2006(H5N1)) partial	linear mRNA	GI:147846246
mRNA for hemagglutinin (ha gene)
146. Influenza A virus	989 bp linear	AM503014.1
(A/chicken/Nigeria/OD8/2006(H5N1)) partial	mRNA	GI:147846264
mRNA for matrix protein 1 (m1 gene)
147. Influenza A virus	1,720 bp	AM503000.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	linear mRNA	GI:147846236
mRNA for hemagglutinin (ha gene)
148. Influenza A virus	988 bp linear	AM503015.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	mRNA	GI:147846266
mRNA for matrix protein 1 (m1 gene)
149. Influenza A virus	1,330 bp	AM503019.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	linear mRNA	GI:147846274
mRNA for neuraminidase (na gene)
150. Influenza A virus	1,531 bp	AM503032.1
(A/chicken/Nigeria/OD9/2006(H5N1)) mRNA for	linear mRNA	GI:147846300
nucleoprotein (np gene)
151. Influenza A virus	827 bp linear	AM503043.1
(A/chicken/Nigeria/OD9/2006(H5N1)) mRNA for	mRNA	GI:147846322
non-structural protein (ns gene)
152. Influenza A virus	2,169 bp	AM503050.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	linear mRNA	GI:147846336
mRNA for polymerase (pa gene)
153. Influenza A virus	2,259 bp	AM503058.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	linear mRNA	GI:147846841
raRNA for polymerase basic protein 1 (pb1 gene)
154. Influenza A virus	2,315 bp	AM503070.1
(A/chicken/Nigeria/OD9/2006(H5N1)) partial	linear mRNA	GI:147846865
mRNA for polymerase basic protein 2 (pb2 gene)
155. Influenza A virus	1,768 bp	X07869.1
(A/chicken/Scotland/59(H5N1)) mRNA for	linear mRNA	GI:60482
haemaggiutinin precursor
156. Influenza A virus	1,445 bp	AJ416625.1
(A/chicken/Scotland/59(H5N1)) N1 gene for	linear mRNA	GI:39840717
neuraminidase, genomic RNA
161. Influenza A virus	1,497 bp	DQ208502.1
(A/chicken/zz/02/2004(H5N1)) nucleoprotein	linear mRNA	GI:77158587
mRNA, complete cds
162. Influenza A virus (A/common	1,707 bp	EF110519.1
coot/Switzerland/V544/2006(H5N1))	linear mRNA	GI:119394676
hemagglutinin (HA) gene, complete cds
163. Influenza A virus (A/domestic	1,735 bp	EU190482.1
goose/Pavlodar/1/2005(H5N1)) hemagglutinin	linear mRNA	GI:158516739
(HA) mRNA, complete cds
164. Influenza A virus (A/duck/Eastern	1,401 bp	EU429750.1
China/145/2003(H5N1)) segment 6	linear mRNA	GI:167859465
neuraminidase (NA) mRNA, complete cds
165. Influenza A virus (A/duck/Eastern	1,407 bp	EU429731.1
China/150/2003(H5N1)) segment 6	linear mRNA	GI:167859427
neuraminidase (NA) mRNA, complete cds
166. Influenza A virus (A/duck/Eastern	1,398 bp	EU429783.1
China/22/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859531
(NA) mRNA, complete cds
167. Influenza A virus (A/duck/Eastern	1,398 bp	EU429747.1
China/304/2002(H5N1)) segment 6	linear mRNA	GI:167859459
neuraminidase (NA) mRNA, complete cds
168. Influenza A virus (A/duck/Eastern	1,401 bp	EU429727.1
China/318/2002(H5N1)) segment 6	linear mRNA	GI:167859419
neuraminidase (NA) mRNA, complete cds
169. Influenza A virus (A/duck/Eastern	1,399 bp	EU429778.1
China/37/2006(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859521
(NA) mRNA, complete cds
170. Influenza A virus (A/duck/Eastern	1,398 bp	EU429757.1
China/40/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859479
(NA) mRNA, complete cds
171. Influenza A virus (A/duck/Eastern	1,398 bp	EU429779.1
China/48/2006(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859523
(NA) mRNA, complete cds
172. Influenza A virus (A/duck/Eastern	1,398 bp	EU429763.1
China/51/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859491
(NA) mRNA, complete cds
173. Influenza A virus (A/duck/Eastern	1,398 bp	EU429758.1
China/54/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859481
(NA) mRNA, complete cds
174. Influenza A virus (A/duck/Eastern	1,398 bp	EU429764.1
China/58/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859493
(NA) mRNA, complete cds
175. Influenza A virus (A/duck/Eastern	1,398 bp	EU429759.1
China/59/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859483
(NA) mRNA, complete cds
176. Influenza A virus (A/duck/Eastern	1,398 bp	EU429765.1
China/89/2005(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859495
(NA) mRNA, complete cds
177. Influenza A virus (A/duck/Eastern	1,399 bp	EU429785.1
China/89/2006(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859535
(NA) mRNA, complete cds
178. Influenza A virus (A/duck/Eastern	1,398 bp	EU429717.1
China/97/2001(H5N1)) segment 6 neuraminidase	linear mRNA	GI:167859399
(NA) mRNA, complete cds
179. Influenza A virus	2,281 bp	AY585504.1
(A/duck/Fujian/01/2002(H5N1)) polymerase	linear mRNA	GI:47156226
basic protein 2 (PB2) mRNA, complete cds
180. Influenza A virus	760 bp linear	AY585378.1
(A/duck/Fujian/01/2002(H5N1)) matrix protein	mRNA	GI:47156310
mRNA, complete cds
181. Influenza A virus	1,357 bp	AY585399.1
(A/duck/Fujian/01/2002(H5N1)) neuraminidase	linear mRNA	GI:47156352
(NA) mRNA, complete cds
182. Influenza A virus	1,497 bp	AY585420.1
(A/duck/Fujian/01/2002(H5N1)) nucleoprotein	linear mRNA	GI:47156394
(NP) mRNA, complete cds
183. Influenza A virus	686 bp linear	AY585441.1
(A/duck/Fujian/01/2002(H5N1)) nonstructural	mRNA	GI:47156436
protein 1 (NS1) mRNA, partial cds
184. Influenza A virus	2,281 bp	AY585505.1
(A/duck/Fujian/13/2002(H5N1)) polymerase	linear mRNA	GI:47156228
basic protein 2 (PB2) mRNA, complete cds
185. Influenza A virus	761 bp linear	AY585379.1
(A/duck/Fujian/13/2002(H5N1)) matrix protein	mRNA	GI:47156312
mRNA, complete cds
186. Influenza A virus	1,357 bp	AY585400.1
(A/duck/Fujian/13/2002(H5N1)) neuraminidase	linear mRNA	GI:47156354
(NA) mRNA, complete cds
187. Influenza A virus	1,499 bp	AY585421.1
(A/duck/Fujian/13/2002(H5N1)) nucleoprotein	linear mRNA	GI:47156396
(NP) mRNA, complete cds
188. Influenza A virus	685 bp linear	AY585442.1
(A/duck/Fujian/13/2002(H5N1)) nonstructural	mRNA	GI:47156438
protein 1 (NS1) mRNA, partial cds
189. Influenza A virus	2,281 bp	AY585506.1
(A/duck/Fujian/17/2001(H5N1)) polymerase	linear mRNA	GI:47156230
basic protein 2 (PB2) mRNA, complete cds
190. Influenza A virus	759 bp linear	AY585380.1
(A/duck/Fujian/17/2001(H5N1)) matrix protein	mRNA	GI:47156314
mRNA, complete cds
191. Influenza A virus	1,418 bp	AY585401.1
(A/duck/Fujian/17/2001(H5N1)) neuraminidase	linear mRNA	GI:47156356
(NA) mRNA, complete cds
192. Influenza A virus	1,498 bp	AY585422.1
(A/duck/Fujian/17/2001(H5N1)) nucleoprotein	linear mRNA	GI:47156398
(NP) mRNA, complete cds
193. Influenza A virus	686 bp linear	AY585443.1
(A/duck/Fujian/17/2001(H5N1)) nonstructural	mRNA	GI:47156440
protein 1 (NS1) mRNA, complete cds
194. Influenza A virus	2,281 bp	AY585507.1
(A/duck/Fujian/19/2000(H5N1)) polymerase	linear mRNA	GI:47156232
basic protein 2 (PB2) mRNA, complete cds
195. Influenza A virus	760 bp linear	AY585381.1
(A/duck/Fujian/19/2000(H5N1)) matrix protein	mRNA	GI:47156316
mRNA, complete cds
196. Influenza A virus	1,355 bp	AY585402.1
(A/duck/Fujian/19/2000(H5N1)) neuraminidase	linear mRNA	GI:47156358
(NA) mRNA, complete cds
197. Influenza A virus	1,498 bp	AY585423.1
(A/duck/Fujian/19/2000(H5N1)) nucleoprotein	linear mRNA	GI:47156400
(NP) mRNA, complete cds
198. Influenza A virus	687 bp linear	AY585444.1
(A/duck/Fujian/19/2000(H5N1)) nonstructural	mRNA	GI:47156442
protein 1 (NS1) mRNA, complete cds
199. Influenza A virus	2,281 bp	AY585508.1
(A/duck/Guangdong/01/2001(H5N1)) polymerase	linear mRNA	GI:47156234
basic protein 2 (PB2) mRNA, complete cds
200. Influenza A virus	760 bp linear	AY585382.1
(A/duck/Guangdong/01/2001(H5N1)) matrix	mRNA	GI:47156318
protein mRNA, complete cds
201. Influenza A virus	1,414 bp	AY585403.1
(A/duck/Guangdong/01/2001(H5N1))	linear mRNA	GI:47156360
neuraminidase (NA) mRNA, complete cds
202. Influenza A virus	1,497 bp	AY585424.1
(A/duck/Guangdong/01/2001(H5N1))	linear mRNA	GI:47156402
nucleoprotein (NP) mRNA, complete cds
203. Influenza A virus	687 bp linear	AY585445.1
(A/duck/Guangdong/01/2001(H5N1))	mRNA	GI:47156444
nonstructural protein 1 (NS1) mRNA, complete cds
204. Influenza A virus	2,280 bp	AY585509.1
(A/duck/Guangdong/07/2000(H5N1)) polymerase	linear mRNA	GI:47156236
basic protein 2 (PB2) mRNA, complete cds
205. Influenza A virus	759 bp linear	AY585383.1
(A/duck/Guangdong/07/2000(H5N1)) matrix	mRNA	GI:47156320
protein mRNA, complete cds
206. Influenza A virus	1,417 bp	AY585404.1
(A/duck/Guangdong/07/2000(H5N1))	linear mRNA	GI:47156362
neuraminidase (NA) mRNA, complete cds
207. Influenza A virus	1,497 bp	AY585425.1
(A/duck/Guangdong/07/2000(H5N1))	linear mRNA	GI:47156404
nucleoprotein (NP) mRNA, complete cds
208. Influenza A virus	690 bp linear	AY585446.1
(A/duck/Guangdong/07/2000(H5N1))	mRNA	GI:47156446
nonstructural protein 1 (NS1) mRNA, partial cds
209. Influenza A virus	2,281 bp	AY585510.1
(A/duck/Guangdong/12/2000(H5N1)) polymerase	linear mRNA	GI:47156238
basic protein 2 (PB2) mRNA, complete cds
210. Influenza A virus	760 bp linear	AY585384.1
(A/duck/Guangdong/12/2000(H5N1)) matrix	mRNA	GI:47156322
protein mRNA, complete cds
211. Influenza A virus	1,359 bp	AY585405.1
(A/duck/Guangdong/12/2000(H5N1))	linear mRNA	GI:47156364
neuraminidase (NA) mRNA, complete cds
212. Influenza A virus	1,498 bp	AY585426.1
(A/duck/Guangdong/12/2000(H5N1))	linear mRNA	GI:47156406
nucleoprotein (NP) mRNA, complete cds
213. Influenza A virus	685 bp linear	AY585447.1
(A/duck/Guangdong/12/2000(H5N1))	mRNA	GI:47156448
nonstructural protein 1 (NS1) mRNA, partial cds
214. Influenza A virus	2,281 bp	AY585511.1
(A/duck/Guangdong/22/2002(H5N1)) polymerase	linear mRNA	GI:47156240
basic protein 2 (PB2) mRNA, complete cds
215. Influenza A virus	760 bp linear	AY585385.1
(A/duck/Guangdong/22/2002(H5N1)) matrix	mRNA	GI:47156324
protein mRNA, complete cds
216. Influenza A virus	1,412 bp	AY585406.1
(A/duck/Guangdong/22/2002(H5N1))	linear mRNA	GI:47156366
neuraminidase (NA) mRNA, complete cds
217. Influenza A virus	1,499 bp	AY585427.1
(A/duck/Guangdong/22/2002(H5N1))	linear mRNA	GI:47156408
nucleoprotein (NP) mRNA, complete cds
218. Influenza A virus	682 bp linear	AY585448.1
(A/duck/Guangdong/22/2002(H5N1))	mRNA	GI:47156450
nonstructural protein 1 (NS1) mRNA, complete cds
219. Influenza A virus	2,281 bp	AY585512.1
(A/duck/Guangdong/40/2000(H5N1)) polymerase	linear mRNA	GI:47156242
basic protein 2 (PB2) mRNA, complete cds
220. Influenza A virus	760 bp linear	AY585386.1
(A/duck/Guangdong/40/2000(H5N1)) matrix	mRNA	GI:47156326
protein mRNA, complete cds
221. Influenza A virus	1,401 bp	AY585407.1
(A/duck/Guangdong/40/2000(H5N1))	linear mRNA	GI:47156368
neuraminidase (NA) mRNA, partial cds
222. Influenza A virus	1,499 bp	AY585428.1
(A/duck/Guangdong/40/2000(H5N1))	linear mRNA	GI:47156410
nucleoprotein (NP) mRNA, complete cds
223. Influenza A virus	689 bp linear	AY585449.1
(A/duck/Guangdong/40/2000(H5N1))	mRNA	GI:47156452
nonstructural protein 1 (NS1) mRNA, partial cds
224. Influenza A virus	2,281 bp	AY585513.1
(A/duck/Guangxi/07/1999(H5N1)) polymerase	linear mRNA	GI:47156244
basic protein 2 (PB2) mRNA, complete cds
225. Influenza A virus	760 bp linear	AY585387.1
(A/duck/Guangxi/07/1999(H5N1)) matrix	mRNA	GI:47156328
protein mRNA, complete cds
226. Influenza A virus	1,421 bp	AY585408.1
(A/duck/Guangxi/07/1999(H5N1)) neuraminidase	linear mRNA	GI:47156370
(NA) mRNA, complete cds
227. Influenza A virus	1,501 bp	AY585429.1
(A/duck/Guangxi/07/1999(H5N1)) nucleoprotein	linear mRNA	GI:47156412
(NP) mRNA, complete cds
228. Influenza A virus	687 bp linear	AY585450.1
(A/duck/Guangxi/07/1999(H5N1)) nonstructural	mRNA	GI:47156454
protein 1 (NS1) mRNA, partial cds
229. Influenza A virus	875 bp linear	DQ366342.1
(A/duck/Guangxi/13/2004(H5N1)) nonstructural	mRNA	GI:86753723
protein 1 mRNA, complete cds
230. Influenza A virus	2,341 bp	DQ366335.1
(A/duck/Guangxi/13/2004(H5N1)) polymerase	linear mRNA	GI:86753733
PB2 mRNA, complete cds
231. Influenza A virus	2,341 bp	DQ366336.1
(A/duck/Guangxi/13/2004(H5N1)) polymerase	linear mRNA	GI:86753743
PB1 mRNA, complete cds
232. Influenza A virus	2,233 bp	DQ366337.1
(A/duck/Guangxi/13/2004(H5N1)) PA protein	linear mRNA	GI:86753753
mRNA, complete cds
233. Influenza A virus	1,776 bp	DQ366338.1
(A/duck/Guangxi/13/2004(H5N1)) hemagglutinin	linear mRNA	GI:86753763
mRNA, complete cds
234. Influenza A virus	1,565 bp	DQ366339.1
(A/duck/Guangxi/13/2004(H5N1)) nucleocapsid	linear mRNA	GI:86753773
mRNA, complete cds
235. Influenza A virus	1,378 bp	DQ366340.1
(A/duck/Guangxi/13/2004(H5N1)) neuraminidase	linear mRNA	GI:86753783
mRNA, complete cds
236. Influenza A virus	1,027 bp	DQ366341.1
(A/duck/Guangxi/13/2004(H5N1)) matrix	linear mRNA	GI:86753793
protein mRNA, complete cds
237. Influenza A virus	2,281 bp	AY585514.1
(A/duck/Guangxi/22/2001(H5N1)) polymerase	linear mRNA	GI:47156246
basic protein 2 (PB2) mRNA, complete cds
238. Influenza A virus	757 bp linear	AY585388.1
(A/duck/Guangxi/22/2001(H5N1)) matrix	mRNA	GI:47156330
protein mRNA, partial cds
239. Influenza A virus	1,414 bp	AY585409.1
(A/duck/Guangxi/22/2001(H5N1)) neuraminidase	linear mRNA	GI:47156372
(NA) mRNA, complete cds
240. Influenza A virus	1,498 bp	AY585430.1
(A/duck/Guangxi/22/2001(H5N1)) nucleoprotein	linear mRNA	GI:47156414
(NP) mRNA, complete cds
241. Influenza A virus	687 bp linear	AY585451.1
(A/duck/Guangxi/22/2001(H5N1)) nonstructural	mRNA	GI:47156456
protein 1 (NS1) mRNA, complete cds
242. Influenza A virus	2,281 bp	AY585515.1
(A/duck/Guangxi/35/2001(H5N1)) polymerase	linear mRNA	GI:47156248
basic protein 2 (PB2) mRNA, complete cds
243. Influenza A virus	760 bp linear	AY585389.1
(A/duck/Guangxi/35/2001(H5N1)) matrix	mRNA	GI:47156332
protein mRNA, complete cds
244. Influenza A virus	1,414 bp	AY585410.1
(A/duck/Guangxi/35/2001(H5N1)) neuraminidase	linear mRNA	GI:47156374
(NA) mRNA, complete cds
245. Influenza A virus	1,498 bp	AY585431.1
(A/duck/Guangxi/35/2001(H5N1)) nucleoprotein	linear mRNA	GI:47156416
(NP) mRNA, complete cds
246. Influenza A virus	685 bp linear	AY585452.1
(A/duck/Guangxi/35/2001(H5N1)) nonstructural	mRNA	GI:47156458
protein 1 (NS1) mRNA, complete cds
247. Influenza A virus	2,281 bp	AY585516.1
(A/duck/Guangxi/50/2001(H5N1)) polymerase	linear mRNA	GI:47156250
basic protein 2 (PB2) mRNA, complete cds
248. Influenza A virus	760 bp linear	AY585398.1
(A/duck/Guangxi/50/2001(H5N1)) matrix	mRNA	GI:47156350
protein mRNA, complete cds
249. Influenza A virus	1,354 bp	AY585411.1
(A/duck/Guangxi/50/2001(H5N1)) neuraminidase	linear mRNA	GI:47156376
(NA) mRNA, complete cds
250. Influenza A virus	1,498 bp	AY585432.1
(A/duck/Guangxi/50/2001(H5N1)) nucleoprotein	linear mRNA	GI:47156418
(NP) mRNA, complete cds
251. Influenza A virus	686 bp linear	AY585453.1
(A/duck/Guangxi/50/2001(H5N1)) nonstructural	mRNA	GI:47156460
protein 1 (NS1) mRNA, complete cds
252. Influenza A virus	2,281 bp	AY585517.1
(A/duck/Guangxi/53/2002(H5N1)) polymerase	linear mRNA	GI:47156252
basic protein 2 (PB2) mRNA, complete cds
253. Influenza A virus	760 bp linear	AY585390.1
(A/duck/Guangxi/53/2002(H5N1)) matrix	mRNA	GI:47156334
protein mRNA, complete cds
254. Influenza A virus	1,361 bp	AY585412.1
(A/duck/Guangxi/53/2002(H5N1)) neuraminidase	linear mRNA	GI:47156378
(NA) mRNA, complete cds
255. Influenza A virus	1,498 bp	AY585433.1
(A/duck/Guangxi/53/2002(H5N1)) nucleoprotein	linear mRNA	GI:47156420
(NP) mRNA, complete cds
256. Influenza A virus	687 bp linear	AY585454.1
(A/duck/Guangxi/53/2002(H5N1)) nonstructural	mRNA	GI:47156462
protein 1 (NS1) mRNA, partial cds
257. Influenza A virus	1,754 bp	DQ449640.1
(A/duck/Kurgan/08/2005(H5N1)) hemagglutinin	linear mRNA	GI:90289674
(HA) mRNA, complete cds
258. Influenza A virus	1,002 bp	DQ449641.1
(A/duck/Kurgan/08/2005(H5N1)) matrix protein	linear mRNA	GI:90289689
1 (M) mRNA, complete cds
259. Influenza A virus	1,373 bp	DQ449642.1
(A/duck/Kurgan/08/2005(H5N1)) neuraminidase	linear mRNA	GI:90289708
(NA) mRNA, complete cds
260. Influenza A virus	1,540 bp	DQ449643.1
(A/duck/Kurgan/08/2005(H5N1)) nucleoprotein	linear mRNA	GI:90289731
(NP) mRNA, complete cds
261. Influenza A virus	850 bp linear	DQ449644.1
(A/duck/Kurgan/08/2005(H5N1)) nonstructural	mRNA	GI:90289739
protein (NS) mRNA, complete cds
262. Influenza A virus	2,208 bp	DQ449645.1
(A/duck/Kurgan/08/2005(H5N1)) polymerase	linear mRNA	GI:90289756
acidic protein (PA) mRNA, complete cds
263. Influenza A virus	2,316 bp	DQ449646.1
(A/duck/Kurgan/08/2005(H5N1)) polymerase	linear mRNA	GI:90289774
basic protein 1 (PB1) mRNA, complete cds
264. Influenza A virus	2,316 bp	DQ449647.1
(A/duck/Kurgan/08/2005(H5N1)) polymerase	linear mRNA	GI:90289783
basic protein 2 (PB2) mRNA, complete cds
266. Influenza A virus	2,281 bp	AY585518.1
(A/duck/Shanghai/08/2001(H5N1)) polymerase	linear mRNA	GI:47156254
basic protein 2 (PB2) mRNA, complete cds
267. Influenza A virus	760 bp linear	AY585391.1
(A/duck/Shanghai/08/2001(H5N1)) matrix	mRNA	GI:47156336
protein mRNA, complete cds
268. Influenza A virus	1,357 bp	AY585413.1
(A/duck/Shanghai/08/2001(H5N1))	linear mRNA	GI:47156380
neuraminidase (NA) mRNA, complete cds
269. Influenza A virus	1,498 bp	AY585434.1
(A/duck/Shanghai/08/2001(H5N1))	linear mRNA	GI:47156422
nucleoprotein (NP) mRNA, complete cds
270. Influenza A virus	685 bp linear	AY585455.1
(A/duck/Shanghai/08/2001(H5N1))	mRNA	GI:47156464
nonstructural protein 1 (NS1) mRNA, partial cds
271. Influenza A virus	2,281 bp	AY585519.1
(A/duck/Shanghai/13/2001(H5N1)) polymerase	linear mRNA	GI:47156256
basic protein 2 (PB2) mRNA, complete cds
272. Influenza A virus	760 bp linear	AY585392.1
(A/duck/Shanghai/13/2001(H5N1)) matrix	mRNA	GI:47156338
protein mRNA, complete cds
273. Influenza A virus	1,417 bp	AY585414.1
(A/duck/Shanghai/13/2001(H5N1))	linear mRNA	GI:47156382
neuraminidase (NA) mRNA, complete cds
274. Influenza A virus	1,499 bp	AY585435.1
(A/duck/Shanghai/13/2001(H5N1))	linear mRNA	GI:47156424
nucleoprotein (NP) mRNA, complete cds
275. Influenza A virus	685 bp linear	AY585456.1
(A/duck/Shanghai/13/2001(H5N1))	mRNA	GI:47156466
nonstructural protein 1 (NS1) mRNA, complete cds
276. Influenza A virus	2,281 bp	AY585520.1
(A/duck/Shanghai/35/2002(H5N1)) polymerase	linear mRNA	GI:47156258
basic protein 2 (PB2) mRNA, complete cds
277. Influenza A virus	760 bp linear	AY585393.1
(A/duck/Shanghai/35/2002(H5N1)) matrix	mRNA	GI:47156340
protein mRNA, complete cds
278. Influenza A virus	1,363 bp	AY585415.1
(A/duck/Shanghai/35/2002(H5N1))	linear mRNA	GI:47156384
neuraminidase (NA) mRNA, complete cds
279. Influenza A virus	1,498 bp	AY585436.1
(A/duck/Shanghai/35/2002(H5N1))	linear mRNA	GI:47156426
nucleoprotein (NP) mRNA, complete cds
280. Influenza A virus	685 bp linear	AY585457.1
(A/duck/Shanghai/35/2002(H5N1))	mRNA	GI:47156468
nonstructural protein 1 (NS1) mRNA, partial cds
281. Influenza A virus	2,281 bp	AY585521.1
(A/duck/Shanghai/37/2002(H5N1)) polymerase	linear mRNA	GI:47156260
basic protein 2 (PB2) mRNA, complete cds
282. Influenza A virus	760 bp linear	AY585394.1
(A/duck/Shanghai/37/2002(H5N1)) matrix	mRNA	GI:47156342
protein mRNA, complete cds
283. Influenza A virus	1,361 bp	AY585416.1
(A/duck/Shanghai/37/2002(H5N1))	linear mRNA	GI:47156386
neuraminidase (NA) mRNA, complete cds
284. Influenza A virus	1,497 bp	AY585437.1
(A/duck/Shanghai/37/2002(H5N1))	linear mRNA	GI:47156428
nucleoprotein (NP) mRNA, complete cds
285. Influenza A virus	685 bp linear	AY585458.1
(A/duck/Shanghai/37/2002(H5N1))	mRNA	GI:47156470
nonstructural protein 1 (NS1) mRNA, partial cds
286. Influenza A virus	2,282 bp	AY585522.1
(A/duck/Shanghai/38/2001(H5N1)) polymerase	linear mRNA	GI:47156262
basic protein 2 (PB2) mRNA, complete cds
287. Influenza A virus	760 bp linear	AY585395.1
(A/duck/Shanghai/38/2001(H5N1)) matrix	mRNA	GI:47156344
protein mRNA, complete cds
288. Influenza A virus	1,355 bp	AY585417.1
(A/duck/Shanghai/38/2001(H5N1))	linear mRNA	GI:47156388
neuraminidase (NA) mRNA, complete cds
289. Influenza A virus	1,499 bp	AY585438.1
(A/duck/Shanghai/38/2001(H5N1))	linear mRNA	GI:47156430
nucleoprotein (NP) mRNA, complete cds
290. Influenza A virus	692 bp linear	AY585459.1
(A/duck/Shanghai/38/2001(H5N1))	mRNA	GI:47156472
nonstructural protein 1 (NS1) mRNA, partial cds
291. Influenza A virus	875 bp linear	DQ354059.1
(A/duck/Sheyang/1/2005(H5N1)) nonstructural	mRNA	GI:87128643
protein (NS) mRNA, complete cds
292. Influenza A virus	1,748 bp	DQ861291.1
(A/duck/Tuva/01/2006(H5N1)) hemagglutinin	linear mRNA	GI:112820195
(HA) mRNA, complete cds
293. Influenza A virus	991 bp linear	DQ861292.1
(A/duck/Tuva/01/2006(H5N1)) matrix protein 1	mRNA	GI:112820197
(Ml) mRNA, complete cds
294. Influenza A virus	1,364 bp	DQ861293.1
(A/duck/Tuva/01/2006(H5N1)) neuraminidase	linear mRNA	GI:112820199
(NA) mRNA, complete cds
295. Influenza A virus	1,531 bp	DQ861294.1
(A/duck/Tuva/01/2006(H5N1)) nucleoprotein	linear mRNA	GI:112820201
(NP) mRNA, complete cds
296. Influenza A virus	842 bp linear	DQ861295.1
(A/duck/Tuva/01/2006(H5N1)) nonstructural	mRNA	GI:112820203
protein (NS) mRNA, complete cds
297. Influenza A virus	890 bp linear	DQ366310.1
(A/duck/Vietnam/1/2005(H5N1)) nonstructural	mRNA	GI:86753715
protein 1 mRNA, complete cds
298. Influenza A virus	2,341 bp	DQ366303.1
(A/duck/Vietnam/1/2005(H5N1)) polymerase PB2	linear mRNA	GI:86753725
mRNA, complete cds
299. Influenza A virus	2,341 bp	DQ366304.1
(A/duck/Vietnam/1/2005(H5N1)) polymerase PB1	linear mRNA	GI:86753735
mRNA, complete cds
300. Influenza A virus	2,233 bp	DQ366305.1
(A/duck/Vietnam/1/2005(H5N1)) PA protein	linear mRNA	GI:86753745
mRNA, complete cds
301. Influenza A virus	1,779 bp	DQ366306.1
(A/duck/Vietnam/1/2005(H5N1)) hemagglutinin	linear mRNA	GI:86753755
mRNA, complete cds
302. Influenza A virus	1,565 bp	DQ366307.1
(A/duck/Vietnam/1/2005(H5N1)) nucleocapsid	linear mRNA	GI:86753765
mRNA, complete cds
303. Influenza A virus	1,401 bp	DQ366308.1
(A/duck/Vietnam/1/2005(H5N1)) neuraminidase	linear mRNA	GI:86753775
mRNA, complete cds
304. Influenza A virus	1,027 bp	DQ366309.1
(A/duck/Vietnam/1/2005(H5N1)) matrix protein	linear mRNA	GI:86753785
mRNA, complete cds
305. Influenza A virus	890 bp linear	DQ366326.1
(A/duck/Vietnam/8/05(H5N1)) nonstructural	mRNA	GI:86753719
protein 1 mRNA, complete cds
306. Influenza A virus	2,341 bp	DQ366319.1
(A/duck/Vietnam/8/05(H5N1)) polymerase PB2	linear mRNA	GI:86753729
mRNA, complete cds
307. Influenza A virus	2,341 bp	DQ366320.1
(A/duck/Vietnam/8/05(H5N1)) polymerase PB1	linear mRNA	GI:86753739
mRNA, complete cds
308. Influenza A virus	2,233 bp	DQ366321.1
(A/duck/Vietnam/8/05(H5N1)) PA protein mRNA,	linear mRNA	GI:86753749
complete cds
309. Influenza A virus	1,779 bp	DQ366322.1
(A/duck/Vietnam/8/05(H5N1)) hemagglutinin	linear mRNA	GI:86753759
mRNA, complete cds
310. Influenza A virus	1,565 bp	DQ366323.1
(A/duck/Vietnam/8/05(H5N1)) nucleocapsid	linear mRNA	GI:86753769
mRNA, complete cds
311. Influenza A virus	1,401 bp	DQ366324.1
(A/duck/Vietnam/8/05(H5N1)) neuraminidase	linear mRNA	GI:86753779
mRNA, complete cds
312. Influenza A virus	1,027 bp	DQ366325.1
(A/duck/Vietnam/8/05(H5N1)) matrix protein	linear mRNA	GI:86753789
mRNA, complete cds
313. Influenza A virus	876 bp linear	DQ354060.1
(A/duck/Yangzhou/232/2004(H5N1))	mRNA	GI:87128645
nonfunctional nonstructural protein (NS)
mRNA, complete sequence
314. Influenza A virus	2,281 bp	AY585523.1
(A/duck/Zhejiang/11/2000(H5N1)) polymerase	linear mRNA	GI:47156264
basic protein 2 (PB2) mRNA, complete cds
315. Influenza A virus	760 bp linear	AY585396.1
(A/duck/Zhejiang/11/2000(H5N1)) matrix	mRNA	GI:47156346
protein mRNA, complete cds
316. Influenza A virus	1,352 bp	AY585418.1
(A/duck/Zhejiang/11/2000(H5N1))	linear mRNA	GI:47156390
neuraminidase (NA) mRNA, complete cds
317. Influenza A virus	1,498 bp	AY585439.1
(A/duck/Zhejiang/11/2000(H5N1))	linear mRNA	GI:47156432
nucleoprotein (NP) mRNA, complete cds
318. Influenza A virus	687 bp linear	AY585460.1
(A/duck/Zhejiang/11/2000(H5N1))	mRNA	GI:47156474
nonstructural protein 1 (NS1) mRNA, partial cds
319. Influenza A virus	2,281 bp	AY585524.1
(A/duck/Zhejiang/52/2000(H5N1)) polymerase	linear mRNA	GI:47156266
basic protein 2 (PB2) mRNA, complete cds
320. Influenza A virus	760 bp linear	AY585397.1
(A/duck/Zhejiang/52/2000(H5N1)) matrix	mRNA	GI:47156348
protein mRNA, complete cds
321. Influenza A virus	1,423 bp	AY585419.1
(A/duck/Zhejiang/52/2000(H5N1))	linear mRNA	GI:47156392
neuraminidase (NA) mRNA, complete cds
322. Influenza A virus	1,499 bp	AY585440.1
(A/duck/Zhejiang/52/2000(H5N1))	linear mRNA	GI:47156434
nucleoprotein (NP) mRNA, complete cds
323. Influenza A virus	686 bp linear	AY585461.1
(A/duck/Zhejiang/52/2000(H5N1))	mRNA	GI:47156476
nonstructural protein 1 (NS1) mRNA, complete cds
324. Influenza A virus (A/Egypt/0636-	1,749 bp	EF382359.1
NAMRU3/2007(H5N1)) hemagglutinin (HA) mRNA,	linear mRNA	GI:124244205
complete cds
325. Influenza A virus	1,707 bp	EF110518.1
(A/goosander/Switzerland/V82/06 (H5N1))	linear mRNA	GI:119394674
hemagglutinin (HA) gene, complete cds
326. Influenza A virus	1,707 bp	AF148678.1
(A/goose/Guangdong/1/96/(H5N1))	linear mRNA	GI:5007022
hemagglutinin mRNA, complete cds
327. Influenza A virus	1,779 bp	DQ201829.1
(A/Goose/Huadong/1/2000(H5N1)) hemagglutinin	linear mRNA	GI:76786306
(HA) mRNA, complete cds
328. Influenza A virus	1,458 bp	DQ201830.1
(A/Goose/Huadong/1/2000(H5N1)) neuraminidase	linear mRNA	GI:76786308
(NA) mRNA, complete cds
329. Influenza A virus	2,287 bp	EF446768.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428373
polymerase PB1 (PB1) mRNA, partial cds
330. Influenza A virus	2,274 bp	EF446769.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428375
polymerase PB2 (PB2) mRNA, partial cds
331. Influenza A virus	2,175 bp	EF446770.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428377
polymerase PA (PA) mRNA, complete cds
332. Influenza A virus	1,735 bp	EF446771.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428379
hemagglutinin (HA) mRNA, complete cds
333. Influenza A virus	1,473 bp	EF446772.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428381
nucleocapsid protein (NP) mRNA, partial cds
334. Influenza A virus	1,311 bp	EF446773.1
(A/goose/Hungary/2823/2/2007(H5N1))	linear mRNA	GI:126428383
neuraminidase (NA) mRNA, partial cds
335. Influenza A virus	971 bp linear	EF446774.1
(A/goose/Hungary/2823/2/2007(H5N1)) matrix	mRNA	GI:126428385
protein 1 (M1) mRNA, partial cds
336. Influenza A virus	795 bp linear	EF446775.1
(A/goose/Hungary/2823/2/2007(H5N1))	mRNA	GI:126428387
nonstructural protein 1 (NS1) mRNA, partial cds
337. Influenza A virus	2,277 bp	EF446776.1
(A/goose/Hungary/3413/2007(H5N1)) polymerase	linear mRNA	GI:126428389
PB1 (PB1) mRNA, partial cds
338. Influenza A virus	2,274 bp	EF446777.1
(A/goose/Hungary/3413/2007(H5N1)) polymerase	linear mRNA	GI:126428391
PB2 (PB2) mRNA, partial cds
339. Influenza A virus	2,163 bp	EF446778.1
(A/goose/Hungary/3413/2007 (H5N1)) polymerase	linear mRNA	GI:126428393
PA (PA) mRNA, partial cds
340. Influenza A virus	1,722 bp	EF446779.1
(A/goose/Hungary/3413/2007 (H5N1))	linear mRNA	GI:126428395
hemagglutinin (HA) mRNA, complete cds
341. Influenza A virus	1,463 bp	EF446780.1
(A/goose/Hungary/3413/2007 (H5N1))	linear mRNA	GI:126428397
nucleocapsid protein (NP) mRNA, partial cds
342. Influenza A virus	1,289 bp	EF446781.1
(A/goose/Hungary/3413/2007(H5N1))	linear mRNA	GI:126428399
neuraminidase (NA) mRNA, partial cds
343. Influenza A virus	955 bp linear	EF446782.1
(A/goose/Hungary/3413/2007(H5N1)) matrix	mRNA	GI:126428401
protein 1 (M1) mRNA, partial cds
344. Influenza A virus	805 bp linear	EF446783.1
(A/goose/Hungary/3413/2007(H5N1))	mRNA	GI:126428403
nonstructural protein 1 (NS1) mRNA, complete cds
345. Influenza A virus	877 bp linear	DQ354061.1
(A/goose/jiangsu/131/2002(H5N1))	mRNA	GI:87128646
nonfunctional nonstructural protein (NS)
mRNA, complete sequence
346. Influenza A virus	875 bp linear	DQ354062.1
(A/goose/Jiangsu/220/2003(H5N1))	mRNA	GI:87128647
nonstructural protein (NS) mRNA, complete cds
347. Influenza A virus	1,754 bp	DQ676840.1
(A/goose/Krasnoozerka/627/2005(H5N1))	linear mRNA	GI:108782531
hemagglutinin (HA) mRNA, complete cds
348. Influenza A virus	1,530 bp	DQ676841.1
(A/goose/Krasnoozerka/627/2005(H5N1))	linear mRNA	GI:108782533
nucleoprotein (NP) mRNA, complete cds
349. Influenza A virus	850 bp linear	DQ676842.1
(A/goose/Krasnoozerka/627/2005(H5N1))	mRNA	GI:108782535
nonstructural protein (NS) mRNA, complete cds
350. Influenza A virus	890 bp linear	DQ366318.1
(A/goose/Vietnam/3/05(H5N1)) nonstructural	mRNA	GI:86753717
protein 1 mRNA, complete cds
351. Influenza A virus	2,341 bp	DQ366311.1
(A/goose/Vietnam/3/05(H5N1)) polymerase PB2	linear mRNA	GI:86753727
mRNA, complete cds
352. Influenza A virus	2,341 bp	DQ366312.1
(A/goose/Vietnam/3/05(H5N1)) polymerase PB1	linear mRNA	GI:86753737
mRNA, complete cds
353. Influenza A virus	2,233 bp	DQ366313.1
(A/goose/Vietnam/3/05(H5N1)) PA protein	linear mRNA	GI:86753747
mRNA, complete cds
354. Influenza A virus	1,779 bp	DQ366314.1
(A/goose/Vietnam/3/05(H5N1)) hemagglutinin	linear mRNA	GI:86753757
mRNA, complete cds
355. Influenza A virus	1,565 bp	DQ366315.1
(A/goose/Vietnam/3/05(H5N1)) nucleocapsid	linear mRNA	GI:86753767
mRNA, complete cds
356. Influenza A virus	1,401 bp	DQ366316.1
(A/goose/Vietnam/3/05(H5N1)) neuraminidase	linear mRNA	GI:86753777
mRNA, complete cds
357. Influenza A virus	1,027 bp	DQ366317.1
(A/goose/Vietnam/3/05(H5N1)) matrix protein	linear mRNA	GI:86753787
mRNA, complete cds
358. Influenza A virus	1,700 bp	AF082043.1
(A/gull/Pennsylvania/4175/83(H5N1))	linear mRNA	GI:4240453
hemagglutinin H5 mRNA, partial cds
360. Influenza A virus	1,388 bp	AF028708.1
(A/HongKong/156/97(H5N1)) neuraminidase	linear mRNA	GI:2865377
mRNA, complete cds
361. Influenza A virus	1,741 bp	AF028709.1
(A/HongKong/156/97(H5N1)) hemagglutinin	linear mRNA	GI:2865379
mRNA, complete cds
362. Influenza A virus	1,549 bp	AF028710.1
(A/HongKong/156/97(H5N1)) nucleoprotein	linear mRNA	GI:2865381
mRNA, complete cds
363. Influenza A virus (A/hooded	1,451 bp	AM503028.1
vulture/Burkina Faso/1/2006(H5N1)) partial	linear mRNA	GI:147846292
mRNA for nucleoprotein (np gene)
364. Influenza A virus (A/hooded	827 bp linear	AM503038.1
vulture/Burkina Faso/1/2006(H5N1)) mRNA for	mRNA	GI:147846312
non-structural protein (ns gene)
365. Influenza A virus (A/hooded	2,169 bp	AM503047.1
vulture/Burkina Faso/1/2006(H5N1)) partial	linear mRNA	GI:147846330
mRNA for polymerase (pa gene)
366. Influenza A virus (A/hooded	1,686 bp	AM503065.1
vulture/Burkina Faso/1/2006(H5N1)) partial	linear mRNA	GI:147846855
mRNA for polymerase basic protein 1 (pb1 gene)
367. Influenza A virus (A/hooded	977 bp linear	AM503006.1
vulture/Burkina Faso/2/2006(H5N1)) partial	mRNA	GI:147846248
mRNA for matrix protein 1 (m1 gene)
368. Influenza A virus (A/hooded	1,336 bp	AM503017.1
vulture/Burkina Faso/2/2006(H5N1)) partial	linear mRNA	GI:147846270
mRNA for neuraminidase (na gene)
369. Influenza A virus (A/hooded	1,499 bp	AM503027.1
vulture/Burkina Faso/2/2006(H5N1)) partial	linear mRNA	GI:147846290
mRNA for nucleoprotein (np gene)
370. Influenza A virus (A/hooded	827 bp linear	AM503039.1
vulture/Burkina Faso/2/2006(H5N1)) mRNA for	mRNA	GI:147846314
non-structural protein (ns gene)
371. Influenza A virus (A/hooded	2,169 bp	AM503048.1
vulture/Burkina Faso/2/2006(H5N1)) partial	linear mRNA	GI:147846332
mRNA for polymerase (pa gene)
372. Influenza A virus (A/hooded	2,259 bp	AM503062.1
vulture/Burkina Faso/2/2006(H5N1)) partial	linear mRNA	GI:147846849
mRNA for polymerase basic protein 1 (pb1 gene)
373. Influenza A virus (A/hooded	2,315 bp	AM503066.1
vulture/Burkina Faso/2/2006(H5N1)) partial	linear mRNA	GI:147846857
mRNA for polymerase basic protein 2 (pb2 gene)
374. Influenza A virus	294 bp linear	EU014135.1
(A/Indonesia/CDC177/2005(H5N1)) M2 protein	mRNA	GI:151336850
mRNA, complete cds
375. Influenza A virus	294 bp linear	EU014138.1
(A/Indonesia/CDC298/2005(H5N1)) M2 protein	mRNA	GI:151336856
mRNA, complete cds
376. Influenza A virus	294 bp linear	EU014136.1
(A/Indonesia/CDC485/2006(H5N1)) M2 protein	mRNA	GI:151336852
mRNA, complete cds
377. Influenza A virus	294 bp linear	EU014134.1
(A/Indonesia/CDC530/2006(H5N1)) M2 protein	mRNA	GI:151336848
mRNA, complete cds
378. Influenza A virus	294 bp linear	EU014133.1
(A/Indonesia/CDC535/2006(H5N1)) M2 protein	mRNA	GI:151336846
mRNA, complete cds
379. Influenza A virus	294 bp linear	EU014132.1
(A/Indonesia/CDC540/2006(H5N1)) M2 protein	mRNA	GI:151336844
mRNA, complete cds
380. Influenza A virus	294 bp linear	EU014137.1
(A/Indonesia/CDC561/2006(H5N1)) M2 protein	mRNA	GI:151336854
mRNA, complete cds
381. Influenza A virus	294 bp linear	EU014139.1
(A/Indonesia/CDC60/2005(H5N1)) M2 protein	mRNA	GI:151336858
mRNA, complete cds
382. Influenza A virus	996 bp linear	U79453.1
(A/mallard/Wisconsin/428/75(H5N1))	mRNA	GI:1840071
hemagglutinin mRNA, partial cds
383. Influenza A virus	441 bp linear	JN157759.1
(A/ostrich/VRLCU/Egypt/2011(H5N1)) segment 4	mRNA	GI:338223304
hemagglutinin (HA) mRNA, partial cds
384. Influenza A virus	875 bp linear	DQ354063.1
(A/quail/yunnan/092/2002(H5N1))	mRNA	GI:87128649
nonstructural protein (NS) mRNA, complete cds
385. Influenza A virus	1,472 bp	AB241613.1
(A/R(Turkey/Ontario/7732/66-	linear mRNA	GI:82581222
Bellamy/42)(H5N1)) HA mRNA for
hemagglutinin, partial cds
386. Influenza A virus (A/Thailand/LFPN-	1,350 bp	AY679513.1
2004/2004(H5N1)) neuraminidase mRNA,	linear mRNA	GI:50843945
complete cds
387. Influenza A virus (A/Thailand/LFPN-	1,704 bp	AY679514.1
2004/2004(H5N1)) hemagglutinin mRNA,	linear mRNA	GI:50843949
complete cds
388. Influenza A virus (A/tiger/Thailand/CU-	534 bp linear	DQ017251.1
T4/04(H5N1)) polymerase basic protein 2	mRNA	GI:65329524
(PB2) mRNA, partial cds
389. Influenza A virus (A/tiger/Thailand/CU-	582 bp linear	DQ017252.1
T5/04(H5N1)) polymerase basic protein 2	mRNA	GI:65329536
(PB2) mRNA, partial cds
390. Influenza A virus (A/tiger/Thailand/CU-	564 bp linear	DQ017253.1
T6/04(H5N1)) polymerase basic protein 2	mRNA	GI:65329553
(PB2) mRNA, partial cds
391. Influenza A virus (A/tiger/Thailand/CU-	582 bp linear	DQ017254.1
T8/04(H5N1)) polymerase basic protein 2	mRNA	GI:65329568
(PB2) mRNA, partial cds
392. Influenza A virus	1,695 bp	EF441263.1
(A/turkey/England/250/2007(H5N1))	linear mRNA	GI:129307104
hemagglutinin (HA) mRNA, partial cds
393. Influenza A virus	943 bp linear	EF441264.1
(A/turkey/England/250/2007(H5N1)) matrix	mRNA	GI:129307106
protein (M) mRNA, partial cds
394. Influenza A virus	812 bp linear	EF441265.1
(A/turkey/England/250/2007(H5N1))	mRNA	GI:129307109
nonstructural protein 1 (NS1) mRNA, complete cds
395. Influenza A virus	2,185 bp	EF441266.1
(A/turkey/England/250/2007(H5N1)) polymerase	linear mRNA	GI:129307111
PA (PA) mRNA, complete cds
396. Influenza A virus	2,272 bp	EF441267.1
(A/turkey/England/250/2007(H5N1)) polymerase	linear mRNA	GI:129307113
PB2 (PB2) mRNA, partial cds
397. Influenza A virus	1,396 bp	EF441268.1
(A/turkey/England/250/2007(H5N1))	linear mRNA	GI:129307115
nucleocapsid (NP) mRNA, partial cds
398. Influenza A virus	2,288 bp	EF441269.1
(A/turkey/England/250/2007(H5N1)) polymerase	linear mRNA	GI:129307117
PB1 (PB1) mRNA, partial cds
399. Influenza A virus	1,276 bp	EF441270.1
(A/turkey/England/250/2007(H5N1))	linear mRNA	GI:129307119
neuraminidase (NA) mRNA, partial cds
A/chicken/Burkina Faso/13.1/2006(H5N1)		AM503016.1
neuraminidase (NA)
A/chicken/Crimea/04/2005(H5N1) neuraminidase		DQ650661.1
(NA)
A/chicken/Crimea/04/2005(H5N1) hemagglutinin		DQ650659.1
A/chicken/Crimea/08/2005(H5N1) polymerase		DQ650669.1
basic protein 1 (PB1)
A/chicken/Crimea/08/2005(H5N1) neuraminidase		DQ650665.1
(NA)
A/chicken/Crimea/08/2005(H5N1) hemagglutinin		DQ650663.1
(HA)
A/chicken/Guangxi/12/2004(H5N1)		DQ366334.1
nonstructural protein 1
A/chicken/Guangxi/12/2004(H5N1)		DQ366332.1
neuraminidase
A/chicken/Guangxi/12/2004(H5N1)		DQ366330.1
hemagglutinin
A/duck/Kurgan/08/2005(H5N1) nucleoprotein		DQ449643.1
(NP)

TABLE 10
Other Influenza A Antigens (H1N*, H2N*, H3N*)
		GenBank/GI
Strain/Protein	Length	Accession Nos.
H1N*
Influenza A virus (A/duck/Hong	1,402 bp	U49097.1
Kong/193/1977(H1N2)) nucleoprotein (NP)	linear mRNA	GI:1912392
mRNA, partial cds
Influenza A virus (A/duck/Hong	258 bp linear	U48285.1
Kong/193/1977(H1N2)) polymerase (PB1) mRNA,	mRNA	GI:1912374
partial cds
Influenza A virus (A/England/2/2002(H1N2))	795 bp linear	AJ519455.1
partial NS1 gene for non structural protein	mRNA	GI:31096426
1 and partial NS2 gene for non structural
protein 2, genomic RNA
Influenza A virus (A/England/3/02(H1N2))	384 bp linear	AJ489497.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526856
Influenza A virus (A/England/3/02(H1N2))	442 bp linear	AJ489488.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526838
gene)
Influenza A virus (A/England/5/02(H1N2))	384 bp linear	AJ489498.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526858
Influenza A virus (A/England/5/02(H1N2))	442 bp linear	AJ489489.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526840
gene)
Influenza A virus (A/England/57/02(H1N2))	384 bp linear	AJ489499.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526860
Influenza A virus (A/England/57/02(H1N2))	442 bp linear	AJ489492.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526846
gene)
Influenza A virus (A/England/691/01(H1N2))	384 bp linear	AJ489496.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526854
Influenza A virus (A/England/73/02(H1N2))	384 bp linear	AJ489500.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526862
Influenza A virus (A/England/73/02(H1N2))	442 bp linear	AJ489493.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526848
gene)
Influenza A virus (A/England/90/02(H1N2))	384 bp linear	AJ489501.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526864
Influenza A virus (A/England/90/02(H1N2))	442 bp linear	AJ489490.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526842
gene)
Influenza A virus (A/England/97/02(H1N2))	384 bp linear	AJ489502.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526866
Influenza A virus (A/England/97/02(H1N2))	442 bp linear	AJ489491.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526844
gene)
Influenza A virus (A/England/627/01(H1N2))	384 bp linear	AJ489494.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526850
Influenza A virus (A/England/627/01(H1N2))	442 bp linear	AJ489485.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526832
gene)
Influenza A virus (A/England/691/01(H1N2))	442 bp linear	AJ489487.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526836
gene)
Influenza A virus (A/Egypt/96/2002(H1N2))	747 bp linear	AJ519457.1
partial NS1 gene for non structural protein	mRNA	GI:31096432
1 and partial NS2 gene for non structural
protein 2, genomic RNA
Influenza A virus (A/Israel/6/2002(H1N2))	773 bp linear	AJ519456.1
partial NS1 gene for non structural protein	mRNA	GI:31096429
1 and partial NS2 gene for non structural
protein 2, genomic RNA
Influenza A virus (A/Saudi	772 bp linear	AJ519453.1
Arabia/2231/2001(H1N2)) partial NS1 gene for	mRNA	GI:31096420
non structural protein 1 and partial NS2
gene for non structural protein 2, genomic RNA
Influenza A virus (A/Scotland/122/01(H1N2))	384 bp linear	AJ489495.1
partial mRNA for nucleoprotein (np gene)	mRNA	GI:27526852
Influenza A virus (A/Scotland/122/01(H1N2))	442 bp linear	AJ489486.1
partial mRNA for polymerase subunit 2 (pb2	mRNA	GI:27526834
gene)
Influenza A virus	832 bp linear	AY861443.1
(A/swine/Bakum/1832/2000(H1N2))	mRNA	GI:57791765
hemagglutinin (HA) mRNA, partial cds
Influenza A virus	467 bp linear	AY870645.1
(A/swine/Bakum/1832/2000(H1N2))	mRNA	GI:58042754
neuraminidase mRNA, partial cds
Influenza A virus (A/swine/Cotes	1,039 bp	AM503547.1
d'Armor/0040/2007(H1N2)) segment 4 partial	linear mRNA	GI:225578611
mRNA
Influenza A virus (A/swine/Cotes	1,136 bp	AM490224.3
d'Armor/0136_17/2006(H1N2)) partial mRNA for	linear mRNA	GI:222062921
haemagglutinin precursor (HA1 gene)
Influenza A virus	1,778 bp	AF085417.1
(A/swine/England/72685/96(H1N2))	linear mRNA	GI:3831770
haemagglutinin precursor, mRNA, complete cds
Influenza A virus	1,778 bp	AF085416.1
(A/swine/England/17394/96(H1N2))	linear mRNA	GI:3831768
haemagglutinin precursor, mRNA, complete cds
Influenza A virus	1,778 bp	AF085415.1
(A/swine/England/690421/95(H1N2))	linear mRNA	GI:3831766
haemagglutinin precursor, mRNA, complete cds
Influenza A virus	1,778 bp	AF085414.1
(A/swine/England/438207/94(H1N2))	linear mRNA	GI:3831764
haemagglutinin precursor, mRNA, complete cds
Influenza A virus	1,427 bp	AY129157.1
(A/Swine/Korea/CY02/02(H1N2)) neuraminidase	linear mRNA	GI:24286064
(NA) mRNA, complete cds
Influenza A virus	952 bp linear	AY129158.1
(A/Swine/Korea/CY02/02(H1N2)) matrix protein	mRNA	GI:24286066
(M) mRNA, complete cds
Influenza A virus	1,542 bp	AY129159.1
(A/Swine/Korea/CY02/02(H1N2)) nucleoprotein	linear mRNA	GI:24286069
(NP) mRNA, complete cds
Influenza A virus	842 bp linear	AY129160.1
(A/Swine/Korea/CY02/02(H1N2)) nonstructural	mRNA	GI:24286081
protein (NS) mRNA, complete cds
Influenza A virus	2,165 bp	AY129161.1
(A/Swine/Korea/CY02/02(H1N2)) polymerase	linear mRNA	GI:24286087
acidic protein 2 (PA) mRNA, complete cds
Influenza A virus	2,274 bp	AY129162.1
(A/Swine/Korea/CY02/02(H1N2)) polymerase	linear mRNA	GI:24286096
subunit 1 (PB1) mRNA, complete cds
Influenza A virus	2,334 bp	AY129163.1
(A/Swine/Korea/CY02/02(H1N2)) polymerase	linear mRNA	GI:24286100
subunit 2 (PB2) mRNA, complete cds
Influenza A virus	1,778 bp	AF085413.1
(A/swine/Scotland/410440/94(H1N2))	linear mRNA	GI:3831762
haemagglutinin precursor, mRNA, complete cds
Influenza A virus (A/swine/Spain/80598-	291 bp linear	EU305436.1
LP4/2007(H1N2)) matrix protein 2 (M2) mRNA,	mRNA	GI:168830657
partial cds
Influenza A virus	975 bp linear	AJ517813.1
(A/Switzerland/3100/2002(H1N2)) partial HA	mRNA	GI:38422519
gene for Haemagglutinin, genomic RNA
Influenza A virus (A/duck/Hong	1,387 bp	U49095.1
Kong/717/1979(H1N3)) nucleoprotein (NP)	linear mRNA	GI:1912388
mRNA, partial cds
Influenza A virus (A/duck/Hong	265 bp linear	U48281.1
Kong/717/1979(H1N3)) polymerase (PB1) mRNA,	mRNA	GI:1912366
partial cds
Influenza A virus (A/herring gull/New	971 bp linear	AY664422.1
Jersey/780/86 (H1N3)) nonfunctional matrix	mRNA	GI:51011826
protein mRNA, partial sequence
Influenza A virus	997 bp linear	AY664426.1
(A/mallard/Alberta/42/77(H1N6))	mRNA	GI:51011830
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	1,020 bp	U85985.1
(A/swine/England/191973/92(H1N7)) matrix	linear mRNA	GI:1835733
protein Ml mRNA, complete cds
Influenza A virus	1,524 bp	U85987.1
(A/swine/England/191973/92(H1N7))	linear mRNA	GI:1835737
nucleoprotein mRNA, complete cds
Influenza A virus	1,458 bp	U85988.1
(A/swine/England/191973/92(H1N7))	linear mRNA	GI:1835739
neuraminidase mRNA, complete cds
Influenza A virus	1,698 bp	U85986.1
(A/swine/England/191973/92 (H1N7) )	linear mRNA	GI:1835735
haemagglutinin HA mRNA, partial cds
H2N*
Influenza A virus (A/ruddy	917 bp linear	AY664465.1
turnstone/Delaware/81/93 (H2N1))	mRNA	GI:51011869
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus (A/ruddy	968 bp linear	AY664429.1
turnstone/Delaware/34/93 (H2N1))	mRNA	GI:51011833
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	925 bp linear	AY 66 4 466.1
(A/Shorebird/Delaware/122/97(H2N1))	mRNA	GI:51011870
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	958 bp linear	AY664454.1
(A/shorebird/Delaware/138/97 (H2N1))	mRNA	GI:51011858
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	958 bp linear	AY664457.1
(A/shorebird/Delaware/111/97 (H2N1))	mRNA	GI:51011861
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	979 bp linear	AY664442.1
(A/shorebird/Delaware/24/98 (H2N1))	mRNA	GI:51011846
nonfunctional matrix protein mRNA, partial
sequence
Influenza virus type A/Leningrad/134/17/57	2,233 bp	M81579.1
(H2N2) PA RNA, complete cds	linear mRNA	GI:324935
Influenza A virus (STRAIN A/MALLARD/NEW	2,151 bp	AJ243994.1
YORK/6750/78) partial mRNA for PA protein	linear mRNA	GI:5918195
Influenza A virus (A/X-7(F1)/(H2N2))	1,467 bp	M11205.1
neuraminidase mRNA, complete cds	linear mRNA	GI:323969
Influenza A virus (A/mallard/Alberta/77/77	1,009 bp	AY664425.1
(H2N3)) nonfunctional matrix protein mRNA,	linear mRNA	GI:51011829
partial sequence
Influenza A virus	968 bp linear	AY664447.1
(A/mallard/Alberta/226/98(H2N3))	mRNA	GI:51011851
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus (A/sanderling/New	846 bp linear	AY664477.1
Jersey/766/86 (H2N7)) nonfunctional matrix	mRNA	GI:51011881
protein mRNA, partial sequence
Influenza A virus (A/laughing gull/New	907 bp linear	AY664471.1
Jersey/798/86 (H2N7)) nonfunctional matrix	mRNA	GI:51011875
protein mRNA, partial sequence
Influenza A virus (A/herring	960 bp linear	AY664440.1
gull/Delaware/471/1986(H2N7)) nonfunctional	mRNA	GI:51011844
matrix protein mRNA, partial sequence
Influenza A virus (A/ruddy	1,011 bp	AY664423.1
turnstone/Delaware/142/98 (H2N8))	linear mRNA	GI:51011827
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus (A/pintail/Alberta/293/77	906 bp linear	AY664473.1
(H2N9)) nonfunctional matrix protein mRNA,	mRNA	GI:51011877
partial sequence
Influenza A virus (A/blue-winged	961 bp linear	AY664449.1
teal/Alberta/16/97 (H2N9)) nonfunctional	mRNA	GI:51011853
matrix protein mRNA, partial sequence
Influenza A virus (A/Laughing gull/New	952 bp linear	AY664437.1
Jersey/75/85 (H2N9)) nonfunctional matrix	mRNA	GI:51011841
protein mRNA, partial sequence
Influenza A virus (A/mallard/Alberta/205/98	959 bp linear	AY664450.1
(H2N9)) nonfunctional matrix protein mRNA,	mRNA	GI:51011854
partial sequence
H3N*
Influenza A virus (A/duck/Eastern	1,458 bp	EU429755.1
China/267/2003(H3N1)) segment 6	linear mRNA	GI:167859475
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429754.1
China/253/2003(H3N1)) segment 6	linear mRNA	GI:167859473
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429753.1
China/252/2003(H3N1)) segment 6	linear mRNA	GI:167859471
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429752.1
China/243/2003(H3N1)) segment 6	linear mRNA	GI:167859469
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429734.1
China/262/2003(H3N1)) segment 6	linear mRNA	GI:167859433
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,459 bp	EU429733.1
China/233/2003(H3N1)) segment 6	linear mRNA	GI:167859431
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429723.1
China/213/2003(H3N1)) segment 6	linear mRNA	GI:167859411
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429719.1
China/341/2003(H3N1)) segment 6	linear mRNA	GI:167859403
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,458 bp	EU429718.1
China/01/2002(H3N1)) segment 6 neuraminidase	linear mRNA	GI:167859401
(NA) mRNA, complete cds
Influenza A virus (A/mallard/Alberta/22/76	1,013 bp	AY664434.1
(H3N6)) nonfunctional matrix protein mRNA,	linear mRNA	GI:51011838
partial sequence
Influenza A virus	970 bp linear	AY664443.1
(A/mallard/Alberta/199/99(H3N6))	mRNA	GI:51011847
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	922 bp linear	AY664461.1
(A/shorebird/Delaware/222/97 (H3N6))	mRNA	GI:51011865
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus (A/Duck/Hokkaido/8/80	984 bp linear	AF079570.1
(H3N8)) hemagglutinin precursor, mRNA,	mRNA	GI:3414978
partial cds
Influenza A virus (A/Duck/Hokkaido/8/80	1,497 bp	AF079571.1
(H3N8)) nucleoprotein mRNA, complete cds	linear mRNA	GI:3414980
Influenza A virus	1,461 bp	EU429797.1
(A/duck/Ukraine/1/1963(H3N8)) segment 6	linear mRNA	GI:167859559
neuraminidase (NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,460 bp	EU429698.1
China/19/2004(H3N8)) segment 6 neuraminidase	linear mRNA	GI:167859361
(NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,460 bp	EU429700.1
China/90/2004(H3N8)) segment 6 neuraminidase	linear mRNA	GI:167859365
(NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,460 bp	EU429787.1
China/18/2005(H3N8)) segment 6 neuraminidase	linear mRNA	GI:167859539
(NA) mRNA, complete cds
Influenza A virus (A/duck/Eastern	1,460 bp	EU429788.1
China/119/2005(H3N8)) segment 6	linear mRNA	GI:167859541
neuraminidase (NA) mRNA, complete cds
Influenza A virus	1,061 bp	AF197246.1
(A/equine/Argentina/1/96(H3N8))	linear mRNA	GI:6651512
hemagglutinin precursor (HA1) mRNA, partial
cds
Influenza A virus	1,061 bp	AF197245.1
(A/equine/Argentina/2/94(H3N8))	linear mRNA	GI:6651510
hemagglutinin precursor (HA1) mRNA, partial
cds
Influenza A virus	1,061 bp	AF197244.1
(A/equine/Argentina/1/95(H3N8))	linear mRNA	GI:6651508
hemagglutinin precursor (HA1) mRNA, partial
cds
Influenza A virus HA partial gene for	1,026 bp	AJ223194.1
haemagglutinin, genomic RNA, strain	linear mRNA	GI:2780201
A/equine/Berlin/3/89(H3N8)
Influenza A virus HA partial gene for	1,006 bp	AJ223195.1
haemagglutinin, genomic RNA, strain	linear mRNA	GI:2780203
A/equine/Berlin/4/89(H3N8)
Influenza A virus	1,061 bp	AF197242.1
(A/equine/Florida/1/94(H3N8)) hemagglutinin	linear mRNA	GI:6651504
precursor (HA1) mRNA, partial cds
Influenza A virus	695 bp linear	AY328471.1
(A/equine/Grobois/1/98(H3N8)) nonstructural	mRNA	GI:32966577
protein NS1 mRNA, complete cds
Influenza A virus (A/equi	473 bp linear	AY919314.1
2/Gotland/01(H3N8)) hemagglutinin HA1	mRNA	GI:60250543
subunit mRNA, partial cds
Influenza A virus (A/eq/Kentucky/81(H3N8))	1,763 bp	U58195.1
hemagglutinin mRNA, complete cds	linear mRNA	GI:1377873
Influenza A virus	1,061 bp	AF197247.1
(A/equine/Kentucky/9/95(H3N8)) hemagglutinin	linear mRNA	GI:6651514
precursor (HA1) mRNA, partial cds
Influenza A virus	1,061 bp	AF197248.1
(A/equine/Kentucky/1/96(H3N8)) hemagglutinin	linear mRNA	GI:6651516
precursor (HA1) mRNA, partial cds
Influenza A virus	1,061 bp	AF197249.1
(A/equine/Kentucky/1/97(H3N8)) hemagglutinin	linear mRNA	GI:6651518
precursor (HA1) mRNA, partial cds
Influenza A virus	1,061 bp	AF197241.1
(A/equine/Kentucky/1/98(H3N8)) hemagglutinin	linear mRNA	GI:6651502
precursor (HA1) mRNA, partial cds
Influenza A virus	1,497 bp	AY383753.1
(A/equine/Santiago/85(H3N8)) nucleoprotein	linear mRNA	GI:37223511
mRNA, complete cds
Influenza A virus	1,698 bp	AY383755.1
(A/equine/Santiago/85(H3N8)) hemagglutinin	linear mRNA	GI:37223515
mRNA, complete cds
Influenza A virus	1,413 bp	AY383754.1
(A/equine/Santiago/85(H3N8)) neuraminidase	linear mRNA	GI:37223513
mRNA, complete cds
Influenza A virus	1,061 bp	AF197243.1
(A/equine/Saskatoon/1/90(H3N8))	linear mRNA	GI:6651506
hemagglutinin precursor (HA1) mRNA, partial
cds
Influenza A virus (A/mallard/Alberta/114/97	1,010 bp	AY664432.1
(H3N8)) nonfunctional matrix protein mRNA,	linear mRNA	GI:51011836
partial sequence
Influenza A virus (A/mallard/Alberta/167/98	961 bp linear	AY664489.1
(H3N8)) nonfunctional matrix protein mRNA,	mRNA	GI:51011893
partial sequence
Influenza A virus	970 bp linear	AY664445.1
(A/pintail/Alberta/37/99(H3N8))	mRNA	GI:51011849
nonfunctional matrix protein mRNA, partial
sequence
Influenza A virus	922 bp linear	AY664455.1
(A/sanderling/Delaware/65/99 (H3N8))	mRNA	GI:51011859
nonfunctional matrix protein mRNA, partial
sequence

TABLE 11
Other Influenza A Antigens (H4N*-H13N*)
                                 GenBank
Strain/Protein                   Access No.
A/chicken/Singapore/1992(H4N1) M2 protein EU014144.1
A/mallard/Alberta/47/98(H4N1) nonfunctional matrix protein AY664488.1
A/duck/Hong Kong/412/1978(H4N2) polymerase (PB1) U48279.1
A/mallard/Alberta/300/77 (H4N3) nonfunctional matrix protein AY664480.1
A/Duck/Czechoslovakia/56(H4N6) segment 4 hemagglutinin AF290436.1
A/duck/Eastern China/376/2004(H4N6) segment 6neuraminidase (NA) EU429792.1
A/duck/Eastern China/01/2007(H4N6) segment 6 neuraminidase (NA) EU429790.1
A/duck/Eastern China/216/2007(H4N6) segment 6 neuraminidase EU429789.1
(NA)
A/duck/Eastern China/166/2004(H4N6) segment 6 neuraminidase EU429746.1
(NA)
A/duck/Eastern China/02/2003(H4N6) segment 6 neuraminidase (NA) EU429713.1
A/duck/Eastern China/160/2002(H4N6) segment 6 neuraminidase EU429706.1
(NA)
A/mallard/Alberta/111/99(H4N6) nonfunctional matrix protein AY664482.1
A/mallard/Alberta/213/99 (H4N6) nonfunctional matrix protein AY664460.1
A/mallard/Alberta/30/98 (H4N6) nonfunctional matrix protein AY664484.1
A/blue-winged teal/Alberta/96/76 (H4N8) nonfunctional matrix AY664420.1
protein
A/chicken/Florida/25717/1993(H5N2) hemagglutinin U05332.1
A/chicken/Hidalgo/26654-1368/1994(H5N2) hemagglutinin (HA) U37172.1
A/chicken/Jalisco/14585-660/1994(H5N2) hemagglutinin (HA) U37181.1
A/chicken/Mexico/26654-1374/1994(H5N2) hemagglutinin (HA) U37173.1
A/chicken/Mexico/31381-3/1994(H5N2) hemagglutinin (HA) U37176.1
A/chicken/Mexico/31381-6/1994(H5N2) hemagglutinin (HA) U37175.1
A/chicken/Mexico/31381-4/1994(H5N2) hemagglutinin (HA) U37174.1
A/chicken/Mexico/31381-5/1994(H5N2) hemagglutinin (HA) U37169.1
A/chicken/Mexico/31381-8/1994(H5N2) hemagglutinin (HA) U37170.1
A/Chicken/Mexico/31381-Avilab/94(H5N2)hemagglutinin (HA) L46585.1
A/chicken/Mexico/31382-1/1994(H5N2)hemagglutinin (HA) U37168.1
A/chicken/Mexico/31381-2/1994(H5N2) hemagglutinin (HA) U37167.1
A/chicken/Mexico/31381-1/1994(H5N2) hemagglutinin (HA) U37166.1
A/chicken/Mexico/31381-7/1994(H5N2) hemagglutinin (HA) U37165.1
A/chicken/Pennsylvania/13609/1993(H5N2) hemagglutinin U05331.1
A/chicken/Pennsylvania/1/1983(H5N2) hemagglutinin esterase M18001.1
precursor
A/chicken/Pennsylvania/1370/1983(H5N2) hemagglutinin esterase M10243.1
precursor
A/Chicken/Puebla/8623-607/94(H5N2) hemagglutinin (HA) L46586.1
A/chicken/Puebla/14586-654/1994(H5N2) hemagglutinin (HA) U37180.1
A/chicken/Puebla/14585-622/1994(H5N2) hemagglutinin (HA) U37179.1
A/chicken/Puebla/8623-607/1994(H5N2)hemagglutinin (HA) U37178.1
A/chicken/Puebla/8624-604/1994(H5N2) hemagglutinin (HA) U37177.1
A/Chicken/Queretaro/14588-19/95(H5N2) hemagglutinin (HA) L46587.1
A/chicken/Queretaro/7653-20/95(H5N2) hemagglutinin (HA) U79448.1
A/chicken/Queretaro/26654-1373/1994(H5N2) hemagglutinin (HA) U37171.1
A/chicken/Queretaro/14588-19/1994(H5N2)hemagglutinin (HA) U37182.1
A/chicken/Singapore/98(H5N2) matrix protein 2 (M2) EF682127.1
A/chicken/Taiwan/1209/03(H5N2) hemagglutinin protein (HA) AY573917.1
A/chicken/Taiwan/1209/03(H5N2) neuraminidase AY573918.1
A/duck/Eastern China/64/2004(H5N2) segment 6 neuraminidase (NA) EU429791.1
A/duck/Eastern China/264/2002(H5N2) segment 6 neuraminidase EU429744.1
(NA)
A/duck/Eastern China/01/2001(H5N2) segment 6 neuraminidase (NA) EU429728.1
A/duck/Eastern China/06/2000(H5N2) segment 6 neuraminidase EU429722.1
(NA)
A/duck/Hong Kong/342/78(H5N2) matrix protein 1 (M) and matrix DQ107452.1
protein 2 (M)
A/duck/Hong Kong/342/78(H5N2) hemagglutinin precursor U20475.1
A/duck/Michigan/80(H5N2) hemagglutinin 1 chain U20474.1
A/duck/Michigan/80(H5N2) hemagglutinin U79449.1
A/duck/MN/1564/81(H5N2) matrix protein 1 (M) and matrix protein DQ107467.1
2 (M)
A/duck/Mongolia/54/2001(H5N2) hemagglutinin (HA) AB241614.2
A/duck/Primorie/2621/01(H5N2) hemagglutinin (HA) AJ621811.3
A/duck/Primorie/2621/01(H5N2)nucleoprotein (NP ) AJ621812.1
A/duck/Primorie/2621/01(H5N2) nonstructural protein (NS) AJ621813.1
A/duck/Pennsylvania/84(H5N2) hemagglutinin 1chain U20473.1
A/duck/Potsdam/1402-6/86(H5N2) hemagglutinin H5 AF082042.1
A/emu/Texas/39442/93(H5N2) hemaglutinin U28920.1
A/emu/Texas/39442/93(H5N2) hemaglutinin U28919.1
A/mallard/Alberta/645/80(H5N2) matrix protein 1 (M) and matrix DQ107471.1
protein 2 (M)
A/mallard/AR/1C/2001(H5N2) matrix protein 1 (M) and matrix DQ107463.1
protein 2 (M)
A/mallard/NY/189/82(H5N2) matrix protein 1 (M) and matrix DQ107465.1
protein 2 (M)
A/mallard/MN/25/80(H5N2) matrix protein 1 (M) and matrix DQ107473.1
protein 2 (M)
A/mallard/MI/18/80(H5N2) matrix protein 1 (M) and matrix DQ107470.1
protein 2 (M)
A/mallard/Ohio/345/88(H5N2) hemagglutinin U79450.1
A/parrot/CA/6032/04(H5N2) polymerase basic protein 2 (PB2) DQ256390.1
A/parrot/CA/6032/04(H5N2) polymerase basic protein 1 (PB1) DQ256389.1
A/parrot/CA/6032/04(H5N2) matrix protein (M) DQ256384.2
A/parrot/CA/6032/04(H5N2) hemagglutinin (HA) DQ256383.1
A/parrot/CA/6032/04(H5N2) neuraminidase (NA) DQ256385.1
A/parrot/CA/6032/04(H5N2) polymerase basic protein 2 (PB2) DQ256390.1
A/parrot/CA/6032/04(H5N2) nucleoprotein (NP) DQ256386.1
A/parrot/CA/6032/04(H5N2)) polymerase (PA) DQ256388.1
A/ruddy turnstone/Delaware/244/91 (H5N2) nonfunctional matrix AY664474.1
protein
A/ruddy turnstone/Delaware/244/91 (H5N2) U05330.1
A/turkey/Colorado/72(H5N2) hemagglutinin 1 chain (HA) U20472.1
A/turkey/England/N28/73 (H5N2) hemagglutinin AY500365.1
A/turkey/TX/14082/81(H5N2) matrix protein 1 (M) and matrix DQ107464.1
protein 2 (M)
A/turkey/MN/1704/82(H5N2)) matrix protein 1 (M) and matrix DQ107472.1
protein 2 (M)
A/turkey/Minnesota/10734/95(H5N2)) hemagglutinin U79455.1
A/turkey/Minnesota/3689-1551/81(H5N2) hemagglutinin U79454.1
A/chicken/Singapore/1997(H5N3) M2 protein EU014141.1
A/duck/Hokkaido/299/04(H5N3) hemagglutinin (HA) AB241626.1
A/duck/Hokkaido/193/04(H5N3) hemagglutinin (HA) AB241625.1
A/duck/Hokkaido/101/04(H5N3) hemagglutinin (HA) AB241624.1
A/duck/Hokkaido/447/00(H5N3) hemagglutinin (HA) AB241620.1
A/duck/Hokkaido/69/00(H5N3) hemagglutinin (HA) AB241619.1
A/duck/Hong Kong/205/77(H5N3) hemagglutinin H5 AF082038.1
A/duck/Hong Kong/698/79(H5N3) hemagglutinin H5 AF082039.1
A/duck/Hong Kong/308/78(H5N3) matrix protein 1 (M) and matrix DQ107457.1
protein 2 (M)
A/duck/Hong Kong/825/80(H5N3) matrix protein 1 (M) and matrix DQ107455.1
protein 2 (M)
A/duck/Hong Kong/820/80(H5N3) matrix protein 1 (M) and matrix DQ107453.1
protein 2 (M)
A/duck/Hong Kong/205/77(H5N3) matrix protein 1 (M) and matrix DQ107456.1
protein 2 (M)
A/Duck/Ho Chi Minh/014/78(H5N3) segment 4 hemagglutinin AF290443.1
A/duck/Jiangxi/6151/2003(H5N3) matrix protein 1 (M) and matrix DQ107451.1
protein 2 (M)
A/duck/Malaysia/F119-3/97(H5N3) hemagglutinin AF303057.1
A/duck/Miyagi/54/76(H5N3)hemagglutinin (HA) AB241615.1
A/duck/Mongolia/596/01(H5N3) hemagglutinin HA) AB241622.1
A/duck/Mongolia/500/01(H5N3)hemagglutinin (HA) AB241621.1
A/duck/Primorie/2633/01(H5N3) matrix protein (M1) AJ621810.1
A/duck/Primorie/2633/01(H5N3)nucleoprotein (NP) AJ621808.1
A/duck/Primorie/2633/01(H5N3)hemagglutinin (HA) AJ621807.1
A/duck/Primorie/2633/01(H5N3)nucleoprotein (NP) AJ621809.1
A/goose/Hong Kong/23/78(H5N3) matrix protein 1 (M) and matrix DQ107454.1
protein 2 (M)
A/mallard/Wisconsin/169/75(H5N3) hemagglutinin U79452.1
A/swan/Hokkaido/51/96(H5N3)hemagglutinin (HA) AB241617.1
A/swan/Hokkaido/4/96(H5N3) hemagglutinin (HA) AB241616.1
A/turkey/CA/6878/79(H5N3) matrix protein 1 (M) and matrix DQ107469.1
protein 2 (M)
A/tern/South Africa/61(H5N3) hemagglutinin precursor (HA) U20460.1
A/gull/Delaware/5/2000(H5N4) matrix protein 1 (M) and matrix DQ107459.1
protein 2 (M)
A/gull/Delaware/4/2000(H5N4) matrix protein 1 (M) and matrix DQ107458.1
protein 2 (M)
A/shorebird/Delaware/109/2000(H5N4) matrix protein 1 (M) DQ107460.1
A/shorebird/Delaware/243/2000(H5N4) matrix protein 1 (M) and DQ107462.1
matrix protein 2 (M)
A/shorebird/Delaware/230/2000(H5N4) matrix protein 1 (M) and DQ107461.1
matrix protein 2 (M)
A/mallard/Wisconsin/34/75(H5N6) hemagglutinin U79451.1
A/duck/Potsdam/2216-4/1984(H5N6) hemagglutinin H5 AF082041.1
A/shorebird/Delaware/207/98 (H5N8) nonfunctional matrix protein AY664456.1
A/shorebird/Delaware/27/98 (H5N8) nonfunctional matrix protein AY664453.1
A/herring gull/Delaware/281/98 (H5N8) nonfunctional matrix AY664452.1
protein
A/mallard/Ohio/556/1987(H5N9) hemagglutinin (HA) U67783.2
A/turkey/Wisconsin/68(H5N9) hemagglutinin U79456.1
A/blue-winged teal/Alberta/685/82(H6N1) matrix protein 1 (M) DQ107448.1
and matrix protein 2 (M)
A/chicken/Taiwan/7-5/99(H6N1) nucleocapsid protein (NP) AF261750.1
A/chicken/Taiwan/7-5/99(H6N1) matrix protein AF262213.1
A/chicken/Taiwan/7-5/99(H6N1) nonstructural protein AF262212.1
A/chicken/Taiwan/7-5/99(H6N1) polymerase (PA) AF262211.1
A/chicken/Taiwan/7-5/99(H6N1) polymerase subunit PB1 AF262210.1
A/chicken/Taiwan/7-5/99(H6N1) nucleocapsid protein (NP) AF261750.1
A/chicken/Taiwan/ns2/99(H6N1) segment 4 hemagglutinin (HA1) AF310985.1
A/chicken/Taiwan/na3/98(H6N1) segment 4 hemagglutinin (HA1) AF310984.1
A/chicken/Taiwan/7-5/99(H6N1) segment 4 hemagglutinin (HA1) AF310983.1
A/duck/Hong Kong/D73/76(H6N1) matrix protein 1 (M) and matrix DQ107432.1
protein 2 (M)
A/duck/Taiwan/9/23-3/2000(H6N1) matrix protein 1 (M) and matrix DQ107407.1
protein 2 (M)
A/pheasant/Hong Kong/FY479/2000(H6N1) matrix protein 1 (M) and DQ107409.1
matrix protein 2 (M)
A/pheasant/Hong Kong/SSP44/2002(H6N1) matrix protein 1 (M) and DQ107412.1
matrix protein 2 (M)
A/quail/Hong Kong/YU421/2002(H6N1) matrix protein 1 (M) and DQ107414.1
matrix protein 2 (M)
A/avian/NY/17150-7/2000(H6N2) matrix protein 1 (M) and matrix DQ107423.1
protein 2 (M)
A/chicken/CA/285/2003(H6N2) matrix protein 1 (M) and matrix DQ107429.1
protein 2 (M)
A/chicken/CA/375TR/2002(H6N2) matrix protein 1 (M) and matrix DQ107428.1
protein 2 (M)
A/chicken/CA/203/2003(H6N2) matrix protein 1 (M) and matrix DQ107426.1
protein 2 (M)
A/chicken/NY/101250-7/2001(H6N2) matrix protein 1 (M) and DQ107419.1
matrix protein 2 (M)
A/chicken/CA/625/2002(H6N2) matrix protein 1 (M) and matrix DQ107418.1
protein 2 (M)
A/Chicken/California/0139/2001(H6N2)nucleoprotein (NP) AF474070.1
A/Chicken/California/650/2000(H6N2) nucleoprotein (NP) AF474069.1
A/Chicken/California/9420/2001(H6N2) neuraminidase N2 (N2) AF474048.1
A/Chicken/California/9174/2001(H6N2) neuraminidase N2 (N2) AF474047.1
A/Chicken/California/8892/2001(H6N2)neuraminidase N2 (N2) AF474046.1
A/Chicken/California/6643/2001(H6N2) neuraminidase N2 (N2) AF474045.1
A/Chicken/California/1316/2001(H6N2)neuraminidase N2 (N2) AF474044.1
A/Chicken/California/0139/2001(H6N2) neuraminidase N2 (N2) AF474043.1
A/Chicken/California/1002/2000(H6N2) neuraminidase N2 (N2) AF474042.1
A/Chicken/California/650/2000(H6N2) neuraminidase N2 (N2) AF474041.1
A/Chicken/California/465/2000(H6N2) neuraminidase N2 (N2) AF474040.1
A/Chicken/California/431/2000(H6N2) neuraminidase N2 (N2) AF474039.1
A/Chicken/California/6643/2001(H6N2) hemagglutinin H6 (H6) AF474035.1
A/Chicken/California/431/2000(H6N2) hemagglutinin H6 (H6) AF474029.1
A/Chicken/California/9420/2001(H6N2) hemagglutinin H6 (H6) AF474038.1
A/Chicken/California/9174/2001(H6N2) hemagglutinin H6 (H6) AF474037.1
A/Chicken/California/8892/2001(H6N2) hemagglutinin H6 (H6) AF474036.1
A/Chicken/California/1316/2001(H6N2) hemagglutinin H6 (H6) AF474034.1
A/Chicken/California/0139/2001(H6N2) hemagglutinin H6 (H6) AF474033.1
A/Chicken/California/1002/2000(H6N2) hemagglutinin H6 (H6) AF474032.1
A/Chicken/California/650/2000(H6N2) hemagglutinin H6 (H6) AF474031.1
A/Chicken/California/465/2000(H6N2) hemagglutinin H6 (H6) AF474030.1
A/cornish cross/CA/139/2001(H6N2) matrix protein 1 (M) and DQ107424.1
matrix protein 2 (M)
A/duck/Eastern China/164/2002(H6N2) segment 6 neuraminidase EU429762.1
(NA)
A/duck/Eastern China/729/2003(H6N2) segment 6 neuraminidase EU429760.1
(NA)
A/duck/Eastern China/262/2002(H6N2) segment 6 neuraminidase EU429743.1
(NA)
A/duck/Eastern China/74/2006(H6N2) segment 6 neuraminidase EU429741.1
(NA)
A/duck/Eastern China/161/2002(H6N2) segment 6 neuraminidase EU429740.1
(NA)
A/duck/Hong Kong/960/80(H6N2)) matrix protein 1 (M) and matrix DQ107435.1
protein 2 (M)
A/duck/Hong Kong/D134/77(H6N2)) matrix protein 1 (M) and matrix DQ107433.1
protein 2 (M)
A/duck/CA/10221/2002(H6N2) matrix protein 1 (M) and matrix DQ107421.1
protein 2 (M)
A/duck/Shantou/5540/2001(H6N2) matrix protein 1 (M) and matrix DQ107431.1
protein 2 (M)
A/guinea fowl/Hong Kong/SSP99/2002(H6N2) matrix protein 1 (M) DQ107413.1
and matrix protein 2 (M)
A/mallard/NY/016/83(H6N2) matrix protein 1 (M) and matrix DQ107449.1
protein 2 (M)
A/mallard/NY/046/83(H6N2) matrix protein 1 (M) and matrix DQ107450.1
protein 2 (M)
A/pintail/Alberta/644/81(H6N2) matrix protein 1 (M) and matrix DQ107445.1
protein 2 (M)
A/quail/Hong Kong/SF792/2000(H6N2) matrix protein 1 (M) and DQ107410.1
matrix protein 2 (M)
A/ruddy turnstone/Delaware/106/98 (H6N2) nonfunctional matrix AY664439.1
protein
A/Shorebird/Delaware/127/97(H6N2) nonfunctional matrix protein AY664467.1
A/shorebird/Delaware/124/2001(H6N2) matrix protein 1 (M) and DQ107417.1
matrix protein 2 (M)
A/shorebird/Delaware/208/2001(H6N2) matrix protein 1 (M) and DQ107427.1
matrix protein 2 (M)
A/turkey/CA/527/2002(H6N2) matrix protein 1 (M) and matrix DQ107420.1
protein 2 (M)
A/turkey/CA/1623CT/2002(H6N2) matrix protein 1 (M) and matrix DQ107425.1
protein 2 (M)
A/turkey/MN/836/80(H6N2) matrix protein 1 (M) and matrix DQ107440.1
protein 2 (M)
A/turkey/MN/735/79(H6N2) matrix protein 1 (M) and matrix DQ107437.1
protein 2 (M)
A/chicken/Hong Kong/17/77(H6N4)) matrix protein 1 (M) and DQ107436.1
matrix protein 2 (M)
A/chicken/Hong Kong/CSW106/2001(H6N4) matrix protein 1 (M) and DQ107406.1
matrix protein 2 (M)
A/gull/Delaware/18/2000(H6N4) matrix protein 1 (M) and matrix DQ107415.1
protein 2 (M)
A/pheasant/Hong Kong/CSW2573/2001(H6N4) matrix protein 1 (M) DQ107411.1
and matrix protein 2 (M)
A/quail/Hong Kong/CSW106/2001(H6N4) matrix protein 1 (M) and DQ107430.1
matrix protein 2 (M)
A/Shorebird/Delaware/194/98(H6N4) nonfunctional matrix protein AY664424.1
A/shorebird/Delaware/259/2000(H6N4) matrix protein 1 (M) and DQ107416.1
matrix protein 2 (M)
A/shearwater/Australia/1/1972(H6N5) segment 6 neuraminidase EU429794.1
(NA)
A/shearwater/Australia/1/1972(H6N5) polymerase A (PA) L25832.1
A/pintail/Alberta/1040/79(H6N5) matrix protein 1 (M) and matrix DQ107439.1
protein 2 (M)
A/blue-winged teal/MN/993/80(H6N6)) matrix protein 1 (M) and DQ107441.1
matrix protein 2 (M)
A/duck/NY/83779/2002(H6N6) matrix protein 1 (M) and matrix DQ107422.1
protein 2 (M)
A/duck/MN/1414/81(H6N6) matrix protein 1 (M) and matrix DQ107444.1
protein 2 (M)
A/mallard/Alberta/289/82(H6N6) matrix protein 1 (M) and matrix DQ107447.1
protein 2 (M)
A/mallard duck/MN/1041/80(H6N6) matrix protein 1 (M) and matrix DQ107442.1
protein 2 (M)
A/pintail/Alberta/189/82(H6N6) matrix protein 1 (M) and matrix DQ107446.1
protein 2 (M)
A/sanderling/Delaware/1258/86(H6N6) nonfunctional matrix AY664436.1
protein
A/blue-winged teal/Alberta/368/78(H6N8)) matrix protein 1 (M) DQ107438.1
and matrix protein 2 (M)
A/ruddy turnstone/Delaware/105/98 (H6N8) nonfunctional matrix AY664428.1
protein
A/domestic duck/NY/81(H6N8)) matrix protein (M) DQ107443.1
A/duck/Eastern China/163/2002(H6N8) segment 6 neuraminidase EU429786.1
(NA)
A/duck/Hong Kong/D182/77(H6N9) matrix protein 1 (M) and matrix DQ107434.1
protein 2 (M)
A/chicken/Hong Kong/SF3/2001(H6) matrix protein 1 (M) and DQ107408.1
matrix protein 2 (M)
A/African starling/England/983/79(H7N1) neuraminidase (N1) AJ416629.1
A/Afri.Star./Eng-Q/938/79(H7N1) hemagglutinin precurosr AF149295.1
A/chicken/Italy/1067/99(H7N1) matrix protein 1 (M1) AJ416630.1
A/chicken/Italy/1067/99(H7N1) neuraminidase (N1) AJ416627.1
A/chicken/Italy/4575/99 (H7N1) hemagglutinin (HA) AJ493469.1
A/chicken/Italy/13474/99(H7N1) haemagglutinin (HA) AJ491720.1
A/chicken/Italy/445/1999(H7N1)   AX537385.1
A/Chicken/Italy/267/00(H7N1) hemagglutinin (HA) AJ493215.1
A/Chicken/Italy/13489/99(H7N1) hemagglutinin (HA) AJ493214.1
A/Chicken/Italy/13307/99(H7N1) hemagglutinin (HA) AJ493212.1
A/chicken/Singapore/1994(H7N1) M2 protein EU014140.1
A/duck/Hong Kong/301/78(H7N1) matrix protein 1 (M) and matrix DQ107475.1
protein 2 (M)
A/Hong Kong/301/78(H7N1) hemagglutinin (HA) AY672090.1
A/fowl plaguq virus/Rostock/34 (H7N1) NP protein AJ243993.1
A/fowl plaguq virus/Rostock/34 (H7N1) PA protein AJ243992.1
A/fowl plaguq virus/Rostock/34 (H7N1) PB2 protein AJ243991.1
A/fowl plaguq virus/Rostock/34 (H7N1) PB1 protein AJ243990.1
A/ostrich/South Africa/5352/92(H7N1) hemagglutinin precursor U20458.1
(HA)
A/rhea/North Carolina/39482/93(H7N1) hemagglutinin precursor U20468.1
(HA)
A/turkey/Italy/3775/99 (H7N1) hemagglutinin (HA) AJ493472.1
A/turkey/Italy/4603/99 (H7N1) hemagglutinin (HA) AJ493471.1
A/turkey/Italy/4602/99 (H7N1) hemagglutinin (HA) AJ493470.1
A/turkey/Italy/4169/99 (H7N1) hemagglutinin (HA) AJ493468.1
A/turkey/Italy/4073/99 (H7N1) hemagglutinin (HA) AJ493467.1
A/turkey/Italy/3889/99 (H7N1) hemagglutinin (HA) AJ493466.1
A/turkey/Italy/12598/99(H7N1) haemagglutinin (HA) AJ489520.1
A/turkey/Italy/4580/99(H7N1) haemagglutinin (HA) AJ416628.1
A/Turkey/Italy/335/00(H7N1) haemagglutinin (HA) AJ493217.1
A/Turkey/Italy/13468/99(H7N1) haemagglutinin (HA) AJ493216.1
A/Turkey/Italy/13467/99(H7N1) haemagglutinin (HA) AJ493213.1
A/chicken/CT/9407/2003(H7N2) matrix protein 1 (M) and matrix DQ107478.1
protein 2 (M)
A/chicken/NY/116124/2003(H7N2) matrix protein 1 (M) and matrix DQ107479.1
protein 2 (M)
A/chicken/PA/143586/2002(H7N2) matrix protein 1 (M) and matrix DQ107477.1
protein 2 (M)
A/duck/Hong Kong/293/78(H7N2) matrix protein 1 (M) and matrix DQ107474.1
protein 2 (M)
A/duck/Hong Kong/293/78(H7N2) hemagglutinin precursor (HA) U20461.1
A/laughing gull/Delaware/2838/87 (H7N2) nonfunctional matrix AY664427.1
protein
A/pheasant/NJ/30739-9/2000(H7N2) matrix protein 1 (M) and DQ107481.1
matrix protein 2 (M)
A/ruddy turnstone/Delaware/130/99 (H7N2) onfunctional matrix AY664451.1
protein
A/unknown/149717-12/2002(H7N2) matrix protein 1 (M) and matrix DQ107480.1
protein 2 (M)
A/unknown/NY/74211-5/2001(H7N2) matrix protein 1 (M) and matrix DQ107476.1
protein 2 (M)
A/unknown/149717-12/2002(H7N2) matrix protein 1 (M) and matrix DQ107480.1
protein 2(M)
A/unknown/NY/74211-5/2001(H7N2) matrix protein 1(M) and matrix DQ107476.1
protein 2 (M)
A/chicken/British Columbia/CN7-3/04 (H7N3) hemagglutinin (HA) AY644402.1
A/chicken/British Columbia/CN7-3/04 (H7N3) matrix protein (M1) AY677732.1
A/chicken/Italy/270638/02(H7N3) hemagglutinin (HA) EU158111.1
A/gadwall/MD/3495/83(H7N3) matrix protein 1 (M) and matrix DQ107488.1
protein 2 (M)
A/mallard/Alberta/22/2001(H7N3) matrix protein 1 (M) and matrix DQ107482.1
protein 2 (M)
A/mallard/Alberta/699/81(H7N3) matrix protein 1 (M) and matrix DQ107487.1
protein 2 (M)
A/pintail/Alberta/25/2001(H7N3) matrix protein 1 (M) and matrix DQ107483.1
protein 2 (M)
A/Quail/Arkansas/16309-7/94 (H7N3) hemagglutinin protein AF072401.1
subunit 1 precursor (HA1)
A/ruddy turnstone/New Jersey/65/85(H7N3) nonfunctional matrix AY664433.1
protein
A/turkey/England/63(H7N3) hemagglutinin precursor (HA) U20462.1
A/Turkey/Colorado/13356/91 (H7N3) hemagglutinin protein subunit AF072400.1
1 precursor (HA1)
A/turkey/MN/1200/80(H7N3)) matrix protein 1 (M) and matrix DQ107486.1
protein 2 (M)
A/turkey/MN/1818/82(H7N3) matrix protein 1 (M) and matrix DQ107489.1
protein 2 (M)
A/turkey/Minnesota/1237/80(H7N3) hemagglutinin precursor (HA) U20466.1
A/turkey/TX/1/79(H7N3) matrix protein 1 (M) and matrix protein DQ107484.1
2 (M)
A/Turkey/0regon/71(H7N3) hemagglutinin AF497557.1
A/Turkey/Utah/24721-10/95 (H7N3) hemagglutinin protein subunit AF072402.1
1 precursor (HA1)
A/softbill/South Africa/142/92(H7N4) hemagglutinin precursor U20464.1
(HA)
A/ruddy turnstone/Delaware/2770/87 (H7N5) nonfunctional matrix AY664476.1
protein
A/chicken/Brescia/1902(H7N7) hemagglutinin 1 chain (HA) U20471.1
A/chicken/Jena/1816/87(H7N7) hemagglutinin precursor (HA) U20469.1
A/chicken/Leipzig/79(H7N7) hemagglutinin precursor (HA) U20459.1
A/duck/Heinersdorf/S495/6/86(H7N7) hemagglutinin precursor (HA) U20465.1
A/equine/Prague/1/56 (H7N7) neuraminidase U85989.1
A/equine/Santiago/77(H7N7) nucleoprotein AY383752.1
A/equine/Santiago/77(H7N7) neuraminidase AY383757.1
A/equine/Santiago/77(H7N7) hemagglutinin AY383756.1
A/FPV/Weybridge(H7N7) matrix protein M38299.1
A/goose/Leipzig/187/7/1979(H7N7) hemagglutinin L43914.1
A/goose/Leipzig/192/7/1979(H7N7) hemagglutinin L43915.1
A/goose/Leipzig/137/8/1979(H7N7) hemagglutinin L43913.1
A/ruddy turnstone/Delaware/134/99 (H7N7) nonfunctional matrix AY664468.1
protein
A/seal/Mass/1/80 H7N7 recombinant S73497.1
A/swan/Potsdam/63/6/81(H7N7) hemagglutinin precursor (HA) U20467.1
A/tern/Potsdam/342/6/79(H7N7) hemagglutinin precursor (HA) U20470.1
A/pintail/Alberta/121/79(H7N8) matrix protein 1 (M) and matrix DQ107485.1
protein 2 (M)
A/Turkey/Minnesota/38429/88(H7N9) hemagglutinin AF497551.1
A/turkey/Ontario/6118/1968(H8N4) segment 6 neuraminidase (NA) EU429793.1
A/Mallard Duck/Alberta/357/84(H8N4) segment 4 hemagglutinin AF310988.1
(HA1)
A/Pintail Duck/Alberta/114/79(H8N4) segment 4 hemagglutinin AF310987.1
(HA1)
A/duck/Eastern China/01/2005(H8N4) segment 6 neuraminidase (NA) EU429780.1
A/Red Kont/Delaware/254/94(H8N4) segment 4 hemagglutinin (HA1) AF310989.1
A/chicken/Amioz/1527/03(H9N2) nucleoprotein DQ116511.1
A/chicken/Amioz/1527/03(H9N2) neuraminidase DQ116081.1
A/chicken/Amioz/1527/03(H9N2) hemagglutinin DQ108911.1
A/chicken/Alonim/1953/104(H9N2) hemagglutinin DQ108928.1
A/chicken/Alonim/1552/03(H9N2) hemagglutinin DQ108914.1
A/chicken/Alonim/1552/03(H9N2) nucleoprotein DQ116514.1
A/chicken/Alonim/1965/04(H9N2) hemagglutinin DQ108929.1
A/Chicken/Anhui/1/98(H9N2) hemagglutinin (HA) AF461511.1
A/Chicken/Beijing/1/95(H9N2) nonfunctional matrix protein AF536719.1
A/Chicken/Beijing/1/95(H9N2) nucleoprotein (NP) AF536699.1
A/Chicken/Beijing/1/95(H9N2) nonfunctional nonstructural AF536729.1
protein
A/Chicken/Beijing/1/95(H9N2) segment 6 neuraminidase (NA) AF536709.1
A/Chicken/Beijing/2/97(H9N2) nucleoprotein (NP) AF536700.1
A/Chicken/Beijing/2/97(H9N2) nonfunctional matrix protein AF536720.1
A/Chicken/Beijing/2/97(H9N2) nonfunctional nonstructural AF536730.1
protein
A/Chicken/Beijing/2/97(H9N2) segment 6 neuraminidase (NA) AF536710.1
A/Chicken/Beijing/1/97(H9N2) hemagglutinin (HA) AF461530.1
A/Chicken/Beijing/3/99(H9N2) nonfunctional matrix protein AF536721.1
A/Chicken/Beijing/3/99(H9N2) nucleoprotein (NP) AF536701.1
A/Chicken/Beijing/3/99(H9N2) nonfunctional nonstructural AF536731.1
protein
A/Chicken/Beijing/3/99(H9N2) segment 6 neuraminidase (NA) AF536711.1
A/chicken/Beit Alfa/1282/03(H9N2)hemagglutinin DQ104476.1
A/chicken/Beit-Aran/29/05(H9N2) hemagglutinin DQ108931.1
A/chicken/Bnei Darom/1557/03(H9N2) hemagglutinin DQ108915.1
A/chicken/Ein Habsor/1808/04(H9N2) hemagglutinin DQ108925.1
A/Chicken/Gangxi/2/00(H9N2) hemagglutinin (HA) AF461514.1
A/Chicken/Gangxi/1/00(H9N2) hemagglutinin (HA) AF461513.1
A/chicken/Gan Shomron/1465/03(H9N2) hemagglutinin DQ104480.1
A/chicken/Gan Shomron/1292/03(H9N2) hemagglutinin DQ104478.1
A/chicken/Gan_Shomron/1465/03(H9N2) nucleoprotein DQ116506.1
A/chicken/Gan_Shomron/1465/03(H9N2) neuraminidase DQ116077.1
A/chicken/Gan Shomron/1543/04(H9N2) nucleoprotein DQ116512.1
A/chicken/Gan Shomron/1543/04(H9N2) hemagglutinin DQ108912.1
A/Chicken/Guangdong/97(H9N2) nonfunctional matrix protein AF536722.1
A/Chicken/Guangdong/97(H9N2) nucleoprotein (NP) AF536702.1
A/Chicken/Guangdong/97(H9N2) nonfunctional nonstructural AF536732.1
protein
A/Chicken/Guangdong/97(H9N2) segment 6 neuraminidase (NA) AF536712.1
A/Chicken/Gansu/1/99(H9N2) hemagglutinin (HA) AF461512.1
A/chicken/Gujrat/India/3697/2004(H9N2) polymerase basic 2 DQ979865.1
(PB2)
A/chicken/Haryana/India/2424/2004(H9N2) polymerase basic 2 DQ979862.1
(PB2)
A/Chicken/Henan/98(H9N2) nonfunctional matrix protein AF536726.1
A/Chicken/Henan/98(H9N2) nucleoprotein (NP) AF536706.1
A/Chicken/Henan/98(H9N2) nonfunctional nonstructural protein AF536736.1
A/Chicken/Henan/2/98(H9N2) hemagglutinin (HA) AF461517.1
A/Chicken/Henan/1/99(H9N2) hemagglutinin (HA) AF461516.1
A/Chicken/Henan/98(H9N2) segment 6 neuraminidase (NA) AF536716.1
A/Chicken/Hebei/1/96(H9N2) nonfunctional matrix protein AF536723.1
A/Chicken/Hebei/1/96(H9N2) segment 6 nonfunctional AF536713.1
neuraminidase protein
A/Chicken/Hebei/1/96(H9N2) nucleoprotein (NP) AF536703.1
A/Chicken/Hebei/1/96(H9N2) nonfunctional nonstructural protein AF536733.1
A/Chicken/Hebei/1/96(H9N2) segment 6 nonfunctional AF536713.1
neuraminidase protein
A/Chicken/Hebei/2/00(H9N2) hemagglutinin (HA) AF461531.1
A/Chicken/Hebei/2/98(H9N2) nonfunctional matrix protein AF536724.1
A/Chicken/Hebei/2/98(H9N2) nucleoprotein (NP) AF536704.1
A/Chicken/Hebei/2/98(H9N2) nonfunctional nonstructural protein AF536734.1
A/Chicken/Hebei/2/98(H9N2) segment 6 neuraminidase (NA) AF536714.1
A/Chicken/Hebei/1/00(H9N2) hemagglutinin (HA) AF461515.1
A/Chicken/Hebei/3/98(H9N2) nucleoprotein (NP) AF536705.1
A/Chicken/Hebei/3/98(H9N2) nonfunctional matrix protein AF536725.1
A/Chicken/Hebei/3/98(H9N2) nonfunctional onstructural protein AF536735.1
A/Chicken/Hebei/3/98(H9N)) segment 6 neuraminidase (NA) AF536715.1
A/chicken/Hong Kong/FY313/2000(H9N2) matrix protein 1 (M) and DQ107508.1
matrix protein 2 (M)
A/chicken/Hong Kong/WF208/2001(H9N2) matrix protein 1 (M) and DQ107513.1
matrix protein 2 (M)
A/chicken/Hong Kong/NT471/2002(H9N2) matrix protein 1 (M) and DQ107514.1
matrix protein 2 (M)
A/chicken/Hong Kong/WF2/99(H9N2) hemagglutinin AY206677.1
A/chicken/Iarah/1376/03(H9N2) nucleoprotein DQ116504.1
A/chicken/Iarah/1376/03(H9N2) neuraminidase DQ116075.1
A/chicken/Iarah/1376/03(H9N2) hemagglutinin DQ108910.1
A/chicken/India/2793/2003(H9N2) hemagglutinin (HA) AY336597.1
A/chicken/Iran/101/1998(H9N2) matrix protein 2 (M2) EU477375.1
A/Chicken/Jiangsu/1/99(H9N)) hemagglutinin (HA) AF461509.1
A/Chicken/Jiangsu/2/98(H9N2) hemagglutinin (HA) AF461510.1
A/chicken/Kfar Monash/636/02(H9N2) hemagglutinin DQ104464.1
A/chicken/Kalanit/1966/06.12.04(H9N2) hemagglutinin DQ108930.1
A/chicken/Kaianit/1946/04(H9N2) hemagglutinin DQ108927.1
A/chicken/Korea/S4/2003(H9N2) matrix protein 1 (M) and matrix DQ107517.1
protein 2 (M)
A/Chicken/Korea/MS96/96(H9N2) matrix protein 1 and 2 (M) AF203788.1
A/Chicken/Korea/MS96/96(H9N2) neuraminidase subtype 2 AF203786.1
A/Chicken/Korea/MS96/96(H9N2) nucleoprotein AF203787.1
A/Chicken/Liaoning/99(H9N2) nonfunctional matrix protein AF536727.1
A/Chicken/Liaoning/1/00(H9N2) hemagglutinin (HA) AF461518.1
A/Chicken/Liaoning/99(H9N2) nucleoprotein (NP) AF536707.1
A/Chicken/Liaoning/99(H9N2) nonfunctional matrix protein AF536727.1
A/Chicken/Liaoning/99(H9N2) nonfunctional onstructural protein AF536737.1
A/Chicken/Liaoning/2/00(H9N2) hemagglutinin (HA) AF461519.1
A/chicken/Liaoning/99(H9N2) segment 6 neuraminidase (NA) AF536717.1
A/chicken/Mudanjiang/0823/2000(H9N2) nucleoprotein (NP) AY496851.1
A/Chicken/Mudanjiang/0823/2000 (H9N2) nonstructural protein AY631868.1
A/Chicken/Mudanjiang/0823/00 (H9N2) hemagglutinin (HA) AY513715.1
A/chicken/Mudanjiang/0823/2000(H9N2) matrix protein (M1) AY496852.1
A/chicken/Mudanjiang/0823/2000(H9N2) nucleoprotein (np) AY496851.1
A/chicken/Maale HaHamisha/90658/00(H9N2) hemagglutinin DQ104472.1
A/chicken/Maanit/1477/03(H9N2) hemagglutinin DQ104483.1
A/chicken/Maanit/1291/03(H9N2) hemagglutinin DQ104477.1
A/chicken/Maanit/1275/03(H9N2) hemagglutinin DQ104457.1
A/chicken/Maanit/1477/03(H9N2) nucleoprotein DQ116508.1
A/chicken/Netohah/1373/03 (H9N2) nucleoprotein DQ116503.1
A/chicken/Netohah/1373/03 (H9N2) neuraminidase DQ116074.1
A/chicken/Netohah/1373/03 (H9N2) hemagglutinin DQ108909.1
A/chicken/Neve Ilan/1504/03(H9N2) hemagglutinin DQ104484.1
A/chicken/Neve_Ilan/1504/03(H9N2) nucleoprotein DQ116509.1
A/chicken/Neve_Ilan/1504/03(H9N2) neuraminidase DQ116079.1
A/chicken/Orissa/India/2317/2004(H9N2) polymerase basic 2 (PB2) DQ979861.1
A/chicken/Pardes-Hana-Carcur/1475/03(H9N2) hemagglutinin DQ104482.1
A/chicken/Pardes-Hana-Carcur/1475/03(H9N2) neuraminidase DQ116078.1
A/chicken/Saar/1456/03(H9N2) hemagglutinin DQ104479.1
A/chicken/Sde_Uziahu/1747/04(H9N2) neuraminidase DQ116068.1
A/chicken/Sede Uzziyyahu/1651/04(H9N2) hemagglutinin DQ108923.1
A/chicken/Sde Uziahu/1747/04(H9N2) DQ108905.1
A/chicken/Singapore/1998(H9N2) M2 protein EU014142.1
A/chicken/Singapore/1998(H9N2) M2 protein EU014142.1
A/Chicken/Shandong/98(H9N2) nonfunctional matrix protein AF536728.1
A/Chicken/Shandong/1/98(H9N2) hemagglutinin (HA) AF461520.1
A/Chicken/Shandong/98(H9N2) nucleoprotein (NP) AF536708.1
A/Chicken/Shandong/98(H9N2) nonfunctional nonstructural protein AF536738.1
A/Chicken/Shandong/98(H9N2) segment 6 neuraminidase (NA) AF536718.1
A/Chicken/Shandong/2/99(H9N2) hemagglutinin (HA) AF461521.1
A/chicken/Shandong/1/02(H9N2) neuraminidase (NA) AY295761.1
A/Chicken/Shanghai/F/98(H9N2) hemagglutinin AF461532.1
A/Chicken/Shanghai/1/02(H9N2) hemagglutinin AY281745.1
A/Chicken/Shanghai/2/99(H9N2)) hemagglutinin (HA) AF461522.1
A/Chicken/Shanghai/3/00(H9N2)) hemagglutinin (HA) AF461523.1
A/Chicken/Shanghai/F/98(H9N2) hemagglutinin (HA) AY743216.1
A/Chicken/Shanghai/4-2/01(H9N2) hemagglutinin (HA) AF461525.1
A/Chicken/Shanghai/4-1/01(H9N2) hemagglutinin (HA) AF461524.1
A/Chicken/Shanghai/4/01(H9N2) hemagglutinin (HA) AY083841.1
A/Chicken/Shanghai/3/01(H9N2) hemagglutinin HA) AY083840.1
A/chicken/Talmei_Elazar/1304/03(H9N2)nucleoprotein DQ116530.1
A/chicken/Talmei_Elazar/1304/03(H9N2) neuraminidase DQ116072.1
A/Chicken/Tianjing/2/96(H9N2) hemagglutinin AF461527.1
A/Chicken/Tianjing/1/96(H9N2) hemagglutinin (HA) AF461526.1
A/chicken/Tel Adashim/811/01 (H9N2) hemagglutinin DQ104467.1
A/chicken/Tel Adashim/811/01 (H9N2) nucleoprotein DQ116527.1
A/ck/Tel_Adashim/811/01(H9N2) neuraminidase DQ116064.1
A/chicken/Tel Adashim/812/01 (H9N2) nucleoprotein DQ116528.1
A/chicken/Tel Adashim/812/01 (H9N2) hemagglutinin DQ104468.1
A/ck/Tel_Adashim/812/01(H9N2) neuraminidase DQ116065.1
A/chicken/Tel Adashim/786/01 (H9N2) nucleoprotein DQ116524.1
A/chicken/Tel Adashim/809/01 (H9N2) hemagglutinin DQ104465.1
A/chicken/Tel Adashim/809/01 (H9N2) nucleoprotein DQ116525.1
A/chicken/Tel Adashim/1469/03 (H9N2) nucleoprotein DQ116507.1
A/chicken/Tel Adashim/1469/303(H9N2) hemagglutinin DQ104481.1
A/chicken/Tel Adashim/1506/03 (H9N2) neuraminidase DQ116080.1
A/chicken/Tel Adashim/1506/03(H9N2) hemagglutinin DQ104474.1
A/chicken/Tel Adashim/1506/03 (H9N2) nucleoprotein DQ116510.1
A/chicken/Tel Adashim/1332/03(H9N2) nucleoprotein DQ116501.1
A/chicken/Tel Adashim/1321/03(H9N2) nucleoprotein DQ116500.1
A/chicken/Tel Adashim/1332/03(H9N2) hemagglutinin DQ108907.1
A/chicken/Tel Adashim/1321/03(H9N2) hemagglutinin DQ108906.1
A/chicken/Telmond/1308/03(H9N2) nucleoprotein DQ116499.1
A/chicken/Telmond/1308/03(H9N2) neuraminidase DQ116073.1
A/chicken/Telmond/1308/03(H9N2) hemagglutinin DQ108921.1
A/chicken/Tzrofa/1568/04(H9N2) nucleoprotein DQ116519.1
A/chicken/Tzrofa/1568/04(H9N2) hemagglutinin DQ108919.1
A/chicken/UP/India/2544/2004(H9N2) polymerase basic 2 (PB2) DQ979864.1
A/chicken/UP/India/2543/2004(H9N2) polymerase basic 2 (PB2) DQ979863.1
A/chicken/Wangcheng/4/2001(H9N2) nucleoprotein AY268949.1
A/chicken/Ysodot/1362/03(H9N2) nucleoprotein DQ116502.1
A/chicken/Ysodot/1362/03(H9N2) hemagglutinin DQ108908.1
A/Chicken/Yunnan/2/00(H9N2) hemagglutinin (HA) AF461529.1
A/Chicken/Yunnan/1/99(H9N2) hemagglutinin (HA) AF461528.1
A/duck/Eastern China/01/2000(H9N2) segment 6 neuraminidase (NA) EU429725.1
A/duck/Eastern China/48/2001(H9N2) segment 6 neuraminidase (NA) EU429707.1
A/duck/Eastern China/66/2003(H9N2) segment 6 neuraminidase (NA) EU429699.1
A/duck/Eastern China/80/2004(H9N2) segment 6 neuraminidase (NA) EU429726.1
A/duck/Hong Kong/448/78(H9N2) matrix protein 1 (M) and matrix DQ107494.1
protein 2 (M)
A/duck/Hong Kong/448/78(H9N2) hemagglutinin precursor AY206673.1
A/duck/Hong Kong/366/78(H9N2) hemagglutinin precursor AY206674.1
A/duck/Hong Kong/784/79(H9N2)) matrix protein 1(M) and matrix DQ107496.1
protein 2 (M)
A/duck/Hong Kong/702/79(H9N2) matrix protein 1 (M) and matrix DQ107495.1
protein 2 (M)
/duck/Hong Kong/702/79(H9N2) hemagglutinin precursor AY206672.1
A/duck/Hong Kong/610/79(H9N2) hemagglutinin precursor AY206680.1
A/duck/Hong Kong/552/79(H9N2) hemagglutinin precursor AY206679.1
A/duck/Hong Kong/644/79(H9N2) hemagglutinin precursor AY206678.1
A/duck/Korea/S13/2003(H9N2) matrix protein 1 (M) and matrix DQ107518.1
protein 2 (M)
A/duck/Nanchang/4-361/2001(H9N2) matrix protein 1 (M) and DQ107511.1
matrix protein 2 (M)
A/duck/NY/83793/2002(H9N2) matrix protein 1 (M) and matrix DQ107499.1
protein 2 (M)
A/goose/MN/5733-1243/80(H9N2) matrix protein 1 (M) and matrix DQ107492.1
protein 2 (M)
A/geese/Tel Adashim/829/01(H9N2) hemagglutinin DQ104469.1
A/geese/Tel Adashim/830/01(H9N2 hemagglutinin DQ104470.1
A/ostrich/Eshkol/1436/03(H9N2) neuraminidase DQ116076.1
A/ostrich/Eshkol/1436/03(H9N2) nucleoprotein DQ116505.1
A/pigeon/Hong Kong/WF286/2000(H9N2) matrix protein 1 (M) and DQ107509.1
matrix protein 2 (M)
A/quail/Hong Kong/YU415/2002(H9N2) matrix protein 1 (M) and DQ107516.1
matrix protein 2 (M)
A/quail/Hong Kong/SSP225/2001(H9) matrix protein 1 (M) and DQ107512.1
matrix protein 2 (M)
A/quail/Hong Kong/YU1495/2000(H9N2) matrix protein 1 (M) and DQ107510.1
matrix protein 2 (M)
A/quail/Hong Kong/A28945/88(H9N2) hemagglutinin precursor AY206675.1
A/shorebird/Delaware/276/99 (H9N2) nonfunctional matrix protein AY664464.1
A/shorebird/Delaware/113/2001(H9N2) matrix protein 1 (M) and DQ107505.1
matrix protein 2 (M)
A/silky chicken/Hong Kong/WF266/2002(H9N2) matrix protein 2 (M) DQ107515.1
and matrix protein 1 (M)
A/shorebird/Delaware/77/2001(H9N2) matrix protein 1 (M) and DQ107497.1
matrix protein 2 (M)
A/guinea fowl/Hong Kong/WF10/99(H9N2) hemagglutinin precursor AY206676.1
A/swine/Hangzhou/1/2006(H9N2) nucleocapsid protein (NP) DQ907704.1
A/swine/Hangzhou/1/2006(H9N2)) matrix protein 1 (M1) EF055887.1
A/swine/Hangzhou/1/2006(H9N2)) nonstructural protein 1 (NS1) DQ823385.1
A/Sw/ShanDong/1/2003(H9N2) hemagglutinin (HA) AY294658.1
A/turkey/CA/6889/80(H9N2) matrix protein 1 (M) and matrix DQ107491.1
protein 2 (M)
A/turkey/TX/28737/81(H9N2) matrix protein 1 (M) and matrix DQ107493.1
protein 2 (M)
A/turkey/MN/511/78(H9N2) matrix protein 1 (M) and matrix DQ107490.1
protein 2 (M)
A/turkey/Beit Herut/1267/03(H9N2) hemagglutinin DQ104485.1
A/turkey/Beit HaLevi/1009/02(H9N2) hemagglutinin DQ104473.1
A/turkey/Beit Herut/1265/03(H9N2) hemagglutinin DQ104456.1
A/turkey/Beit_HaLevi/1562/03(H9N2) nucleoprotein DQ116515.1
A/turkey/Beit_HaLevi/1566/04(H9N2) nucleoprotein DQ116517.1
A/turkey/Beit_HaLevi/1562/03(H9N2) neuraminidase DQ116083.1
A/turkey/Beit_HaLevi/1566/04(H9N2) neuraminidase DQ116084.1
A/turkey/Beit_Herut/1267/03(H9N2) neuraminidase DQ116070.1
A/turkey/Beit_Herut/1265/03(H9N2) neuraminidase DQ116069.1
A/turkey/Beit HaLevi/1566/04(H9N2) hemagglutinin DQ108917.1
A/turkey/Bezat/89/05(H9N2) hemagglutinin DQ108922.1
A/turkey/Brosh/1276/03(H9N2) hemagglutinin DQ104458.1
A/turkey/Brosh/1276/03(H9N2) neuraminidase DQ116071.1
A/turkey/Emek Hefer/1272/03(H9N2) hemagglutinin DQ104475.1
A/turkey/Ein Habsor/1804/04(H9N2) hemagglutinin DQ108924.1
A/turkey/Ein Tzurim/1172/02(H9N2) hemagglutinin DQ104451.1
A/turkey/Ein Tzurim/1738/04(H9N2) hemagglutinin DQ108920.1
A/turkey/Ein_Tzurim/1738/04(H9N2) neuraminidase DQ116085.1
A/turkey/Gyvat Haim Ehud/1544/03(H9N2)hemagglutinin DQ108913.1
A/turkey/Givat Haim/810/01 (H9N2) hemagglutinin DQ104466.1
A/turkey/Givat Haim/810/01 (H9N2) nucleoprotein DQ116526.1
A/turkey/Givat Haim/868/02(H9N2) hemagglutinin DQ104471.1
A/turkey/Givat Haim/622/02(H9N2) hemagglutinin DQ104462.1
A/turkey/Givat_Haim/965/02(H9N2) nucleoprotein DQ116498.1
A/turkey/Gyvat_Haim_Ehud/1544/03(H9N2) nucleoprotein DQ116513.1
A/turkey/Gyvat_Haim_Ehud/1544/03(H9N2) neuraminidase DQ116082.1
A/tk/Givat_Haim/810/25.12.01(H9N2) neuraminidase DQ116063.1
A/turkey/Givat_Haim/622/02(H9N2)) neuraminidase DQ116060.1
A/turkey/Givat_Haim/965/02(H9N2) neuraminidase DQ116057.1
A/turkey/Hod_Ezyon/699/02(H9N2) neuraminidase DQ116062.1
A/turkey/Mishmar Hasharon/619/02 (H9N2) hemagglutinin DQ104461.1
A/turkey/Mishmar_Hasharon/619/02(H9N2) neuraminidase DQ116059.1
A/turkey/Kfar_Vitkin/616/02(H9N2) neuraminidase DQ116058.1
A/turkey/Kfar Vitkin/616/02 (H9N2) hemagglutinin DQ104460.1
A/turkey/Kfar Vitkin/615/02 (H9N2)hemagglutinin DQ104459.1
A/turkey/Kfar Vitkin/615/02 (H9N2) nucleoprotein DQ116520.1
A/turkey/Kfar_Vitkin/616/02(H9N2)) nucleoprotein DQ116521.1
A/turkey/Kfar Warburg/1224/03(H9N2) hemagglutinin DQ104455.1
A/tk/Kfar_Vitkin/615/02(H9N)) neuraminidase DQ116067.1
A/turkey/Mishmar_Hasharon/619/02(H9N2) nucleoprotein DQ116522.1
A/turkey/Naharia/1013/02(H9N2) hemagglutinin DQ104449.1
A/turkey/Nahalal/1547/04(H9N2) hemagglutinin DQ108932.1
A/turkey/Neve Ilan/90710/00 (H9N2) nucleoprotein DQ116529.1
A/tk/Neve_Ilan/90710/00(H9N2) neuraminidase DQ116066.1
A/turkey/Qevuzat_Yavne/1242/03(H9N2) neuraminidase DQ116086.1
A/turkey/Sapir/1199/02(H9N2) hemagglutinin DQ104452.1
A/turkey/Shadmot Dvorah/1567/04(H9N2) nucleoprotein DQ116518.1
A/turkey/Shadmot Dvorah/1567/04(H9N2) hemagglutinin DQ108918.1
A/turkey/Tzur Moshe/1565/04(H9N2) nucleoprotein DQ116516.1
A/turkey/Tzur Moshe/1565/04(H9N2) hemagglutinin DQ108916.1
A/turkey/Yedidia/625/02 (H9N2) hemagglutinin DQ104463.1
A/turkey/Yedidia/625/02 (H9N2) nucleoprotein DQ116523.1
A/turkey/Yedidia/625/02 (H9N2) neuraminidase DQ116061.1
A/turkey/Yedidia/911/02(H9N2) hemagglutinin DQ104448.1
A/turkey/Avigdor/1215/03(H9N2) hemagglutinin DQ104454.1
A/turkey/Avigdor/1209/03(H9N2) hemagglutinin DQ104453.1
A/turkey/Avichail/1075/02(H9N2) hemagglutinin DQ104450.1
A/turkey/Avigdor/1920/04(H9N2) hemagglutinin DQ108926.1
A/pintail/Alberta/49/2003(H9N5) matrix protein 1 (M) and matrix DQ107498.1
protein 2 (M)
A/red knot/Delaware/2552/87 (H9N5) nonfunctional matrix protein AY664472.1
A/duck/Hong Kong/147/77(H9N6) hemagglutinin precursor AY206671.1
A/shorebird/Delaware/270/2001(H9N7) matrix protein 1 (M) and DQ107504.1
matrix protein 2 (M)
A/shorebird/Delaware/277/2000(H9N7) matrix protein 1 (M) and DQ107507.1
matrix protein 2 (M)
A/shorebird/Delaware/275/2001(H9N7)) matrix protein 2 (M) and DQ107506.1
matrix protein 1 (M)
A/ruddy turnstone/Delaware/116/98 (H9N8) nonfunctional matrix AY664435.1
protein
A/shorebird/Delaware/141/2002(H9N9) matrix protein 1 (M) and DQ107503.1
matrix protein 2 (M)
A/ruddy turnstone/Delaware/103/2002(H9N9) matrix protein 1 (M) DQ107502.1
and matrix protein 2 (M)
A/shorebird/Delaware/29/2002(H9N9) matrix protein 1 (M) and DQ107501.1
matrix protein 2 (M)
A/shorebird/Delaware/18/2002(H9N9) matrix protein 1 (M) and DQ107500.1
matrix protein 2 (M)
A/ruddy turnstone/Delaware/259/98 (H9N9) nonfunctional matrix AY664469.1
protein
A/duck/Eastern China/527/2003(H10N3) segment 6 neuraminidase EU429716.1
(NA)
A/duck/Eastern China/495/2003(H10N3) segment 6 neuraminidase EU429715.1
(NA)
A/duck/Eastern China/372/2003(H10N3) segment 6 neuraminidase EU429714.1
(NA)
A/duck/Eastern China/488/2003(H10N3) segment 6 neuraminidase EU429712.1
(NA)
A/duck/Eastern China/453/2002(H10N3) segment 6 neuraminidase EU429711.1
(NA)
A/duck/Eastern China/412/2003(H10N3) segment 6 neuraminidase EU429710.1
(NA)
A/duck/Eastern China/404/2003(H10N3) segment 6 neuraminidase EU429709.1
(NA)
A/duck/Eastern China/397/2003(H10N3) segment 6 neuraminidase EU429708.1
(NA)
A/duck/Eastern China/502/2003(H10N3) segment 6 neuraminidase EU429705.1
(NA)
A/duck/Eastern China/395/2003(H10N3) segment 6 neuraminidase EU429704.1
(NA)
A/duck/Eastern China/356/2003(H10N3) segment 6 neuraminidase EU429703.1
(NA)
A/duck/Eastern China/368/2003(H10N3) segment 6 neuraminidase EU429702.1
(NA)
A/chicken/Singapore/1993(H10N5) M2 protein EU014145.1
A/red knot/Delaware/2561/87 (H10N5) nonfunctional matrix AY664441.1
protein
A/chicken/Germany/N/1949(H10N7) segment 6 neuraminidase (NA) EU429796.1
A/ruddy turnstone/Delaware/2764/87 (H10N7) nonfunctional matrix AY664462.1
protein
A/mallard/Alberta/71/98 (H10N7) nonfunctional matrix protein AY664485.1
A/mallard/Alberta/90/97 (H10N7) nonfunctional matrix protein AY664446.1
A/mallard/Alberta/110/99(Hl0N7) nonfunctional matrix protein AY664481.1
A/mallard/Alberta/297/77 (H10N7) nonfunctional matrix protein AY664430.1
A/mallard/Alberta/223/98 (H10N8) nonfunctional matrix protein AY664486.1
A/ruddy turnstone/New Jersey/51/85 (H11N1) nonfunctional matrix AY664479.1
protein
A/duck/Nanchang/1749/1992(H11N2) nucleoprotein (NP) U49094.1
A/duck/Hong Kong/62/1976(H11N2) polymerase (PB1) U48280.1
A/duck/Yangzhou/906/2002(H11N2) hemagglutinin DQ080993.1
A/shorebird/Delaware/86/99 (H11N2) nonfunctional matrix protein AY664463.1
A/ruddy turnstone/Delaware Bay/2762/1987(H11N2)polymerase PB2 CY126279.1
(PB2)
A/ruddy turnstone/Delaware/2762/87 (H11N2) nonfunctional AY664459.1
matrix protein
A/ruddy turnstone/Delaware Bay/2762/1987(H11N2) polymerase PB1 CY126278.1
(PB1) and PB1-F2 protein (PB1-F2)
A/ruddy turnstone/Delaware/2589/87 (H11N4) nonfunctional matrix AY664478.1
protein
A/duck/England/1/1956(H11N6) segment 6 neuraminidase (NA) EU429795.1
A/mallard/Alberta/125/99 (H11N6) nonfunctional matrix protein AY664483.1
A/duck/Memphis/546/1974(H11N9) segment 6 neuraminidase (NA) EU429798.1
A/mallard/Alberta/122/99 (H11N9) nonfunctional matrix protein AY664444.1
A/Mallard Duck/Alberta/342/83(H12N1) segment 4 hemagglutinin AF310991.1
(HA1)
A/ruddy turnstone/Delaware/67/98(H12N4) nonfunctional matrix AY664470.1
protein
A/Ruddy Turnstone/Delaware/67/98(H12N4) segment 4 hemagglutinin AF310990.1
(HA1)
A/mallard/Alberta/52/97 (H12N5) nonfunctional matrix protein AY664448.1
A/mallard/Alberta/223/77 (H12N5) nonfunctional matrix protein AY664431.1
A/Laughing Gull/New Jersey/171/92(H12N5) segment 4 AF310992.1
hemagglutinin (HA1)
A/ruddy turnstone/Delaware/265/98 (H12N8) nonfunctional matrix AY664438.1
protein
A/herring gull/New Jersey/782/86 (H13N2) nonfunctional matrix AY664475.1
protein
A/shorebird/Delaware/224/97 (H13N6) nonfunctional matrix AY664421.1
protein
A/PR/8/34 (H1N1) × A/England/939/69 (H3N2) PB1 protein AJ564806.1
A/PR/8/34 (H1N1) × A/England/939/69 (H3N2)PB2 protein AJ564804.1
A/duck/Czechslovakia/56(H4N6) × A/USSR/90/77(H1N1)) EU643639.1
neuraminidase (NA)
A/duck/Czechslovakia/56(H4N6) × A/USSR/90/77(H1N1)) EU643638.1
neuraminidase (NA)
A/duck/Ukraine/63(H3N8) × A/USSR/90/77(H1N1)) neuraminidase EU643637.1
(NA)
A/duck/Ukraine/63(H3N8) × A/USSR/90/77(H1N1)) neuraminidase EU643636.1
(NA)
RCB1-XXI: A/USSR/90/77(H1N1) × A/Duck/Czechoslov 56 (H4N6) AF290438.1
segment 4 hemagglutinin
RCB1: A/USSR/90/77(H1N1) × A/Duck/Czechoslov 56 (H4N6) AF290437.1
hemagglutinin
PX14-XIII (A/USSR/90/77(H1N1) × A/Pintail AF290442.1
Duck/Primorie/695/76(H2N3)) segment 4 hemagglutinin
PX14(A/USSR/90/77(H1N1) × A/Pintail Duck/Primorie/695/76(H2N3)) AF290441.1
segment 4 hemagglutinin
PX8-XIII(A/USSR/90/77(H1N1) × A/Pintail
Duck/Primorie/695/76(H2N3)) segment 4 hemagglutinin
PX8(A/USSR/90/77(H1N1) × A/Pintail Duck/Primorie/695/76(H2N3)) AF290439.1
segment 4 hemagglutinin
A/swine/Schleswig-Holstein/1/93 hemagglutinin (HA) U72669.1
A/swine/England/283902/93 hemagglutinin (HA) U72668.1
A/swine/England/195852/92 hemagglutinin (HA) U72667.1
A/swine/England/117316/86 hemagglutinin (HA) U72666.1
A/turkey/Germany/2482/90) hemagglutinin (HA) U96766.1

TABLE 12
Influenza B Antigens
                                 GenBank
Strain/Protein                   Access No.
B/Daeku/47/97 hemagglutinin      AF521237.1
B/Daeku/45/97 hemagglutinin      AF521236.1
B/Daeku/10/97 hemagglutinin      AF521221.1
B/Daeku/9/97 hemagglutinin       AF521220.1
B/Gyeonggi/592/2005 neuraminidase DQ231543.1
B/Gyeonggi/592/2005 hemagglutinin DQ231538.1
B/Hong Kong/5/72 neuraminidase   AF305220.1
B/Hong Kong/5/72 hemagglutinin   AF305219.1
B/Hong Kong/157/99 hemagglutinin AF387503.1
B/Hong Kong/157/99 hemagglutinin AF387502.1
B/Hong Kong/156/99 hemagglutinin AF387501.1
B/Hong Kong/156/99 hemagglutinin AF387500.1
B/Hong Kong/147/99 hemagglutinin AF387499.1
B/Hong Kong/147/99 hemagglutinin AF387498.1
B/Hong Kong/110/99 hemagglutinin AF387497.1
B/Hong Kong/110/99 hemagglutinin AF387496.1
B/Incheon/297/2005 hemagglutinin DQ231539.1
B/Incheon/297/2005 neuraminidase DQ231542.1
B/Lee/40 polymerase protein (PB1) D00004.1
B/Michigan/22572/99 hemagglutinin AY129961.1
B/Michigan/22723/99 hemagglutinin (HA) AY112992.1
B/Michigan/22631/99 hemagglutinin (HA) AY112991.1
B/Michigan/22587/99 hemagglutinin (HA) AY112990.1
B/New York/20139/99 hemagglutinin AY129960.1
B/Panama/45/90 nucleoprotein     AF005739.1
B/Panama/45/90 polymerase (PA)   AF005738.1
B/Panama/45/90 polymerase (PB2)  AF005737.1
B/Panama/45/90 polymerase (PB1)  AF005736.1
B/Pusan/250/99 hemagglutinin     AF521218.1
B/Pusan/255/99 hemagglutinin     AF521226.1
B/Pusan/270/99 hemagglutinin     AF521219.1
B/Pusan/285/99 hemagglutinin     AF521217.1
B/Riyadh/01/2007 segment 8 nuclear export protein (NEP) GU135839.1
and non structural protein 1 (NS1)
B/Seoul/6/88 hemagglutinin       AF521238.1
B/Seoul/12/88 hemagglutinin      AF521239.1
B/Seoul/1/89 hemagglutinin       AF521230.1
B/Seoul/37/91 hemagglutinin      AF521229.1
B/Seoul/38/91 hemagglutinin      AF521227.1
B/Seoul/40/91 hemagglutinin      AF521235.1
B/Seoul/41/91 hemagglutinin      AF521228.1
B/Seoul/13/95 hemagglutinin      AF521225.1
B/Seoul/12/95 hemagglutinin      AF521223.1
B/Seoul/17/95 hemagglutinin      AF521222.1
B/Seoul/21/95 hemagglutinin      AF521224.1
B/Seoul/16/97 hemagglutinin      AF521233.1
B/Seoul/19/97 hemagglutinin      AF521231.1
B/Seoul/28/97 hemagglutinin      AF521234.1
B/Seoul/31/97 hemagglutinin      AF521232.1
B/Seoul/232/2004 neuraminidase   DQ231541.1
B/Seoul/1163/2004 neuraminidase  DQ231540.1
B/Seoul/1163/2004 hemagglutinin  DQ231537.1
B/Sichuan/379/99 hemagglutinin (HA) AF319590.1
B/Sichuan/38/2000 hemagglutinin (HA) AF319589.1
B/South Carolina/25723/99 hemagglutinin AY129962.1
B/Switzerland/4291/97 hemagglutinin AF387505.1
B/Switzerland/4291/97 hemagglutinin AF387504.1
B/Taiwan/21706/97 nonstructural protein 1 (NS1) AF492479.1
B/Taiwan/21706/97 hemagglutinin (HA) AF026162.1
B/Taiwan/3143/97 nonstructural protein 1 (NS1) AF492478.1
B/Taiwan/3143/97 haemagglutinin (HA) AF026161.1
B/Taiwan/2026/99 nonstructural protein 1 (NS1) AF492481.1
B/Taiwan/2026/99 hemagglutinin   AY604741.1
B/Taiwan/2027/99 nonstructural protein 1 (NS1) AF492480.1
B/Taiwan/2027/99 hemagglutinin   AY604742.1
B/Taiwan/1243/99 nonstructural protein NS1(NS1) AF380504.1
B/Taiwan/1243/99 hemagglutinin   AY604740.1
B/Taiwan/2195/99 hemagglutinin   AY604743.1
B/Taiwan/2195/99 nonstructural protein 1 (NS1) AF492482.1
B/Taiwan/1293/2000 nonstructural protein NS1(NS1) AF380509.1
B/Taiwan/1293/00 hemagglutinin   AY604746.1
B/Taiwan/1293/2000 hemagglutinin (HA) AF492477.1
B/Taiwan/1265/2000 nonstructural protein NS1 (NS1) AF380508.1
B/Taiwan/1265/00 hemagglutinin   AY604745.1
B/Taiwan/4184/2000 nonstructural protein NS1 (NS1) AF380507.1
B/Taiwan/4184/00 hemagglutinin (HA) AY604750.1
B/Taiwan/31511/2000 nonstructural protein NS1 (NS1) AF380505.1
B/Taiwan/31511/00 hemagglutinin (HA) AY604748.1
B/Taiwan/12192/2000 hemagglutinin AY604747.1
B/Taiwan/41010/00 hemagglutinin (HA) AY604749.1
B/Taiwan/41010/2000 nonstructural protein NS1 (NS1) AF380506.1
B/Taiwan/0409/00 hemagglutinin (HA) AY604744.1
B/Taiwan/202/2001 nonstructural protein 1 (NS1) AF380512.1
B/Taiwan/202/2001 hemagglutinin (HA) AF366076.1
B/Taiwan/11515/2001 nonstructural protein 1 (NS1) AF380511.1
B/Taiwan/11515/01 hemagglutinin  AY604754.1
B/Taiwan/11515/2001 hemagglutinin (HA) AF366075.1
B/Taiwan/1103/2001 nonstructural protein NS1 (NS1) AF380510.1
B/Taiwan/1103/01 hemagglutinin   AY604755.1
B/Taiwan/114/2001 hemagglutinin (HA), HA-4 allele AF492476.1
B/Taiwan/2805/2001 hemagglutinin (HA) AF400581.1
B/Taiwan/2805/01 hemagglutinin (HA) AY604752.1
B/Taiwan/0114/01 hemagglutinin (HA) AY604753.1
B/Taiwan/0202/01 hemagglutinin (HA) AY604751.1
B/Taiwan/4119/02 hemagglutinin (HA) AY604778.1
B/Taiwan/4602/02 hemagglutinin (HA) AY604777.1
B/Taiwan/1950/02 hemagglutinin (HA) AY604776.1
B/Taiwan/1949/02 hemagglutinin (HA) AY604775.1
B/Taiwan/1584/02 hemagglutinin (HA) AY604774.1
B/Taiwan/1561/02 hemagglutinin (HA) AY604773.1
B/Taiwan/1536/02 hemagglutinin (HA) AY604772.1
B/Taiwan/1534/02 hemagglutinin (HA) AY604771.1
B/Taiwan/1503/02 hemagglutinin (HA) AY604770.1
B/Taiwan/1502/02 hemagglutinin (HA) AY604769.1
B/Taiwan/1013/02 hemagglutinin (HA) AY604768.1
B/Taiwan/0993/02 hemagglutinin (HA) AY604766.1
B/Taiwan/0932/02 hemagglutinin (HA) AY604765.1
B/Taiwan/0927/02 hemagglutinin (HA) AY604764.1
B/Taiwan/0880/02 hemagglutinin (HA) AY604763.1
B/Taiwan/0874/02 hemagglutinin (HA) AY604762.1
B/Taiwan/0730/02 hemagglutinin (HA) AY604761.1
B/Taiwan/0722/02 hemagglutinin (HA) AY604760.1
B/Taiwan/0702/02 hemagglutinin (HA) AY604759.1
B/Taiwan/0654/02 hemagglutinin (HA) AY604758.1
B/Taiwan/0600/02 hemagglutinin (HA) AY604757.1
B/Taiwan/0409/02 hemagglutinin (HA) AY604756.1
B/Taiwan/0879/02 nonfunctional hemagglutinin AY604767.1
B/Taiwan/3532/03 hemagglutinin (HA) AY604794.1
B/Taiwan/2551/03 hemagglutinin (HA) AY604793.1
B/Taiwan/1618/03 hemagglutinin (HA) AY604792.1
B/Taiwan/1574/03 hemagglutinin (HA) AY604791.1
B/Taiwan/1013/03 hemagglutinin (HA) AY604790.1
B/Taiwan/0833/03 hemagglutinin (HA) AY604789.1
B/Taiwan/0735/03 hemagglutinin (HA) AY604788.1
B/Taiwan/0699/03 hemagglutinin (HA) AY604787.1
B/Taiwan/0684/03 hemagglutinin (HA) AY604786.1
B/Taiwan/0616/03 hemagglutinin (HA) AY604785.1
B/Taiwan/0615/03 hemagglutinin (HA) AY604784.1
B/Taiwan/0610/03 hemagglutinin (HA) AY604783.1
B/Taiwan/0576/03 hemagglutinin (HA) AY604782.1
B/Taiwan/0569/03 hemagglutinin (HA) AY604781.1
B/Taiwan/0562/03 hemagglutinin (HA) AY604780.1
B/Taiwan/0002/03 hemagglutinin (HA) AY604779.1
B/Taiwan/773/2004 hemagglutinin (HA) EU068195.1
B/Taiwan/187/2004 hemagglutinin (HA) EU068194.1
B/Taiwan/3892/2004 hemagglutinin (HA) EU068193.1
B/Taiwan/562/2004 hemagglutinin (HA) EU068191.1
B/Taiwan/234/2004 hemagglutinin (HA) EU068188.1
B/Taiwan/4897/2004 hemagglutinin (HA) EU068186.1
B/Taiwan/8579/2004 hemagglutinin (HA) EU068184.1
B/Taiwan/184/2004 hemagglutinin (HA) EU068183.1
B/Taiwan/647/2005 hemagglutinin (HA) EU068196.1
B/Taiwan/877/2005 hemagglutinin (HA) EU068198.1
B/Taiwan/521/2005 hemagglutinin (HA) EU068189.1
B/Taiwan/1064/2005 hemagglutinin (HA) EU068192.1
B/Taiwan/3722/2005 hemagglutinin (HA) EU068197.1
B/Taiwan/5049/2005 hemagglutinin (HA) EU068190.1
B/Taiwan/5011/2005 hemagglutinin (HA) EU068187.1
B/Taiwan/4659/2005 hemagglutinin (HA) EU068185.1
B/Taiwan/25/2005 hemagglutinin (HA) EU068182.1
B/Taiwan/1037/2005 hemagglutinin (HA) EU068181.1
B/Taiwan/62/2005 hemagglutinin (HA) EU068180.1
B/Taiwan/591/2005 hemagglutinin (HA) EU068179.1
B/Taiwan/649/2005 hemagglutinin (HA) EU068178.1
B/Taiwan/4554/2005 hemagglutinin (HA) EU068177.1
B/Taiwan/987/2005 hemagglutinin (HA) EU068176.1
B/Taiwan/2607/2006 hemagglutinin (HA) EU068175.1
B/Vienna/1/99 hemagglutinin      AF387495.1
B/Vienna/1/99 hemagglutinin      AF387494.1
B/Vienna/1/99 hemagglutinin      AF387493.1
B/Vienna/1/99 hemagglutinin      AF387492.1

TABLE 13
Influenza C Antigens
                                 GenBank
Strain/Protein                   Access No.
C/JHB/1/66) hemagglutinin-esterase-fusion AY880247.1
protein (HEF) mRNA, complete cds.
STRAIN C/ANN ARBOR/1/50) persistent variant AF102027.1
segment 7 non-structural protein 1 (NS1) mRNA,
complete cds
(STRAIN C/ANN ARBOR/1/50) wild type segment 7 AF102026.1
non-structural protein 1 (NS1) mRNA, complete cds
(C/JHB/1/66) hemagglutinin-esterase-fusion protein AY880247.1
(HEF) mRNA, complete cds
(STRAIN C/BERLIN/1/85) mRNA for basic polymerase X55992.1
2 precursor

TABLE 14
H7 Hemagglutinin Amino Acid Sequences
Accession No/
Strain/		SEQ ID
Protein	Amino Acid Sequence	NO:
AAM19228	ACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVVNATETVETA	1
A/turkey/Minnesota/	NIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFESDLIIERR
38429/1988	EGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGIITNGAT
1988// HA	SACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIVW
20335017	GIHHSGSTTEQTKLYGSGNKLITVESSKYQQSFTPSPGARPQVNG
	ESGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFKGESLGVQSD
	VPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQPSLL
	LATGMRNVPENPKTRGLFGAIAGFIEKDGGSHYG
AAY46211	MNTQILVFALVAIIPINADKICLGHHAVSNGTKVNTLTERGVEVV	2
A/mallard/Sweden/	NATETVERTNVPRICSRGKRTVDLGQCGLLGTITGPPQCDQFLEF
91/2002	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2002// HA	SGIRTNGAPSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
66394828	RNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFMCVKNGNMRCTICI
ABI84694	MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVV	3
A/turkey/Minnesota/	NATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
1/1988	ESDLIIERREGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
1988 Jul. 13 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
115278573	RNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFK
	GESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHAQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
ABS89409	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	4
A/blue-winged	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
teal/Ohio/566/	DTDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2006 2006// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
155016324	RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVRLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
ACD03594	MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTLTEKGIEVV	5
A/ruddy	NATETVESANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
turnstone/DE/1538/	DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2000	SGIRTNGATSACRRLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
2000// HA	RNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTPS
187384848	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELM
	DNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLIFICIKNGNMRCTICI
BAH22785	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	6
A/duck/Mongolia/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
119/2008	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIGKETMGFTY
2008// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
223717820	RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
CAY39406	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	7
A/Anas	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
crecca/Spain/1460/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2008	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2008 Jan. 26 HA	RKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
254674376	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
ACX53683	MNIQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	8
A/goose/Czech	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
Republic/1848-	SADLIIERRGGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
K9/2009	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2009 Feb. 4 HA	RKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
260907763	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLK
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
ACZ48625	MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVV	9
A/turkey/Minnesota/	NATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
38429/1988	ESDLIIERREGNDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
1988// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
269826341	RNKPALIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASFFK
	GESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQPSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEL
ADC29485	STQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQIGNVINWT	10
A/mallard/Spain/	RDSMTEVWSYNAELLVAMENQHTIDLADSEMNKLYERVKRQLREN
08.00991.3/2005	AEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQID
2005/11/	PVKLSSGYKDVILWFSFGASCFILL
HA 284927336
ADK71137	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	11
A/blue-winged	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
teal/Guatemala/	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
CIP049-	SGIRTNGATSACRRSGSSSYAEMKWLLSNSDNAAFPQMTKSYRNP
01/2008	RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
2008 Feb. 7 HA	PGTRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLR
301333785	GKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQHFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
ADK71148	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	12
A/blue-winged	NXTETVETANIKKICTHGKRPTDLGQCGLLGTLIGPPQCDRFLEF
teal/Guatemala/	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
CIP049-	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
02/2008	RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
2008 Mar. 5 HA	PGTRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFLR
301333804	GKSLGIQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
ADN34727	MNIQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	13
A/goose/Czech	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
Republic/1848-	SADLIIERRGGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
T14/2009	SGIRTNGXTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2009 Feb. 4 HA	RKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
307141869	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLK
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AEK84760	PAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNLP	14
A/wild	FQNINSRAVGKCPRYVKQESLMLATGMKNVPELPKGRGLFGAIAG
bird/Korea/A14/	FIENGWEGLIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLN
2011 2011/02/	RLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSMTEVWSYNAEL
HA 341610308	LVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHK
	CDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILW
	FSFGASCFILLAIAMGLVFICVKNGNMRCTICI
AEK84761	ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERGVEVFNATE	15
A/wild	TVERTNVPRICSKGKKTVDLGQCGLRGTITGPPQCDQFLKFSPDL
bird/Korea/A3/	IIERQKGSDVCYPGKFVNEKPLRQILRESGGIDKETMGFAYNGIK
2011 2011/02/	TNGPPIACRKSGSSFYAKMKWLLSNTDKAAFPQMTKSYKNTRRNP
HA 341610310	ALIVWGIHHSGSTTKQTKLYGIGSNLITVGSSNYQQSFVPSPGAR
	PQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIPPDRASFLRGKSM
	GIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVK
	QESLMLATGMKNVPELPKGKGLFGAIAGFIENGWEGLIDGWYGFR
	HQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEF
	TEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEM
	NKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHS
	KYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGL
	VFICVKNGNMRCTICI
AEK84763	ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERGVEFFNATE	16
A/wild	TVEPTNVPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEFSADL
bird/Korea/A9/	IIERREGSDVCYPGKFVNEKALRQILRESGGIDKETMGFAYSGIK
2011 2011/02/	TNGPPIACRKSGSSFYAKMKWLLSNTDKAAFPQMTKSYKNIRRDP
HA 341610314	ALIVWGIHHSGSTTKQTNLYGIGSNLITVGSSNYQQSFVPSPGAR
	PQVNGQSGRIDFHWLILNPNDTVTFIFNGAFIAPDRASFLIGKSM
	GIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVK
	QESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGFR
	HQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEF
	TEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEM
	NKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHS
	KYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGL
	VFICVKNGNMRCTICI
AEK84765	LVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATET	17
A/spot-billed	VERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLI
duck/Korea/447/	IERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGIRT
2011 2011/04/	NGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
HA 341610318	LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGARP
	QVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMG
	IQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQ
	ESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGWYGFRH
	QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFT
	EVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMN
	KLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMARIRNNTYDHSK
	YREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLV
	FICVKNGNMRCTICI
AEM98291	SILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNAT	18
A/wild	ETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSAD
duck/Mongolia/	LIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGI
1-241/2008	RTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKD
2008/04/HA	PALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGA
344196120	RPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKS
	MGIQSGVQVDANCEGDCYHSGGSIISNLPFQNINSRAVGKCPRYV
	KQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGF
	RHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNE
	FTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSE
	MNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDH
	SKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMG
	LVFICVKNGNMRCTI
AFM09439	QILAFIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVVNAT	19
A/emperor	ETVETVNIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFDAD
goose/Alaska/44063-	LIIERRKGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGI
061/2006	RTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNK
2006 May 23 HA	PALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFVPSPGA
390535062	RPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPERASFFRGES
	LGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYV
	KQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGF
	RHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNE
	FSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSE
	MNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDH
	TQYRTESLQNRIQINPVKLSSGYKDIILWFSFGASCFLLLAIAMG
	LVFICIKNGNMRCTICI
AFV33945	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERRIEVV	20
A/guinea	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
fowl/Nebraska/	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
17096-1/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
2011 Apr. 5 HA	RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS
409676820	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AFV33947	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	21
A/goose/Nebraska/	NATETVETANIKKICTQGKRPTDLGQCGLLGTLTGPPQCDQFLEF
17097-	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
4/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
2011 Apr. 5 HA	RNKPALIVWGVHHSASATEQTKLYGSGSKLITVGSSKYQQSFTPS
409676827	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AFX85260	MNTQILAFIACMLIGINGDKICLGHHAVANGTKVNTLTERGIEVV	22
A/ruddy	NATETVETANIKRICTQGKRPTDLGQCGLLGTLTGPPQCDQFLEF
turnstone/Delaware	DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
Bay/220/1995	SGIRTNGATSACIRLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
1995 May 21 HA	RNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTPS
423514912	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGRCP
	RYVKQTSLLLATGMKNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AGE08098	MNTQILTLIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	23
A/northern	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
shover1/Mississippi/	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
11OS145/	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
2011	RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
2011 Jan. 8 HA	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
444344488	GESLGVQSDVPLDSGCEGDCFHNGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AGI60301	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	24
A/Hangzhou/1/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Mar. 24	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 475662454	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGISGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGI60292	MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTLTERGVEVV	25
A/Shanghai/4664T/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Mar. 5 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
476403560	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCHHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGJ72861	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVV	26
A/chicken/Zhejiang/	NATETVERTNIPRICSKGKKTVDLGQGGPRGTITGPPQCDQFLEF
DTID-	SADLIMERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
ZJU01/2013	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013/04/HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
479280294	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGJ73503	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	27
A/Nanjing/1/2013	NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF
2013 Mar. 28	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 479285761	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
BAN16711	MNTQVLVFALMAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	28
A/duck/Gunma/466/	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2011 2011//	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
HA 482661571	SGIRTNGTTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RRDPALIAWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDDTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGK84857	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	29
A/Hangzhou/2/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 1	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 485649824	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQITKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGL44438	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	30
A/Shanghai/02/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Mar. 5 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
496493389	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGL33692	GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTN	31
A/Shanghai/4655T/	QQFELIDNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
2013	HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA
2013 Feb. 26 HA	SIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASC
491874175	FILLAIAMGLVFICVKNGNMRCTICI
AGL33693	GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTN	32
A/Shanghai/4659T/	QQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
2013	HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA
2013 Feb. 27 HA	SIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASC
491874186	FILLAIVMGLVFICVKNGNMRCTICI
AGL95088	VFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETV	33
A/Taiwan/S02076/	ERTNIPRICSKGKRTVDLGQCGLLGTITGDPQCDQFLEFSADLII
2013	ERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTN
2013 Apr. 22 HA	GATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPAL
501485301	IVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQ
	VNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGI
	QSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQR
	SLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQ
	NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNE
	VEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDK
	LYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKY
	REEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF
	ICVKNGNMR
AGL95098	LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATET	34
A/Taiwan/T02081/	VERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLI
2013	IERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRT
2013 Apr. 22 HA	NGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
501485319	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARP
	QVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMG
	IQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQ
	RSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRH
	QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFN
	EVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMD
	KLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSK
	YREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV
	FICVKNGNMRCT
AGM53883	GFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELID	35
A/Shanghai/5083T/	NEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLAD
2013	SEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTY
2013 Apr. 20 HA	DHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIV
507593986	MGLVFICVKNGNMRCT
AGM53884	AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEV	36
A/Shanghai/5180T/	EKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKL
2013	YERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR
2013 Apr. 23 HA	EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFI
507593988	CVKNGNMRCTICI
AGM53885	QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFN	37
A/Shanghai/5240T/	EVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMD
2013	KLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSK
2013 Apr. 25 HA	YREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV
507593990	FICVKNGNMRCT
AGM53886	NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNE	38
A/Shanghai/4842T/	VEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDK
2013	LYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKY
2013 Apr. 13 HA	REEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF
507593992	ICVKNGNMRCT
AGM53887	NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNE	39
A/Shanghai/4701T/	VEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDK
2013	LYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKY
2013 Apr. 6 HA	REEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF
507593994	ICVKNGNMRCTIC
AGN69462	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	40
A/Wuxi/2/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Mar. 31 HA	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
511105778	SGIRTNGSTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGN69474	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	41
A/Wuxi/1/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Mar. 31 HA	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
511105798	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLINGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGO51387	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	42
A/Jiangsu/2/2013	NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 20	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 514390990	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYRXEAMXBXIQIDPVKLSSGYKDVXJWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
BAN59726	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	43
A/duck/Mongolia/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
147/2008	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIGKETMGFTY
2008 Aug. 29 HA	SGIRTNGATSACRRSRSSFYAEMKWLLSNTDNAAFPQMTRSYKNT
519661951	RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRTVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIERTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSNGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
BAN59727	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	44
A/duck/Mongolia/	NATETVERINVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
129/2010	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2010// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
519661954	RKDPALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGQ80952	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	45
A/duck/Jiangxi/	NATETVERTSIPRICSKGKRAVDLGQCGLLGTITGPPQCDQFLEF
3096/2009	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2009// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNT
523788794	RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGQ80989	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	46
A/duck/Jiangxi/	NATETVERTSIPRICSKGKRAVDLGQCGLLGTITGPPQCDQFLEF
3257/2009	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2009// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNT
523788868	RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGXSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHNGGTIISNLPFQNINSRAVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGQ81043	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	47
A/chicken/Rizhao/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
515/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEEMGFTY
2013// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
523788976	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR33894	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	48
A/chicken/Rizhao/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
719b/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
524845213	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDRSKYREEAMQNRXXXXXXXXXXXXKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49399	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	49
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
SD001/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2013 May 3 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
525338528	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49495	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	50
A/chicken/Shanghai/	NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF
S1358/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 3	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
HA 525338689	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIKNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49506	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	51
A/chicken/Shanghai/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
S1410/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 3	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
HA 525338708	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49554	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	52
A/chicken/Zhejiang/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
SD033/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 11	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
HA 525338789	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49566	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	53
A/duck/Anhui/SC702/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 16 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
525338809	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49722	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	54
A/homing	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
pigeon/Jiangsu/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
SD184/2013	SEIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Apr. 20 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
525339071	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49734	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	55
A/pigeon/Shanghai/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
S1069/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 2 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
525339091	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTITFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR49770	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	56
A/wild	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
pigeon/Jiangsu/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
SD001/2013	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Apr. 17 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
525339151	PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGY41893	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	57
A/Huizhou/01/2013	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2013 Aug. 8	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 552049496	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGY42258	FALVAIIPINADKICLGHHAVSNGTKVNTLTERGVEVVNATETVE	58
A/mallard/Sweden/	RTNVPRICSRGKRTVDLGQCGLLGTIXGPPQCDQFLEFSADLIIE
91/2002	RREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTYSGIRTNG
2002 Dec. 12 HA	AXSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPALI
552052155	IWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGARPQV
	NGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQ
	SGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYVKQES
	LLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQN
	AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEV
	EKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSEMNKL
	YERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR
	EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIAMGLVFM
	CVKNGNMRCTICI
AHA11441	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	59
A/guinea	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
fowl/Nebraska/	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
17096/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
2011 Apr. 10 HA	RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS
557478572	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHA11452	MNTQILALIACMLVGTKGDKICLGHHAVANGTKVNTLTERGIEVV	60
A/turkey/Minnesota/	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
32710/2011	DADLIIERREGTDVCYPGKFTNEEPLRQILRGSGGIDKESMGFTY
2011 Jul. 12	SGIRTNGATSTCRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
HA 557478591	RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEMI
	DNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHA11461	MNTQILALIACMLVGTKGDKICLGHHAVANGTKVNTLTERGIEVV	61
A/turkey/Minnesota/	NATETVETANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
31900/2011	DADLIIERREGTDVCYPGKFTNEEPLRQILRGSGGIDKESMGFTY
2011 Jul. 5	SGIRTNGATSTCRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
HA 557478606	RNKPALIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHKGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRAESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHK10585	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	62
A/chicken/Guangdong/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
G1/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 May 5 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
587680636	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGG53366	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	63
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/CSM	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGLTY
42-34/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2011/03/HA	RRDPALIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPS
459252887	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGG53377	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	64
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/CSM	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGLTY
42-1/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2011/03/HA	RRDPALIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSFVPS
459252925	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCT
AGG53399	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	65
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/MHC	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
39-26/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2011/03/HA	RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
459253005	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGG53432	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	66
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/MHC	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
35-41/2011	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2011/03/HA	RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
459253136	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPEPPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCT
AGG53476	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	67
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/SH19-	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
27/2010	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2010/12/HA	RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
459253257	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTI
AGG53487	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	68
A/wild	NATETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
duck/Korea/SH19-	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
50/2010	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2010/01/HA	RRDPALIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
459253278	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDASCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AGG53520	QILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNAT	69
A/wild	ETVERTNVPRICSKGKRTVDLGQCGLLGTITGPPQCDQLLEFSAD
duck/Korea/SH20-	LIIERREGTDVCYPGKFVNEEALRQILRESGGIEKETMGFTYSGI
27/2008	RTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKD
2008/12/HA	PALIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPGA
459253409	RPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKS
	MGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCPRYV
	KQESLMLATGMKNVPELPKGRGLFGAIAGFIENGWEGLIDGWYGF
	RHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNE
	FTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADSE
	MNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDH
	SKYREEAMQNRIQINPVKLSSGYKDVILWFSFGASCFILLAIAMG
	LVFICVKNGNMR
AGL43637	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	70
A/Taiwan/1/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013// HA	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
496297389	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGPSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIINNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGL97639	IACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVVNATETVET	71
A/mallard/Minnesota/	ANIKKLCTQGKRPTDLGQCGLLGTLIGPPQCDQFLEFDADLIIER
AI09-	REGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTYSGIRTNGA
3770/2009	TSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALII
2009 Sep. 12 HA	WGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVN
505555371	GQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFRGESLGVQS
	DVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCPRYVKQTSL
	LLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNA
	QGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIE
	QQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADSEMNKLY
	ERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNTYDHTQYRT
	ESLQNRIQIDPVKLS
AGO02477	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	72
A/Xuzhou/1/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 25	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 512403688	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKSRNMRCTICI
AGR84942	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	73
A/Suzhou/5/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 12	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 526304561	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AGR84954	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	74
A/Nanjing/6/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 11	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 526304594	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNRNMRCTICI
AGR84978	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	75
A/Wuxi/4/2013	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 7 HA	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
526304656	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKSRNMRCTICI
AGR84990	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	76
A/Wuxi/3/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 7 HA	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
526304688	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKSRNMRCTICI
AGR85002	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	77
A/Zhenjiang/1/	NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 7 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
526304708	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKSRNKRCTICI
AGR85026	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	78
A/Nanjing/2/2013	NATETVERTNIPRICSKGKMTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 5	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 526304762	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKSRNMRCTICI
AGU02230	LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVVNATET	79
A/Zhejiang/DTID-	VERTNIPRICSKGKRTVDLGQCGLRGTITGPPQCDQFLEFSADLI
ZJU05/2013	IERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRT
2013/04/HA	NGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
532808765	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARP
	QVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMG
	IQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQ
	RSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRH
	QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFN
	EVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMD
	KLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSK
	YREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLV
	FICVKNGNMRCT
AGU02233	FALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEVVNATETVE	80
A/Zhejiang/DTID-	RTNFPRICSKGKRTVDLGQCGLRGTITGPPQCDQFLEFSADLIIE
ZJU08/2013	RREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTNG
2013/04/HA	ATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALI
532808788	VWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQV
	NGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQ
	SGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRYVKQRS
	LLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQN
	AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEV
	EKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKL
	YERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR
	EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFI
	CVKNGNMRCT
AGW82588	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	81
A/tree	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
sparrow/Shanghai/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
01/2013	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 May 9 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
546235348	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTIGI
AGW82600	ALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNATETVER	82
A/Shanghai/CN01/	TNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSADLIIER
2013	REGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSGIRTNGA
2013 Apr. 11 HA	TSACRRSRSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIV
546235368	WGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARPQVN
	GLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGKSMGIQS
	GVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCPRYVKQRSL
	LLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNA
	QGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVE
	KQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLY
	ERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYRE
	EAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVFIC
	VKNGNMRCTICI
AGW82612	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	83
A/Shanghai/JS01/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 3 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
546235388	RKNPALIVWGIHHSGSTAEQTKLYGSGNKLVTVGSSNYQQSFAPS
	PGARTQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFICVKNGNMRCTICI
AHA11472	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	84
A/turkey/Minnesota/	NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
31676/2009	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2009 Dec. 8	SGIRTNGETSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
HA 557478625	RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITNKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHA11483	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	85
A/turkey/Minnesota/	NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
14135-	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2/2009	SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
2009 Aug. 7 HA	RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
557478644	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHA11500	TQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVVNA	86
A/Zhejiang/DTID-	TETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEFSA
ZJU10/2013	DLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTYSG
2013 Oct. 14 HA	IRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRK
557478676	SPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPG
	ARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLRGK
	SMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCPRY
	VKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGWYG
	FRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
	EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADS
	EMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNTYD
	HSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAIVM
	GLVFICVKN
AHA57050	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	87
A/turkey/Minnesota/	NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
14659/2009	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2009 Aug. 12	SGIRTNGATSACRRSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNP
HA 558484427	RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHNCDDQCMESIRNNT
	YDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHA57072	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTLTERGIEVV	88
A/turkey/Minnesota/	NATETVETANVKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
18421/2009	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
2009 Sep. 9	SGIRTNGATSACRRSGSSFYAEMKWLLSNSNDAAFPQMTKSYRNP
HA 558484465	RDKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPEKPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRKESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHD25003	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	89
A/Guangdong/02/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2013 2013/10/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
HA 568260567	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNM
AHF20528	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	90
A/Hong	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
Kong/470129/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Nov. 30	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
HA 570933555	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHF20568	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	91
A/Shanghai/CN02/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Apr. 2 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
570933626	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHH25185	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	92
A/Guangdong/04/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY
2013 Dec. 16 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
576106234	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHJ57411	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	93
A/Shanghai/PD-	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
01/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 17 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
585478041	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVSS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCKGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHJ57418	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	94
A/Shanghai/PD-	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
02/2014	SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 17 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
585478256	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLK
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHK10800	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	95
A/Shanghai/01/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 3 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
587681014	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHM24224	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	96
A/Beijing/3/2013	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2013 Apr. 16	SADLIIERREGSDVCYPGKFVKEEALRQILRESGGIDKEAMGFTY
HA 594704802	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHN96472	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	97
A/chicken/Shanghai/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
PD-CN-	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
02/2014	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Jan. 21 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
602701641	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHZ39686	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	98
A/Anhui/DEWH72-	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
01/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNT
632807036	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHZ39710	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	99
A/Anhui/DEWH72-	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
03/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013// HA	SGIRTDGATSACRRSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNT
632807076	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHZ39746	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	100
A/Anhui/DEWH72-	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
06/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013// HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
632807136	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGERPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AHZ41929	MNTQILVFALVAIIPINADKICLGHHAVSNGTKVNTLTERGVEVV	101
A/mallard/Sweden/	NATETVERTNVPRICSRGKRTVDLGQCGLLGTITGPPQCDQFLEF
1621/2002	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKETMGFTY
2002 Dec. 12 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
632810949	RNDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQIDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	AMGLVFMCVKNGNMRCTICI
AHZ42537	MNTQILAFIACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVV	102
A/mallard/Minnesota/	NATETVETANIKKLCTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
AI09-	DADLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
3770/2009	SGIRTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNP
2009 Sep. 12 HA	RNKPALIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFTPS
632811964	PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFFR
	GESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQNINPRTVGKCP
	RYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELI
	DNEFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNNT
	YDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLAI
	AMGLVFICIKNGNMRCTICI
AHZ42549	MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTLTEKGIEVV	103
A/ruddy	NATETVESANIKKICTQGKRPTDLGQCGLLGTLIGPPQCDQFLEF
turnstone/Delaware/	DSDLIIERREGTDVCYPGKFTNEESLRQILRGSGGIDKESMGFTY
AI00-	SGIRTNGATSACRRLGSSSFYAEMKWLLSNSDNAAFPQMTKSYRN
1538/2000	PRNKPALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSFTP
2000 May 20 HA	SPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRASFF
632811984	RGESLGIQSDVPLDSSCGGDCFHSGGTIVSSLPFQNINPRTVGKC
	PRYVKQTSLLLATGMRNVPENPKTRGLFGAIAGFIENGWEGLIDG
	WYGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEL
	MDNEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDL
	ADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCMESIRNN
	TYDHTQYRTESLQNRIQIDPVKLSSGYKDIILWFSFGASCFLLLA
	IAMGLIFICIKNGNMRCTICI
AID70634	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	104
A/Shanghai/Mix1/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 3 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
660304650	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELI
	DNEFNEVEKQISNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AIN76383	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	105
A/Zhejiang/LS01/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 8 HA	SGIRTNGTTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
684694637	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AIU46619	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	106
A/chicken/Zhejiang/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
DTID-	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
ZJU06/2013	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013/12/HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
699978931	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVEVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AIU47013	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	107
A/chicken/Suzhou/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
040201H/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013/04/HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
699979673	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDMILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90490	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	108
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
742/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 10 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755178094	RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90526	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	109
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
898/2013	SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 9 HA	SGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755178154	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90538	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	110
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Shenzhen/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
918/2013	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Dec. 9 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755178174	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90576	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	111
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1665/2013	SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 12 HA	SGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755178238	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90588	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	112
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2110/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 13 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755178258	RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90661	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	113
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2912/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 18 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755178380	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90673	MNTQILVFALTAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	114
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
3049/2013	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Dec. 18 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755178400	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90795	MNTQILVFALIAIIPTNADKICLGHHAVPNGTKVNTLTERGVEVV	115
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
3281/2013	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Dec. 18 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755178604	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90891	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	116
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
3520/2013	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Dec. 19 HA	RKXPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755178764	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ90951	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	117
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
3544/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 19 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYRNT
755178864	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91035	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	118
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
3780/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 19 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755179004	RRSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDNRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91155	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	119
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
4037/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 19 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755179204	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ92005	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	120
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
801/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 9 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180629	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94254	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	121
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1374/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184382	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94606	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	122
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
191/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184968	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96552	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	123
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTIDLGQCGLLGTITGPPQCDQFLEF
12206/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Mar. 16 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188219	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96684	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKINTLTERGVEVV	124
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
13207/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Mar. 30 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188439	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96732	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	125
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
13223/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Mar. 30 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188519	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJK00354	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	126
A/duck/Zhejiang/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
LS02/2014	SADLIVERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 12 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755194469	RKDPALIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPS
	PGARPLVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNINSRAVGKCP
	RYVKQESLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQVTGKLNRLIEKTNQQFELI
	DHEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLA
	DSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91264	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	127
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
4129/2013	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2013 Dec. 19 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755179386	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLMEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91314	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	128
A/chicken/Shaoxing/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2417/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Oct. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755179470	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91402	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	129
A/chicken/Huzhou/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
4045/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Oct. 24 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755179618	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKEVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91476	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	130
A/chicken/Huzhou/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
4076/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2013 Oct. 24 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755179743	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91725	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	131
A/chicken/Shaoxing/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
5201/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Oct. 28 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180161	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91885	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	132
A/Shenzhen/SP4/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 16 HA	SGIRANGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180429	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91909	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	133
A/Shenzhen/SP26/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 20 HA	SGIRANGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180469	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDGCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSRGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91945	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	134
A/Shenzhen/SP38/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 22 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180529	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIGGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91957	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	135
A/Shenzhen/SP44/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 23 HA	SGIRANGTTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180549	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISSLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91969	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	136
A/Shenzhen/SP48/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 23 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180569	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ91993	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	137
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
4119/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 19 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180609	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLLGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFTLLAI
	VMGLVFICVKNGNMRCTICI
AJJ92031	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	138
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
4064/2013	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2013 Dec. 19 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755180672	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVESSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ92967	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	139
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Jiangxi/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
9469/2014	SGIRTNGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 16 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755182232	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93027	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	140
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
9558/2014	SADLIIERREGSDVCYPGKFVKEEALRQILRESGGIDKEAMGFTY
2014 Feb. 16 HA	SGIRTNGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755182332	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93051	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	141
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
10573/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 18 HA	SGIRTNGVTSACRRSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNT
755182372	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93845	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	142
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
157/2014	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 20 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755183695	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93857	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	143
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
169/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRTNGATSACMRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183715	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93869	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	144
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF
173/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183735	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93881	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	145
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF
189/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183755	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	KYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93907	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	146
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
449/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183799	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93931	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	147
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
536/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183839	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISKLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93943	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	148
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
568/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755183859	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ93979	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	149
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTVTGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
656/2014	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 20 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755183919	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFGLI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94134	MNTQILVLALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	150
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1051/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184182	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVXLSXGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94158	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	151
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1075/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184222	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94182	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	152
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1177/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACKRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184262	RKSPALIVWGIHHSVSIAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94194	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	153
A/silkie	NATETVERTNIPRICSKGKKTIDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
1264/2014	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 21 HA	RKSPALIVWGIHHSVSIAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755184282	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQVTGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI
	VMGLVFICVKNGNMRCTICI
AJJ94206	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	154
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
1268/2014	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 21 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755184302	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISDLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94344	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	155
A/silkie	NSTETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
1451/2014	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 21 HA	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755184532	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRTVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94356	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	156
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1456/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184552	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94396	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	157
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1494/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755184618	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94754	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	158
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
748/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185215	RKSPALIVWGIHHSVSNAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94838	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	159
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
835/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185356	RKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFGFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94862	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	160
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
843/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY
2014 Feb. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185396	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94886	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	161
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
851/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185436	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94910	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	162
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
874/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 20 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185476	RKSPALIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ94959	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	163
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
967/2014	SGIRANGATSACXRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 21 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755185558	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95048	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	164
A/chicken/Dongguan/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
1009/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185708	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPETPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDNDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95171	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	165
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1314/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755185913	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFNFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95227	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	166
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1382/2014	SADLIIERREGSDICYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186006	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95251	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	167
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1401/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186046	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95346	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	168
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1548/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186206	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYKRVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHNKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95382	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	169
A/chicken/Dongguan/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
1690/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Feb. 21 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186266	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSIGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95464	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	170
A/chicken/Shenzhen/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
138/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 19 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186404	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI
	VMGLVFICVKNGNMRCTICI
AJJ95572	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	171
A/chicken/Dongguan/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
1100/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIEKEAMGFTY
2014 Feb. 21 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186584	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSGGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95584	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	172
A/silkie	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Dongguan/	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
1519/2014	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Feb. 21 HA	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755186604	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPERASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYRGEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFMLLAI
	VMGLVFICVKNGNMRCTICI
AJJ95596	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	173
A/Shenzhen/SP58/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jan. 25 HA	SGIRANGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186624	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ95620	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	174
A/Shenzhen/SP75/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 15 HA	SGIRTNGSTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755186664	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAV
	VMGLVFICVKNGNMRCTICI
AJJ95632	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	175
A/Shenzhen/SP62/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 5 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNATFPQMTKSYKNT
755186684	RKSPALIIWGIHHSVSIAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96720	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	176
A/chicken/Jiangxi/	NATETVERTTIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
13220/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Mar. 30 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188499	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96817	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	177
A/chicken/Jiangxi/	NATEIVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
9513/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Feb. 16 HA	SGIRTNGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188661	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96841	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	178
A/Shenzhen/SP139/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Apr. 2 HA	SGIRTNGATSTCRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188701	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRACFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVERQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96889	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	179
A/chicken/Jiangxi/	NATETVERTXIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
13496/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKXAMGFTY
2014 Apr. 11 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188781	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96901	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	180
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
13502/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 11 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188801	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSXGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ96925	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	181
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13513/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 11 HA	NGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755188841	RKSPAIIVWGIHHTVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDLHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97267	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	182
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13252/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Mar. 30 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189411	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97291	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	183
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13493/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 6 HA	NGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189451	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97331	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	184
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13512/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 6 HA	NGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189517	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSIGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97373	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	185
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13521/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 6 HA	NGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189587	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPXRASFLR
	GKSXGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97443	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	186
A/chicken/Jiangxi/	NATETVERTTIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
13530/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 6 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189702	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSRGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97582	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	187
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
14023/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 13 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755189933	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97697	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	188
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
14517/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190125	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCDGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97709	MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTLTERGVEVV	189
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
14518/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 20 HA	NGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190145	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGNCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97745	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	190
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
14554/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 20 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190205	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELM
	DNEFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97757	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	191
A/chicken/Shantou/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
2537/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Apr. 16 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190225	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFKHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97841	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	192
A/duck/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
15044/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Apr. 27 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190365	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVRLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97899	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	193
A/chicken/Jiangxi/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPPQCDQFLEF
15524/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 May 5 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190462	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHRKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFMCVKNGNMRCTICI
AJJ97925	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	194
A/silkie	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
chicken/Shantou/	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2050/2014	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
2014 Mar. 25 HA	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
755190506	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97973	MNTQILVFALISIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	195
A/chicken/Shantou/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
4325/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRKSGGIDKEAMGFTY
2014 Jul. 1 HA	SGIRTNGVTSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190586	RKSPAIIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDADCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQRSLLLATGMKNVPEVPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI
AJJ97998	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTLTERGVEVV	196
A/chicken/Shantou/	NATETVERTNIPRICSKGKKTVDLGQCGLLGTITGPPQCDQFLEF
4816/2014	SADLIIERREGSDVCYPGKFVNEEALRQILRESGGIDKEAMGFTY
2014 Jul. 22 HA	SGIRTNGATSACRRSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNT
755190628	RKSPALIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPS
	PGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRASFLR
	GKSMGIQSGVQVDANCEGDCYHSGGTIISNLPFQNIDSRAVGKCP
	RYVKQKSLLLATGMKNVPEIPKGRGLFGAIAGFIENGWEGLIDGW
	YGFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELV
	DNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
	DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMASIRNNT
	YDHSKYREEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLAI
	VMGLVFICVKNGNMRCTICI

TABLE 15
H10 Hemagglutinin Amino Acid Sequences
	Accession No/
SEQ ID	Strain/		SEQ ID
NO:	Protein	Amino Acid Sequence	NO:
	AAM19228	ACVLVEAKGDKICLGHHAVVNGTKVNTLTEKGIEVVN	197
	A/turkey/Minnesota/	ATETVETANIGKICTQGKRPTDLGQCGLLGTLIGPPQ
	38429/1988	CDQFLEFESDLIIERREGNDVCYPGKFTNEESLRQIL
	1988// HA	RGSGGIDKESMGFTYSGIITNGATSACRRSGSSFYAE
	20335017	MKWLLSNSDNAAFPQMTKSYRNPRNKPALIVWGIHHS
		GSTTEQTKLYGSGNKLITVESSKYQQSFTPSPGARPQ
		VNGESGRIDFHWMLLDPNDTVTFTFNGAFIAPDRASF
		FKGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQN
		INPRTVGKCPRYVKQPSLLLATGMRNVPENPKTRGLF
		GAIAGFIEKDGGSHYG
	AAY46211	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	198
	A/mallard/Sweden/	TERGVEVVNATETVERTNVPRICSRGKRTVDLGQCGL
	91/2002	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2002// HA	NEEALRQILRESGGIDKETMGFTYSGIRTNGAPSACR
	66394828	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFMCVKNGNMR
		CTICI
	ABI84694	MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTL	199
	A/turkey/Minnesota/	TEKGIEVVNATETVETANIGKICTQGKRPTDLGQCGL
	1/1988	LGTLIGPPQCDQFLEFESDLIIERREGNDVCYPGKFT
	1988 Jul. 13 HA	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	115278573	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
		LIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGA
		FIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHAQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	ABS89409	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	200
	A/blue-winged	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	teal/Ohio/566/	LGTLIGPPQCDQFLEFDTDLIIERREGTDVCYPGKFT
	2006 2006// HA	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	155016324	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
		LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVRLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	ACD03594	MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTL	201
	A/ruddy	TEKGIEVVNATETVESANIKKICTQGKRPTDLGQCGL
	turnstone/DE/1538/	LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT
	2000	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2000// HA	RLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	187384848	LIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGIQSDVPLDSSCGGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMDN
		EFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLIFICIKNGNMR
		CTICI
	BAH22785	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	202
	A/duck/Mongolia/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	119/2008	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2008// HA	NEEALRQILRESGGIGKETMGFTYSGIRTNGATSACR
	223717820	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGT
		IISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		NGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	CAY39406	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	203
	A/Anascrecca/	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	Spain/1460/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2008	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2008 Jan. 26 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
	254674376	LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	ACX53683	MNIQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	204
	A/goose/Czech	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	Republic/1848-	LGTITGPPQCDQFLEFSADLIIERRGGSDVCYPGKFV
	K9/2009	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2009 Feb. 4 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
	260907763	LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	ACZ48625	MNTQILVFIACVLVEAKGDKICLGHHAVVNGTKVNTL	205
	A/turkey/Minnesota/	TEKGIEVVNATETVETANIGKICTQGKRPTDLGQCGL
	38429/1988	LGTLIGPPQCDQFLEFESDLIIERREGNDVCYPGKFT
	1988// HA	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	269826341	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
		LIVWGIHHSGSTTEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWMLLDPNDTVTFTFNGA
		FIAPDRASFFKGESLGVQSDVPLDSSCGGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQPSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEL
	ADC29485	STQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEKQ	206
	A/mallard/Spain/	IGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLADS
	08.00991.3/2005	EMNKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA
	2005/11/	SIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVIL
	HA 284927336	WFSFGASCFILL
	ADK71137	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	207
	A/blue-winged	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	teal/Guatemala/	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	CIP049-	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	01/2008	RSGSSSYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	2008 Feb. 7 HA	LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
	301333785	TPSPGTRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFLRGKSLGIQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQHFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	ADK71148	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	208
	A/blue-winged	TERGIEVVNXTETVETANIKKICTHGKRPTDLGQCGL
	teal/Guatemala/	LGTLIGPPQCDRFLEFDADLIIERREGTDVCYPGKFT
	CIP049-	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	02/2008	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	2008 Mar. 5 HA	LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
	301333804	TPSPGTRPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFLRGKSLGIQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	ADN34727	MNIQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	209
	A/goose/Czech	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	Republic/1848-	LGTITGPPQCDQFLEFSADLIIERRGGSDVCYPGKFV
	T14/2009	NEEALRQILRESGGIDKETMGFTYSGIRTNGXTSACR
	2009 Feb. 4 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
	307141869	LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AEK84760	PAFIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSG	210
	A/wild	GTIISNLPFQNINSRAVGKCPRYVKQESLMLATGMKN
	bird/Korea/A14/	VPELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNA
	2011 2011/02/	QGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELI
	HA 341610308	DNEFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAME
		NQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEI
		FHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVK
		LSSGYKDVILWFSFGASCFILLAIAMGLVFICVKNGN
		MRCTICI
	AEK84761	ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERG	211
	A/wild	VEVFNATETVERTNVPRICSKGKKTVDLGQCGLRGTI
	bird/Korea/A3/	TGPPQCDQFLKFSPDLIIERQKGSDVCYPGKFVNEKP
	2011 2011/02/	LRQILRESGGIDKETMGFAYNGIKTNGPPIACRKSGS
	HA 341610310	SFYAKMKWLLSNTDKAAFPQMTKSYKNTRRNPALIVW
		GIHHSGSTTKQTKLYGIGSNLITVGSSNYQQSFVPSP
		GARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIPP
		DRASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISN
		LPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPK
		GKGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTA
		ADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTE
		VEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTID
		LADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDD
		DCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYK
		DVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTIC
		I
	AEK84763	ILVFALVAIIPTNANKIGLGHHAVSNGTKVNTLTERG	212
	A/wild	VEFFNATETVEPTNVPRICSKGKKTVDLGQCGLLGTI
	bird/Korea/A9/	TGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEKA
	2011 2011/02/	LRQILRESGGIDKETMGFAYSGIKTNGPPIACRKSGS
	HA 341610314	SFYAKMKWLLSNTDKAAFPQMTKSYKNIRRDPALIVW
		GIHHSGSTTKQTNLYGIGSNLITVGSSNYQQSFVPSP
		GARPQVNGQSGRIDFHWLILNPNDTVTFIFNGAFIAP
		DRASFLIGKSMGIQSGVQVDASCEGDCYHSGGTIISN
		LPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELPK
		GRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTA
		ADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTE
		VEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTID
		LADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDD
		DCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYK
		DVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTIC
		I
	AEK84765	LVFALVAIIPTNADKICLGHHAVSNGTKVNTLTERGV	213
	A/spot-billed	EVVNATETVERTNVPRICSKGKRTVDLGQCGLLGTIT
	duck/Korea/447/	GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL
	2011 2011/04/	RQILRESGGIDKETMGFTYSGIRTNGATSACRRSGSS
	HA 341610318	FYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPALIVWG
		IHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPSPG
		ARPQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPD
		RASFLRGKSMGIQSGVQVDASCEGDCYHSGGTIISNL
		PFQNINSRAVGKCPRYVKQESLMLATGMKNVPEPPKG
		RGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAA
		DYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEV
		EKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDL
		ADSEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDD
		CMARIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKD
		VILWFSFGASCFILLAIAMGLVFICVKNGNMRCTICI
	AEM98291	SILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTER	214
	A/wild	GVEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGT
	duck/Mongolia/	ITGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEE
	1-241/2008	ALRQILRESGGIDKETMGFTYSGIRTNGATSACRRSG
	2008/04/HA	SSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALII
	344196120	WGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
		PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIA
		PDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGSIIS
		NLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELP
		KGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGT
		AADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFT
		EVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTI
		DLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCD
		DDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGY
		KDVILWFSFGASCFILLAIAMGLVFICVKNGNMRCTI
	AFM09439	QILAFIACMLIGAKGDKICLGHHAVANGTKVNTLTER	215
	A/emperor	GIEVVNATETVETVNIKKICTQGKRPTDLGQCGLLGT
	goose/Alaska/44063-	LIGPPQCDQFLEFDADLIIERRKGTDVCYPGKFTNEE
	061/2006	SLRQILRGSGGIDKESMGFTYSGIRTNGATSACRRSG
	2006 May 23 HA	SSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALII
	390535062	WGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSFVPS
		PGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIA
		PERASFFRGESLGVQSDVPLDSGCEGDCFHSGGTIVS
		SLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVPENP
		KTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGT
		AADYKSTQSAIDQITGKLNRLIDKTNQQFELIDNEFS
		EIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQHTI
		DLADSEMNKLYERVRKQLRENAEEDGTGCFEIFHKCD
		DQCMESIRNNTYDHTQYRTESLQNRIQINPVKLSSGY
		KDIILWFSFGASCFLLLAIAMGLVFICIKNGNMRCTI
		CI
	AFV33945	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	216
	A/guinea	TERRIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	fowl/Nebraska/	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	17096-1/2011	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2011 Apr. 5 HA	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA
	409676820	LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AFV33947	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	217
	A/goose/Nebraska/	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	17097-	LGTLIGPPQCDQFLEFDADLIIERREGIDVCYPGKFT
	4/2011	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2011 Apr. 5 HA	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	409676827	LIVWGVHHSASATEQTKLYGSGSKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AFX85260	MNTQILAFIACMLIGINGDKICLGHHAVANGTKVNTL	218
	A/ruddy	TERGIEVVNATETVETANIKRICTQGKRPIDLGQCGL
	turnstone/Delaware	LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT
	Bay/220/1995	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACI
	1995 May 21 HA	RLGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	423514912	LIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSSCGGDCFHSGGT
		IVSSLPFQNINPRTVGRCPRYVKQTSLLLATGMKNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AGE08098	MNTQILTLIACMLIGAKGDKICLGHHAVANGTKVNTL	219
	A/northern	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	shoverl/Mississippi/	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	11OS145/	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2011	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	2011 Jan. 8 HA	LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
	444344488	TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHNGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AGI60301	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	220
	A/Hangzhou/1/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Mar. 24	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 475662454	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGISGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGI60292	MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTL	221
	A/Shanghai/4664T/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Mar. 5 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	476403560	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCHHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGJ72861	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	222
	A/chicken/Zhejiang/	TERGGEVVNATETVERTNIPRICSKGKKTVDLGQGGP
	DTID-	RGTITGPPQCDQFLEFSADLIMERREGSDVCYPGKFV
	ZJU01/2013	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2013/04/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	479280294	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGJ73503	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	223
	A/Nanjing/1/2013	TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL
	2013 Mar. 28	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 479285761	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	BAN16711	MNTQVLVFALMAIIPTNADKICLGHHAVSNGTKVNTL	224
	A/duck/Gunma/466/	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	2011 2011//	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 482661571	NEEALRQILRESGGIDKETMGFTYSGIRTNGTTSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
		LIAWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDDTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGK84857	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	225
	A/Hangzhou/2/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 1	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 485649824	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQITKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGL44438	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	226
	A/Shanghai/02/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Mar. 5 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	496493389	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGL33692	GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL	227
	A/Shanghai/4655T/	NRLIEKTNQQFELIDNEFTEVEKQIGNVINWTRDSIT
	2013	EVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQL
	2013 Feb. 26 HA	RENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR
	491874175	EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLA
		IAMGLVFICVKNGNMRCTICI
	AGL33693	GMIDGWYGFRHQNAQGEGTAADYKSTQSAIDQITGKL	228
	A/Shanghai/4659T/	NRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSIT
	2013	EVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQL
	2013 Feb. 27 HA	RENAEEDGTGCFEIFHKCDDDCMASIRNNTYDHSKYR
	491874186	EEAMQNRIQIDPVKLSSGYKDVILWFSFGASCFILLA
		IVMGLVFICVKNGNMRCTICI
	AGL95088	VFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVE	229
	A/Taiwan/S02076/	VVNATETVERTNIPRICSKGKRTVDLGQCGLLGTITG
	2013	PPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALR
	2013 Apr. 22 HA	QILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSF
	501485301	YAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGI
		HHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGA
		RPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDR
		ASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLP
		FQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGR
		GLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAAD
		YKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVE
		KQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLA
		DSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDC
		MASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDV
		ILWFSFGASCFILLAIVMGLVFICVKNGNMR
	AGL95098	LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGV	230
	A/Taiwan/T02081/	EVVNATETVERTNIPRICSKGKRTVDLGQCGLLGTIT
	2013	GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL
	2013 Apr. 22 HA	RQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSS
	501485319	FYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWG
		IHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPG
		ARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPD
		RASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNL
		PFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKG
		RGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAA
		DYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEV
		EKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDL
		ADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDD
		CMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKD
		VILWFSFGASCFILLAIVMGLVFICVKNGNMRCT
	AGM53883	GFRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKT	231
	A/Shanghai/5083T/	NQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNA
	2013	ELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEED
	2013 Apr. 20 HA	GTGCFEIFHKCDDDCMASIRNNTYDHSKYREEAMQNR
	507593986	IQIDPVKLSSGYKDVILWFSFGASCFILLAIVMGLVF
		ICVKNGNMRCT
	AGM53884	AQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFEL	232
	A/Shanghai/5180T/	IDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAM
	2013	ENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFE
	2013 Apr. 23 HA	IFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPV
	507593988	KLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKNG
		NMRCTICI
	AGM53885	QNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQF	233
	A/Shanghai/5240T/	ELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLV
	2013	AMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGC
	2013 Apr. 25 HA	FEIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQID
	507593990	PVKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVK
		NGNMRCT
	AGM53886	NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFE	234
	A/Shanghai/4842T/	LIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVA
	2013	MENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCF
	2013 Apr. 13 HA	EIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDP
	507593992	VKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKN
		GNMRCT
	AGM53887	NAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFE	235
	A/Shanghai/4701T/	LIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVA
	2013	MENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCF
	2013 Apr. 6 HA	EIFHKCDDDCMASIRNNTYDHSKYREEAMQNRIQIDP
	507593994	VKLSSGYKDVILWFSFGASCFILLAIVMGLVFICVKN
		GNMRCTIC
	AGN69462	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	236
	A/Wuxi/2/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Mar. 31 HA	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	511105778	NEEALRQILRESGGIDKEAMGFTYSGIRTNGSTSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGN69474	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	236
	A/Wuxi/1/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Mar. 31 HA	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	511105798	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLINGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGO51387	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	238
	A/Jiangsu/2/2013	TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL
	2013 Apr. 20	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 514390990	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYRXEAMXBXIQIDPVKLS
		SGYKDVXJWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	BAN59726	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	239
	A/duck/Mongolia/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	147/2008	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2008 Aug. 29 HA	NEEALRQILRESGGIGKETMGFTYSGIRTNGATSACR
	519661951	RSRSSFYAEMKWLLSNTDNAAFPQMTRSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGT
		IISNLPFQNINSRTVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIERTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		NGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	BAN59727	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	240
	A/duck/Mongolia/	TERGVEVVNATETVERINVPRICSKGKRTVDLGQCGL
	129/2010	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2010// HA	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	519661954	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQINPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGQ80952	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	241
	A/duck/Jiangxi/	TERGVEVVNATETVERTSIPRICSKGKRAVDLGQCGL
	3096/2009	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2009// HA	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	523788794	RSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGT
		IISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGQ80989	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	242
	A/duck/Jiangxi/	TERGVEVVNATETVERTSIPRICSKGKRAVDLGQCGL
	3257/2009	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2009// HA	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	523788868	RSGSSFYAEMKWLLSNTDNAAFPQTTKSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGXSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHNGGT
		IISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVERQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGQ81043	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	243
	A/chicken/Rizhao/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	515/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013// HA	NEEALRQILRESGGIDKEEMGFTYSGIRTNGATSACR
	523788976	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR33894	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	244
	A/chicken/Rizhao/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	719b/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013// HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	524845213	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDRSKYREEAMQNRXXXXXXXXX
		XXXKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49399	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	245
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	SDOOl/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 May 3 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	525338528	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49495	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	246
	A/chicken/Shanghai/	TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL
	S1358/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 3	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	HA 525338689	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIKNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49506	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	247
	A/chicken/Shanghai/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	S1410/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 3	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	HA 525338708	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49554	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	248
	A/chicken/Zhejiang/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	SD033/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 11	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	HA 525338789	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49566	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	249
	A/duck/Anhui/SC702/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 16 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	525338809	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49722	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	250
	A/homing	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	pigeon/Jiangsu/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	SD184/2013	NEEALRQILRESGGIDKEAMGFTYSEIRTNGATSACR
	2013 Apr. 20 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	525339071	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49734	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	251
	A/pigeon/Shanghai/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	S1069/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 2 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	525339091	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTITFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR49770	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	252
	A/wild	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	pigeon/Jiangsu/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	SD001/2013	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2013 Apr. 17 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	525339151	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGY41893	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	253
	A/Huizhou/01/2013	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2013 Aug. 8	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 552049496	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGY42258	FALVAIIPINADKICLGHHAVSNGTKVNTLTERGVEV	254
	A/mallard/Sweden/	VNATETVERTNVPRICSRGKRTVDLGQCGLLGTIXGP
	91/2002	PQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQ
	2002 Dec. 12 HA	ILRESGGIDKETMGFTYSGIRTNGAXSACRRSGSSFY
	552052155	AEMKWLLSNTDNAAFPQMTKSYKNTRNDPALIIWGIH
		HSGSTTEQTKLYGSGNKLITVGSSNYQQSFVPSPGAR
		PQVNGQSGRIDFHWLILNPNDTVTFSFNGAFIAPDRA
		SFLRGKSMGIQSGVQIDANCEGDCYHSGGTIISNLPF
		QNINSRAVGKCPRYVKQESLLLATGMKNVPEIPKGRG
		LFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADY
		KSTQSAIDQITGKLNRLIEKTNQQFELIDNEFTEVEK
		QIGNVINWTRDSMTEVWSYNAELLVAMENQHTIDLAD
		SEMNKLYERVRRQLRENAEEDGTGCFEIFHKCDDDCM
		ASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVI
		LWFSFGASCFILLAIAMGLVFMCVKNGNMRCTICI
	AHA11441	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	255
	A/guinea	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	fowl/Nebraska/	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	17096/2011	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2011 Apr. 10 HA	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA
	557478572	LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHA11452	MNTQILALIACMLVGTKGDKICLGHHAVANGTKVNTL	256
	A/turkey/Minnesota/	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	32710/2011	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2011 Jul. 12	NEEPLRQILRGSGGIDKESMGFTYSGIRTNGATSTCR
	HA 557478591	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA
		LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFEMIDN
		EFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHA11461	MNTQILALIACMLVGTKGDKICLGHHAVANGTKVNTL	257
	A/turkey/Minnesota/	TERGIEVVNATETVETANIKKICTQGKRPTDLGQCGL
	31900/2011	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2011 Jul. 5	NEEPLRQILRGSGGIDKESMGFTYSGIRTNGATSTCR
	HA 557478606	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRNKPA
		LIVWGVHHSGSATEQTKLYGSGSKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHKGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEIWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRAESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHK10585	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	258
	A/chicken/Guangdong/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	G1/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 May 5 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	587680636	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGG53366	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	259
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/CSM	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	42-34/2011	NEEALRQILRESGGIDKETMGLTYSGIRTNGATSACR
	2011/03/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459252887	LIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGG53377	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	260
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/CSM	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	42-1/2011	NEEALRQILRESGGIDKETMGLTYSGIRTNGATSACR
	2011/03/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459252925	LIVWGIHHSGSSTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVRLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CT
	AGG53399	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	261
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/MHC	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	39-26/2011	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2011/03/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459253005	LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		EPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGG53432	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	262
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/MHC	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	35-41/2011	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2011/03/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459253136	LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		EPPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CT
	AGG53476	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	263
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/SH19-	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	27/2010	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2010/12/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459253257	LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTI
	AGG53487	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	264
	A/wild	TERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGL
	duck/Korea/SH19-	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	50/2010	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	2010/01/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRDPA
	459253278	LIVWGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDASCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLMLATGMKNVP
		ELPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AGG53520	QILVFALVAIIPTNADKICLGHHAVSNGTKVNTLTER	265
	A/wild	GVEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGT
	duck/Korea/SH20-	ITGPPQCDQLLEFSADLIIERREGTDVCYPGKFVNEE
	27/2008	ALRQILRESGGIEKETMGFTYSGIRTNGATSACRRSG
	2008/12/HA	SSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPALII
	459253409	WGIHHSGSTTEQTKLYGSGSKLITVGSSNYQQSFVPS
		PGARPQVNGQSGRIDFHWLMLNPNDTVTFSFNGAFIA
		PDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIIS
		NLPFQNINSRAVGKCPRYVKQESLMLATGMKNVPELP
		KGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGT
		AADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFT
		EVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQHTI
		DLADSEMNKLYERVKRQLRENAEEDGTGCFEIFHKCD
		DDCMASIRNNTYDHSKYREEAMQNRIQINPVKLSSGY
		KDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
	AGL43637	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	266
	A/Taiwan/1/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013// HA	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	496297389	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGPSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IINNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGL97639	IACMLVGAKGDKICLGHHAVANGTKVNTLTERGIEVV	267
	A/mallard/Minnesota/	NATETVETANIKKLCTQGKRPTDLGQCGLLGTLIGPP
	AI09-	QCDQFLEFDADLIIERREGTDVCYPGKFTNEESLRQI
	3770/2009	LRGSGGIDKESMGFTYSGIRTNGATSACRRSGSSFYA
	2009 Sep. 12 HA	EMKWLLSNSDNAAFPQMTKSYRNPRNKPALIIWGVHH
	505555371	SGSATEQTKLYGSGNKLITVGSSKYQQSFTPSPGARP
		QVNGQSGRIDFHWLLLDPNDTVTFTFNGAFIAPDRAS
		FFRGESLGVQSDVPLDSGCEGDCFHSGGTIVSSLPFQ
		NINPRTVGKCPRYVKQTSLLLATGMRNVPENPKTRGL
		FGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYK
		STQSAIDQITGKLNRLIDKTNQQFELIDNEFSEIEQQ
		IGNVINWTRDSMTELWSYNAELLVAMENQHTIDLADS
		EMNKLYERVRKQLRENAEEDGTGCFEIFHKCDDQCME
		SIRNNTYDHTQYRTESLQNRIQIDPVKLS
	AGO02477	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	268
	A/Xuzhou/1/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 25	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 512403688	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR
		CTICI
	AGR84942	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	269
	A/Suzhou/5/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 12	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 526304561	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGSKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AGR84954	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	270
	A/Nanjing/6/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 11	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 526304594	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNRNMR
		CTICI
	AGR84978	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	271
	A/Wuxi/4/2013	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2013 Apr. 7 HA	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	526304656	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR
		CTICI
	AGR84990	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	272
	A/Wuxi/3/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 7 HA	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	526304688	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR
		CTICI
	AGR85002	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	273
	A/Zhenjiang/1/	TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 7 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	526304708	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNKR
		CTICI
	AGR85026	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	274
	A/Nanjing/2/2013	TERGVEVVNATETVERTNIPRICSKGKMTVDLGQCGL
	2013 Apr. 5	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 526304762	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKSRNMR
		CTICI
	AGU02230	LVFALIAIIPTNADKICLGHHAVSNGTKVNTLTERGG	275
	A/Zhejiang/DTID-	EVVNATETVERTNIPRICSKGKRTVDLGQCGLRGTIT
	ZJU05/2013	GPPQCDQFLEFSADLIIERREGSDVCYPGKFVNEEAL
	2013/04/HA	RQILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSS
	532808765	FYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWG
		IHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPG
		ARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPD
		RASFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNL
		PFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKG
		RGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAA
		DYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEV
		EKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDL
		ADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDD
		CMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKD
		VILWFSFGASCFILLAIVMGLVFICVKNGNMRCT
	AGU02233	FALIAIIPTNADKICLGHHAVSNGTKVNTLTERGGEV	276
	A/Zhejiang/DTID-	VNATETVERTNFPRICSKGKRTVDLGQCGLRGTITGP
	ZJU08/2013	PQCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQ
	2013/04/HA	ILRESGGIDKEAMGFTYSGIRTNGATSACRRSGSSFY
	532808788	AEMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIH
		HSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGAR
		PQVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRA
		SFLRGKSMGIQSGVQVDANCEGDCYHSGGTIISNLPF
		QNIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRG
		LFGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADY
		KSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEK
		QIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLAD
		SEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCM
		ASIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVI
		LWFSFGASCFILLAIVMGLVFICVKNGNMRCT
	AGW82588	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	277
	A/tree	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	sparrow/Shanghai/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	01/2013	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2013 May 9 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	546235348	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTIGI
	AGW82600	ALIAIIPTNADKICLGHHAVSNGTKVNTLTERGVEVV	278
	A/Shanghai/CN01/	NATETVERTNIPRICSKGKRTVDLGQCGLLGTITGPP
	2013	QCDQFLEFSADLIIERREGSDVCYPGKFVNEEALRQI
	2013 Apr. 11 HA	LRESGGIDKEAMGFTYSGIRTNGATSACRRSRSSFYA
	546235368	EMKWLLSNTDNAAFPQMTKSYKNTRKSPALIVWGIHH
		SVSTAEQTKLYGSGNKLVTVGSSNYQQSFVPSPGARP
		QVNGLSGRIDFHWLMLNPNDTVTFSFNGAFIAPDRAS
		FLRGKSMGIQSGVQVDANCEGDCYHSGGTIMSNLPFQ
		NIDSRAVGKCPRYVKQRSLLLATGMKNVPEIPKGRGL
		FGAIAGFIENGWEGLIDGWYGFRHQNAQGEGTAADYK
		STQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQ
		IGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADS
		EMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDCMA
		SIRNNTYDHSKYREEAMQNRIQIDPVKLSSGYKDVIL
		WFSFGASCFILLAIVMGLVFICVKNGNMRCTICI
	AGW82612	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	280
	A/Shanghai/JS01/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 3 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	546235388	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKNPA
		LIVWGIHHSGSTAEQTKLYGSGNKLVTVGSSNYQQSF
		APSPGARTQVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFICVKNGNMR
		CTICI
	AHA11472	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	281
	A/turkey/Minnesota/	TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL
	31676/2009	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2009 Dec. 8	NEESLRQILRGSGGIDKESMGFTYSGIRTNGETSACR
	HA 557478625	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPA
		LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		EKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITNKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHA11483	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	282
	A/turkey/Minnesota/	TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL
	14135-	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2/2009	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2009 Aug. 7 HA	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPA
	557478644	LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		EKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHA11500	TQILVFALIAIIPTNADKICLGHHAVSNGTKVNTLTE	283
	A/Zhejiang/DTID-	RGVEVVNATETVERTNIPRICSKGKRTVDLGQCGLLG
	ZJU10/2013	TITGPPQCDQFLEFSADLIIERREGSDVCYPGKFVNE
	2013 Oct. 14 HA	EALRQILRESGGIDKEAMGFTYSGIRTNGATSACRRS
	557478676	GSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPALI
		VWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSFVP
		SPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGAFI
		APDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGTII
		SNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVPEI
		PKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQGEG
		TAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEF
		NEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHT
		IDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKC
		DDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLSSG
		YKDVILWFSFGASCFILLAIVMGLVFICVKN
	AHA57050	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	284
	A/turkey/Minnesota/	TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL
	14659/2009	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2009 Aug. 12	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	HA 558484427	RSGSSFYAEMKWLLSNSNNAAFPQMTKSYRNPRDKPA
		LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		EKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITSKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		NCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHA57072	MNTQILALIACMLIGAKGDKICLGHHAVANGTKVNTL	285
	A/turkey/Minnesota/	TERGIEVVNATETVETANVKKICTQGKRPTDLGQCGL
	18421/2009	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	2009 Sep. 9	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	HA 558484465	RSGSSFYAEMKWLLSNSNDAAFPQMTKSYRNPRDKPA
		LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		EKPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRKESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHD25003	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	286
	A/Guangdong/02/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2013 2013/10/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 568260567	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNM
	AHF20528	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	287
	A/Hong	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	Kong/470129/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Nov. 30	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	HA 570933555	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHF20568	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	288
	A/Shanghai/CN02/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Apr. 2 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	570933626	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IMSNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHH25185	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	289
	A/Guangdong/04/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 16 HA	NEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR
	576106234	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHJ57411	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	290
	A/Shanghai/PD-	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	01/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 17 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	585478041	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VSSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCKGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHJ57418	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	291
	A/Shanghai/PD-	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	02/2014	LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV
	2014 Jan. 17 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	585478256	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLKGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHK10800	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	292
	A/Shanghai/01/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 3 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	587681014	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHM24224	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	293
	A/Beijing/3/2013	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2013 Apr. 16	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	HA 594704802	KEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
		RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHN96472	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	294
	A/chicken/Shanghai/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	PD-CN-	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	02/2014	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2014 Jan. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	602701641	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHZ39686	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	295
	A/Anhui/DEWH72-	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	01/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013// HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	632807036	RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHZ39710	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	296
	A/Anhui/DEWH72-	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	03/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013// HA	NEEALRQILRESGGIDKEAMGFTYSGIRTDGATSACR
	632807076	RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHZ39746	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	297
	A/Anhui/DEWH72-	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	06/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013// HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	632807136	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGERPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AHZ41929	MNTQILVFALVAIIPINADKICLGHHAVSNGTKVNTL	298
	A/mallard/Sweden/	TERGVEVVNATETVERTNVPRICSRGKRTVDLGQCGL
	1621/2002	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2002 Dec. 12 HA	NEEALRQILRESGGIDKETMGFTYSGIRTNGATSACR
	632810949	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRNDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPQVNGQSGRIDFHWLILNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQIDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIAMGLVFMCVKNGNMR
		CTICI
	AHZ42537	MNTQILAFIACMLVGAKGDKICLGHHAVANGTKVNTL	299
	A/mallard/Minnesota/	TERGIEVVNATETVETANIKKLCTQGKRPTDLGQCGL
	AI09-	LGTLIGPPQCDQFLEFDADLIIERREGTDVCYPGKFT
	3770/2009	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	2009 Sep. 12 HA	RSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPA
	632811964	LIIWGVHHSGSATEQTKLYGSGNKLITVGSSKYQQSF
		TPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNGA
		FIAPDRASFFRGESLGVQSDVPLDSGCEGDCFHSGGT
		IVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNVP
		ENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELIDN
		EFSEIEQQIGNVINWTRDSMTELWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIFH
		KCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKLS
		SGYKDIILWFSFGASCFLLLAIAMGLVFICIKNGNMR
		CTICI
	AHZ42549	MNTQILAFIACMLVGVRGDKICLGHHAVANGTKVNTL	300
	A/ruddy	TEKGIEVVNATETVESANIKKICTQGKRPTDLGQCGL
	turnstone/Delaware/	LGTLIGPPQCDQFLEFDSDLIIERREGTDVCYPGKFT
	AI00-	NEESLRQILRGSGGIDKESMGFTYSGIRTNGATSACR
	1538/2000	RLGSSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKP
	2000 May 20 HA	ALIIWGVHHSGSANEQTKLYGSGNKLITVGSSKYQQS
	632811984	FTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNG
		AFIAPDRASFFRGESLGIQSDVPLDSSCGGDCFHSGG
		TIVSSLPFQNINPRTVGKCPRYVKQTSLLLATGMRNV
		PENPKTRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQ
		GEGTAADYKSTQSAIDQITGKLNRLIDKTNQQFELMD
		NEFNEIEQQIGNVINWTRDSMTEVWSYNAELLVAMEN
		QHTIDLADSEMNKLYERVRKQLRENAEEDGTGCFEIF
		HKCDDQCMESIRNNTYDHTQYRTESLQNRIQIDPVKL
		SSGYKDIILWFSFGASCFLLLAIAMGLIFICIKNGNM
		RCTICI
	AID70634	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	301
	A/Shanghai/Mix	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	1/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 3 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	660304650	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRIIEKTNQQFELIDN
		EFNEVEKQISNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AIN76383	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL	302
	A/Zhejiang/LS01/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 8 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGTTSACR
	684694637	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AIU46619	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	303
	A/chicken/Zhejiang/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	DTID-	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	ZJU06/2013	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2013/12/HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	699978931	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVEVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AIU47013	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	304
	A/chicken/Suzhou/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	040201H/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013/04/HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	699979673	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDMILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90490	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	305
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	742/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 10 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755178094	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90526	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	306
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	898/2013	LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV
	2013 Dec. 9 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK
	755178154	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		RGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90538	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	307
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Shenzhen/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	918/2013	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2013 Dec. 9 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755178174	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90576	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	308
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1665/2013	LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV
	2013 Dec. 12 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK
	755178238	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		RGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90588	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	309
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2110/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 13 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755178258	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90661	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	310
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2912/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 18 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755178380	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90673	MNTQILVFALTAIIPTNADKICLGHHAVSNGTKVNTL	311
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	3049/2013	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2013 Dec. 18 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755178400	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90795	MNTQILVFALIAIIPTNADKICLGHHAVPNGTKVNTL	312
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	3281/2013	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2013 Dec. 18 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755178604	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90891	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	313
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	3520/2013	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2013 Dec. 19 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKXPA
	755178764	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ90951	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	314
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	3544/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755178864	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYRNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91035	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	315
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	3780/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755179004	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRRSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDNRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91155	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	316
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	4037/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755179204	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ92005	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	317
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	801/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 9 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755180629	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		RGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94254	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	318
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1374/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755184382	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94606	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	319
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	191/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755184968	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96552	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	320
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTIDLGQCGL
	12206/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Mar. 16 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755188219	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96684	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKINTL	321
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	13207/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Mar. 30 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755188439	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96732	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	322
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	13223/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Mar. 30 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755188519	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJK00354	MNTQILVFALVAIIPTNADKICLGHHAVSNGTKVNTL	323
	A/duck/Zhejiang/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	LS02/2014	LGTITGPPQCDQFLEFSADLIVERREGSDVCYPGKFV
	2014 Jan. 12 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755194469	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKDPA
		LIIWGIHHSGSTTEQTKLYGSGNKLITVGSSNYQQSF
		VPSPGARPLVNGQSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNINSRAVGKCPRYVKQESLLLATGMKNVP
		EVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQVTGKLNRLIEKTNQQFELIDH
		EFTEVEKQIGNVINWTRDSMTEVWSYNAELLVAMENQ
		HTIDLADSEMNKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91264	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	324
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	4129/2013	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2013 Dec. 19 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755179386	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLMEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91314	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	325
	A/chicken/Shaoxing/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2417/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Oct. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755179470	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPPVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91402	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	326
	A/chicken/Huzhou/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	4045/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Oct. 24 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755179618	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKEVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91476	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	327
	A/chicken/Huzhou/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	4076/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Oct. 24 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755179743	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91725	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	328
	A/chicken/Shaoxing/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	5201/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Oct. 28 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755180161	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91885	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	329
	A/Shenzhen/SP4/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 16 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGVTSACR
	755180429	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		RGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91909	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	330
	A/Shenzhen/SP26/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV
	2014 Jan. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACK
	755180469	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDGCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		RGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91945	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL	331
	A/Shenzhen/SP38/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 22 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755180529	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIGGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91957	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	332
	A/Shenzhen/SP44/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 23 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGTTSACR
	755180549	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISSLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91969	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	333
	A/Shenzhen/SP48/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 23 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755180569	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ91993	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	334
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	4119/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755180609	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLLGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFTLLAIVMGLVFICVKNGNMR
		CTICI
	AJJ92031	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	335
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	4064/2013	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2013 Dec. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755180672	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVESSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ92967	MNTQILVFALIAIVPINADKICLGHHAVSNGTKVNTL	336
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Jiangxi/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	9469/2014	NEEALRQILRESGGIDKEAMGFTYSGIRTNGVTSACR
	2014 Feb. 16 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755182232	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93027	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL	337
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	9558/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 16 HA	KEEALRQILRESGGIDKEAMGFTYSGIRTNGVTSACR
	755182332	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93051	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL	338
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	10573/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 18 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGVTSACR
	755182372	RSGSSFYAEMKWLLSNTDDAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93845	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	339
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	157/2014	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2014 Feb. 20 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755183695	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93857	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	340
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	169/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACM
	755183715	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93869	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	341
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	173/2014	LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755183735	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93881	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	342
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	189/2014	LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755183755	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPKYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93907	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	343
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	449/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755183799	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93931	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	344
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	536/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755183839	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISKLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93943	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	345
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	568/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR
	755183859	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		GGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ93979	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	346
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTVTGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	656/2014	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2014 Feb. 20 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755183919	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFGLIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94134	MNTQILVLALIAIIPTNADKICLGHHAVSNGTKVNTL	347
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1051/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755184182	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVXLS
		XGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94158	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	348
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1075/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755184222	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94182	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	349
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1177/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACK
	755184262	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94194	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	350
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTIDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	1264/2014	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2014 Feb. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755184282	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQVTGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94206	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	351
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	1268/2014	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	2014 Feb. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755184302	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISDLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94344	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	352
	A/silkie	TERGVEVVNSTETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	1451/2014	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	2014 Feb. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755184532	IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRTVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94356	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	353
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1456/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755184552	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94396	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	354
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1494/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755184618	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		ETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94754	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	355
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	748/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR
	755185215	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSNAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		GGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94838	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	356
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	835/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755185356	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFGFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94862	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	357
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	843/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIEKEAMGFTYSGIRTNGATSACR
	755185396	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		GGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94886	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL	358
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	851/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755185436	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94910	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	359
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	874/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755185476	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSASTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ94959	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	360
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	967/2014	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACX
	2014 Feb. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755185558	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95048	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	361
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	1009/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755185708	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		ETPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDNDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95171	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	362
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1314/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755185913	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFNFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95227	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	363
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1382/2014	LGTITGPPQCDQFLEFSADLIIERREGSDICYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755186006	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95251	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	364
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1401/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755186046	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95346	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	365
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1548/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755186206	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYKRVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHNKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95382	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	366
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	1690/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755186266	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSIGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95464	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	367
	A/chicken/Shenzhen/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	138/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 19 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755186404	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95572	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	368
	A/chicken/Dongguan/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	1100/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 21 HA	NEEALRQILRESGGIEKEAMGFTYSGIRANGATSACR
	755186584	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		GGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95584	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	369
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	chicken/Dongguan/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	1519/2014	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	2014 Feb. 21 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755186604	LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPERASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYRGEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFMLLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95596	MNTQILAFALIAIIPTNADKICLGHHAVSNGTKVNTL	370
	A/Shenzhen/SP58/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jan. 25 HA	NEEALRQILRESGGIDKEAMGFTYSGIRANGATSACR
	755186624	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ95620	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	371
	A/Shenzhen/SP75/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 15 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGSTSACR
	755186664	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAVVMGLVFICVKNGNMR
		CTICI
	AJJ95632	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	372
	A/Shenzhen/SP62/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 5 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755186684	RSGSSFYAEMKWLLSNTDNATFPQMTKSYKNTRKSPA
		LIIWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVETQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96720	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	373
	A/chicken/Jiangxi/	TERGVEVVNATETVERTTIPRICSKGKKTVDLGQCGL
	13220/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Mar. 30 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755188499	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96817	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL	374
	A/chicken/Jiangxi/	TERGVEVVNATEIVERTNIPRICSKGKKTVDLGQCGL
	9513/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Feb. 16 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGVTSACR
	755188661	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96841	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	375
	A/Shenzhen/SP139/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 2 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSTCR
	755188701	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRACFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVERQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96889	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	376
	A/chicken/Jiangxi/	TERGVEVVNATETVERTXIPRICSKGKKTVDLGQCGL
	13496/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 11 HA	NEEALRQILRESGGIDKXAMGFTYSGIRTNGATSACR
	755188781	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96901	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	377
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	13502/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 11 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755188801	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSXGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ96925	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	378
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	13513/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 11 HA	NEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR
	755188841	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHTVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDLHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97267	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	379
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	13252/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Mar. 30 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755189411	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97291	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	380
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	13493/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 6 HA	NEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR
	755189451	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97331	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	381
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	13512/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 6 HA	NEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR
	755189517	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSIGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97373	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	382
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	13521/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 6 HA	NEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR
	755189587	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPXRASFLRGKSXGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97443	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	383
	A/chicken/Jiangxi/	TERGVEVVNATETVERTTIPRICSKGKRTVDLGQCGL
	13530/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 6 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755189702	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSRGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97582	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	384
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	14023/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 13 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755189933	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97697	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	385
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	14517/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755190125	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCDGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97709	MNTQILVFALIAIIPANADKICLGHHAVSNGTKVNTL	386
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	14518/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 20 HA	NEEALRQILRESGGIDKEAMGFTYNGIRTNGATSACR
	755190145	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGNCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97745	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	387
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	14554/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 20 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755190205	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELMDN
		EFNEVEKQIGNVINWTRDSITELWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97757	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	388
	A/chicken/Shantou/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	2537/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 16 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	755190225	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFKHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97841	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	389
	A/duck/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	15044/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Apr. 27 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755190365	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVRLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97899	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	390
	A/chicken/Jiangxi/	TERGVEVVNATETVERTNIPRICSKGKRTVDLGQCGL
	15524/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 May 5 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755190462	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIAKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHRKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFMCVKNGNMR
		CTICI
	AJJ97925	MNTQILVFALIAIIPTNADKICLGHHAVSNGTKVNTL	391
	A/silkie	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	chicken/Shantou/	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2050/2014	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGATSACR
	2014 Mar. 25 HA	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
	755190506	IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97973	MNTQILVFALISIIPTNADKICLGHHAVSNGTKVNTL	392
	A/chicken/Shantou/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	4325/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jul. 1 HA	NEEALRQILRKSGGIDKEAMGFTYSGIRTNGVTSACR
	755190586	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		IIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDADCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQRSLLLATGMKNVP
		EVPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI
	AJJ97998	MNTQILVFALIAIVPTNADKICLGHHAVSNGTKVNTL	393
	A/chicken/Shantou/	TERGVEVVNATETVERTNIPRICSKGKKTVDLGQCGL
	4816/2014	LGTITGPPQCDQFLEFSADLIIERREGSDVCYPGKFV
	2014 Jul. 22 HA	NEEALRQILRESGGIDKEAMGFTYSGIRTNGATSACR
	755190628	RSGSSFYAEMKWLLSNTDNAAFPQMTKSYKNTRKSPA
		LIVWGIHHSVSTAEQTKLYGSGNKLVTVGSSNYQQSF
		VPSPGARPQVNGLSGRIDFHWLMLNPNDTVTFSFNGA
		FIAPDRASFLRGKSMGIQSGVQVDANCEGDCYHSGGT
		IISNLPFQNIDSRAVGKCPRYVKQKSLLLATGMKNVP
		EIPKGRGLFGAIAGFIENGWEGLIDGWYGFRHQNAQG
		EGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELVDN
		EFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQ
		HTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFH
		KCDDDCMASIRNNTYDHSKYREEAMQNRIQIDPVKLS
		SGYKDVILWFSFGASCFILLAIVMGLVFICVKNGNMR
		CTICI

TABLE 16
Exemplary Influenza HA Stem Antigens
		SEQ ID		SEQ ID
Strain	Foldon version	NO:	AA seq	NO:
H1N1	DTVDTVLEKNVTVTHSVNL	394	METPAQLLFLLLLWLPDTTGDT	403
A/Puerto	LEDSHGSANSSLPYQNTHP		VDTVLEKNVTVTHSVNLLEDSH
Rico/8/1934	TTNGESPKYVRSAKLRMVT		GSANSSLPYQNTHPTTNGESPK
	GLRNGSAGSATQNAINGIT		YVRSAKLRMVTGLRNGSAGSAT
	NKVNTVIEKMNIQDTATGK		QNAINGITNKVNTVIEKMNIQD
	EFNKDEKRMENLNKKVDDG		TATGKEFNKDEKRMENLNKKVD
	FLDIWTYNAELLVLLENER		DGFLDIWTYNAELLVLLENERT
	TLDAHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H1N1	DTVDTVLEKNVTVTHSVNL	395	METPAQLLFLLLLWLPDTTGDT	404
A/Viet	LEDKHGSANTSLPFQNTHP		VDTVLEKNVTVTHSVNLLEDKH
Nam/850/2009	TTNGKCPKYVKSTKLRLAT		GSANTSLPFQNTHPTTNGKCPK
	GLRNGSAGSATQNAIDEIT		YVKSTKLRLATGLRNGSAGSAT
	NKVNSVIEKMNTQDTATGK		QNAIDEITNKVNSVIEKMNTQD
	EFNHDEKRIENLNKKVDDG		TATGKEFNHDEKRIENLNKKVD
	FLDIWTYNAELLVLLENER		DGFLDIWTYNAELLVLLENERT
	TLDAHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H1N1	DTVDTVLEKNVTVTHSVNL	396	METPAQLLFLLLLWLPDTTGDT	405
A/New	LEDSHGSANSSLPFQNTHP		VDTVLEKNVTVTHSVNLLEDSH
Caledonia/20/	TTNGESPKYVRSAKLRMVT		GSANSSLPFQNTHPTTNGESPK
99	GLRNGSAGSATQNAINGIT		YVRSAKLRMVTGLRNGSAGSAT
	NKVNSVIEKMNTQDTAVGK		QNAINGITNKVNSVIEKMNTQD
	EFNKDERRMENLNKKVDDG		TAVGKEFNKDERRMENLNKKVD
	FLDIWTYNAELLVLLENER		DGFLDIWTYNAELLVLLENERT
	TLDAHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H1N1	DTVDTVLEKNVTVTHSVNL	397	METPAQLLFLLLLWLPDTTGDT	406
A/California/	LEDKHGSANTSLPFQNTHP		VDTVLEKNVTVTHSVNLLEDKH
04/2009	TTNGKSPKYVKSTKLRLAT		GSANTSLPFQNTHPTTNGKSPK
	GLRNGSAGSATQNAIDEIT		YVKSTKLRLATGLRNGSAGSAT
	NKVNSVIEKMNTQDTAVGK		QNAIDEITNKVNSVIEKMNTQD
	EFNHDEKRIENLNKKVDDG		TAVGKEFNHDEKRIENLNKKVD
	FLDIWTYNAELLVLLENER		DGFLDIWTYNAELLVLLENERT
	TLDAHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewvllstfl		AYVRKDGEWVLLSTFL
H3N2	HAVPNGTIVKTITNDQIEV	398	METPAQLLFLLLLWLPDTTGHA	407
A/Wisconsin/	TNATEgsaPNDKPFQNtNR		VPNGTIVKTITNDQIEVTNATE
67/2005	tTtGACPRYVKQNTLKLAT		GSAPNDKPFQNTNRTTTGACPR
	GMRNgsagsaTQAAINQIN		YVKQNTLKLATGMRNGSAGSAT
	GKLNRLIGKTNEKdHQdEK		QAAINQINGKLNRLIGKTNEKD
	EFSEdEGRIQDLEKYVEDT		HQDEKEFSEDEGRIQDLEKYVE
	KIDLWSYNAELLVALENQH		DTKIDLWSYNAELLVALENQHT
	TIDaTDSQGTgggyipeap		IDATDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H5N1	EQVDTIMEKNVTVTHAQDI	399	METPAQLLFLLLLWLPDTTGEQ	408
A/Vietnam/	LEKTHGSANSSMPFHNTHP		VDTIMEKNVTVTHAQDILEKTH
1203/2004	NTTGESPKYVKSNRLVLAT		GSANSSMPFHNTHPNTTGESPK
	GLRNGSAGSATQKAIDGVT		YVKSNRLVLATGLRNGSAGSAT
	NKVNSIIDKMNTQFEADGR		QKAIDGVTNKVNSIIDKMNTQF
	EFNNDERRIENLNKKMEDG		EADGREFNNDERRIENLNKKME
	FLDVWTYNAELLVLMENER		DGFLDVWTYNAELLVLMENERT
	TLDAHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H7N9	TKVNTLTERGVEVVNATET	400	METPAQLLFLLLLWLPDTTGTK	409
(A/Anhui/1/	VERTgsaISNLPFQNtDSt		VNTLTERGVEVVNATETVERTG
2013)	AnGKCPRYVKQRSLLLATG		SAISNLPFQNTDSTANGKCPRY
	MKNgsagsaTQSAIDQITG		VKQRSLLLATGMKNGSAGSATQ
	KLNRLIEKTNQQdELtDNE		SAIDQITGKLNRLIEKTNQQDE
	FNEdEKQIGNVINWIRDSI		LIDNEFNEDEKQIGNVINWTRD
	TEVWSYNAELLVAMENQHT		SITEVWSYNAELLVAMENQHTI
	IDaADSQGTgggyipeapr		DAADSQGTGGGYIPEAPRDGQA
	dgqayyrkdgewvllstfl		YVRKDGEWVLLSTFL
H9N2	ETVDTLTETNVPVTHAKEL	401	METPAQLLFLLLLWLPDTTGET	410
A/Hong	LHTEHgsaNSTLPFHNtSK		VDTLTETNVPVTHAKELLHTEH
Kong/1073/	tAnGTCPKYVRVNSLKLAV		GSANSTLPFHNTSKTANGTCPK
99	GLRNgsagsaTQKAIDKIT		YVRVNSLKLAVGLRNGSAGSAT
	SKVNNIVDKMNKQdEItDH		QKAIDKITSKVNNIVDKMNKQD
	EFSEdETRLNMINNKIDDQ		EITDHEFSEDETRLNMINNKID
	IQDVWAYNAELLVLLENQK		DQIQDVWAYNAELLVLLENQKT
	TLDaHDSQGTgggyipeap		LDAHDSQGTGGGYIPEAPRDGQ
	rdgqayyrkdgewyllstfl		AYVRKDGEWVLLSTFL
H10N8	TIVKTLINEQEEVTNATET	402	METPAQLLFLLLLWLPDTTGTI	411
A/JX346/2013	VESTGgsaNTRLPFQNtSP		VKTLTNEQEEVTNATETVESTG
	tTnGQCPKYVNRRSLMLAT		GSANTRLPFQNTSPTTNGQCPK
	GMRNgsagsaTQAAIDQIT		YVNRRSLMLATGMRNGSAGSAT
	GKLNRLVEKTNTEdSItSE		QAAIDQITGKLNRLVEKTNTED
	FSEIEHQIGNVINWTKDSI		SITSEFSEIEHQIGNVINWTKD
	TDIWTYQAELLVAMENQHT		SITDIWTYQAELLVAMENQHTI
	IDaADSQGTgggyipeapr		DAADSQGTGGGYIPEAPRDGQA
	dgqayyrkdgewvllstfl		YVRKDGEWVLLSTFL
H3N2			METPAQLLFLLLLWLPDTTGAS	412
A/Hong			PNGTLVKTITDDQIEVTNATEL
Kong/1/1968			VQSSGSAGSANDKPFQNTNKRT
stem			SGASPKYVKQNTLKLATGQRGS
RNA			AGSAATDQINGKLNRVIEKTNE
			KDHQIEKEFSEDEGRIQDLEKY
			VEDTKIDLWSYNAELLVALENQ
			HTIDLTDSQGTGGGYIPEAPRD
			GQAYVRKDGEWVLLSTFL

The first underlined sequence for each of the amino acid sequences listed in Table 16, indicates a signal or secretory sequence, which may be substituted by an alternative sequence that achieves the same or similar function, or the signal or secretory sequence may be deleted. The second underlined sequence for the amino acid sequences listed in Table 16, indicates a foldon sequence, which is a heterologous sequence that naturally trimerizes, to bring 3 HA stems together in a trimer. Such foldon sequence may be substituted by an alternative sequence, which achieves the same or similar function.

TABLE 17
Exemplary Influenza Constructs
Construct
Description	ORF	SEQ ID NO:
Influenza	METPAQLLFLLLLWLPDTTGGLFGAIAGFIENGWEGMIDGWYGFRH	413
H3HA6	QNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKDHQIEKEFSE
	DEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKL
	FEKTRRQLRENAEEMGNGCFKIYHKCDNACIESIRNGTYDHDVYRD
	EALNNRFQGSAGSAGDNSTATLCLGHHAVPNGTLVKTITDDQIEVT
	NATELVQSSGSAGSANDKPFQNTNKETTGATPKYVKQNTLKLATGMR
Influenza	METPAQLLELLLLWLPDTTGGLFGAIAGFIEGGWTGMIDGWYGYHH	414
H1HA6	QNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQDTAIGKEFNK
	DEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNL
	YEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSE
	ESKLNREKGSAGSAAADADTICIGYHANNSTDTVDTVLEKNVTVTH
	SVNLLEDSHGSANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRN
	IP
Influenza	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS	415
H1HA10-	ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGGAGSATQNAI
Foldon_ΔNgly1	NGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI
	WTYNAELLVLLENERTLDAHDSQGTGGGYIPEAPRDGQAYVRKDGE
	WVLLSTFL
Influenza	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV	416
eH1HA	THSVNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLP
	VRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFP
	KESSWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPNLKNSY
	VNKKGKEVLVLWGIHHPSNSKEQQNLYQNENAYVSVVTSNYNRRFT
	PEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFAL
	SRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGEC
	PKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWY
	GYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGK
	EFNKLEKRMENLNKKVDDGELDIWTYNAELLVLLENERTLDFHDSN
	VKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYP
	KYSEESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKD
	GEWVLLSTFL
Influenza	MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHS	417
eH1HA_Native	VNLLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRS
SS	WSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKES
	SWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPNLKNSYVNK
	KGKEVLVLWGIHHPSNSKEQQNLYQNENAYVSVVTSNYNRRFTPEI
	AERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAFALSRG
	FGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKY
	VRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYH
	HQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFTAVGKEFN
	KLEKRMENLNKKVDDGELDIWTYNAELLVLLENERTLDFHDSNVKN
	LYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYS
	EESKLNREKVDGVKLESMGIGSAGSAGYIPEAPRDGQAYVRKDGEW
	VLLSTEL
H1HA10TM-	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS	418
PR8 (H1A/	ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI
Puerto	NGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI
Rico/8/34 HA),	WTYNAELLVLLENERTLDAHDSQGTGGILAIYSTVASSLVLLVSLG
with TM	AISFWMCSNGSLQCRICI
domain, without
foldon (with
IgG Kappa
leader)
H1HA10-PR8-	METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVTHSVNLLEDSHGS	419
DS (H1A/	ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI
Puerto	NCITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI
Rico/8/34 HA),	WTYNAELLVLLENERTLDAHDS
ds bond,
without foldon
(with IgG
Kappa leader)
pH1HA10-	METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVTHSVNLLEDKHGS	420
Cal04-DS (H1A/	ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI
California/04/	DCITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI
2009 HA), ds	WTYNAELLVLLENERTLDAHDS
bond, without
foldon (with
IgG Kappa
leader)
Nucleoprotein	MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCTE	421
from H3N2 (no	LKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKKT
IgG Kappa	GGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDDATAGLTHMMI
leader)	WHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVK
	GIGTMVMELIRMIKRGINDRNFWRGENGRKTRSAYERMCNILKGKF
	QTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRGSVAHKSCL
	PACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENP
	AHKSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGVQIASN
	ENMDNMESSTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSV
	QRNLPFEKSTVMAAFTGNTEGRTSDMRAEIIRMMEGAKPEEVSFRG
	RGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN
HA10 version	METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVTGVIPLITTPTGS	422
for Influenza B	ANKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYGSAGSATQEAI
strain	NKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADT
	ISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAYVRKDGEW
	VLLSTFL
B/Yamagata/16/	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	423
1988 mHA	LTTTPTKSHFANLKGTKTRGKLCPNCLNCTDLDVALGRPMCMGTIP
	SAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSTHN
	VINAERAPGGPYRLGTSGSCPNVTSRNGFFATMAWAVPRDNKTATN
	PLTVEVPYICTKGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSA
	NGVTTHYVSQIGDFPNQTEDGGLPQSGRIVVDYMVQKPCKTGTIVY
	QRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPY
	YTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAG
	FLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNS
	LSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAV
	LLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQ
	TCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYS
	TAASSLAVTLMIAIFIVYMVSRDNVSCSICL
B/Yamagata/16/	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	424
1988 sHA	LTTTPTKSHFANLKGTKTRGKLCPNCLNCTDLDVALGRPMCMGTIP
	SAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYENIRLSTHN
	VINAERAPGGPYRLGTSGSCPNVTSRNGFFATMAWAVPRDNKTATN
	PLTVEVPYICTKGEDQITVWGFHSDDKTQMKNLYGDSNPQKFTSSA
	NGVTTHYVSQIGDFPNQTEDGGLPQSGRIVVDYMVQKPCKTGTIVY
	QRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKPY
	YTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAG
	FLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNS
	LSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAV
	LLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCNQ
	TCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHT
B/Victoria/02/1987	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	425
mHA	LTTTPTKSHFANLKGTKTRGKLCPKCLNCTDLDVALGRPKCTGTIP
	SAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHN
	VINAETAPGGPYKVGTSGSCPNVTNGNGFFATMAWAVPKNDNNKTA
	TNPLTVEVPYICTEGEDQITVWGFHSDNEAQMVKLYGDSKPQKFTS
	SANGVTTHYVSQIGGFPNQAEDGGLPQSGRIVVDYMVQKSGKTGTI
	TYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSK
	PYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKEKGFFGAI
	AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNL
	NSLSELEVKNLQRLSGAMDELHNKILELDEKVDDLRADTISSQIEL
	AVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKC
	NQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHTILLY
	YSTAASSLAVTLMIAIFIVYMVSRDNVSCSICl
B/Victoria/02/1987	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	426
sHA	LTTTPTKSHFANLKGTKTRGKLCPKCLNCTDLDVALGRPKCTGTIP
	SAKASILHEVKPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHN
	VINAETAPGGPYKVGTSGSCPNVTNGNGFFATMAWAVPKNDNNKTA
	TNPLTVEVPYICTEGEDQITVWGFHSDNEAQMVKLYGDSKPQKFTS
	SANGVTTHYVSQIGGFPNQAEDGGLPQSGRIVVDYMVQKSGKTGTI
	TYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSK
	PYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKEKGFFGAI
	AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNL
	NSLSELEVKNLQRLSGAMDELHNKILELDEKVDDLRADTISSQIEL
	AVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKC
	NQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDNHT
B/Brisbane/60/2008	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	427
mHA	LTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIP
	SARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHN
	VINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTA
	TNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTS
	SANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTI
	TYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSK
	PYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAI
	AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNL
	NSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIEL
	AVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKC
	NQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLY
	YSTAASSLAVTLMIAIFVVYMVSRDNVSCSICL
B/Brisbane/60/2008	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	428
sHA	LTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIP
	SARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHIRLSTHN
	VINAENAPGGPYKIGTSGSCPNITNGNGFFATMAWAVPKNDKNKTA
	TNPLTIEVPYICTEGEDQITVWGFHSDNETQMAKLYGDSKPQKFTS
	SANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTI
	TYQRGILLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSK
	PYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAI
	AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNL
	NSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIEL
	AVLLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKC
	NQTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHT
B/Phuket/3073/	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	429
2013 mHA	LTTTPTKSYFANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTP
	SAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQN
	VIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNAT
	NPLTVEVPYICTEGEDQITVWGFHSDNKTQMKSLYGDSNPQKFTSS
	ANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPCKTGTIV
	YQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKP
	YYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIA
	GFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQFAINKITKNLN
	SLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELA
	VLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCN
	QTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLYY
	STAASSLAVTLMLAIFIVYMVSRDNVSCSICL
B/Phuket/3073/	MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP	430
2013 sHA	LTTTPTKSYFANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGITP
	SAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQN
	VIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNAT
	NPLTVEVPYICTEGEDQITVWGFHSDNKTQMKSLYGDSNPQKFTSS
	ANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPCKTGTIV
	YQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEKYGGLNKSKP
	YYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIA
	GFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLN
	SLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELA
	VLLSNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKCN
	QTCLDRIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHT
Pandemic	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS	431
H1HA10 from	ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI
California 04	DEITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI
strain, without	WTYNAELLVLLENERTLDAHDSQGTGGDIIKLLNEQVNKEMQSSNL
foldon and with	YMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQ
ferritin fusion	LTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHA
for particle	TFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGI
formation	AKSRKS
Gen6 HA SS	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV	432
construct with	THSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVDCW
ferritin	YGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSGGSGTD
	LAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEF
	YHKCNNECMESVKNGTYDYPKYSEESKLNREKIDSGGDIIKLLNEQ
	VNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLII
	FLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIV
	DHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGL
	YLADQYVKGIAKSRKS
Gen6 HA SS	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV	433
construct with	THSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWIGMVDGW
foldon	YGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSGGSGTD
	LAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEF
	YHKCNNECMESVKNGTYDYPKYSEESKLNREKIDPGSGYIPEAPRD
	GQAYVRKDGEWVLLSTFL
#4900 construct	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVTV	434
without	THSVNLLENGGGGKYVCSAKLRMVTGLRNKPSKQSQGLFGAIAGFT
cleavage site	EGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNSVI
and tag	EKMNTQYTAIGCEYNKSERCMKQIEDKIEEIESKIWCYNAELLVLL
	ENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDEC
	MESVKNGTYDYPKYSEESKLNREKIDGVKLESMGVYQ
Pandemic	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS	435
H1HA10 from	ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI
California 04	DEITNKVNSVIEKMNTQDTAVGKEFNHDEKRIENLNKKVDDGFLDI
strain, without	WTDLAELLVLLENERTLDAHDS
foldon and with
Y94D/N95L
mutation for
trimerization
Pandemic	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDKHGS	436
H1HA10 from	ANTSLPFQNTHPTTNGKSPKYVKSTKLRLATGLRNGSAGSATQNAI
California 04	DEITNKVNSVIEKMNTQDTAVGCEFNHDEKCIENLNKKVDDGFLDI
strain, without	WTYNAELLVLLENERTLDAHDS
foldon and with
K68C/R76C
mutation for
trimerization
H1HA10 from	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS	437
A/Puerto	ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI
Rico/8/34	NGITNKVNTVIEKMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI
strain, without	WTDLAELLVLLENERTLDAHDS
foldon and with
Y94D/N95L
mutation for
trimerization
H1HA10 from	METPAQLLFLLLLWLPDTTGDTVDTVLEKNVTVTHSVNLLEDSHGS	438
A/Puerto	ANSSLPYQNTHPTTNGESPKYVRSAKLRMVTGLRNGSAGSATQNAI
Rico/8/34	NGITNKVNTVIEKMNIQDTATGCEFNKDEKCMENLNKKVDDGFLDI
strain, without	WTYNAELLVLLENERTLDAHDS
foldon and with
K68C/R76C
mutation for
trimerization
>sp|P06821|M2_I34A1	MSLLTEVETPIRNEWGCRCNGSSDPLAIAANIIGILHLILWILDRL	439
Matrix	FFKCIYRRFKYGLKGGPSTEGVPKSMREEYRKEQQSAVDADDGHFV
protein 2	SIELE
OS = Influenza A
virus (strain
A/Puerto
Rico/8/1934
H1N1) GN = M
PE = 3 SV = 1
A Matrix 1	MSLLTEVETYVLSIIPSGPLKAEIAQRLESVFAGKNTDLEALMEWL	440
(A/California/04/	KTRPILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNN
2009(H1N1),	MDRAVKLYKKLKREITFHGAKEVSLSYSTGALASCMGLIYNRMGTV
ACP44152)	TTEAAFGLVCATCEQIADSQHRSHRQMATTTNPLIRHENRMVLAST
	TAKAMEQMAGSSEQAAEAMEVANQTRQMVHAMRTIGTHPSSSAGLK
	DDLLENLQAYQKRMGVQMQRFK
BHA10-2	METPAQLLFLLLLWLPDTTG HVVKTATQGEVNVTGVIPLTTTPTGS	441
	ANKSKPYYTGEHAKATGNCPIWVKTPLKLANGTKYGSAGSATQEAI
	NKITKNLNSLSELEVKNLQRLSGASDETHNEILELDEKVDDLRADT
	ISSQIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAYVRKDGEW
	VLLSTFL
BHA10-2*	HVVKTATQGEVNVTGVIPLTTTPTGSANKSKPYYTGEHAKATGNCP	442
	IWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQR
	LSGASDETHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSE
	DEGTGGGYIPEAPRDGQAYVRKDGEWVLLSTFL
BHA10-3	METPAQLLFLLLLWLPDTTG HVVKTATQGEVNVTGVIPLTTTPTGS	443
	ANKSKPYYTGEHAKATGNCPIWVKTPLKLANGTKYGSAGSATQEAI
	NKITKNLNSLSELEVKNLQRLSCASDETHNCILELDEKVDDLRADT
	ISSLIELAVLLSNEGIINSEDE
BHA10-3 *	HVVKTATQGEVNVTGVIPLTTTPTGSANKSKPYYTGEHAKATGNCP	444
	IWVKTPLKLANGTKYGSAGSATQEAINKITKNLNSLSELEVKNLQR
	LSCASDETHNCILELDEKVDDLRADTISSLIELAVLLSNEGIINSE
	DE

5′UTR for each construct:

(SEQ ID NO: 445)
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGA
AATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC

3′UTR for each construct:

(SEQ ID NO: 446)
TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCT
CCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTT
GAATAAAGTCTGAGTGGGCGGC

The first underlined sequence for each of the amino acid sequences listed in Table 17, indicates a signal or secretory sequence, which may be substituted by an alternative sequence that achieves the same or similar function, or the signal or secretory sequence may be deleted.

TABLE 18
Influenza Nucleic Acids
Construct
Description	ORF	SEQ ID NO:
B/Yamagata/16/1988	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAACGCAG	447
mHA	ATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGT
	CAAAACAGCTACTCAAGGGGAAGTTAATGTGACTGGTGTGATACCA
	CTGACAACAACACCAACAAAATCTCATTTTGCAAATCTCAAAGGAA
	CAAAGACCAGAGGGAAACTATGCCCAAACTGTCTCAACTGCACAGA
	TCTGGATGTGGCCTTGGGCAGACCAATGTGTATGGGGACCATACCT
	TCGGCAAAAGCTTCAATACTCCACGAAGTCAGACCTGTTACATCCG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGACAGCTACC
	CAATCTTCTCAGAGGATATGAAAATATCAGATTATCAACCCATAAC
	GTTATCAACGCAGAAAGGGCACCAGGAGGACCCTACAGACTTGGAA
	CCTCAGGATCTTGCCCTAACGTTACCAGTAGAAACGGATTCTTCGC
	AACAATGGCTTGGGCTGTCCCAAGGGACAACAAAACAGCAACGAAT
	CCACTAACAGTAGAAGTACCATACATTTGCACAAAAGGAGAAGACC
	AAATTACTGTTTGGGGGTTCCATTCTGATGACAAAACCCAAATGAA
	AAACCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCTGCC
	AATGGAGTAACCACACATTATGTTTCTCAGATTGGTGACTTCCCAA
	ATCAAACAGAAGACGGAGGGCTACCACAAAGCGGCAGAATTGTTGT
	TGATTACATGGTGCAAAAACCTGGGAAAACAGGAACAATTGTCTAT
	CAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCAAGTGGCA
	GGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGTGAAGCAGA
	TTGCCTTCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTAC
	TACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGG
	TGAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACCTCC
	TGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGT
	TTCTTAGAGGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGAT
	ACACATCTCATGGAGCACATGGAGTGGCAGTGGCAGCAGACCTTAA
	GAGCACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCT
	TTGAGTGAGCTAGAAGTAAAGAATCTTCAAAGACTAAGTGGTGCCA
	TGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGTGGA
	TGATCTCAGAGCTGACACAATAAGCTCGCAAATAGAGCTTGCAGTC
	TTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTAT
	TGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGCTGT
	AGACATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAG
	ACCTGCTTAGACAGGATAGCTGCTGGCACCTTTAATGCAGGAGAAT
	TTTCTCTTCCCACTTTTGATTCACTGAATATTACTGCTGCATCTTT
	AAATGATGATGGATTGGATAATCATACTATACTGCTCTACTACTCA
	ACTGCTGCTTCTAGTTTGGCCGTAACATTGATGATAGCTATTTTTA
	TTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCATCTGTCT
	A
B/Yamagata/16/1988	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAACGCAG	448
sHA	ATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGT
	CAAAACAGCTACTCAAGGGGAAGTTAATGTGACTGGTGTGATACCA
	CTGACAACAACACCAACAAAATCTCATTTTGCAAATCTCAAAGGAA
	CAAAGACCAGAGGGAAACTATGCCCAAACTGTCTCAACTGCACAGA
	TCTGGATGTGGCCTTGGGCAGACCAATGTGTATGGGGACCATACCT
	TCGGCAAAAGCTTCAATACTCCACGAAGTCAGACCTGTTACATCCG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGACAGCTACC
	CAATCTTCTCAGAGGATATGAAAATATCAGATTATCAACCCATAAC
	GTTATCAACGCAGAAAGGGCACCAGGAGGACCCTACAGACTTGGAA
	CCTCAGGATCTTGCCCTAACGTTACCAGTAGAAACGGATTCTTCGC
	AACAATGGCTTGGGCTGTCCCAAGGGACAACAAAACAGCAACGAAT
	CCACTAACAGTAGAAGTACCATACATTTGCACAAAAGGAGAAGACC
	AAATTACTGTTTGGGGGTTCCATTCTGATGACAAAACCCAAATGAA
	AAACCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCTGCC
	AATGGAGTAACCACACATTATGTTTCTCAGATTGGTGACTTCCCAA
	ATCAAACAGAAGACGGAGGGCTACCACAAAGCGGCAGAATTGTTGT
	TGATTACATGGTGCAAAAACCTGGGAAAACAGGAACAATTGTCTAT
	CAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCAAGTGGCA
	GGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGTGAAGCAGA
	TTGCCTTCACGAAAAATACGGTGGATTAAACAAAAGCAAGCCTTAC
	TACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATATGGG
	TGAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACCTCC
	TGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATTGCTGGT
	TTCTTAGAGGGAGGATGGGAAGGAATGATTGCAGGTTGGCACGGAT
	ACACATCTCATGGAGCACATGGAGTGGCAGTGGCAGCAGACCTTAA
	GAGCACGCAAGAAGCCATAAACAAGATAACAAAAAATCTCAATTCT
	TTGAGTGAGCTAGAAGTAAAGAATCTTCAAAGACTAAGTGGTGCCA
	TGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGTGGA
	TGATCTCAGAGCTGACACAATAAGCTCGCAAATAGAGCTTGCAGTC
	TTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGCATCTAT
	TGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGCTGT
	AGACATAGGGAATGGATGCTTCGAAACCAAACACAAGTGCAACCAG
	ACCTGCTTAGACAGGATAGCTGCTGGCACCTTTAATGCAGGAGAAT
	TTTCTCTTCCCACTTTTGATTCACTGAATATTACTGCTGCATCTTT
	AAATGATGATGGATTGGATAATCATACT
B/Victoria/02/1987	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG	449
mHA	ATCGAATCTGCACTGGGATAACATCGTCAAACTCACCCCATGTGGT
	CAAAACTGCTACTCAAGGGGAAGTCAATGTGACTGGTGTGATACCA
	CTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAA
	CAAAAACCAGAGGGAAACTATGCCCAAAGTGTCTCAACTGCACAGA
	TCTGGACGTGGCCTTGGGCAGACCAAAGTGCACGGGGACCATACCT
	TCGGCAAAAGCTTCAATACTCCACGAAGTCAAACCTGTTACATCTG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTACC
	CAATCTTCTCAGAGGATACGAACATATCAGGTTATCAACCCATAAC
	GTTATCAACGCAGAAACGGCACCAGGAGGACCCTACAAAGTTGGAA
	CCTCAGGGTCTTGCCCTAACGTTACCAATGGAAACGGATTCTTCGC
	AACAATGGCTTGGGCTGTCCCAAAAAACGACAACAACAAAACAGCA
	ACAAATCCATTAACAGTAGAAGTACCATACATTTGTACAGAAGGAG
	AAGACCAAATTACTGTTTGGGGGTTCCACTCTGATAACGAAGCCCA
	AATGGTAAAACTCTATGGAGACTCAAAGCCTCAGAAGTTCACCTCA
	TCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCT
	TCCCAAATCAAGCAGAAGACGGAGGGCTACCACAAAGCGGTAGAAT
	TGTTGTTGATTACATGGTGCAAAAATCTGGAAAAACAGGAACAATT
	ACCTACCAAAGAGGTATTTTATTGCCTCAAAAAGTGTGGTGCGCAA
	GTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGCGA
	AGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAG
	CCTTACTACACAGGGGAACATGCAAAAGCCATAGGAAATTGCCCAA
	TATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAG
	ACCTCCTGCAAAACTATTAAAGGAAAAGGGTTTCTTCGGAGCTATT
	GCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGC
	ACGGATACACATCCCATGGAGCACATGGAGTAGCAGTGGCAGCAGA
	CCTTAAGAGTACGCAAGAAGCCATAAACAAGATAACAAAAAATCTC
	AATTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCG
	GTGCCATGGATGAACTCCACAACAAAATACTCGAACTGGATGAGAA
	AGTGGATGATCTCAGAGCTGATACAATAAGCTCGCAAATAGAGCTC
	GCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGC
	ATCTCTTGGCGCTTGAAAGAAAACTGAAGAAAATGCTGGGCCCCTC
	TGCTGTAGAGATAGGGAATGGATGCTTCGAAACCAAACACAAGTGC
	AACCAGACCTGCCTCGACAGAATAGCTGCTGGCACCTTTAATGCAG
	GAGAATTTTCTCTCCCCACCTTTGATTCACTAAATATTACTGCTGC
	ATCTTTAAATGATGATGGATTGGATAATCATACTATACTGCTTTAC
	TACTCAACTGCTGCTTCCAGTTTGGCTGTAACATTGATGATAGCTA
	TCTTTATTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCAT
	CTGTCTA
B/Victoria/02/1987	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG	450
sHA	ATCGAATCTGCACTGGGATAACATCGTCAAACTCACCCCATGTGGT
	CAAAACTGCTACTCAAGGGGAAGTCAATGTGACTGGTGTGATACCA
	CTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAA
	CAAAAACCAGAGGGAAACTATGCCCAAAGTGTCTCAACTGCACAGA
	TCTGGACGTGGCCTTGGGCAGACCAAAGTGCACGGGGACCATACCT
	TCGGCAAAAGCTTCAATACTCCACGAAGTCAAACCTGTTACATCTG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTACC
	CAATCTTCTCAGAGGATACGAACATATCAGGTTATCAACCCATAAC
	GTTATCAACGCAGAAACGGCACCAGGAGGACCCTACAAAGTTGGAA
	CCTCAGGGTCTTGCCCTAACGTTACCAATGGAAACGGATTCTTCGC
	AACAATGGCTTGGGCTGTCCCAAAAAACGACAACAACAAAACAGCA
	ACAAATCCATTAACAGTAGAAGTACCATACATTTGTACAGAAGGAG
	AAGACCAAATTACTGTTTGGGGGTTCCACTCTGATAACGAAGCCCA
	AATGGTAAAACTCTATGGAGACTCAAAGCCTCAGAAGTTCACCTCA
	TCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCT
	TCCCAAATCAAGCAGAAGACGGAGGGCTACCACAAAGCGGTAGAAT
	TGTTGTTGATTACATGGTGCAAAAATCTGGAAAAACAGGAACAATT
	ACCTACCAAAGAGGTATTTTATTGCCTCAAAAAGTGTGGTGCGCAA
	GTGGCAGGAGCAAGGTAATAAAAGGGTCCTTGCCTTTAATTGGCGA
	AGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAG
	CCTTACTACACAGGGGAACATGCAAAAGCCATAGGAAATTGCCCAA
	TATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAG
	ACCTCCTGCAAAACTATTAAAGGAAAAGGGTTTCTTCGGAGCTATT
	GCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGC
	ACGGATACACATCCCATGGAGCACATGGAGTAGCAGTGGCAGCAGA
	CCTTAAGAGTACGCAAGAAGCCATAAACAAGATAACAAAAAATCTC
	AATTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCG
	GTGCCATGGATGAACTCCACAACAAAATACTCGAACTGGATGAGAA
	AGTGGATGATCTCAGAGCTGATACAATAAGCTCGCAAATAGAGCTC
	GCAGTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGATGAGC
	ATCTCTTGGCGCTTGAAAGAAAACTGAAGAAAATGCTGGGCCCCTC
	TGCTGTAGAGATAGGGAATGGATGCTTCGAAACCAAACACAAGTGC
	AACCAGACCTGCCTCGACAGAATAGCTGCTGGCACCTTTAATGCAG
	GAGAATTTTCTCTCCCCACCTTTGATTCACTAAATATTACTGCTGC
	ATCTTTAAATGATGATGGATTGGATAATCATACT
B/Brisbane/60/2008	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG	451
mHA	ATCGAATCTGCACTGGGATAACATCGTCAAACTCACCACATGTCGT
	CAAAACTGCTACTCAAGGGGAGGTCAATGTGACTGGTGTAATACCA
	CTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAA
	CAGAAACCAGGGGGAAACTATGCCCAAAATGCCTCAACTGCACAGA
	TCTGGACGTAGCCTTGGGCAGACCAAAATGCACGGGGAAAATACCC
	TCGGCAAGAGTTTCAATACTCCATGAAGTCAGACCTGTTACATCTG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTGCC
	TAACCTTCTCCGAGGATACGAACATATCAGGTTATCAACCCATAAC
	GTTATCAATGCAGAAAATGCACCAGGAGGACCCTACAAAATTGGAA
	CCTCAGGGTCTTGCCCTAACATTACCAATGGAAACGGATTTTTCGC
	AACAATGGCTTGGGCCGTCCCAAAAAACGACAAAAACAAAACAGCA
	ACAAATCCATTAACAATAGAAGTACCATACATTTGTACAGAAGGAG
	AAGACCAAATTACCGTTTGGGGGTTCCACTCTGACGACGAGACCCA
	AATGGCAAAGCTCTATGGGGACTCAAAGCCCCAGAAGTTCACCTCA
	TCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCT
	TCCCAAATCAAACAGAAGACGGAGGACTACCACAAAGTGGTAGAAT
	TGTTGTTGATTACATGGTGCAAAAATCTGGGAAAACAGGAACAATT
	ACCTATCAAAGGGGTATTTTATTGCCTCAAAAGGTGTGGTGCGCAA
	GTGGCAGGAGCAAGGTAATAAAAGGATCCTTGCCTTTAATTGGAGA
	AGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAG
	CCTTACTACACAGGGGAACATGCAAAGGCCATAGGAAATTGCCCAA
	TATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAG
	ACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATT
	GCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGC
	ACGGATACACATCCCATGGGGCACATGGAGTAGCGGTGGCAGCAGA
	CCTTAAGAGCACTCAAGAGGCCATAAACAAGATAACAAAAAATCTC
	AACTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCG
	GTGCCATGGATGAACTCCACAACGAAATACTAGAACTAGATGAGAA
	AGTGGATGATCTCAGAGCTGATACAATAAGCTCACAAATAGAACTC
	GCAGTCCTGCTTTCCAATGAAGGAATAATAAACAGTGAAGATGAAC
	ATCTCTTGGCGCTTGAAAGAAAGCTGAAGAAAATGCTGGGCCCCTC
	TGCTGTAGAGATAGGGAATGGATGCTTTGAAACCAAACACAAGTGC
	AACCAGACCTGTCTCGACAGAATAGCTGCTGGTACCTTTGATGCAG
	GAGAATTTTCTCTCCCCACCTTTGATTCACTGAATATTACTGCTGC
	ATCTTTAAATGACGATGGATTGGATAATCATACTATACTGCTTTAC
	TACTCAACTGCTGCCTCCAGTTTGGCTGTAACACTGATGATAGCTA
	TCTTTGTTGTTTATATGGTCTCCAGAGACAATGTTTCTTGCTCCAT
	CTGTCTA
B/Brisbane/60/2008	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG	452
sHA	ATCGAATCTGCACTGGGATAACATCGTCAAACTCACCACATGTCGT
	CAAAACTGCTACTCAAGGGGAGGTCAATGTGACTGGTGTAATACCA
	CTGACAACAACACCCACCAAATCTCATTTTGCAAATCTCAAAGGAA
	CAGAAACCAGGGGGAAACTATGCCCAAAATGCCTCAACTGCACAGA
	TCTGGACGTAGCCTTGGGCAGACCAAAATGCACGGGGAAAATACCC
	TCGGCAAGAGTTTCAATACTCCATGAAGTCAGACCTGTTACATCTG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATTAGACAGCTGCC
	TAACCTTCTCCGAGGATACGAACATATCAGGTTATCAACCCATAAC
	GTTATCAATGCAGAAAATGCACCAGGAGGACCCTACAAAATTGGAA
	CCTCAGGGTCTTGCCCTAACATTACCAATGGAAACGGATTTTTCGC
	AACAATGGCTTGGGCCGTCCCAAAAAACGACAAAAACAAAACAGCA
	ACAAATCCATTAACAATAGAAGTACCATACATTTGTACAGAAGGAG
	AAGACCAAATTACCGTTTGGGGGTTCCACTCTGACGACGAGACCCA
	AATGGCAAAGCTCTATGGGGACTCAAAGCCCCAGAAGTTCACCTCA
	TCTGCCAACGGAGTGACCACACATTACGTTTCACAGATTGGTGGCT
	TCCCAAATCAAACAGAAGACGGAGGACTACCACAAAGTGGTAGAAT
	TGTTGTTGATTACATGGTGCAAAAATCTGGGAAAACAGGAACAATT
	ACCTATCAAAGGGGTATTTTATTGCCTCAAAAGGTGTGGTGCGCAA
	GTGGCAGGAGCAAGGTAATAAAAGGATCCTTGCCTTTAATTGGAGA
	AGCAGATTGCCTCCACGAAAAATACGGTGGATTAAACAAAAGCAAG
	CCTTACTACACAGGGGAACATGCAAAGGCCATAGGAAATTGCCCAA
	TATGGGTGAAAACACCCTTGAAGCTGGCCAATGGAACCAAATATAG
	ACCTCCTGCAAAACTATTAAAGGAAAGGGGTTTCTTCGGAGCTATT
	GCTGGTTTCTTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGC
	ACGGATACACATCCCATGGGGCACATGGAGTAGCGGTGGCAGCAGA
	CCTTAAGAGCACTCAAGAGGCCATAAACAAGATAACAAAAAATCTC
	AACTCTTTGAGTGAGCTGGAAGTAAAGAATCTTCAAAGACTAAGCG
	GTGCCATGGATGAACTCCACAACGAAATACTAGAACTAGATGAGAA
	AGTGGATGATCTCAGAGCTGATACAATAAGCTCACAAATAGAACTC
	GCAGTCCTGCTTTCCAATGAAGGAATAATAAACAGTGAAGATGAAC
	ATCTCTTGGCGCTTGAAAGAAAGCTGAAGAAAATGCTGGGCCCCTC
	TGCTGTAGAGATAGGGAATGGATGCTTTGAAACCAAACACAAGTGC
	AACCAGACCTGTCTCGACAGAATAGCTGCTGGTACCTTTGATGCAG
	GAGAATTTTCTCTCCCCACCTTTGATTCACTGAATATTACTGCTGC
	ATCTTTAAATGACGATGGATTGGATAATCATACT
B/Phuket/3073/2013	ATGAAGGCAATAATTGTACTACTCATGGTAGTAACATCCAATGCAG	453
mHA	ATCGAATCTGCACTGGGATAACATCTTCAAACTCACCTCATGTGGT
	CAAAACAGCTACTCAAGGGGAGGTCAATGTGACTGGCGTGATACCA
	CTGACAACAACACCAACAAAATCTTATTTTGCAAATCTCAAAGGAA
	CAAGGACCAGAGGGAAACTATGCCCGGACTGTCTCAACTGTACAGA
	TCTGGATGTGGCCTTGGGCAGGCCAATGTGTGTGGGGACCACACCT
	TCTGCTAAAGCTTCAATACTCCACGAGGTCAGACCTGTTACATCCG
	GGTGCTTTCCTATAATGCACGACAGAACAAAAATCAGGCAACTACC
	CAATCTTCTCAGAGGATATGAAAAGATCAGGTTATCAACCCAAAAC
	GTTATCGATGCAGAAAAAGCACCAGGAGGACCCTACAGACTTGGAA
	CCTCAGGATCTTGCCCTAACGCTACCAGTAAAATCGGATTTTTCGC
	AACAATGGCTTGGGCTGTCCCAAAGGACAACTACAAAAATGCAACG
	AACCCACTAACAGTAGAAGTACCATACATTTGTACAGAAGGGGAAG
	ACCAAATTACTGTTTGGGGGTTCCATTCAGACAACAAAACCCAAAT
	GAAGAGCCTCTATGGAGACTCAAATCCTCAAAAGTTCACCTCATCT
	GCTAATGGAGTAACCACACATTATGTTTCTCAGATTGGCGACTTCC
	CAGATCAAACAGAAGACGGAGGACTACCACAAAGCGGCAGAATTGT
	TGTTGATTACATGATGCAAAAACCTGGGAAAACAGGAACAATTGTC
	TATCAAAGAGGTGTTTTGTTGCCTCAAAAGGTGTGGTGCGCGAGTG
	GCAGGAGCAAAGTAATAAAAGGGTCATTGCCTTTAATTGGTGAAGC
	AGATTGCCTTCATGAAAAATACGGTGGATTAAACAAAAGCAAGCCT
	TACTACACAGGAGAACATGCAAAAGCCATAGGAAATTGCCCAATAT
	GGGTAAAAACACCTTTGAAGCTTGCCAATGGAACCAAATATAGACC
	TCCTGCAAAACTATTGAAGGAAAGGGGTTTCTTCGGAGCTATTGCT
	GGTTTCCTAGAAGGAGGATGGGAAGGAATGATTGCAGGTTGGCACG
	GATACACATCTCACGGAGCACATGGAGTGGCAGTGGCGGCAGACCT
	TAAGAGTACACAAGAAGCTATAAATAAGATAACAAAAAATCTCAAT
	TCTTTGAGTGAGCTAGAAGTAAAGAACCTTCAAAGACTAAGTGGTG
	CCATGGATGAACTCCACAACGAAATACTCGAGCTGGATGAGAAAGT
	GGATGATCTCAGAGCTGACACTATAAGCTCACAAATAGAACTTGCA
	GTCTTGCTTTCCAACGAAGGAATAATAAACAGTGAAGACGAGCATC
	TATTGGCACTTGAGAGAAAACTAAAGAAAATGCTGGGTCCCTCTGC
	TGTAGACATAGGAAACGGATGCTTCGAAACCAAACACAAATGCAAC
	CAGACCTGCTTAGACAGGATAGCTGCTGGCACCTTTGATGCAGGAG
	AATTTTCTCTCCCCACTTTTGATTCATTGAACATTACTGCTGCATC
	TTTAAATGATGATGGATTGGATAACCATACTATACTGCTCTATTAC
	TCAACTGCTGCTTCTAGTTTGGCTGTAACATTAATGCTAGCTATTT
	TTATTGTTTATATGGTCTCCAGAGACAACGTTTCATGCTCCATCTG
	TCTA

5′UTR for each construct:

(SEQ ID NO: 445)
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGA
AATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC

3′ UTR for each construct:

(SEQ ID NO: 446)
TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCT
CCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTT
GAATAAAGTCTGAGTGGGCGGC

TABLE 19
Examples of Wild Type Hemagglutinin Antigens
Protein/
Strain	Nucleic Acid Sequence	SEQ ID NO:
H1	AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCAAACCTACTG	454
	GTCCTGTTATGTGCACTTGCAGCTGCAGATGCAGACACAATATGTATAGG
	CTACCATGCGAACAATTCAACCGACACTGTTGACACAGTGCTCGAGAAGA
	ATGTGACAGTGACACACTCTGTTAACCTGCTCGAAGACAGCCACAACGGA
	AAACTATGTAGATTAAAAGGAATAGCCCCACTACAATTGGGGAAATGTAA
	CATCGCCGGATGGCTCTTGGGAAACCCAGAATGCGACCCACTGCTTCCAG
	TGAGATCATGGTCCTACATTGTAGAAACACCAAACTCTGAGAATGGAATA
	TGTTATCCAGGAGATTTCATCGACTATGAGGAGCTGAGGGAGCAATTGAG
	CTCAGTGTCATCATTCGAAAGATTCGAAATATTTCCCAAAGAAAGCTCAT
	GGCCCAACCACAACACAACCAAAGGAGTAACGGCAGCATGCTCCCATGCG
	GGGAAAAGCAGTTTTTACAGAAATTTGCTATGGCTGACGGAGAAGGAGGG
	CTCATACCCAAAGCTGAAAAATTCTTATGTGAACAAGAAAGGGAAAGAAG
	TCCTTGTACTGTGGGGTATTCATCACCCGTCTAACAGTAAGGATCAACAG
	AATATCTATCAGAATGAAAATGCTTATGTCTCTGTAGTGACTTCAAATTA
	TAACAGGAGATTTACCCCGGAAATAGCAGAAAGACCCAAAGTAAGAGATC
	AAGCTGGGAGGATGAACTATTACTGGACCTTGCTAAAACCCGGAGACACA
	ATAATATTTGAGGCAAATGGAAATCTAATAGCACCAAGGT
	ATGCTTTCGCACTGAGTAGAGGCTTTGGGTCCGGCATCATCACCTCAAAC
	GCATCAATGCATGAGTGTAACACGAAGTGTCAAACACCCCTGGGAGCTAT
	AAACAGCAGTCTCCCTTTCCAGAATATACACCCAGTCACAATAGGAGAGT
	GCCCAAAATACGTCAGGAGTGCCAAATTGAGGATGGTTACAGGACTAAGG
	AACATTCCGTCCATTCAATCCAGAGGTCTATTTGGAGCCATTGCCGGTTT
	TATTGAAGGGGGATGGACTGGAATGATAGATGGATGGTACGGTTATCATC
	ATCAGAATGAACAGGGATCAGGCTATGCAGCGGATCAAAAAAGCACACAA
	AATGCCATTAACGGGATTACAAACAAGGTGAACTCTGTTATCGAGAAAAT
	GAACATTCAATTCACAGCTGTGGGTAAAGAATTCAACAAATTAGAAAAAA
	GGATGGAAAATTTAAATAAAAAAGTTGATGATGGATTTCTGGACATTTGG
	ACATATAATGCAGAATTGTTAGTTCTACTGGAAAATGAAAGGACTCTGGA
	TTTCCATGACTCAAATGTGAAGAATCTGTATGAGAAAGTAAAAAGCCAAT
	TAAAGAATAATGCCAAAGAAATCGGAAATGGATGTTTTGAGTTCTACCAC
	AAGTGTGACAATGAATGCATGGAAAGTGTAAGAAATGGGACTTATGATTA
	TCCCAAATATTCAGAAGAGTCAAAGTTGAACAGGGAAAAGGTAGATGGAG
	TGAAATTGGAATCAATGGGGATCTATCAGATTCTGGCGATCTACTCAACT
	GTCGCCAGTTCACTGGTGCTTTTGGTCTCCCTGGGGGCAATCAGTTTCTG
	GATGTGTTCTAATGGATCTTTGCAGTGCAGAATATGCATCTGAGATTAGA
	ATTTCAGAAATATGAGGAAAAACACCCTTGTTTCTACT
H7	AGCGAAAGCAGGGGATACAAAATGAACACTCAAATCCTGGTATTCGCTCT	455
	GATTGCGATCATTCCAACAAATGCAGACAAAATCTGCCTCGGACATCATG
	CCGTGTCAAACGGAACCAAAGTAAACACATTAACTGAAAGAGGAGTGGAA
	GTCGTCAATGCAACTGAAACAGTGGAACGAACAAACATCCCCAGGATCTG
	CTCAAAAGGGAAAAGGACAGTTGACCTCGGTCAATGTGGACTCCTGGGGA
	CAATCACTGGACCACCTCAATGTGACCAATTCCTAGAATTTTCAGCCGAT
	TTAATTATTGAGAGGCGAGAAGGAAGTGATGTCTGTTATCCTGGGAAATT
	CGTGAATGAAGAAGCTCTGAGGCAAATTCTCAGAGAATCAGGCGGAATTG
	ACAAGGAAGCAATGGGATTCACATACAGTGGAATAAGAACTAATGGAGCA
	ACCAGTGCATGTAGGAGATCAGGATCTTCATTCTATGCAGAAATGAAATG
	GCTCCTGTCAAACACAGATGATGCTGCATTCCCGCAGATGACTAAGTCAT
	ATAAAAATACAAGAAAAAGCCCAGCTCTAATAGTATGGGGGATCCATCAT
	TCCGTATCAACTGCAGAGCAAACCAAGCTATATGGGAGTGGAAACAAACT
	GGTGACAGTTGGGAGTTCTAATTATCAACAATCTTTTGTACCGAGTCCAG
	GAGCGAGACCACAAGTTAATGGTCTATCTGGAAGAATTGACTTTCATTGG
	CTAATGCTAAATCCCAATGATACAGTCACTTTCAGTTTCAATGGGGCTTT
	CATAGCTCCAGACCGTGCAAGCTTCCTGAGAGGAAAATCTATGGGAATCC
	AGAGTGGAGTACAGGTTGATGCCAATTGTGAAGGGGACTGCTATCATAGT
	GGAGGGACAATAATAAGTAACTTGCCATTTCAGAACATAGATAGCAGGGC
	AGTTGGAAAATGTCCGAGATATGTTAAGCAAAGGAGTCTGCTGCTAGCAA
	CAGGGATGAAGAATGTTCCTGAGATTCCAAAGGGAAGAGGCCTATTTGGT
	GCTATAGCGGGTTTCATTGAAAATGGATGGGAAGGCCTAATTGATGGTTG
	GTATGGTTTCAGACACCAGAATGCACAGGGAGAGGGAACTGCTGCAGATT
	ACAAAAGCACTCAATCGGCAATTGATCAAATAACAGGAAAATTAAACCGG
	CTTATAGAAAAAACCAACCAACAATTTGAGTTGATAGACAATGAATTCAA
	TGAGGTAGAGAAGCAAATCGGTAATGTGATAAATTGGACCAGAGATTCTA
	TAACAGAAGTGTGGTCATACAATGCTGAACTCTTGGTAGCAATGGAGAAC
	CAGCATACAATTGATCTGGCTGATTCAGAAATGGACAAACTGTACGAACG
	AGTGAAAAGACAGCTGAGAGAGAATGCTGAAGAAGATGGCACTGGTTGCT
	TTGAAATATTTCACAAGTGTGATGATGACTGTATGGCCAGTATTAGAAAT
	AACACCTATGATCACAGCAAATACAGGGAAGAGGCAATGCAAAATAGAAT
	ACAGATTGACCCAGTCAAACTAAGCAGCGGCTACAAAGATGTGATACTTT
	GGTTTAGCTTCGGGGCATCATGTTTCATACTTCTAGCCATTGTAATGGGC
	CTTGTCTTCATATGTGTAAAGAATGGAAACATGCGGTGCACTATTTGTAT
	ATAAGTTTGGAAAAAAACACCCTTGTTTCTAC
H10	ATGTACAAAATAGTAGTGATAATCGCGCTCCTTGGAGCTGTGAAAGGTCT	456
	TGATAAAATCTGTCTAGGACATCATGCAGTGGCTAATGGGACCATCGTAA
	AGACTCTCACAAACGAACAGGAAGAGGTAACCAACGCTACTGAAACAGTG
	GAGAGTACAGGCATAAACAGATTATGTATGAAAGGAAGAAAACATAAAGA
	CCTGGGCAACTGCCATCCAATAGGGATGCTAATAGGGACTCCAGCTTGTG
	ATCTGCACCTTACAGGGATGTGGGACACTCTCATTGAACGAGAGAATGCT
	ATTGCTTACTGCTACCCTGGAGCTACTGTAAATGTAGAAGCACTAAGGCA
	GAAGATAATGGAGAGTGGAGGGATCAACAAGATAAGCACTGGCTTCACTT
	ATGGATCTTCCATAAACTCGGCCGGGACCACTAGAGCGTGCATGAGGAAT
	GGAGGGAATAGCTTTTATGCAGAGCTTAAGTGGCTGGTATCAAAGAGCAA
	AGGACAAAACTTCCCTCAGACCACGAACACTTACAGAAATACAGACACGG
	CTGAACACCTCATAATGTGGGGAATTCATCACCCTTCTAGCACTCAAGAG
	AAGAATGATCTATATGGAACACAATCACTGTCCATATCAGTCGGGAGTTC
	CACTTACCGGAACAATTTTGTTCCGGTTGTTGGAGCAAGACCTCAGGTCA
	ATGGACAAAGTGGCAGAATTGATTTTCACTGGACACTAGTACAGCCAGGT
	GACAACATCACCTTCTCACACAATGGGGGCCTGATAGCACCGAGCCGAGT
	TAGCAAATTAATTGGGAGGGGATTGGGAATCCAATCAGACGCACCAATAG
	ACAATAATTGTGAGTCCAAATGTTTTTGGAGAGGGGGTTCTATAAATACA
	AGGCTTCCCTTTCAAAATTTGTCACCAAGAACAGTGGGTCAGTGTCCTAA
	ATATGTGAACAGAAGAAGCTTGATGCTTGCAACAGGAATGAGAAACGTAC
	CAGAACTAATACAAGGGAGAGGTCTATTTGGTGCAATAGCAGGGTTTTTA
	GAGAATGGGTGGGAAGGAATGGTAGATGGCTGGTATGGTTTCAGACATCA
	AAATGCTCAGGGCACAGGCCAGGCCGCTGATTACAAGAGTACTCAGGCAG
	CTATTGATCAAATCACTGGGAAACTGAATAGACTTGTTGAAAAAACCAAT
	ACTGAGTTCGAGTCAATAGAATCTGAGTTCAGTGAGATCGAACACCAAAT
	CGGTAACGTCATCAATTGGACTAAGGATTCAATAACCGACATTTGGACTT
	ATCAGGCTGAGCTGTTGGTGGCAATGGAGAACCAGCATACAATCGACATG
	GCTGACTCAGAGATGTTGAATCTATATGAAAGAGTGAGGAAACAACTAAG
	GCAGAATGCAGAAGAAGATGGGAAAGGATGTTTTGAGATATATCATGCTT
	GTGATGATTCATGCATGGAGAGCATAAGAAACAACACCTATGACCATTCA
	CAGTACAGAGAGGAAGCTCTTTTGAACAGATTGAATATCAACCCAGTGAC
	ACTCTCTTCTGGATATAAAGACATCATTCTCTGGTTTAGCTTCGGGGCAT
	CATGTTTTGTTCTTCTAGCCGTTGTCATGGGTCTTTTCTTTTTCTGTCTG
	AAGAATGGAAACATGCGATGCACAATCTGTATTTAG

TABLE 20
Additional Flu Constructs
		SEQ ID
Name	Sequence	NO:
MRK_LZ_NP-	ATGGCCAGCCAGGGCACCAAGAGAAGCTACGAGCAGATGGAG	457
H3N2	ACCGACGGCGAGAGACAGAACGCCACCGAGATCAGAGCCAGC
SQ-031687	GTGGGCAAGATGATCGACGGCATCGGCAGATTCTACATCCAGA
CX-003145	TGTGCACCGAGCTCAAGCTGAGCGACTACGAGGGCAGACTGAT
	CCAGAACAGCCTGACCATCGAAAGAATGGTTCTGAGCGCCTTC
	GACGAGAGAAGAAACAGATACCTGGAGGAGCACCCCAGCGCC
	GGCAAGGACCCCAAGAAGACCGGCGGCCCCATCTACAAGAGA
	GTGGACGGCAGATGGATGAGAGAGCTGGTGCTGTACGACAAGG
	AGGAGATCAGAAGAATCTGGAGACAGGCCAACAACGGCGACG
	ACGCCACCGCCGGCCTGACCCACATGATGATCTGGCACAGCAA
	CCTGAACGACACCACCTACCAGAGAACCAGAGCCCTGGTGAGA
	ACCGGCATGGACCCCAGAATGTGCAGCTTAATGCAGGGCAGCA
	CCCTGCCCAGAAGATCCGGCGCCGCTGGTGCCGCCGTCAAGGG
	CATCGGCACCATGGTGATGGAGCTGATCCGCATGATCAAGCGC
	GGCATCAACGACAGAAACTTCTGGAGAGGCGAAAACGGCAGA
	AAGACCAGAAGCGCCTACGAGAGAATGTGCAACATCCTGAAGG
	GCAAGTTCCAGACCGCCGCCCAAAGAGCCATGATGGACCAGGT
	GAGAGAGAGCAGAAACCCCGGCAACGCCGAGATCGAAGACCT
	GATCTTCAGCGCCAGATCGGCCCTGATCCTGAGAGGCAGCGTG
	GCCCACAAGAGCTGCCTGCCCGCCTGCGTGTATGGCCCCGCCGT
	GAGCAGCGGCTACAACTTCGAGAAGGAGGGCTACAGCCTGGTG
	GGCATCGACCCCTTCAAGCTGCTGCAGAACTCTCAGGTGTATAG
	CCTGATCAGACCCAACGAGAACCCCGCCCACAAGAGCCAGCTG
	GTGTGGATGGCCTGCCACAGCGCCGCCTTCGAGGACCTGAGAC
	TGCTGAGCTTCATCAGAGGTACCAAGGTGTCCCCCAGAGGCAA
	GCTGAGCACCAGAGGTGTGCAGATCGCCAGCAATGAGAACATG
	GACAATATGGAGAGCAGCACCCTGGAGCTAAGAAGCAGGTACT
	GGGCCATCCGGACCAGAAGCGGCGGCAATACCAACCAGCAGA
	GAGCCAGCGCCGGCCAGATCAGCGTGCAGCCCACCTTCAGCGT
	GCAGAGAAACCTGCCCTTTGAGAAGAGCACCGTGATGGCCGCC
	TTCACCGGCAACACCGAGGGCAGAACCAGCGACATGAGAGCCG
	AGATCATCAGAATGATGGAGGGCGCCAAGCCCGAGGAGGTGA
	GCTTTAGAGGCAGAGGCGTGTTCGAGCTGAGCGACGAGAAGGC
	CACCAACCCAATTGTGCCCAGCTTCGACATGTCGAACGAGGGC
	AGCTACTTCTTCGGCGACAACGCCGAGGAGTACGACAAC
MRK_LZ_NP-	MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCT	458
H3N2	ELKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKK
SQ-031687	TGGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDDATAGLTH
CX-003145	MMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGA
	AGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGRKTRSAYERM
	CNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRG
	SVAHKSCLPACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVY
	SLIRPNENPAHKSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLS
	TRGVQIASNENMDNMESSTLELRSRYWAIRTRSGGNTNQQRASAG
	QISVQPTFSVQRNLPFEKSTVMAAFTGNTEGRTSDMRAEIIRMMEG
	AKPEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEY
	DN
MRK_LZ_NIHGen6HASS-	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGCT	459
TM2	GCCCGACACCACCGGCGACACCATCTGCATCGGCTACCACGCC
SQ-034074	AACAACAGCACCGACACCGTGGACACCGTGCTGGAGAAGAAC
CX-000553	GTGACCGTGACCCACAGCGTGAACCTGGGCAGCGGCCTGAGGA
	TGGTGACCGGCCTGAGGAACATCCCCCAGAGGGAGACCAGGGG
	CCTGTTCGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACC
	GGCATGGTGGACGGCTGGTACGGCTACCACCACCAGAACGAGC
	AGGGCAGCGGCTACGCCGCCGACCAGAAGAGCACCCAGAACG
	CCATCAACGGCATCACCAACATGGTGAACAGCGTGATCGAGAA
	GATGGGCAGCGGCGGCAGCGGCACCGACCTGGCCGAGCTGCTG
	GTGCTGCTGCTGAACGAGAGGACCCTGGACTTCCACGACAGCA
	ACGTGAAGAACCTGTACGAGAAGGTGAAGAGCCAGCTGAAGA
	ACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCA
	CAAGTGCAACAACGAGTGCATGGAGAGCGTGAAGAACGGCAC
	CTACGACTACCCCAAGTACAGCGAGGAGAGCAAGCTGAACAGG
	GAGAAGATCGACGGAGTGAAATTGGAATCAATGGGGGTCTATC
	AGATCCTGGCCATCTACAGCACCGTGGCCAGCAGCCTGGTGCT
	GCTGGTGAGCCTGGGCGCCATCAGCTTCTGGATGTGCAGCAAC
	GGCAGCCTGCAGTGCAGAATCTGCATC
MRK_LZ_NIHGen6HASS-	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVT	460
TM2	VTHSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVD
SQ-034074	GWYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSG
CX-000553	GSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIG
	NGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDGVKLE
	SMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI
MRK_LZ_NIHGen6HASS-	ATGGAGACCCCCGCCCAGCTGCTGTTCCTGCTGCTGCTGTGGCT	461
foldon	GCCCGACACCACCGGCGACACCATCTGCATCGGCTACCACGCC
SQ-032106	AACAACAGCACCGACACCGTGGACACCGTGCTGGAGAAGAAC
CX-000596	GTGACCGTGACCCACAGCGTGAACCTGGGCAGCGGCCTGAGGA
	TGGTGACCGGCCTGAGGAACATCCCCCAGAGGGAGACCAGGGG
	CCTGTTCGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACC
	GGCATGGTGGACGGCTGGTACGGCTACCACCACCAGAACGAGC
	AGGGCAGCGGCTACGCCGCCGACCAGAAGAGCACCCAGAACG
	CCATCAACGGCATCACCAACATGGTGAACAGCGTGATCGAGAA
	GATGGGCAGCGGCGGCAGCGGCACCGACCTGGCCGAGCTGCTG
	GTGCTGCTGCTGAACGAGAGGACCCTGGACTTCCACGACAGCA
	ACGTGAAGAACCTGTACGAGAAGGTGAAGAGCCAGCTGAAGA
	ACAACGCCAAGGAGATCGGCAACGGCTGCTTCGAGTTCTACCA
	CAAGTGCAACAACGAGTGCATGGAGAGCGTGAAGAACGGCAC
	CTACGACTACCCCAAGTACAGCGAGGAGAGCAAGCTGAACAGG
	GAGAAGATCGACCCCGGCAGCGGCTACATCCCCGAGGCCCCCA
	GGGACGGCCAGGCCTACGTGAGGAAGGACGGCGAGTGGGTGC
	TGCTGAGCACCTTCCTG
MRK_LZ_NIHGen6HASS-	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDTVDTVLEKNVT	462
foldon	VTHSVNLGSGLRMVTGLRNIPQRETRGLFGAIAGFIEGGWTGMVD
SQ-032106	GWYGYHHQNEQGSGYAADQKSTQNAINGITNMVNSVIEKMGSG
CX-000596	GSGTDLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKEIG
	NGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDPGSGY
	IPEAPRDGQAYVRKDGEWVLLSTFL

The underlined sequence for each of the amino acid sequences listed in Table 20, indicates a signal or secretory sequence, which may be substituted by an alternative sequence that achieves the same or similar function, or the signal or secretory sequence may be deleted.

TABLE 21
Additional Flu Sequences
		SEQ ID
Name	Sequence	NO:
BHA10-2: HA10 version for	METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVT	463
Influenza B strain, with	GVIPLTTTPTGSANKSKPYYTGEHAKATGNCPIWV
exposed hydrophobic	KTPLKLANGTKYGSAGSATQEAINKITKNLNSLSEL
residues mutated	EVKNLQRLSGASDETHNEILELDEKVDDLRADTISS
	QIELAVLLSNEGIINSEDEGTGGGYIPEAPRDGQAY
	VRKDGEWVLLSTFL
BHA10-3: HA10 version for	METPAQLLFLLLLWLPDTTGHVVKTATQGEVNVT	464
Influenza B strain, with	GVIPLTTTPTGSANKSKPYYTGEHAKATGNCPIWV
exposed hydrophobic	KTPLKLANGTKYGSAGSATQEAINKITKNLNSLSEL
residues mutated, with	EVKNLQRLSCASDETHNCILELDEKVDDLRADTISS
K68C/R76C/N95L	LIELAVLLSNEGIINSEDE
mutations for trimerization
NIHGen6HASS-TM: Gen6	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDT	465
HA SS construct without	VDTVLEKNVTVTHSVNLGSGLRMVTGLRNIPQRET
foldon or ferritin, with	RGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGS
transmembrane domain,	GYAADQKSTQNAINGITNMVNSVIEKMGSGGSGT
version 1	DLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLK
	NNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
	YSEESKLNREKIDQGTGGILAIYSTVASSLVLLVSL
	GAISFWMCSNGSLQCRICI
NIHGen6HASS-TM2: Gen6	METPAQLLFLLLLWLPDTTGDTICIGYHANNSTDT	466
HA SS construct without	VDTVLEKNVTVTHSVNLGSGLRMVTGLRNIPQRET
foldon or ferritin, with	RGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGS
transmembrane domain,	GYAADQKSTQNAINGITNMVNSVIEKMGSGGSGT
version 2	DLAELLVLLLNERTLDFHDSNVKNLYEKVKSQLK
	NNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPK
	YSEESKLNREKIDGVKLESMGVYQILAIYSTVASSL
	VLLVSLGAISFWMCSNGSLQCRICI
H1HA10-PR8-DS-ferritin:	METPAQLLFLLLLWLPDTTGDTVDTVCEKNVTVT	467
H1HA10 from PR8 strain,	HSVNLLEDSHGSANSSLPYQNTHPTTNGESPKYVR
with additional disulfide	SAKLRMVTGLRNGSAGSATQNAINCITNKVNTVIE
mutation, without foldon	KMNIQDTATGKEFNKDEKRMENLNKKVDDGFLDI
and with ferritin fusion for	WTYNAELLVLLENERTLDAHDSQGTGGDIIKLLNE
particle formation	QVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD
	HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFE
	GLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATF
	NFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLY
	LADQYVKGIAKSRKS
ConH1: consensus HA	MKAKLLVLLCAFTATDADTICIGYHANNSTDTVDT	468
sequence for subtype H1	VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG
	KCNIAGWILGNPECESLISKRSWSYIVETPNSENGT
	CYPGDFADYEELREQLSSVSSFERFEIFPKESSWPN
	HNVTKGVTAACSHAGKSSFYRNLLWLTEKNGSYP
	KLSKSYVNNKEKEVLVLWGVHHPSNITDQRTLYQ
	NENAYVSVVSSHYNRRFTPEIAKRPKVRGQAGRIN
	YYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSG
	IITSNAPMHECDTKCQTPQGAINSSLPFQNVHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLEKRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	NECMESVKNGTYDYPKYSEESKLNREKIDGVKLES
	MGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS
	LQCRICI
ConH3: consensus HA	MKTIIALSYIFCLVFAQKLPGNDNSTATLCLGHHAV	469
sequence for subtype H3	PNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPH
	RILDGTNCTLIDALLGDPHCDGFQNKEWDLFVERS
	KAYSNCYPYDVPDYASLRSLVASSGTLEFNNEGFN
	WTGVTQNGGSSACKRGSDKSFFSRLNWLHKLKYK
	YPALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSL
	YVQASGRVTVSTKRSQQTVIPNIGSRPWVRGLSSRI
	SIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIM
	RSDAPIGTCNSECITPNGSIPNDKPFQNVNRITYGAC
	PRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE
	NGWEGMVDGWYGFRHQNSEGTGQAADLKSTQA
	AIDQINGKLNRLIEKTNEKFHQIEKEFSEVEGRIQDL
	EKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEM
	NKLFERTRKQLRENAEDMGNGCFKIYHKCDNACI
	GSIRNGTYDHDVYRDEALNNRFQIKGVELKSGYK
	DWILWISFAISCFLLCVVLLGFIMWACQKGNIRCNI
	CI
MRK_pH1_Con: consensus	MKAILVVLLYTFATANADTLCIGYHANNSTDTVDT	470
HA sequence for pandemic	VLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHL
H1 strains	GKCNIAGWILGNPECESLSTASSWSYIVETSSSDNG
	TCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPN
	HDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYP
	KLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQN
	ADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNY
	YWTLVEPGDKITFEATGNLVVPRYAFAMERNAGS
	GIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIG
	KCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFI
	EGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQ
	NAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIE
	NLNKKVDDGFLDIWTYNAELLVLLENERTLDYHD
	SNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDN
	TCMESVKNGTYDYPKYSEEAKLNREEIDGVKLEST
	RIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQ
	CRICI
MRK_sH1_Con: consensus	MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDT	471
HA sequence for seasonal	VLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPLQLG
H1 strains	NCSVAGWILGNPECELLISKESWSYIVETPNPENGT
	CYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN
	HTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPN
	LSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHT
	ENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINY
	YWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGII
	TSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTIG
	ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFI
	EGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	DECMESVKNGTYDYPKYSEESKLNREKIDGVKLES
	MGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS
	LQCRICI
Cobra_P1: consensus HA	MKARLLVLLCALAATDADTICIGYHANNSTDTVDT	472
sequence P1 for H1 subtype	VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG
	KCNIAGWLLGNPECESLLSARSWSYIVETPNSENG
	TCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPN
	HNTTKGVTAACSHAGKSSFYRNLLWLTKKGGSYP
	KLSKSYVNNKGKEVLVLWGVHHPSTSTDQQSLYQ
	NENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRM
	NYYWTLLEPGDTIIFEATGNLIAPWYAFALSRGSGS
	GIITSNASMHECNTKCQTPQGAINSSLPFQNIHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNNLEKRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLRNNAKEIGNGCFEFYHKCD
	NECMESVKNGTYDYPKYSEESKLNREKIDGVKLES
	MGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS
	LQCRICI
Cobra_X3: consensus HA	MEARLLVLLCAFAATNADTICIGYHANNSTDTVDT	473
sequence X3 for H1 subtype	VLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLG
	NCSVAGWILGNPECESLFSKESWSYIAETPNPENGT
	CYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN
	HTVTKGVTASCSHNGKSSFYRNLLWLTEKNGLYP
	NLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYH
	TENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRIN
	YYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSG
	IITSNASMDECDAKCQTPQGAINSSLPFQNVHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	NECMESVKNGTYDYPKYSEESKLNREKIDGVKLES
	MGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGS
	LQCRICI
ConH1_ferritin: consensus	MKAKLLVLLCAFTATDADTICIGYHANNSTDTVDT	474
HA sequence for subtype	VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG
H1, with ferritin for particle	KCNIAGWILGNPECESLISKRSWSYIVETPNSENGT
formation	CYPGDFADYEELREQLSSVSSFERFEIFPKESSWPN
	HNVTKGVTAACSHAGKSSFYRNLLWLTEKNGSYP
	KLSKSYVNNKEKEVLVLWGVHHPSNITDQRTLYQ
	NENAYVSVVSSHYNRRFTPEIAKRPKVRGQAGRIN
	YYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSG
	IITSNAPMHECDTKCQTPQGAINSSLPFQNVHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLEKRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	NECMESVKNGTYDYPKYSEESKLNREKIDSGGDII
	KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG
	LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPE
	HKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD
	HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNEN
	HGLYLADQYVKGIAKSRKS
ConH3_ferritin: consensus	MKTIIALSYIFCLVFAQKLPGNDNSTATLCLGHHAV	475
HA sequence for subtype	PNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPH
H3, with ferritin for particle	RILDGTNCTLIDALLGDPHCDGFQNKEWDLFVERS
formation	KAYSNCYPYDVPDYASLRSLVASSGTLEFNNEGFN
	WTGVTQNGGSSACKRGSDKSFFSRLNWLHKLKYK
	YPALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSL
	YVQASGRVTVSTKRSQQTVIPNIGSRPWVRGLSSRI
	SIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGKSSIM
	RSDAPIGTCNSECITPNGSIPNDKPFQNVNRITYGAC
	PRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIE
	NGWEGMVDGWYGFRHQNSEGTGQAADLKSTQA
	AIDQINGKLNRLIEKTNEKFHQIEKEFSEVEGRIQDL
	EKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEM
	NKLFERTRKQLRENAEDMGNGCFKIYHKCDNACI
	GSIRNGTYDHDVYRDEALNNRFQIKSGGDIIKLLNE
	QVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFD
	HAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFE
	GLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATF
	NFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLY
	LADQYVKGIAKSRKS
Merck_pH1_Con_ferritin:	MKAILVVLLYTFATANADTLCIGYHANNSTDTVDT	476
consensus HA sequence for	VLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHL
pandemic H1 strains, with	GKCNIAGWILGNPECESLSTASSWSYIVETSSSDNG
ferritin for particle	TCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPN
formation	HDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYP
	KLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQN
	ADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNY
	YWTLVEPGDKITFEATGNLVVPRYAFAMERNAGS
	GIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIG
	KCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFI
	EGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQ
	NAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIE
	NLNKKVDDGFLDIWTYNAELLVLLENERTLDYHD
	SNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDN
	TCMESVKNGTYDYPKYSEEAKLNREEIDSGGDIIK
	LLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLF
	LFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEH
	KFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDH
	ATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENH
	GLYLADQYVKGIAKSRKS
Merck_sH1_Con_ferritin:	MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDT	477
consensus HA sequence for	VLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPLQLG
seasonal H1 strains, with	NCSVAGWILGNPECELLISKESWSYIVETPNPENGT
ferritin for particle	CYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN
formation	HTVTGVSASCSHNGKSSFYRNLLWLTGKNGLYPN
	LSKSYANNKEKEVLVLWGVHHPPNIGDQRALYHT
	ENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRINY
	YWTLLEPGDTIIFEANGNLIAPRYAFALSRGFGSGII
	TSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTIG
	ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFI
	EGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	DECMESVKNGTYDYPKYSEESKLNREKIDSGGDII
	KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG
	LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPE
	HKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD
	HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNEN
	HGLYLADQYVKGIAKSRKS
Cobra_P1_ferritin:	MKARLLVLLCALAATDADTICIGYHANNSTDTVDT	478
consensus HA sequence P1	VLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPLQLG
for H1 subtype, with ferritin	KCNIAGWLLGNPECESLLSARSWSYIVETPNSENG
for particle formation	TCYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPN
	HNTTKGVTAACSHAGKSSFYRNLLWLTKKGGSYP
	KLSKSYVNNKGKEVLVLWGVHHPSTSTDQQSLYQ
	NENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRM
	NYYWTLLEPGDTIIFEATGNLIAPWYAFALSRGSGS
	GIITSNASMHECNTKCQTPQGAINSSLPFQNIHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNNLEKRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLRNNAKEIGNGCFEFYHKCD
	NECMESVKNGTYDYPKYSEESKLNREKIDSGGDII
	KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG
	LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPE
	HKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD
	HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNEN
	HGLYLADQYVKGIAKSRKS
Cobra_X3_ferritin:	MEARLLVLLCAFAATNADTICIGYHANNSTDTVDT	479
consensus HA sequence X3	VLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPLQLG
for H1 subtype, with ferritin	NCSVAGWILGNPECESLFSKESWSYIAETPNPENGT
for particle formation	CYPGYFADYEELREQLSSVSSFERFEIFPKESSWPN
	HTVTKGVTASCSHNGKSSFYRNLLWLTEKNGLYP
	NLSKSYVNNKEKEVLVLWGVHHPSNIGDQRAIYH
	TENAYVSVVSSHYSRRFTPEIAKRPKVRDQEGRIN
	YYWTLLEPGDTIIFEANGNLIAPWYAFALSRGFGSG
	IITSNASMDECDAKCQTPQGAINSSLPFQNVHPVTI
	GECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGF
	IEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQ
	NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRM
	ENLNKKVDDGFLDIWTYNAELLVLLENERTLDFH
	DSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCN
	NECMESVKNGTYDYPKYSEESKLNREKIDSGGDII
	KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAG
	LFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPE
	HKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKD
	HATFNFLQWYVAEQHEEEVLFKDILDKIELIGNEN
	HGLYLADQYVKGIAKSRKS

TABLE 22
Signal Peptides
		SEQ ID
Description	Sequence	NO:
HuIgGk signal	METPAQLLFLLLLWLPDTTG	480
peptide
IgE heavy chain	MDWTWILFLVAAATRVHS	481
epsilon-1 signal
peptide
Japanese	MLGSNSGQRVVFTILLLLVAPAYS	482
encephalitis PRM
signal sequence
VSVg protein	MKCLLYLAFLFIGVNCA	483
signal sequence
Japanese	MWLVSLAIVTACAGA	484
encephalitis JEV
signal sequence

TABLE 23
Flagellin Nucleic Acid Sequences
Name	Sequence	SEQ ID NO:
NT (5′	TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCA	485
UTR, ORF,	CTATAGGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAA
3′ UTR)	ATATAAGAGCCACCATGGCACAAGTCATTAATACAAACA
	GCCTGTCGCTGTTGACCCAGAATAACCTGAACAAATCCC
	AGTCCGCACTGGGCACTGCTATCGAGCGTTTGTCTTCCGG
	TCTGCGTATCAACAGCGCGAAAGACGATGCGGCAGGACA
	GGCGATTGCTAACCGTTTTACCGCGAACATCAAAGGTCT
	GACTCAGGCTTCCCGTAACGCTAACGACGGTATCTCCATT
	GCGCAGACCACTGAAGGCGCGCTGAACGAAATCAACAAC
	AACCTGCAGCGTGTGCGTGAACTGGCGGTTCAGTCTGCG
	AATGGTACTAACTCCCAGTCTGACCTCGACTCCATCCAGG
	CTGAAATCACCCAGCGCCTGAACGAAATCGACCGTGTAT
	CCGGCCAGACTCAGTTCAACGGCGTGAAAGTCCTGGCGC
	AGGACAACACCCTGACCATCCAGGTTGGTGCCAACGACG
	GTGAAACTATCGATATTGATTTAAAAGAAATCAGCTCTA
	AAACACTGGGACTTGATAAGCTTAATGTCCAAGATGCCT
	ACACCCCGAAAGAAACTGCTGTAACCGTTGATAAAACTA
	CCTATAAAAATGGTACAGATCCTATTACAGCCCAGAGCA
	ATACTGATATCCAAACTGCAATTGGCGGTGGTGCAACGG
	GGGTTACTGGGGCTGATATCAAATTTAAAGATGGTCAAT
	ACTATTTAGATGTTAAAGGCGGTGCTTCTGCTGGTGTTTA
	TAAAGCCACTTATGATGAAACTACAAAGAAAGTTAATAT
	TGATACGACTGATAAAACTCCGTTGGCAACTGCGGAAGC
	TACAGCTATTCGGGGAACGGCCACTATAACCCACAACCA
	AATTGCTGAAGTAACAAAAGAGGGTGTTGATACGACCAC
	AGTTGCGGCTCAACTTGCTGCAGCAGGGGTTACTGGCGC
	CGATAAGGACAATACTAGCCTTGTAAAACTATCGTTTGA
	GGATAAAAACGGTAAGGTTATTGATGGTGGCTATGCAGT
	GAAAATGGGCGACGATTTCTATGCCGCTACATATGATGA
	GAAAACAGGTGCAATTACTGCTAAAACCACTACTTATAC
	AGATGGTACTGGCGTTGCTCAAACTGGAGCTGTGAAATT
	TGGTGGCGCAAATGGTAAATCTGAAGTTGTTACTGCTACC
	GATGGTAAGACTTACTTAGCAAGCGACCTTGACAAACAT
	AACTTCAGAACAGGCGGTGAGCTTAAAGAGGTTAATACA
	GATAAGACTGAAAACCCACTGCAGAAAATTGATGCTGCC
	TTGGCACAGGTTGATACACTTCGTTCTGACCTGGGTGCGG
	TTCAGAACCGTTTCAACTCCGCTATCACCAACCTGGGCAA
	TACCGTAAATAACCTGTCTTCTGCCCGTAGCCGTATCGAA
	GATTCCGACTACGCAACCGAAGTCTCCAACATGTCTCGC
	GCGCAGATTCTGCAGCAGGCCGGTACCTCCGTTCTGGCG
	CAGGCGAACCAGGTTCCGCAAAACGTCCTCTCTTTACTGC
	GTTGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGC
	CCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCAC
	CCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCG
	GC
ORF	ATGGCACAAGTCATTAATACAAACAGCCTGTCGCTGTTG	486
Sequence,	ACCCAGAATAACCTGAACAAATCCCAGTCCGCACTGGGC
NT	ACTGCTATCGAGCGTTTGTCTTCCGGTCTGCGTATCAACA
	GCGCGAAAGACGATGCGGCAGGACAGGCGATTGCTAACC
	GTTTTACCGCGAACATCAAAGGTCTGACTCAGGCTTCCCG
	TAACGCTAACGACGGTATCTCCATTGCGCAGACCACTGA
	AGGCGCGCTGAACGAAATCAACAACAACCTGCAGCGTGT
	GCGTGAACTGGCGGTTCAGTCTGCGAATGGTACTAACTC
	CCAGTCTGACCTCGACTCCATCCAGGCTGAAATCACCCA
	GCGCCTGAACGAAATCGACCGTGTATCCGGCCAGACTCA
	GTTCAACGGCGTGAAAGTCCTGGCGCAGGACAACACCCT
	GACCATCCAGGTTGGTGCCAACGACGGTGAAACTATCGA
	TATTGATTTAAAAGAAATCAGCTCTAAAACACTGGGACT
	TGATAAGCTTAATGTCCAAGATGCCTACACCCCGAAAGA
	AACTGCTGTAACCGTTGATAAAACTACCTATAAAAATGG
	TACAGATCCTATTACAGCCCAGAGCAATACTGATATCCA
	AACTGCAATTGGCGGTGGTGCAACGGGGGTTACTGGGGC
	TGATATCAAATTTAAAGATGGTCAATACTATTTAGATGTT
	AAAGGCGGTGCTTCTGCTGGTGTTTATAAAGCCACTTATG
	ATGAAACTACAAAGAAAGTTAATATTGATACGACTGATA
	AAACTCCGTTGGCAACTGCGGAAGCTACAGCTATTCGGG
	GAACGGCCACTATAACCCACAACCAAATTGCTGAAGTAA
	CAAAAGAGGGTGTTGATACGACCACAGTTGCGGCTCAAC
	TTGCTGCAGCAGGGGTTACTGGCGCCGATAAGGACAATA
	CTAGCCTTGTAAAACTATCGTTTGAGGATAAAAACGGTA
	AGGTTATTGATGGTGGCTATGCAGTGAAAATGGGCGACG
	ATTTCTATGCCGCTACATATGATGAGAAAACAGGTGCAA
	TTACTGCTAAAACCACTACTTATACAGATGGTACTGGCGT
	TGCTCAAACTGGAGCTGTGAAATTTGGTGGCGCAAATGG
	TAAATCTGAAGTTGTTACTGCTACCGATGGTAAGACTTAC
	TTAGCAAGCGACCTTGACAAACATAACTTCAGAACAGGC
	GGTGAGCTTAAAGAGGTTAATACAGATAAGACTGAAAAC
	CCACTGCAGAAAATTGATGCTGCCTTGGCACAGGTTGAT
	ACACTTCGTTCTGACCTGGGTGCGGTTCAGAACCGTTTCA
	ACTCCGCTATCACCAACCTGGGCAATACCGTAAATAACC
	TGTCTTCTGCCCGTAGCCGTATCGAAGATTCCGACTACGC
	AACCGAAGTCTCCAACATGTCTCGCGCGCAGATTCTGCA
	GCAGGCCGGTACCTCCGTTCTGGCGCAGGCGAACCAGGT
	TCCGCAAAACGTCCTCTCTTTACTGCGT
mRNA	G*GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAU	487
Sequence	AUAAGAGCCACCAUGGCACAAGUCAUUAAUACAAACAG
(assumes	CCUGUCGCUGUUGACCCAGAAUAACCUGAACAAAUCCC
T100 tail)	AGUCCGCACUGGGCACUGCUAUCGAGCGUUUGUCUUCC
	GGUCUGCGUAUCAACAGCGCGAAAGACGAUGCGGCAGG
	ACAGGCGAUUGCUAACCGUUUUACCGCGAACAUCAAAG
	GUCUGACUCAGGCUUCCCGUAACGCUAACGACGGUAUC
	UCCAUUGCGCAGACCACUGAAGGCGCGCUGAACGAAAU
	CAACAACAACCUGCAGCGUGUGCGUGAACUGGCGGUUC
	AGUCUGCGAAUGGUACUAACUCCCAGUCUGACCUCGAC
	UCCAUCCAGGCUGAAAUCACCCAGCGCCUGAACGAAAU
	CGACCGUGUAUCCGGCCAGACUCAGUUCAACGGCGUGA
	AAGUCCUGGCGCAGGACAACACCCUGACCAUCCAGGUU
	GGUGCCAACGACGGUGAAACUAUCGAUAUUGAUUUAAA
	AGAAAUCAGCUCUAAAACACUGGGACUUGAUAAGCUUA
	AUGUCCAAGAUGCCUACACCCCGAAAGAAACUGCUGUA
	ACCGUUGAUAAAACUACCUAUAAAAAUGGUACAGAUCC
	UAUUACAGCCCAGAGCAAUACUGAUAUCCAAACUGCAA
	UUGGCGGUGGUGCAACGGGGGUUACUGGGGCUGAUAUC
	AAAUUUAAAGAUGGUCAAUACUAUUUAGAUGUUAAAG
	GCGGUGCUUCUGCUGGUGUUUAUAAAGCCACUUAUGAU
	GAAACUACAAAGAAAGUUAAUAUUGAUACGACUGAUA
	AAACUCCGUUGGCAACUGCGGAAGCUACAGCUAUUCGG
	GGAACGGCCACUAUAACCCACAACCAAAUUGCUGAAGU
	AACAAAAGAGGGUGUUGAUACGACCACAGUUGCGGCUC
	AACUUGCUGCAGCAGGGGUUACUGGCGCCGAUAAGGAC
	AAUACUAGCCUUGUAAAACUAUCGUUUGAGGAUAAAAA
	CGGUAAGGUUAUUGAUGGUGGCUAUGCAGUGAAAAUG
	GGCGACGAUUUCUAUGCCGCUACAUAUGAUGAGAAAAC
	AGGUGCAAUUACUGCUAAAACCACUACUUAUACAGAUG
	GUACUGGCGUUGCUCAAACUGGAGCUGUGAAAUUUGGU
	GGCGCAAAUGGUAAAUCUGAAGUUGUUACUGCUACCGA
	UGGUAAGACUUACUUAGCAAGCGACCUUGACAAACAUA
	ACUUCAGAACAGGCGGUGAGCUUAAAGAGGUUAAUACA
	GAUAAGACUGAAAACCCACUGCAGAAAAUUGAUGCUGC
	CUUGGCACAGGUUGAUACACUUCGUUCUGACCUGGGUG
	CGGUUCAGAACCGUUUCAACUCCGCUAUCACCAACCUG
	GGCAAUACCGUAAAUAACCUGUCUUCUGCCCGUAGCCG
	UAUCGAAGAUUCCGACUACGCAACCGAAGUCUCCAACA
	UGUCUCGCGCGCAGAUUCUGCAGCAGGCCGGUACCUCC
	GUUCUGGCGCAGGCGAACCAGGUUCCGCAAAACGUCCU
	CUCUUUACUGCGUUGAUAAUAGGCUGGAGCCUCGGUGG
	CCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCC
	UCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUA
	AAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	AAAAAAUCUAG

TABLE 24
Flagellin Amino Acid Sequences
Name	Sequence	SEQ ID NO:
ORF	MAQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAK	488
Sequence,	DDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALN
AA	EINNNLQRVRELAVQSANGTNSQSDLDSIQAEITQRLNEIDR
	VSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKEISSKT
	LGLDKLNVQDAYTPKETAVTVDKTTYKNGTDPITAQSNTDI
	QTAIGGGATGVTGADIKFKDGQYYLDVKGGASAGVYKAT
	YDETTKKVNIDTTDKTPLATAEATAIRGTATITHNQIAEVTK
	EGVDTTTVAAQLAAAGVTGADKDNTSLVKLSFEDKNGKVI
	DGGYAVKMGDDFYAATYDEKTGAITAKTTTYTDGTGVAQ
	TGAVKFGGANGKSEVVTATDGKTYLASDLDKHNFRTGGEL
	KEVNTDKTENPLQKIDAALAQVDTLRSDLGAVQNRFNSAIT
	NLGNTVNNLSSARSRIEDSDYATEVSNMSRAQILQQAGTSV
	LAQANQVPQNVLSLLR
Flagellin-	MAQVINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAK	489
GS linker-	DDAAGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALN
circumsporozoite	EINNNLQRVRELAVQSANSTNSQSDLDSIQAEITQRLNEIDR
protein	VSGQTQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQ
(CSP)	TLGLDTLNVQQKYKVSDTAATVTGYADTTIALDNSTFKAS
	ATGLGGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGY
	YEVSVDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVA
	NADLTEAKAALTAAGVTGTASVVKMSYTDNNGKTIDGGL
	AVKVGDDYYSATQNKDGSISINTTKYTADDGTSKTALNKL
	GGADGKTEVVSIGGKTYAASKAEGHNFKAQPDLAEAAATT
	TENPLQKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVN
	NLTSARSRIEDSDYATEVSNMSRAQILQQAGTSVLAQANQV
	PQNVLSLLRGGGGSGGGGSMMAPDPNANPNANPNANPNA
	NPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
	ANPNANPNANPNANPNANPNANPNKNNQGNGQGHNMPND
	PNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKIKNSIST
	EWSPCSVTCGNGIQVRIKPGSANKPKDELDYENDIEKKICK
	MEKCSSVFNVVNS
Flagellin-	MMAPDPNANPNANPNANPNANPNANPNANPNANPNANPN	490
RPVT	ANPNANPNANPNANPNANPNANPNANPNANPNANPNANP
linker-	NANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNN
circumsporozoite	NNEEPSDKHIEQYLKKIKNSISTEWSPCSVTCGNGIQVRIKPG
protein	SANKPKDELDYENDIEKKICKMEKCSSVFNVVNSRPVTMAQ
(CSP)	VINTNSLSLLTQNNLNKSQSALGTAIERLSSGLRINSAKDDA
	AGQAIANRFTANIKGLTQASRNANDGISIAQTTEGALNEINN
	NLQRVRELAVQSANSTNSQSDLDSIQAEITQRLNEIDRVSGQ
	TQFNGVKVLAQDNTLTIQVGANDGETIDIDLKQINSQTLGL
	DTLNVQQKYKVSDTAATVTGYADTTIALDNSTFKASATGL
	GGTDQKIDGDLKFDDTTGKYYAKVTVTGGTGKDGYYEVS
	VDKTNGEVTLAGGATSPLTGGLPATATEDVKNVQVANADL
	TEAKAALTAAGVTGTASVVKMSYTDNNGKTIDGGLAVKV
	GDDYYSATQNKDGSISINTTKYTADDGTSKTALNKLGGAD
	GKTEVVSIGGKTYAASKAEGHNFKAQPDLAEAAATTTENPL
	QKIDAALAQVDTLRSDLGAVQNRFNSAITNLGNTVNNLTSA
	RSRIEDSDYATEVSNMSRAQILQQAGTSVLAQANQVPQNVL
	SLLR

TABLE 25
Influenza mRNA Constructs
Influenza mRNA Sequences
Construct		SEQ ID
Description	ORF	NO:
B/Yamagata/16/1988	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	491
mHA	CAACGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAAA
	CUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAAGU
	UAAUGUGACUGGUGUGAUACCACUGACAACAACACCAAC
	AAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAGACCA
	GAGGGAAACUAUGCCCAAACUGUCUCAACUGCACAGAUC
	UGGAUGUGGCCUUGGGCAGACCAAUGUGUAUGGGGACC
	AUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAGA
	CCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUCAGACAGCUACCCAAUCUUCUCAGAGGAUAU
	GAAAAUAUCAGAUUAUCAACCCAUAACGUUAUCAACGC
	AGAAAGGGCACCAGGAGGACCCUACAGACUUGGAACCUC
	AGGAUCUUGCCCUAACGUUACCAGUAGAAACGGAUUCU
	UCGCAACAAUGGCUUGGGCUGUCCCAAGGGACAACAAAA
	CAGCAACGAAUCCACUAACAGUAGAAGUACCAUACAUUU
	GCACAAAAGGAGAAGACCAAAUUACUGUUUGGGGGUUC
	CAUUCUGAUGACAAAACCCAAAUGAAAAACCUCUAUGG
	AGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCCAAUGG
	AGUAACCACACAUUAUGUUUCUCAGAUUGGUGACUUCCC
	AAAUCAAACAGAAGACGGAGGGCUACCACAAAGCGGCA
	GAAUUGUUGUUGAUUACAUGGUGCAAAAACCUGGGAAA
	ACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUUGCC
	UCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAA
	UAAAAGGGUCCUUGCCUUUAAUUGGUGAAGCAGAUUGC
	CUUCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCC
	UUACUACACAGGAGAACAUGCAAAAGCCAUAGGAAAUU
	GCCCAAUAUGGGUGAAAACACCUUUGAAGCUUGCCAAU
	GGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGA
	AAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAGG
	GAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUAC
	ACAUCUCAUGGAGCACAUGGAGUGGCAGUGGCAGCAGA
	CCUUAAGAGCACGCAAGAAGCCAUAAACAAGAUAACAA
	AAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGAAU
	CUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACAAC
	GAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUCAG
	AGCUGACACAAUAAGCUCGCAAAUAGAGCUUGCAGUCU
	UGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAG
	CAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUGCU
	GGGUCCCUCUGCUGUAGACAUAGGGAAUGGAUGCUUCG
	AAACCAAACACAAGUGCAACCAGACCUGCUUAGACAGGA
	UAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUU
	CCCACUUUUGAUUCACUGAAUAUUACUGCUGCAUCUUUA
	AAUGAUGAUGGAUUGGAUAAUCAUACUAUACUGCUCUA
	CUACUCAACUGCUGCUUCUAGUUUGGCCGUAACAUUGAU
	GAUAGCUAUUUUUAUUGUUUAUAUGGUCUCCAGAGACA
	AUGUUUCUUGCUCCAUCUGUCUA
B/Yamagata/16/1988	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	492
sHA	CAACGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAAA
	CUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAAGU
	UAAUGUGACUGGUGUGAUACCACUGACAACAACACCAAC
	AAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAGACCA
	GAGGGAAACUAUGCCCAAACUGUCUCAACUGCACAGAUC
	UGGAUGUGGCCUUGGGCAGACCAAUGUGUAUGGGGACC
	AUACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAGA
	CCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUCAGACAGCUACCCAAUCUUCUCAGAGGAUAU
	GAAAAUAUCAGAUUAUCAACCCAUAACGUUAUCAACGC
	AGAAAGGGCACCAGGAGGACCCUACAGACUUGGAACCUC
	AGGAUCUUGCCCUAACGUUACCAGUAGAAACGGAUUCU
	UCGCAACAAUGGCUUGGGCUGUCCCAAGGGACAACAAAA
	CAGCAACGAAUCCACUAACAGUAGAAGUACCAUACAUUU
	GCACAAAAGGAGAAGACCAAAUUACUGUUUGGGGGUUC
	CAUUCUGAUGACAAAACCCAAAUGAAAAACCUCUAUGG
	AGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCCAAUGG
	AGUAACCACACAUUAUGUUUCUCAGAUUGGUGACUUCCC
	AAAUCAAACAGAAGACGGAGGGCUACCACAAAGCGGCA
	GAAUUGUUGUUGAUUACAUGGUGCAAAAACCUGGGAAA
	ACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUUGCC
	UCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCAAGGUAA
	UAAAAGGGUCCUUGCCUUUAAUUGGUGAAGCAGAUUGC
	CUUCACGAAAAAUACGGUGGAUUAAACAAAAGCAAGCC
	UUACUACACAGGAGAACAUGCAAAAGCCAUAGGAAAUU
	GCCCAAUAUGGGUGAAAACACCUUUGAAGCUUGCCAAU
	GGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAAGGA
	AAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAGAGG
	GAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGAUAC
	ACAUCUCAUGGAGCACAUGGAGUGGCAGUGGCAGCAGA
	CCUUAAGAGCACGCAAGAAGCCAUAAACAAGAUAACAA
	AAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGAAU
	CUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACAAC
	GAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUCAG
	AGCUGACACAAUAAGCUCGCAAAUAGAGCUUGCAGUCU
	UGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUGAG
	CAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUGCU
	GGGUCCCUCUGCUGUAGACAUAGGGAAUGGAUGCUUCG
	AAACCAAACACAAGUGCAACCAGACCUGCUUAGACAGGA
	UAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUCUU
	CCCACUUUUGAUUCACUGAAUAUUACUGCUGCAUCUUUA
	AAUGAUGAUGGAUUGGAUAAUCAUACU
B/Victoria/02/1987	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	493
mHA	CAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAA
	ACUCACCCCAUGUGGUCAAAACUGCUACUCAAGGGGAAG
	UCAAUGUGACUGGUGUGAUACCACUGACAACAACACCCA
	CCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAAACCA
	GAGGGAAACUAUGCCCAAAGUGUCUCAACUGCACAGAUC
	UGGACGUGGCCUUGGGCAGACCAAAGUGCACGGGGACCA
	UACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAAAC
	CUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUUAGACAGCUACCCAAUCUUCUCAGAGGAUAC
	GAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAACGCA
	GAAACGGCACCAGGAGGACCCUACAAAGUUGGAACCUCA
	GGGUCUUGCCCUAACGUUACCAAUGGAAACGGAUUCUUC
	GCAACAAUGGCUUGGGCUGUCCCAAAAAACGACAACAAC
	AAAACAGCAACAAAUCCAUUAACAGUAGAAGUACCAUA
	CAUUUGUACAGAAGGAGAAGACCAAAUUACUGUUUGGG
	GGUUCCACUCUGAUAACGAAGCCCAAAUGGUAAAACUCU
	AUGGAGACUCAAAGCCUCAGAAGUUCACCUCAUCUGCCA
	ACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGC
	UUCCCAAAUCAAGCAGAAGACGGAGGGCUACCACAAAGC
	GGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGG
	AAAAACAGGAACAAUUACCUACCAAAGAGGUAUUUUAU
	UGCCUCAAAAAGUGUGGUGCGCAAGUGGCAGGAGCAAG
	GUAAUAAAAGGGUCCUUGCCUUUAAUUGGCGAAGCAGA
	UUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCA
	AGCCUUACUACACAGGGGAACAUGCAAAAGCCAUAGGA
	AAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCC
	AAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAA
	GGAAAAGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAG
	AAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGA
	UACACAUCCCAUGGAGCACAUGGAGUAGCAGUGGCAGCA
	GACCUUAAGAGUACGCAAGAAGCCAUAAACAAGAUAAC
	AAAAAAUCUCAAUUCUUUGAGUGAGCUGGAAGUAAAGA
	AUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACA
	ACAAAAUACUCGAACUGGAUGAGAAAGUGGAUGAUCUC
	AGAGCUGAUACAAUAAGCUCGCAAAUAGAGCUCGCAGU
	CUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUG
	AGCAUCUCUUGGCGCUUGAAAGAAAACUGAAGAAAAUG
	CUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUU
	CGAAACCAAACACAAGUGCAACCAGACCUGCCUCGACAG
	AAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUC
	UCCCCACCUUUGAUUCACUAAAUAUUACUGCUGCAUCUU
	UAAAUGAUGAUGGAUUGGAUAAUCAUACUAUACUGCUU
	UACUACUCAACUGCUGCUUCCAGUUUGGCUGUAACAUUG
	AUGAUAGCUAUCUUUAUUGUUUAUAUGGUCUCCAGAGA
	CAAUGUUUCUUGCUCCAUCUGUCUA
B/Victoria/02/1987	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	494
sHA	CAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAA
	ACUCACCCCAUGUGGUCAAAACUGCUACUCAAGGGGAAG
	UCAAUGUGACUGGUGUGAUACCACUGACAACAACACCCA
	CCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAAAAACCA
	GAGGGAAACUAUGCCCAAAGUGUCUCAACUGCACAGAUC
	UGGACGUGGCCUUGGGCAGACCAAAGUGCACGGGGACCA
	UACCUUCGGCAAAAGCUUCAAUACUCCACGAAGUCAAAC
	CUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUUAGACAGCUACCCAAUCUUCUCAGAGGAUAC
	GAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAACGCA
	GAAACGGCACCAGGAGGACCCUACAAAGUUGGAACCUCA
	GGGUCUUGCCCUAACGUUACCAAUGGAAACGGAUUCUUC
	GCAACAAUGGCUUGGGCUGUCCCAAAAAACGACAACAAC
	AAAACAGCAACAAAUCCAUUAACAGUAGAAGUACCAUA
	CAUUUGUACAGAAGGAGAAGACCAAAUUACUGUUUGGG
	GGUUCCACUCUGAUAACGAAGCCCAAAUGGUAAAACUCU
	AUGGAGACUCAAAGCCUCAGAAGUUCACCUCAUCUGCCA
	ACGGAGUGACCACACAUUACGUUUCACAGAUUGGUGGC
	UUCCCAAAUCAAGCAGAAGACGGAGGGCUACCACAAAGC
	GGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCUGG
	AAAAACAGGAACAAUUACCUACCAAAGAGGUAUUUUAU
	UGCCUCAAAAAGUGUGGUGCGCAAGUGGCAGGAGCAAG
	GUAAUAAAAGGGUCCUUGCCUUUAAUUGGCGAAGCAGA
	UUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAGCA
	AGCCUUACUACACAGGGGAACAUGCAAAAGCCAUAGGA
	AAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGGCC
	AAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAAA
	GGAAAAGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUAG
	AAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGA
	UACACAUCCCAUGGAGCACAUGGAGUAGCAGUGGCAGCA
	GACCUUAAGAGUACGCAAGAAGCCAUAAACAAGAUAAC
	AAAAAAUCUCAAUUCUUUGAGUGAGCUGGAAGUAAAGA
	AUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCACA
	ACAAAAUACUCGAACUGGAUGAGAAAGUGGAUGAUCUC
	AGAGCUGAUACAAUAAGCUCGCAAAUAGAGCUCGCAGU
	CUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGAUG
	AGCAUCUCUUGGCGCUUGAAAGAAAACUGAAGAAAAUG
	CUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCUU
	CGAAACCAAACACAAGUGCAACCAGACCUGCCUCGACAG
	AAUAGCUGCUGGCACCUUUAAUGCAGGAGAAUUUUCUC
	UCCCCACCUUUGAUUCACUAAAUAUUACUGCUGCAUCUU
	UAAAUGAUGAUGGAUUGGAUAAUCAUACU
B/Brisbane/60/2008	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	495
mHA	CAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAA
	ACUCACCACAUGUCGUCAAAACUGCUACUCAAGGGGAGG
	UCAAUGUGACUGGUGUAAUACCACUGACAACAACACCCA
	CCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAGAAACCA
	GGGGGAAACUAUGCCCAAAAUGCCUCAACUGCACAGAUC
	UGGACGUAGCCUUGGGCAGACCAAAAUGCACGGGGAAA
	AUACCCUCGGCAAGAGUUUCAAUACUCCAUGAAGUCAGA
	CCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUUAGACAGCUGCCUAACCUUCUCCGAGGAUAC
	GAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAAUGC
	AGAAAAUGCACCAGGAGGACCCUACAAAAUUGGAACCUC
	AGGGUCUUGCCCUAACAUUACCAAUGGAAACGGAUUUU
	UCGCAACAAUGGCUUGGGCCGUCCCAAAAAACGACAAAA
	ACAAAACAGCAACAAAUCCAUUAACAAUAGAAGUACCA
	UACAUUUGUACAGAAGGAGAAGACCAAAUUACCGUUUG
	GGGGUUCCACUCUGACGACGAGACCCAAAUGGCAAAGCU
	CUAUGGGGACUCAAAGCCCCAGAAGUUCACCUCAUCUGC
	CAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUG
	GCUUCCCAAAUCAAACAGAAGACGGAGGACUACCACAAA
	GUGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCU
	GGGAAAACAGGAACAAUUACCUAUCAAAGGGGUAUUUU
	AUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCA
	AGGUAAUAAAAGGAUCCUUGCCUUUAAUUGGAGAAGCA
	GAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAG
	CAAGCCUUACUACACAGGGGAACAUGCAAAGGCCAUAGG
	AAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGG
	CCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAA
	AGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUA
	GAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGG
	AUACACAUCCCAUGGGGCACAUGGAGUAGCGGUGGCAGC
	AGACCUUAAGAGCACUCAAGAGGCCAUAAACAAGAUAA
	CAAAAAAUCUCAACUCUUUGAGUGAGCUGGAAGUAAAG
	AAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCAC
	AACGAAAUACUAGAACUAGAUGAGAAAGUGGAUGAUCU
	CAGAGCUGAUACAAUAAGCUCACAAAUAGAACUCGCAG
	UCCUGCUUUCCAAUGAAGGAAUAAUAAACAGUGAAGAU
	GAACAUCUCUUGGCGCUUGAAAGAAAGCUGAAGAAAAU
	GCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCU
	UUGAAACCAAACACAAGUGCAACCAGACCUGUCUCGACA
	GAAUAGCUGCUGGUACCUUUGAUGCAGGAGAAUUUUCU
	CUCCCCACCUUUGAUUCACUGAAUAUUACUGCUGCAUCU
	UUAAAUGACGAUGGAUUGGAUAAUCAUACUAUACUGCU
	UUACUACUCAACUGCUGCCUCCAGUUUGGCUGUAACACU
	GAUGAUAGCUAUCUUUGUUGUUUAUAUGGUCUCCAGAG
	ACAAUGUUUCUUGCUCCAUCUGUCUA
B/Brisbane/60/2008	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	496
sHA	CAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCGUCAA
	ACUCACCACAUGUCGUCAAAACUGCUACUCAAGGGGAGG
	UCAAUGUGACUGGUGUAAUACCACUGACAACAACACCCA
	CCAAAUCUCAUUUUGCAAAUCUCAAAGGAACAGAAACCA
	GGGGGAAACUAUGCCCAAAAUGCCUCAACUGCACAGAUC
	UGGACGUAGCCUUGGGCAGACCAAAAUGCACGGGGAAA
	AUACCCUCGGCAAGAGUUUCAAUACUCCAUGAAGUCAGA
	CCUGUUACAUCUGGGUGCUUUCCUAUAAUGCACGACAGA
	ACAAAAAUUAGACAGCUGCCUAACCUUCUCCGAGGAUAC
	GAACAUAUCAGGUUAUCAACCCAUAACGUUAUCAAUGC
	AGAAAAUGCACCAGGAGGACCCUACAAAAUUGGAACCUC
	AGGGUCUUGCCCUAACAUUACCAAUGGAAACGGAUUUU
	UCGCAACAAUGGCUUGGGCCGUCCCAAAAAACGACAAAA
	ACAAAACAGCAACAAAUCCAUUAACAAUAGAAGUACCA
	UACAUUUGUACAGAAGGAGAAGACCAAAUUACCGUUUG
	GGGGUUCCACUCUGACGACGAGACCCAAAUGGCAAAGCU
	CUAUGGGGACUCAAAGCCCCAGAAGUUCACCUCAUCUGC
	CAACGGAGUGACCACACAUUACGUUUCACAGAUUGGUG
	GCUUCCCAAAUCAAACAGAAGACGGAGGACUACCACAAA
	GUGGUAGAAUUGUUGUUGAUUACAUGGUGCAAAAAUCU
	GGGAAAACAGGAACAAUUACCUAUCAAAGGGGUAUUUU
	AUUGCCUCAAAAGGUGUGGUGCGCAAGUGGCAGGAGCA
	AGGUAAUAAAAGGAUCCUUGCCUUUAAUUGGAGAAGCA
	GAUUGCCUCCACGAAAAAUACGGUGGAUUAAACAAAAG
	CAAGCCUUACUACACAGGGGAACAUGCAAAGGCCAUAGG
	AAAUUGCCCAAUAUGGGUGAAAACACCCUUGAAGCUGG
	CCAAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUAA
	AGGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCUUA
	GAAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGG
	AUACACAUCCCAUGGGGCACAUGGAGUAGCGGUGGCAGC
	AGACCUUAAGAGCACUCAAGAGGCCAUAAACAAGAUAA
	CAAAAAAUCUCAACUCUUUGAGUGAGCUGGAAGUAAAG
	AAUCUUCAAAGACUAAGCGGUGCCAUGGAUGAACUCCAC
	AACGAAAUACUAGAACUAGAUGAGAAAGUGGAUGAUCU
	CAGAGCUGAUACAAUAAGCUCACAAAUAGAACUCGCAG
	UCCUGCUUUCCAAUGAAGGAAUAAUAAACAGUGAAGAU
	GAACAUCUCUUGGCGCUUGAAAGAAAGCUGAAGAAAAU
	GCUGGGCCCCUCUGCUGUAGAGAUAGGGAAUGGAUGCU
	UUGAAACCAAACACAAGUGCAACCAGACCUGUCUCGACA
	GAAUAGCUGCUGGUACCUUUGAUGCAGGAGAAUUUUCU
	CUCCCCACCUUUGAUUCACUGAAUAUUACUGCUGCAUCU
	UUAAAUGACGAUGGAUUGGAUAAUCAUACU
B/Phuket/3073/2013	AUGAAGGCAAUAAUUGUACUACUCAUGGUAGUAACAUC	497
mHA	CAAUGCAGAUCGAAUCUGCACUGGGAUAACAUCUUCAA
	ACUCACCUCAUGUGGUCAAAACAGCUACUCAAGGGGAGG
	UCAAUGUGACUGGCGUGAUACCACUGACAACAACACCAA
	CAAAAUCUUAUUUUGCAAAUCUCAAAGGAACAAGGACC
	AGAGGGAAACUAUGCCCGGACUGUCUCAACUGUACAGA
	UCUGGAUGUGGCCUUGGGCAGGCCAAUGUGUGUGGGGA
	CCACACCUUCUGCUAAAGCUUCAAUACUCCACGAGGUCA
	GACCUGUUACAUCCGGGUGCUUUCCUAUAAUGCACGACA
	GAACAAAAAUCAGGCAACUACCCAAUCUUCUCAGAGGAU
	AUGAAAAGAUCAGGUUAUCAACCCAAAACGUUAUCGAU
	GCAGAAAAAGCACCAGGAGGACCCUACAGACUUGGAACC
	UCAGGAUCUUGCCCUAACGCUACCAGUAAAAUCGGAUUU
	UUCGCAACAAUGGCUUGGGCUGUCCCAAAGGACAACUAC
	AAAAAUGCAACGAACCCACUAACAGUAGAAGUACCAUAC
	AUUUGUACAGAAGGGGAAGACCAAAUUACUGUUUGGGG
	GUUCCAUUCAGACAACAAAACCCAAAUGAAGAGCCUCUA
	UGGAGACUCAAAUCCUCAAAAGUUCACCUCAUCUGCUAA
	UGGAGUAACCACACAUUAUGUUUCUCAGAUUGGCGACU
	UCCCAGAUCAAACAGAAGACGGAGGACUACCACAAAGCG
	GCAGAAUUGUUGUUGAUUACAUGAUGCAAAAACCUGGG
	AAAACAGGAACAAUUGUCUAUCAAAGAGGUGUUUUGUU
	GCCUCAAAAGGUGUGGUGCGCGAGUGGCAGGAGCAAAG
	UAAUAAAAGGGUCAUUGCCUUUAAUUGGUGAAGCAGAU
	UGCCUUCAUGAAAAAUACGGUGGAUUAAACAAAAGCAA
	GCCUUACUACACAGGAGAACAUGCAAAAGCCAUAGGAA
	AUUGCCCAAUAUGGGUAAAAACACCUUUGAAGCUUGCC
	AAUGGAACCAAAUAUAGACCUCCUGCAAAACUAUUGAA
	GGAAAGGGGUUUCUUCGGAGCUAUUGCUGGUUUCCUAG
	AAGGAGGAUGGGAAGGAAUGAUUGCAGGUUGGCACGGA
	UACACAUCUCACGGAGCACAUGGAGUGGCAGUGGCGGCA
	GACCUUAAGAGUACACAAGAAGCUAUAAAUAAGAUAAC
	AAAAAAUCUCAAUUCUUUGAGUGAGCUAGAAGUAAAGA
	ACCUUCAAAGACUAAGUGGUGCCAUGGAUGAACUCCACA
	ACGAAAUACUCGAGCUGGAUGAGAAAGUGGAUGAUCUC
	AGAGCUGACACUAUAAGCUCACAAAUAGAACUUGCAGU
	CUUGCUUUCCAACGAAGGAAUAAUAAACAGUGAAGACG
	AGCAUCUAUUGGCACUUGAGAGAAAACUAAAGAAAAUG
	CUGGGUCCCUCUGCUGUAGACAUAGGAAACGGAUGCUUC
	GAAACCAAACACAAAUGCAACCAGACCUGCUUAGACAGG
	AUAGCUGCUGGCACCUUUGAUGCAGGAGAAUUUUCUCU
	CCCCACUUUUGAUUCAUUGAACAUUACUGCUGCAUCUUU
	AAAUGAUGAUGGAUUGGAUAACCAUACUAUACUGCUCU
	AUUACUCAACUGCUGCUUCUAGUUUGGCUGUAACAUUA
	AUGCUAGCUAUUUUUAUUGUUUAUAUGGUCUCCAGAGA
	CAACGUUUCAUGCUCCAUCUGUCUA
H1	AGCAAAAGCAGGGGAAAAUAAAAACAACCAAAAUGAAG	498
	GCAAACCUACUGGUCCUGUUAUGUGCACUUGCAGCUGCA
	GAUGCAGACACAAUAUGUAUAGGCUACCAUGCGAACAA
	UUCAACCGACACUGUUGACACAGUGCUCGAGAAGAAUG
	UGACAGUGACACACUCUGUUAACCUGCUCGAAGACAGCC
	ACAACGGAAAACUAUGUAGAUUAAAAGGAAUAGCCCCA
	CUACAAUUGGGGAAAUGUAACAUCGCCGGAUGGCUCUU
	GGGAAACCCAGAAUGCGACCCACUGCUUCCAGUGAGAUC
	AUGGUCCUACAUUGUAGAAACACCAAACUCUGAGAAUG
	GAAUAUGUUAUCCAGGAGAUUUCAUCGACUAUGAGGAG
	CUGAGGGAGCAAUUGAGCUCAGUGUCAUCAUUCGAAAG
	AUUCGAAAUAUUUCCCAAAGAAAGCUCAUGGCCCAACCA
	CAACACAACCAAAGGAGUAACGGCAGCAUGCUCCCAUGC
	GGGGAAAAGCAGUUUUUACAGAAAUUUGCUAUGGCUGA
	CGGAGAAGGAGGGCUCAUACCCAAAGCUGAAAAAUUCU
	UAUGUGAACAAGAAAGGGAAAGAAGUCCUUGUACUGUG
	GGGUAUUCAUCACCCGUCUAACAGUAAGGAUCAACAGA
	AUAUCUAUCAGAAUGAAAAUGCUUAUGUCUCUGUAGUG
	ACUUCAAAUUAUAACAGGAGAUUUACCCCGGAAAUAGC
	AGAAAGACCCAAAGUAAGAGAUCAAGCUGGGAGGAUGA
	ACUAUUACUGGACCUUGCUAAAACCCGGAGACACAAUAA
	UAUUUGAGGCAAAUGGAAAUCUAAUAGCACCAAGGU
	AUGCUUUCGCACUGAGUAGAGGCUUUGGGUCCGGCAUC
	AUCACCUCAAACGCAUCAAUGCAUGAGUGUAACACGAAG
	UGUCAAACACCCCUGGGAGCUAUAAACAGCAGUCUCCCU
	UUCCAGAAUAUACACCCAGUCACAAUAGGAGAGUGCCCA
	AAAUACGUCAGGAGUGCCAAAUUGAGGAUGGUUACAGG
	ACUAAGGAACAUUCCGUCCAUUCAAUCCAGAGGUCUAUU
	UGGAGCCAUUGCCGGUUUUAUUGAAGGGGGAUGGACUG
	GAAUGAUAGAUGGAUGGUACGGUUAUCAUCAUCAGAAU
	GAACAGGGAUCAGGCUAUGCAGCGGAUCAAAAAAGCAC
	ACAAAAUGCCAUUAACGGGAUUACAAACAAGGUGAACU
	CUGUUAUCGAGAAAAUGAACAUUCAAUUCACAGCUGUG
	GGUAAAGAAUUCAACAAAUUAGAAAAAAGGAUGGAAAA
	UUUAAAUAAAAAAGUUGAUGAUGGAUUUCUGGACAUUU
	GGACAUAUAAUGCAGAAUUGUUAGUUCUACUGGAAAAU
	GAAAGGACUCUGGAUUUCCAUGACUCAAAUGUGAAGAA
	UCUGUAUGAGAAAGUAAAAAGCCAAUUAAAGAAUAAUG
	CCAAAGAAAUCGGAAAUGGAUGUUUUGAGUUCUACCAC
	AAGUGUGACAAUGAAUGCAUGGAAAGUGUAAGAAAUGG
	GACUUAUGAUUAUCCCAAAUAUUCAGAAGAGUCAAAGU
	UGAACAGGGAAAAGGUAGAUGGAGUGAAAUUGGAAUCA
	AUGGGGAUCUAUCAGAUUCUGGCGAUCUACUCAACUGU
	CGCCAGUUCACUGGUGCUUUUGGUCUCCCUGGGGGCAAU
	CAGUUUCUGGAUGUGUUCUAAUGGAUCUUUGCAGUGCA
	GAAUAUGCAUCUGAGAUUAGAAUUUCAGAAAUAUGAGG
	AAAAACACCCUUGUUUCUACU
H7	AGCGAAAGCAGGGGAUACAAAAUGAACACUCAAAUCCU	499
	GGUAUUCGCUCUGAUUGCGAUCAUUCCAACAAAUGCAG
	ACAAAAUCUGCCUCGGACAUCAUGCCGUGUCAAACGGAA
	CCAAAGUAAACACAUUAACUGAAAGAGGAGUGGAAGUC
	GUCAAUGCAACUGAAACAGUGGAACGAACAAACAUCCCC
	AGGAUCUGCUCAAAAGGGAAAAGGACAGUUGACCUCGG
	UCAAUGUGGACUCCUGGGGACAAUCACUGGACCACCUCA
	AUGUGACCAAUUCCUAGAAUUUUCAGCCGAUUUAAUUA
	UUGAGAGGCGAGAAGGAAGUGAUGUCUGUUAUCCUGGG
	AAAUUCGUGAAUGAAGAAGCUCUGAGGCAAAUUCUCAG
	AGAAUCAGGCGGAAUUGACAAGGAAGCAAUGGGAUUCA
	CAUACAGUGGAAUAAGAACUAAUGGAGCAACCAGUGCA
	UGUAGGAGAUCAGGAUCUUCAUUCUAUGCAGAAAUGAA
	AUGGCUCCUGUCAAACACAGAUGAUGCUGCAUUCCCGCA
	GAUGACUAAGUCAUAUAAAAAUACAAGAAAAAGCCCAG
	CUCUAAUAGUAUGGGGGAUCCAUCAUUCCGUAUCAACU
	GCAGAGCAAACCAAGCUAUAUGGGAGUGGAAACAAACU
	GGUGACAGUUGGGAGUUCUAAUUAUCAACAAUCUUUUG
	UACCGAGUCCAGGAGCGAGACCACAAGUUAAUGGUCUA
	UCUGGAAGAAUUGACUUUCAUUGGCUAAUGCUAAAUCC
	CAAUGAUACAGUCACUUUCAGUUUCAAUGGGGCUUUCA
	UAGCUCCAGACCGUGCAAGCUUCCUGAGAGGAAAAUCUA
	UGGGAAUCCAGAGUGGAGUACAGGUUGAUGCCAAUUGU
	GAAGGGGACUGCUAUCAUAGUGGAGGGACAAUAAUAAG
	UAACUUGCCAUUUCAGAACAUAGAUAGCAGGGCAGUUG
	GAAAAUGUCCGAGAUAUGUUAAGCAAAGGAGUCUGCUG
	CUAGCAACAGGGAUGAAGAAUGUUCCUGAGAUUCCAAA
	GGGAAGAGGCCUAUUUGGUGCUAUAGCGGGUUUCAUUG
	AAAAUGGAUGGGAAGGCCUAAUUGAUGGUUGGUAUGGU
	UUCAGACACCAGAAUGCACAGGGAGAGGGAACUGCUGC
	AGAUUACAAAAGCACUCAAUCGGCAAUUGAUCAAAUAA
	CAGGAAAAUUAAACCGGCUUAUAGAAAAAACCAACCAA
	CAAUUUGAGUUGAUAGACAAUGAAUUCAAUGAGGUAGA
	GAAGCAAAUCGGUAAUGUGAUAAAUUGGACCAGAGAUU
	CUAUAACAGAAGUGUGGUCAUACAAUGCUGAACUCUUG
	GUAGCAAUGGAGAACCAGCAUACAAUUGAUCUGGCUGA
	UUCAGAAAUGGACAAACUGUACGAACGAGUGAAAAGAC
	AGCUGAGAGAGAAUGCUGAAGAAGAUGGCACUGGUUGC
	UUUGAAAUAUUUCACAAGUGUGAUGAUGACUGUAUGGC
	CAGUAUUAGAAAUAACACCUAUGAUCACAGCAAAUACA
	GGGAAGAGGCAAUGCAAAAUAGAAUACAGAUUGACCCA
	GUCAAACUAAGCAGCGGCUACAAAGAUGUGAUACUUUG
	GUUUAGCUUCGGGGCAUCAUGUUUCAUACUUCUAGCCA
	UUGUAAUGGGCCUUGUCUUCAUAUGUGUAAAGAAUGGA
	AACAUGCGGUGCACUAUUUGUAUAUAAGUUUGGAAAAA
	AACACCCUUGUUUCUAC
H10	AUGUACAAAAUAGUAGUGAUAAUCGCGCUCCUUGGAGC	500
	UGUGAAAGGUCUUGAUAAAAUCUGUCUAGGACAUCAUG
	CAGUGGCUAAUGGGACCAUCGUAAAGACUCUCACAAACG
	AACAGGAAGAGGUAACCAACGCUACUGAAACAGUGGAG
	AGUACAGGCAUAAACAGAUUAUGUAUGAAAGGAAGAAA
	ACAUAAAGACCUGGGCAACUGCCAUCCAAUAGGGAUGCU
	AAUAGGGACUCCAGCUUGUGAUCUGCACCUUACAGGGA
	UGUGGGACACUCUCAUUGAACGAGAGAAUGCUAUUGCU
	UACUGCUACCCUGGAGCUACUGUAAAUGUAGAAGCACU
	AAGGCAGAAGAUAAUGGAGAGUGGAGGGAUCAACAAGA
	UAAGCACUGGCUUCACUUAUGGAUCUUCCAUAAACUCGG
	CCGGGACCACUAGAGCGUGCAUGAGGAAUGGAGGGAAU
	AGCUUUUAUGCAGAGCUUAAGUGGCUGGUAUCAAAGAG
	CAAAGGACAAAACUUCCCUCAGACCACGAACACUUACAG
	AAAUACAGACACGGCUGAACACCUCAUAAUGUGGGGAA
	UUCAUCACCCUUCUAGCACUCAAGAGAAGAAUGAUCUAU
	AUGGAACACAAUCACUGUCCAUAUCAGUCGGGAGUUCCA
	CUUACCGGAACAAUUUUGUUCCGGUUGUUGGAGCAAGA
	CCUCAGGUCAAUGGACAAAGUGGCAGAAUUGAUUUUCA
	CUGGACACUAGUACAGCCAGGUGACAACAUCACCUUCUC
	ACACAAUGGGGGCCUGAUAGCACCGAGCCGAGUUAGCAA
	AUUAAUUGGGAGGGGAUUGGGAAUCCAAUCAGACGCAC
	CAAUAGACAAUAAUUGUGAGUCCAAAUGUUUUUGGAGA
	GGGGGUUCUAUAAAUACAAGGCUUCCCUUUCAAAAUUU
	GUCACCAAGAACAGUGGGUCAGUGUCCUAAAUAUGUGA
	ACAGAAGAAGCUUGAUGCUUGCAACAGGAAUGAGAAAC
	GUACCAGAACUAAUACAAGGGAGAGGUCUAUUUGGUGC
	AAUAGCAGGGUUUUUAGAGAAUGGGUGGGAAGGAAUGG
	UAGAUGGCUGGUAUGGUUUCAGACAUCAAAAUGCUCAG
	GGCACAGGCCAGGCCGCUGAUUACAAGAGUACUCAGGCA
	GCUAUUGAUCAAAUCACUGGGAAACUGAAUAGACUUGU
	UGAAAAAACCAAUACUGAGUUCGAGUCAAUAGAAUCUG
	AGUUCAGUGAGAUCGAACACCAAAUCGGUAACGUCAUC
	AAUUGGACUAAGGAUUCAAUAACCGACAUUUGGACUUA
	UCAGGCUGAGCUGUUGGUGGCAAUGGAGAACCAGCAUA
	CAAUCGACAUGGCUGACUCAGAGAUGUUGAAUCUAUAU
	GAAAGAGUGAGGAAACAACUAAGGCAGAAUGCAGAAGA
	AGAUGGGAAAGGAUGUUUUGAGAUAUAUCAUGCUUGUG
	AUGAUUCAUGCAUGGAGAGCAUAAGAAACAACACCUAU
	GACCAUUCACAGUACAGAGAGGAAGCUCUUUUGAACAG
	AUUGAAUAUCAACCCAGUGACACUCUCUUCUGGAUAUA
	AAGACAUCAUUCUCUGGUUUAGCUUCGGGGCAUCAUGU
	UUUGUUCUUCUAGCCGUUGUCAUGGGUCUUUUCUUUUU
	CUGUCUGAAGAAUGGAAACAUGCGAUGCACAAUCUGUA
	UUUAG
MRK_LZ_NP-	AUGGCCAGCCAGGGCACCAAGAGAAGCUACGAGCAGAUG	501
H3N2	GAGACCGACGGCGAGAGACAGAACGCCACCGAGAUCAGA
SQ-031687	GCCAGCGUGGGCAAGAUGAUCGACGGCAUCGGCAGAUUC
CX-003145	UACAUCCAGAUGUGCACCGAGCUCAAGCUGAGCGACUAC
	GAGGGCAGACUGAUCCAGAACAGCCUGACCAUCGAAAGA
	AUGGUUCUGAGCGCCUUCGACGAGAGAAGAAACAGAUA
	CCUGGAGGAGCACCCCAGCGCCGGCAAGGACCCCAAGAA
	GACCGGCGGCCCCAUCUACAAGAGAGUGGACGGCAGAUG
	GAUGAGAGAGCUGGUGCUGUACGACAAGGAGGAGAUCA
	GAAGAAUCUGGAGACAGGCCAACAACGGCGACGACGCCA
	CCGCCGGCCUGACCCACAUGAUGAUCUGGCACAGCAACC
	UGAACGACACCACCUACCAGAGAACCAGAGCCCUGGUGA
	GAACCGGCAUGGACCCCAGAAUGUGCAGCUUAAUGCAGG
	GCAGCACCCUGCCCAGAAGAUCCGGCGCCGCUGGUGCCG
	CCGUCAAGGGCAUCGGCACCAUGGUGAUGGAGCUGAUCC
	GCAUGAUCAAGCGCGGCAUCAACGACAGAAACUUCUGGA
	GAGGCGAAAACGGCAGAAAGACCAGAAGCGCCUACGAG
	AGAAUGUGCAACAUCCUGAAGGGCAAGUUCCAGACCGCC
	GCCCAAAGAGCCAUGAUGGACCAGGUGAGAGAGAGCAG
	AAACCCCGGCAACGCCGAGAUCGAAGACCUGAUCUUCAG
	CGCCAGAUCGGCCCUGAUCCUGAGAGGCAGCGUGGCCCA
	CAAGAGCUGCCUGCCCGCCUGCGUGUAUGGCCCCGCCGU
	GAGCAGCGGCUACAACUUCGAGAAGGAGGGCUACAGCCU
	GGUGGGCAUCGACCCCUUCAAGCUGCUGCAGAACUCUCA
	GGUGUAUAGCCUGAUCAGACCCAACGAGAACCCCGCCCA
	CAAGAGCCAGCUGGUGUGGAUGGCCUGCCACAGCGCCGC
	CUUCGAGGACCUGAGACUGCUGAGCUUCAUCAGAGGUAC
	CAAGGUGUCCCCCAGAGGCAAGCUGAGCACCAGAGGUGU
	GCAGAUCGCCAGCAAUGAGAACAUGGACAAUAUGGAGA
	GCAGCACCCUGGAGCUAAGAAGCAGGUACUGGGCCAUCC
	GGACCAGAAGCGGCGGCAAUACCAACCAGCAGAGAGCCA
	GCGCCGGCCAGAUCAGCGUGCAGCCCACCUUCAGCGUGC
	AGAGAAACCUGCCCUUUGAGAAGAGCACCGUGAUGGCCG
	CCUUCACCGGCAACACCGAGGGCAGAACCAGCGACAUGA
	GAGCCGAGAUCAUCAGAAUGAUGGAGGGCGCCAAGCCCG
	AGGAGGUGAGCUUUAGAGGCAGAGGCGUGUUCGAGCUG
	AGCGACGAGAAGGCCACCAACCCAAUUGUGCCCAGCUUC
	GACAUGUCGAACGAGGGCAGCUACUUCUUCGGCGACAAC
	GCCGAGGAGUACGACAAC
MRK_LZ_NIHGen6HASS-	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCUG	502
TM2	UGGCUGCCCGACACCACCGGCGACACCAUCUGCAUCGGC
SQ-034074	UACCACGCCAACAACAGCACCGACACCGUGGACACCGUG
CX-000553	CUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUG
	GGCAGCGGCCUGAGGAUGGUGACCGGCCUGAGGAACAUC
	CCCCAGAGGGAGACCAGGGGCCUGUUCGGCGCCAUCGCC
	GGCUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGC
	UGGUACGGCUACCACCACCAGAACGAGCAGGGCAGCGGC
	UACGCCGCCGACCAGAAGAGCACCCAGAACGCCAUCAAC
	GGCAUCACCAACAUGGUGAACAGCGUGAUCGAGAAGAU
	GGGCAGCGGCGGCAGCGGCACCGACCUGGCCGAGCUGCU
	GGUGCUGCUGCUGAACGAGAGGACCCUGGACUUCCACGA
	CAGCAACGUGAAGAACCUGUACGAGAAGGUGAAGAGCC
	AGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCU
	UCGAGUUCUACCACAAGUGCAACAACGAGUGCAUGGAG
	AGCGUGAAGAACGGCACCUACGACUACCCCAAGUACAGC
	GAGGAGAGCAAGCUGAACAGGGAGAAGAUCGACGGAGU
	GAAAUUGGAAUCAAUGGGGGUCUAUCAGAUCCUGGCCA
	UCUACAGCACCGUGGCCAGCAGCCUGGUGCUGCUGGUGA
	GCCUGGGCGCCAUCAGCUUCUGGAUGUGCAGCAACGGCA
	GCCUGCAGUGCAGAAUCUGCAUC
MRK_LZ_NIHGen6HASS-	AUGGAGACCCCCGCCCAGCUGCUGUUCCUGCUGCUGCUG	503
foldon	UGGCUGCCCGACACCACCGGCGACACCAUCUGCAUCGGC
SQ-032106	UACCACGCCAACAACAGCACCGACACCGUGGACACCGUG
CX-000596	CUGGAGAAGAACGUGACCGUGACCCACAGCGUGAACCUG
	GGCAGCGGCCUGAGGAUGGUGACCGGCCUGAGGAACAUC
	CCCCAGAGGGAGACCAGGGGCCUGUUCGGCGCCAUCGCC
	GGCUUCAUCGAGGGCGGCUGGACCGGCAUGGUGGACGGC
	UGGUACGGCUACCACCACCAGAACGAGCAGGGCAGCGGC
	UACGCCGCCGACCAGAAGAGCACCCAGAACGCCAUCAAC
	GGCAUCACCAACAUGGUGAACAGCGUGAUCGAGAAGAU
	GGGCAGCGGCGGCAGCGGCACCGACCUGGCCGAGCUGCU
	GGUGCUGCUGCUGAACGAGAGGACCCUGGACUUCCACGA
	CAGCAACGUGAAGAACCUGUACGAGAAGGUGAAGAGCC
	AGCUGAAGAACAACGCCAAGGAGAUCGGCAACGGCUGCU
	UCGAGUUCUACCACAAGUGCAACAACGAGUGCAUGGAG
	AGCGUGAAGAACGGCACCUACGACUACCCCAAGUACAGC
	GAGGAGAGCAAGCUGAACAGGGAGAAGAUCGACCCCGG
	CAGCGGCUACAUCCCCGAGGCCCCCAGGGACGGCCAGGC
	CUACGUGAGGAAGGACGGCGAGUGGGUGCUGCUGAGCA
	CCUUCCUG

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.

All references, including patent documents, disclosed herein are incorporated by reference in their entirety.

Claims

1. An influenza virus vaccine, comprising: at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one influenza virus antigenic polypeptide or an immunogenic fragment thereof, formulated in a lipid nanoparticle.

2. The influenza vaccine of claim 1, wherein the at least one antigenic polypeptide is influenza hemagglutinin 1 (HA1), hemagglutinin 2 (HA2), an immunogenic fragment of HA1 or HA2, or a combination of any two or more of the foregoing.

3. The influenza vaccine of claim 1, wherein at least one antigenic polypeptide is HA1, HA2, or a combination of HA1 and HA2, and at least one antigenic polypeptide is selected from the group consisting of neuraminidase (NA), nucleoprotein (NP), matrix protein 1 (M1), matrix protein 2 (M2), non-structural protein 1 (NS1) and non-structural protein 2 (NS2).

4. The influenza vaccine of claim 3, wherein at least one antigenic polypeptide is HA2 and at least one antigenic polypeptide is selected from the group consisting of NA, NP, M1, M2, NS1 and NS2.

5. The influenza vaccine of claim 4, wherein at least one antigenic polypeptide is HA2 and at least one antigenic polypeptides is selected from the group consisting of NA, NP, M1, M2, NS1 and NS2.

6. The influenza vaccine of any one of claims 1-5, wherein the at least one antigenic polypeptide is from influenza virus strain H1/PuertoRico/8/1934, H1/New Caledonia/20/1999, H1/California/04/2009, H5/Vietnam/1194/2004, H2/Japan/305/1957, H9/Hong Kong/1073/99, H3/Aichi/2/1968, H3/Brisbane/10/2007, H7/Anhui/1/2013, H10/Jiangxi-Donghu/346/2013, H3/Wisconsin/67/2005, H1/Vietnam/850/2009, or a combination thereof.

7. The vaccine of any one of claims 1-6, wherein the at least one antigenic polypeptide comprises an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479.

8. The vaccine of any one of claims 1-7, wherein the at least one RNA polypeptide is encoded by a nucleic acid sequence identified by any one of SEQ ID NO: 447-457, 459, 461, and/or wherein the at least one RNA polypeptide comprises a nucleic acid sequence identified by any one of SEQ ID NO: 491-503.

9. The vaccine of any one of claims 1-8, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479.

10. The vaccine of any one of claims 1-9, wherein the at least one antigenic polypeptide has an amino acid sequence that has 95%-99% identity to an amino acid sequence identified by any one of SEQ ID NO: 1-444, 458, 460, 462-479.

11. The vaccine of any one of claims 1-10, wherein the at least one antigenic polypeptide has an amino acid sequence that has at least 90% identity to an amino acid sequence of SEQ ID NO: 1-444, 458, 460, 462-479 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

12. The vaccine of any one of claims 1-11, wherein the at least one antigenic polypeptide has an amino acid sequence that has 90%-99% identity to an amino acid sequence of SEQ ID NO: 1-444, 458, 460, 462-479 and wherein the antigenic polypeptide or immunogenic fragment thereof has membrane fusion activity, attaches to cell receptors, causes fusion of viral and cellular membranes, and/or is responsible for binding of the virus to a cell being infected.

13. The vaccine of any one of claims 1-2, wherein the open reading frame is codon-optimized.

14. The vaccine of any one of claims 1-3, wherein the vaccine is multivalent.

15. The vaccine of any one of claims 1-4 formulated in an effective amount to produce an antigen-specific immune response.

16. A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine of any one of claims 1-15 in an amount effective to produce an antigen-specific immune response in the subject.

17. The method of claim 16, wherein the antigen specific immune response comprises a T cell response or a B cell response.

18. The method of claim 16 or 17, wherein the subject is administered a single dose of the vaccine.

19. The method of claim 16 or 17, wherein the subject is administered a booster dose of the vaccine.

20. The method of any one of claims 16-19, wherein the vaccine is administered to the subject by intradermal injection or intramuscular injection.

21. The method of any one of claims 16-20, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by at least 1 log relative to a control.

22. The method of any one of claims 16-21, wherein an anti-antigenic polypeptide antibody titer produced in the subject is increased by 1-3 log relative to a control.

23. The method of any one of claims 16-22, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased at least 2 times relative to a control.

24. The method of any one of claims 16-23, wherein the anti-antigenic polypeptide antibody titer produced in the subject is increased 2-10 times relative to a control.

25. The method of any one of claims 21-24, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has not been administered a vaccine against the virus.

26. The method of any one of claims 21-24, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a live attenuated vaccine or an inactivated vaccine against the virus.

27. The method of any one of claims 21-24, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a recombinant protein vaccine or purified protein vaccine against the virus.

28. The method of any one of claims 21-24, wherein the control is an anti-antigenic polypeptide antibody titer produced in a subject who has been administered a VLP vaccine against the virus.

29. The method of any one of claims 16-28, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a recombinant protein vaccine or a purified protein vaccine against the virus, respectively.

30. The method of any one of claims 16-28, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a live attenuated vaccine or an inactivated vaccine against the virus, respectively.

31. The method of any one of claims 16-28, wherein the effective amount is a dose equivalent to an at least 2-fold reduction in the standard of care dose of a VLP vaccine against the virus, and wherein an anti-antigenic polypeptide antibody titer produced in the subject is equivalent to an anti-antigenic polypeptide antibody titer produced in a control subject administered the standard of care dose of a VLP vaccine against the virus.

32. The method of any one of claims 16-31, wherein the effective amount is a total dose of 50 μg-1000 μg.

33. The method of claim 32, wherein the effective amount is a dose of 25 μg, 100 μg, 400 μg, or 500 μg administered to the subject a total of two times.

34. The method of any one of claims 16-33, wherein the efficacy of the vaccine against the virus is greater than 65%.

35. The method of any one of claims 16-34, wherein the vaccine immunizes the subject against the virus for up to 2 years.

36. The method of any one of claims 16-34, wherein the vaccine immunizes the subject against the virus for more than 2 years.

37. The method of any one of claims 16-36, wherein the subject has been exposed to the virus, wherein the subject is infected with the virus, or wherein the subject is at risk of infection by the virus.

38. The method of any one of claims 16-37, wherein the subject is immunocompromised.

39. The vaccine of any one of claims 1-15 for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.

40. Use of the vaccine of any one of claims 1-15 in the manufacture of a medicament for use in a method of inducing an antigen specific immune response in a subject, the method comprising administering to the subject the vaccine in an amount effective to produce an antigen specific immune response in the subject.

41. An engineered nucleic acid encoding at least one RNA polynucleotide of a vaccine of any one of claims 1-15.

42. An expression vector comprising engineered nucleic acid encoding at least one RNA polynucleotide of a vaccine of any one of claims 1-15.

43. A host cell comprising an engineered nucleic acid encoding at least one RNA polynucleotide of a vaccine of any one of claims 1-16.

44. A method of producing a polypeptide, comprising culturing the host cell of claim 43 in a medium under conditions permitting expression of a polypeptide encoded by the nucleic acid, and purifying the polypeptide from the cultured cell or the medium of the cell.

45. A multiple consensus subtype vaccine comprising at least one ribonucleic acid (RNA) polynucleotide having an open reading frame encoding at least one influenza virus antigenic polypeptide or an immunogenic fragment thereof, wherein the vaccine provides cross-reactivity against a variety of influenza strains, the vaccine comprising at least one consensus hemagglutinin antigen.

46. The vaccine of claim 45, wherein the consensus hemagglutinin antigen is selected from the group consisting of influenza hemagglutinin 1 (HA1), hemagglutinin 2 (HA2), an immunogenic fragment of HA1 or HA2, or a combination of any two or more of the foregoing.

47. The vaccine of claim 45, wherein at least one antigenic polypeptide is HA1, HA2, or a combination of HA1 and HA2, and at least one antigenic polypeptide is selected from the group consisting of neuraminidase (NA), nucleoprotein (NP), matrix protein 1 (M1), matrix protein 2 (M2), non-structural protein 1 (NS1) and non-structural protein 2 (NS2).

48. The vaccine of claim 47, wherein at least one antigenic polypeptide is HA2 and at least one antigenic polypeptide is selected from the group consisting of NA, NP, M1, M2, NS1 and NS2.

49. The vaccine of claim 48, wherein at least one antigenic polypeptide is HA2 and at least one antigenic polypeptides is selected from the group consisting of NA, NP, M1, M2, NS1 and NS2.

50. The vaccine of any one of claims 45-49, wherein the at least one antigenic polypeptide is from influenza virus strain H1/PuertoRico/8/1934, H1/New Caledonia/20/1999, H1/California/04/2009, H5/Vietnam/1194/2004, H2/Japan/305/1957, H9/Hong Kong/1073/99, H3/Aichi/2/1968, H3/Brisbane/10/2007, H7/Anhui/1/2013, H10/Jiangxi-Donghu/346/2013, H3/Wisconsin/67/2005, H1/Vietnam/850/2009, or a combination thereof.

51. The vaccine of any one of claims 45-49, formulated in a lipid nanoparticle.

52. The vaccine of claim 51 or any one of claims 1-15, wherein the nanoparticle has a mean diameter of 50-200 nm.

53. The vaccine of claim 51 or any one of claims 1-15, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol and a non-cationic lipid.

54. The vaccine of claim 53, wherein the lipid nanoparticle carrier comprises a molar ratio of about 20-60% cationic lipid, 0.5-15% PEG-modified lipid, 25-55% sterol, and 25% non-cationic lipid.

55. The vaccine of claim 54, wherein the cationic lipid is an ionizable cationic lipid and the non-cationic lipid is a neutral lipid, and the sterol is a cholesterol.

56. The vaccine of claim 54, wherein the cationic lipid is selected from 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

57. The vaccine of any one of claims 51-56, wherein the nanoparticle has a polydispersity value of less than 0.4.

58. The vaccine of any one of claims 51-57, wherein the nanoparticle has a net neutral charge at a neutral pH value.

59. The vaccine of any one of claims 1-15 or 45-58, wherein the at least one RNA polynucleotide comprises at least one chemical modification.

60. The vaccine of claim 59, wherein the chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine.

61. A method of inducing cross-reactivity against a variety of influenza strains in a mammal, the method comprising administering to the mammal in need thereof the vaccine of any one of claims 1-15 or 45-60.

62. The method of claim 61, wherein at least two ribonucleic acid (RNA) polynucleotides having an open reading frame each encoding a consensus hemagglutinin antigen are administered to the mammal separately.

63. The method of claim 61, wherein at least two ribonucleic acid (RNA) polynucleotides having an open reading frame each encoding a consensus hemagglutinin antigen are administered to the mammal simultaneously.

64. A pharmaceutical composition for use in vaccination of a subject comprising an effective dose of mRNA encoding an influenza virus antigen, wherein the effective dose is sufficient to produce detectable levels of antigen as measured in serum of the subject at 1-72 hours post administration.

65. The composition of claim 64, wherein the cut off index of the antigen is 1-2.

66. A pharmaceutical composition for use in vaccination of a subject comprising an effective dose of mRNA encoding an influenza virus antigen, wherein the effective dose is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against said antigen as measured in serum of the subject at 1-72 hours post administration.